MICHIGAN CANCER SURVEILLANCE PROGRAM
CANCER PROGRAM MANUAL

DCH-0916 Rev. 6/26/2017

Michigan Department of Health and Human Services
Division for Vital Records and Health Statistics
Michigan Cancer Surveillance Program
By Authority of Act 82, P.A. 1984
MICHIGAN CANCER SURVEILLANCE PROGRAM
CANCER PROGRAM MANUAL

Nick Lyon
Director
Michigan Department of Health and Human Services

Susan Moran, MPH
Senior Deputy Director
Population Health Administration

Sarah Lyon-Calvo
Director
Bureau of Epidemiology and Population Health

Glenn Copeland, MBA
Division Director and State Registrar
Division for Vital Records and Health Statistics

Georgetta “Jetty” Alverson, CTR
Manager
Cancer & Birth Defects Surveillance Section
A note about this manual:

The MCSP Cancer Program Manual is designed to be downloaded to your computer and used as an electronic PDF file. The PDF contains links to internal bookmarks as well as links to external web documents with URL addresses.

You may print this PDF to use as a printed reference, but you must refer to the PDF to utilize the built-in navigation tools and hyperlinks.
TABLE OF CONTENTS

Introduction ........................................................................................................................................... 7
    Contact Registry Staff ......................................................................................................................... 7
History of the Michigan Central Cancer Registry ................................................................................. 9
    Purpose ........................................................................................................................................... 9
    Confidentiality ................................................................................................................................. 10
    Revised Reporting Requirements ....................................................................................................... 10
Act 82 of 1984 Establishing the Central Cancer Registry................................................................. 11
Administrative Rules on Cancer Reporting ......................................................................................... 13
Responsibilities of Michigan Hospitals and Laboratories ............................................................... 19
Responsibilities of the Michigan Cancer Surveillance Program (MCSP) ............................................. 21
Preparation of the Cancer Report Form (Abstract) ........................................................................... 23
    General Reporting Instructions ........................................................................................................ 23
    Manual Submission (includes instructions for submission of data) .................................................. 24
    Electronic Submission (includes instructions for submission of data) ............................................... 25
    Submitting Updates (Corrections) ...................................................................................................... 26
    Text Documentation ......................................................................................................................... 28
Required Level of Follow-Back Effort by Item and Facility Type ....................................................... 29
    Facility Types ................................................................................................................................ 29
    Required Level of Follow-Back Effort ................................................................................................ 29
    Table: Follow-Back Requirements by Data Item and Facility Type (Data Item List) ....................... 30
General coding Instructions for First Course of Treatment Data Items ............................................. 37
    Surgery .......................................................................................................................................... 38
    Radiation ....................................................................................................................................... 40
    Systemic Therapy ............................................................................................................................ 41
    Other Treatment .............................................................................................................................. 42
Instructions for Completing All MCSP Reportable Data Items .......................................................... 43

The following list contains frequently queried data items. To view ALL data items, click here

    Alcohol Use ................................................................................................................................. 49
    Behavior Code ICD-O-3 .................................................................................................................. 50
    Class of Case ................................................................................................................................. 53
    Diagnostic Confirmation ................................................................................................................... 62
    Family History of Cancer .............................................................................................................. 65
    Grade ............................................................................................................................................ 66

Go to Table of Contents                 Go to Data Item List                 MCSP Cancer Program Manual • 5
INTRODUCTION

The Michigan Department of Health and Human Services (MDHHS) is mandated by Act 82 of 1984, effective July 1, 1984, to establish a cancer registry for the State of Michigan. This statute states “the department shall establish a registry to record cases of cancer and other specified tumorous and precancerous diseases that occur in the state, and to record information concerning these cases as the department considers necessary and appropriate in order to conduct epidemiologic surveys of cancer and cancer-related diseases in the state.”

Reports of diagnosed cancers are required of a facility diagnosing and/or treating a cancer patient. ALL hospitals, clinical laboratories, physician offices, dentists and clinic directors who have knowledge of a case of cancer shall report the case to the MDHHS.

Reporting of diagnosed cancers statewide is effective for those cases diagnosed on or after January 1, 1985. This manual is intended to provide those responsible for reporting with specific instructions on the proper and complete reporting of cancer diagnoses.

In October 1, 2004, the Michigan Cancer Surveillance Program (MCSP) implemented the collection of benign/borderline intracranial and Central Nervous System (CNS) tumors as a new requirement.

CONTACT REGISTRY STAFF

If you need assistance, please contact the MCSP staff below:

**Reporting Issues/Registry Services**
*Research use of statewide registry or hospital planning data*
Glenn Copeland, State Registrar
E-mail: copelandg@michigan.gov
Phone: 517-335-8677
Fax: 517-335-8711

*Cancer reporting requirements or submission of data*
Georgetta “Jetty” Alverson, CTR, Manager
Email: alversong@michigan.gov
Phone: 517-33508855
Fax: 517-335-9513

**Statistical Support Unit**
*Population based data*
Georgia Spivak, Statistician
E-mail: spivak@michigan.gov
Phone: 517-335-8702
Fax: 517-335-9513

*Cancer cluster investigation*
Elisia Ray, Epidemiologist
Email: rave7@michigan.gov
Phone: 517-284-4994
Fax: 517-335-9513
Quality Assurance Unit
Stacey Coltrain, RHIT, CTR (MPHI Contractor)
Quality Improvement Field Representative
E-mail: coltrains@michigan.gov
Phone: 517-373-0758
Fax: 517-335-9513

Claudia Hardin, CTR
Quality Improvement Field Representative
E-mail: hardinc@michigan.gov
Phone: 517-335-9967
Fax: 517-335-9513

Doug Koster, RHIT, CTR
Quality Improvement Field Representative
E-mail: kosterd@michigan.gov
Phone: 517-335-8348
Fax: 517-335-9513

Registry Operations Unit
David Westover
Registry Operations Unit Analyst
E-mail: westoverd1@michigan.gov
Phone: 517-335-9624
Fax: 517-335-9513

Reporting - out-of-state data exchange/special studies (mailings)
Wendy Stinnett, Registry Operations Technician
E-mail: stinnettw@michigan.gov
Phone: 517-335-8747
Fax: 517-335-9513

Reporting cancer data manually
Elaine Snyder, Registry Operations Technician
E-mail: snydere@michigan.gov
Phone: 517-335-8949
Fax: 517-335-9513

Death clearance
Mary Stephens
E-mail: stephensm2@michigan.gov
Phone: 517-335-9403
Fax: 517-335-9513
HISTORY OF THE MICHIGAN CENTRAL CANCER REGISTRY

The history of cancer reporting in Michigan dates back to 1947 when an administrative rule was enacted to require the reporting of cancer cases. This rule was never effectively enforced until 1978, when a governor's task force was empaneled to examine the need for cancer reporting in Michigan. The recommendations from this panel prompted the department in 1980, to initiate a pilot program. By 1984, 52 hospitals were reporting cancer cases on a voluntary basis, which resulted in approximately 6,000 cases being reported each year. As the pilot project progressed, legislation to require state wide reporting was developed. On April 17, 1984, a bill to mandate state wide reporting was signed into law.

A panel was assembled to develop and design the rules for reporting incidence of cancer to the state wide central cancer registry. In 1984, the “Task Force on Administrative Rules to Implement Act 82” began meeting. The task force consisted of professional groups throughout the state who in some way dealt with cancer patients or cancer data systems. In addition, public health officials involved in health programs concerned with cancer control, and individuals involved with epidemiological cancer research, were also assigned to the task force.

The objective of the task force was to “provide advice to the department on a set of administrative rules as required by the authorizing legislation.” This panel made recommendations on data items to be collected, methods of reporting, quality control issues, confidentiality, as well as rules for reporting facilities. These cancer reporting rules were developed and outlined in the original 1984 Cancer Reporting Manual, which was approved by the original task force. On January 1, 1985, the rules for reporting cancer cases went into effect.

MCSP began tabulating cancer incidence reports on January 1, 1985. By the end of 2016, the state central cancer registry contained 2.2 million reports with 1.7 million individual cancer cases. Currently the central registry processes approximately 59,000 new reports yearly. These cases represent approximately 165 reporting facilities, which include hospitals, physician offices and laboratories.

The Detroit Metropolitan Cancer Surveillance System operates a Surveillance Epidemiology End Results (SEER) registry which reports for all hospitals and majority of the laboratories within Oakland, Macomb, and Wayne counties. The SEER registry represents approximately 60 hospitals and laboratories in these three counties.

Facilities are able to report cancer cases to the state central cancer registry either manually on the cancer report form or electronically through the State’s free online abstracting feature in Web Plus. Hospital registries are becoming more sophisticated in their collection and transferal methods since the state cancer registry began in 1985. As of November 2016, approximately 95 percent of the cases from hospitals and regional registries are involved in an automated reporting system. Automated facilities send their data through Web Plus, which is a web-based application that collects cancer data securely over the public Internet.

State cancer data has been compiled and analyzed annually since 1985. These yearly reports are produced using the submitted data and are made available on the Michigan Department of Health and Human Services - Cancer Statistics web site. As new annual reports are prepared, updated data for prior years is developed and released to ensure that the most complete information is made available. Processing time for a report from diagnosis to manual statistics is approximately two years.

PURPOSE

A state wide population based cancer registry is the only means whereby state wide incidence data for cancers by type and by area of residence can be developed. Timely information on cancer cases is employed as a basis for cancer surveillance, as a tool for initial evaluation of cancer incidence within regions of particular interest, and as a source of baseline incidence data. The registry is of value in examining the frequency of cancer by demographic
characteristics such as age, race and sex and is of significant value to researchers in epidemiological case control studies. This data is also helpful in the areas of planning health education and addressing public health concerns.

**CONFIDENTIALITY**

Cancer incidence reports and data files on cancer cases which are received by the department are afforded confidential handling as required by Act 82 of 1984, being section 2631 of Act 368 of 1978 as amended, and by administrative rule. The release of data in identifiable form is specifically prohibited, except as outlined in Rule Four. Under the rules, release of this data or reports is permitted to the individual patient or to the patient’s legal representative. Information may be provided to a researcher conducting approved research, following specific protocol based upon the nature of the research. Release is permitted to a cancer registry from another state with regard to residents of that state so long as the state agrees to restrict the use of the information to statistical tabulations. Further protection of the data is afforded by sections 2632 and 2633 of Act 368 of 1978 which designates that the reports or information thereon are inadmissible as evidence in a court and which establishes a shield from liability for furnishing the information. In addition, the privacy regulations enacted in conjunction with the Health Insurance Portability and Accountability Act (HIPAA) has a specific exemption to permit disclosing identifiable patient data to the official public health agency of a state.

**REVISED REPORTING REQUIREMENTS**

In 2011, changes to the information being reported for cancer cases was initiated. These new reporting standards are designed to ensure that the registry in Michigan conforms as closely to central incidence registries operated in other states. The new data set collected conforms to the items recommended for collection by the North American Association of Central Cancer Registries (NAACCR) and are nearly the same as the recommendations by the National Program for Cancer Registries (NPCR).

The decision to change the reporting requirements was precipitated by two important developments. The first was the release of standards for the operation of a central registry which were produced by NAACCR in 2011. Concurrent with the release of these new standards were recommendations on standard items for collection released by NPCR within the Centers for Disease Control (CDC). The information being collected in Michigan did not conform to these two new sets of standards. It was apparent that the long term usefulness of the state central cancer registry hinged upon careful review of the new standards and the development of specific recommendations for implementation in Michigan.

The initial structure for cancer reporting used in Michigan was developed in consultation with an “ad hoc task force” with members representing key organizations of cancer care and cancer research in Michigan. This group provided counsel on a number of important matters that needed to be addressed when the registry was first established. These issues included determining who was responsible for reporting, the manner the information was to be reported, timeliness requirements, and finally the specific items to be reported. The advice of this group proved to be an important key to the success of the state wide cancer registry. This same approach was adopted with regard to re-evaluating the basic operational principles for the Michigan registry in light of the recommendations of NAACCR and NPCR.

The standards set forth by the Commission on Cancer (CoC) were also taken under advisement. A strategy for required data sets takes place in a tiered priority which conforms to the requirements of the CoC. Those facilities approved by the CoC, are required to submit more detailed information, which includes further information on staging and treatment. Those facilities with CoC approved cancer registries are perceived to have the ability of their staff to supply the central registry with this further information. A table has been developed to distinguish the reporting requirements for approved facilities, non-approved facilities and laboratories.
ACT NO. 82 OF 1984 ESTABLISHING THE CENTRAL CANCER REGISTRY

Act No. 82
Public Acts of 1984
Approved by the Governor
April 17, 1984

Filed with the Secretary of State
April 19, 1984

STATE OF MICHIGAN
82ND LEGISLATURE
REGULAR SESSION OF 1984

Introduced by Reps. Spaniola, Hertel, Barns, Dutko, Porreca, Sitz, Maynard and DeMars

ENROLLED HOUSE BILL No. 4090
AN ACT to amend Act No. 368 of the Public Acts of 1978, entitled “An act to protect and promote the public health; to codify, revise, consolidate, classify, and add to the laws relating to public health; to provide for the prevention and control of diseases and disabilities; to provide for the classification, administration, regulation, financing, and maintenance of personal, environmental, and other health services and activities; to create or continue, and prescribe the powers and duties of, departments, boards, commissions, councils, committees, task forces, and other agencies; to prescribe the powers and duties for governmental entities and officials; to regulate occupations, facilities, and agencies affecting the public health; to promote the efficient and economical delivery of health care services, to provide for the appropriate utilization of health care facilities and services, and to provide for the closure of hospitals or consolidation of hospitals or services; to provide for the collection and use of data and information; to provide for the transfer of property; to provide the certain immunity from liability; to provide for penalties and remedies; and to repeal certain acts and parts of acts,” as amended, being sections 333.1101 to 333.25211 of the Michigan Compiled Laws, by adding section 2619.

The People of the State of Michigan enact:

Section 1. Act No. 368 of the Public Acts of 1978, as amended, being sections 333.1101 to 333.25211 of the Michigan Compiled Laws, is amended by adding section 2619 to read as follows:

Sec. 2619. (1) The department shall establish a registry to record cases of cancer and other specified tumorous and precancerous diseases that occur in the state, and to record information concerning these cases as the department considers necessary and appropriate in order to conduct epidemiologic surveys of cancer and cancer-related diseases in the state.
(2) Each diagnosed case of cancer and other specified tumorous and precancerous diseases shall be reported to the department pursuant to subsection (4), or reported to a cancer reporting registry if the cancer reporting registry meets standards established pursuant to subsection (4) to ensure that accuracy and completeness of the reported information. A person or facility required to report a diagnosis pursuant to subsection (4) may elect to report the diagnosis to the state through an existing cancer registry only if the registry meets minimum reporting standards established by the department.
(3) The department shall maintain comprehensive records of all reports submitted pursuant to this section. These report shall be subject to the same requirements of confidentiality as provided in section 2631 for data or records concerning medical research projects.
(4) The director shall promulgate rules which provide for all of the following:
(a) A list of tumorous and precancerous disease other than cancer to be reported pursuant to subsection (2).
(b) The quality and manner in which the cases and other information described in subsection (1) are reported to the department.
(c) The terms and conditions under which records disclosing the name and medical condition of a specific individual and kept pursuant to this section are released by the department.
(5) This section does not compel an individual to submit to medical or department examination or supervision.
(6) The department may contract for the collection and analysis of, and research related to, the epidemiologic data required under this section.
(7) Within 2 years after the effective date of this section, the department shall begin evaluating the reports collected pursuant to subsection (2). The department shall publish and make available to the public reports summarizing the information collected. The first summary report shall be published not later than 180 days after the end of the first 2 full calendar years after the effective date of this section. Subsequent annual summary reports shall be made on a full calendar year basis and published not later than 180 days after the end of each calendar year.
(8) Reporting pursuant to subsection (2) shall begin the next calendar year after the effective date of this section.
(9) This section shall take effect July 1, 1984.

This act is ordered to take immediate effect.

William A. Ryan  
..................................................  
Clerk of the House of Representatives

William C. Kandler  
..................................................  
Secretary of the Senate

Approved. ..............................................

..................................................  
Governor
ADMINISTRATIVE RULES ON CANCER REPORTING

DEPARTMENT OF HEALTH AND HUMAN SERVICES
OFFICE OF THE STATE REGISTRAR

Filed with the Secretary of State on April 16, 1985. These rules take effect 15 days after filing with the Secretary of State.

(By authority conferred on the department of public health by section 2619 of Act No. 368 of the Public Acts of 1978, as amended, being 333.2619 of the Michigan Compiled Laws.)

R 325.9050, R 325.9051, and R 325.9052 are amended; and R 325.9057 is rescinded (Eff. May 27, 2016).

R 325.9050 Registry

Rule 9050. (1) The department shall establish a registry to record cases of cancer and other specified tumorous and precancerous diseases that occur in the state. The registry shall include information concerning these cases as the department considers necessary and appropriate to conduct epidemiologic surveys of cancer and cancer-related diseases in the state.

(2) Each diagnosed case of cancer and other specified tumorous and precancerous diseases shall be reported to the department pursuant to subrule (4) of this rule, or reported to a cancer reporting registry if the cancer reporting registry meets standards established pursuant to subrule (4) of this rule by a reporting entity as defined in R 325.9051 to ensure the accuracy and completeness of the reported information. A reporting entity required to report a diagnosis pursuant to subrule (4) of this rule may elect to report the diagnosis to the state through an existing cancer registry only if the registry meets minimum reporting standards established by the department.

(3) The department shall maintain comprehensive records of all reports submitted pursuant to this rule. These reports shall be subject to the same requirements of confidentiality as provided in section 2631 of the public health code, 1978 PA 368, MCL 333.2619 for data or records concerning medical research projects.

(4) The director shall provide for all of the following:

(a) A list of tumorous and precancerous disease other than cancer to be reported pursuant to subrule (2) of this rule.

(b) The quality and manner in which the cases and other information described in subrule (1) of this rule are reported to the department.

(c) The terms and conditions under which records disclosing the name and medical condition of a specific individual and kept pursuant to this rule are released by the department.

(5) This rule does not require an individual to submit to medical or department examination or supervision.

(6) The department may contract for the collection and analysis of, and research related to, the epidemiologic data required by this rule.

(7) Within 2 years after the effective date of these rules, the department shall begin evaluating the reports collected pursuant to subrule (2) of this rule. The department shall publish and make available to the public reports summarizing the information collected.

(8) Reporting pursuant to subrule (2) of this rule shall begin the next calendar year after the effective date of this rule.


R 325.9051 Definitions

Rule 9051. As used in these rules:

(a) "Primary brain-related tumor" means a primary tumor, whether malignant or benign, of the brain, meninges, spinal cord, cauda equina, a cranial nerve or nerves, or any part of the central nervous system or of the pituitary gland, pineal gland, or craniopharyngeal gland.
(b) "Cancer" means all diagnoses with a behavior code of 2 (carcinoma in situ) or 3 (malignant primary site) which is listed in publication found in department policy and made available to the public including carcinomas of skin of the vagina, prepuce, clitoris, vulva, labia, penis, and scrotum but excluding basal, epithelial, papillary, and squamous cell carcinomas of the skin.

(c) "Department" means the department of health and human services.

(d) “Reporting entity or reporting entities” means an individual, facility, or other entity described in these rules as required to report patient information with a diagnosed cancer or other reportable condition to the state cancer registry. A reporting entity includes the following:

(i) Physician as defined in sections 17001 and 17501 of the public health code, 1978 PA 368, MCL 333.17001 and 333.17501.

(ii) Dentist as defined in section 16601 of the public health code, 1978 PA 368, MCL 333.16601.

(iii) Hospital as defined in section 20106 of the public health code, 368 PA 1978 of the public health code, MCL 333.20106.

(iv) Clinic defined as an outpatient facility that provides advice, counseling, diagnosis, treatment, surgery, care, or services relating to the preservation or maintenance of health.

(v) Clinical laboratory as defined in section 20104 of the public health code, 1978 PA 368, MCL 333.20104.


R 325.9052 Reportable diagnoses

Rule 9052. (1) Cancer diagnoses, diagnoses of benign brain-related tumors, and any tumorous and precancerous diseases otherwise required to be reported by state or federal law shall be reported to the department in a manner consistent with these rules and procedures issued by the department.

(2) Diagnoses shall be reported by all reporting entities.

(3) A reporting entity may elect to report cases through a hospital or regional cancer registry that meets the rules set by the department.

(4) Reports shall be submitted within 180 days of a diagnosis on a form prescribed or approved by the department, except for reports forwarded on electronic media.

(5) Reports submitted on electronic media shall meet data quality, format, and timeliness standards prescribed by the department.


R 325.9053 Quality assurance

Rule 3. (1) For the purpose of assuring the quality of submitted data, each reporting entity shall allow the department to inspect such parts of a patient's medical records as are necessary to verify the accuracy of submitted data.

(2) A reporting entity which meets the standards of quality and completeness set by the department shall be subject to inspection not more than once every 2 years for the purpose of assessing the quality and completeness of reporting from the entity.

(3) A reporting entity shall, upon request of the department, supply missing information, if known, or clarify information submitted to the department.

(4) Upon mutual agreement between a reporting entity and the department, the reporting entity may elect to submit copies of medical records instead of inspection. Each copy of a medical record or part thereof submitted to the department pursuant to this rule shall be used only for verification of corresponding reported data, shall not be recopied by the department, and shall be kept in a locked file cabinet when not being used. Such copies shall be destroyed promptly following verification of the corresponding reported data or, if the reported data appears to be inaccurate, following clarification or correction of the reported data.

(5) Both of the following provisions shall be complied with to preserve the confidentiality of each patient's medical records:
(a) Each reporting entity shall provide to the department, for inspection only, all of the following records and reports:
(i) Reports of tissue analyses which have been performed for the purpose of determining the presence or absence of malignant disease.
(ii) Reports of radiological examinations performed for the purpose of determining the presence or absence of malignant disease.
(iii) Reports of diagnoses of malignant disease and notations of the reasons for such diagnoses, including both the primary clinician's reports and consultation reports.
(iv) Those parts of medical records which contain the specific information required to be reported.
(b) A reporting entity shall not be required by this rule to allow inspection of any part of any patient's medical record other than those parts listed in subrule (3) of this rule. A reporting entity may allow the inspection of medical records from which parts, other than those specified, have been deleted, masked, crossed out, or otherwise rendered illegible.


R 325.9054 Confidentiality of reports

Rule 4. (1) The department shall maintain the confidentiality of all reports of cancer submitted to the department and shall not release such reports, or any information which, because of name, identifying number, mark, or description, can be readily associated with a particular individual, except in accordance with subrules (2), (3), (4), and (5) of this rule. The department shall not release any information that would indicate whether or not the name of a particular person is listed in the cancer registry, except in accordance with subrules (2), (3), (4), and (5) of this rule.

(2) A report of cancer submitted to the department concerning a particular individual, and any other information maintained in the cancer reporting system which, because of name, identifying number, mark, or description, can be readily associated with a particular individual, shall be released as follows:
(a) To the particular individual upon compliance with both of the following provisions:
   (i) Receipt of a written request which is signed by the particular individual and which is witnessed or notarized as required by subrule (3) of this rule.
   (ii) Presentation by the particular individual of suitable identification as required by subrule (4) of this rule.
(b) If the particular individual is a minor, to a parent of the particular individual upon compliance with all of the following provisions:
   (i) Receipt of a written request which is signed by the parent and which is witnessed or notarized as required by subrule (3) of this rule.
   (ii) Receipt of a certified copy of the birth certificate of the particular individual.
   (iii) Presentation by the parent of suitable identification as required by subrule (4) of this rule.
(c) If the particular individual has a court-appointed guardian or if the particular individual is deceased, to the court-appointed guardian or to the executor or administrator of the particular individual's estate upon compliance with all the following provisions:
   (i) Receipt of a written request which is signed by the court-appointed guardian, executor, or administrator and which is witnessed or notarized as required by subrule (3) of this rule.
   (ii) Receipt of a certified copy of the order or decree which appoints the guardian, executor, or administrator.
   (iii) Presentation by the guardian, executor, or administrator of suitable identification as required by subrule (4) of this rule.
(d) To an attorney or other person designated by the particular individual upon compliance with both of the following provisions:
   (i) Receipt of a written request which is signed by the particular individual, which is witnessed or notarized as required by subrule (3) of this rule, and which requests release of the information to the attorney or other person.
   (ii) Presentation by the attorney or other person of suitable identification as required by subrule (4) of this rule.
(e) To an attorney or other person designated by the court-appointed guardian of the particular individual or designated by the executor or administrator of the estate of the particular individual upon compliance with all of the following provisions:

(i) Receipt of a written request which is signed by the court-appointed guardian, executor, or administrator, which is witnessed or notarized as required by subrule (3) of this rule, and which requests release of the information to the attorney or other person.

(ii) Receipt of a certified copy of the order or decree which appoints the guardian, executor, or administrator.

(iii) Presentation by the attorney or other person of suitable identification as required by subrule (4) of this rule.

(f) If the particular individual is a minor, to an attorney or other person designated by the parent of the particular individual upon compliance with all of the following provisions:

(i) Receipt of a written request which is signed by the parent, which is witnessed or notarized as required by subrule (3) of this rule, and which requests release of the information to the attorney or other person.

(ii) Receipt of a certified copy of the birth certificate of the particular individual.

(iii) Presentation by the attorney or other person of suitable identification as required by subrule (4) of this rule.

(3) Every written request for the release of information submitted pursuant to subrule (2) of this rule shall be signed by the person making the written request. Such signature shall comply with either of the following provisions:

(a) Be witnessed by an employee of the department who has been designated to witness such requests and to whom the person making the request presents suitable identification as required by subrule (4) of this rule.

(b) Be notarized by a notary public or magistrate.

(4) Any person who is required by subrule (2) or (3) of this rule to present suitable identification shall present an identification document, such as a driver's license, or other document which contains both a picture of the person and the signature or mark of the person.

(5) The director of the department may, pursuant to R 325.9055, release information from the cancer reporting system to an authorized representative of a study or research project reviewed by the scientific advisory panel and approved by the director. The department shall not release any part of a patient's medical record obtained pursuant to R 325.9053.


R 325.9055 Scientific advisory panel; release of information for research

Rule 5. (1) The director of the department shall appoint a scientific advisory panel of not less than 3 scientists to review research proposals whereby a release of information maintained by the department which identifies an individual reported to have a diagnosis of cancer is required.

(2) All research proposals which require the release of information that identifies individuals with reported diagnoses of cancer shall be reviewed by the scientific advisory panel.

(3) The panel shall, in writing, advise the director concerning the merits of the study.

(4) The release of information for research which identifies individuals with reported diagnoses of cancer shall be subject to the terms and conditions set by the department. Such study or research project shall not publish the name of any individual who is or was the subject of a report of cancer submitted to the department, and such study or research project shall not release any identifying number, mark, or description which can be readily associated with an individual who is or was the subject of a report of cancer submitted to the department.

(5) A reporting entity shall, upon notification that the director has approved a research project, provide to the department or a researcher named by the director the name of the primary physician responsible for the medical care of persons selected for the research study as indicated in the reporting entity's records.


R 325.9056 Exchange of records

Rule 6. The department, by agreement, may transmit transcripts or copies of reports of cancer diagnoses to state or national cancer registries when the reports relate to residents of other states or countries. The agreement shall
require that the transcripts or records be used for statistical purposes only as specified in the agreement and that the identity of a person subject to the report shall not be released.


R 325.9057 Rescinded

Rule 7. The publication entitled “International Classifications of Diseases for Oncology,” 1976, specified in R 325.9051 is adopted by reference in these rules. Copies of the adopted matter may be obtained from the World Health Organization Publications Center, U.S.A., 49 Sheridan Avenue, Albany, NY 12210, or from the Department of Public Health, Box 30035, 3500 N. Martin Luther King, Jr. Blvd., Lansing, Michigan 48909. At the time of adoption of these rules the cost per copy is $10.00.


R 325.971 Reporting of cancer

Rule 1. (1) On and after May 1, 1947, every physician, dentists, hospital superintendent, and clinic director who has knowledge of a case of cancer shall, within 10 days, report the same to the Michigan department of health on a form provided by said department. The report shall contain the name and address of the patient and either the name and address of the physician, or of the dentist, or of the hospital superintendent and hospital, or of the clinic director and clinic, and such other data as may be required.

(2) All such reports and records of the Michigan department of health pertaining to cancer are hereby declared to be confidential.


Editor’s note: This rule appears in the Michigan Administrative code of 1954 as R 325.975.
REPORTING RESPONSIBILITIES

RESPONSIBILITIES OF MICHIGAN HOSPITALS AND LABORATORIES

1. Know the MCSP reporting requirements and attend the educational workshops when rules change or deemed necessary by the quality assurance field representative.

2. Select an abstract reporting option; whether on paper or electronic and establish a schedule for regular reporting. Notify the MCSP of any changes in the method of reporting.

3. Perform all casefinding activities to ensure completeness of reporting.

4. Regardless of submission format (paper forms or electronic file), all reportable cases MUST be submitted to the MCSP within six months or 180 days from the initial date of diagnosis. Refer to the table below to determine when abstracts are to be submitted based upon the date of diagnosis.

5. Electronic data submissions are required on a monthly basis and are to be received by MCSP on or before the first working day of each month.


<table>
<thead>
<tr>
<th>Month of Diagnosis</th>
<th>Submit Abstract to MCSP no later than</th>
</tr>
</thead>
<tbody>
<tr>
<td>January</td>
<td>July</td>
</tr>
<tr>
<td>February</td>
<td>August</td>
</tr>
<tr>
<td>March</td>
<td>September</td>
</tr>
<tr>
<td>April</td>
<td>October</td>
</tr>
<tr>
<td>May</td>
<td>November</td>
</tr>
<tr>
<td>June</td>
<td>December</td>
</tr>
<tr>
<td>July</td>
<td>January</td>
</tr>
<tr>
<td>August</td>
<td>February</td>
</tr>
<tr>
<td>September</td>
<td>March</td>
</tr>
<tr>
<td>October</td>
<td>April</td>
</tr>
<tr>
<td>November</td>
<td>May</td>
</tr>
<tr>
<td>December</td>
<td>June</td>
</tr>
</tbody>
</table>

6. Inform the MCSP of ALL facility or contact person changes (e.g., mailing address, contact name, phone, email) using the “Reporting Facility Contact Information Form” on the MCSP website.

7. Facilities will be involved in periodic quality control visits by a quality improvement field representative from the MCSP. These reporting facilities will be requested to do the following:
8. Maintain some type of accession log or master file of submissions which will serve as a quick reference of all cases sent to the MCSP. This may be as simple as keeping copies of the cancer report forms or maintaining a reporting log which includes name, primary site, date of diagnosis, and date case was submitted to the state.

9. Download to your computer and/or print the following manuals to use when completing the required data items on the cancer report form or abstracting a case using Web Plus.

There are certain advantages to using online or electronic versions of reference manuals over printed versions. Online versions are always current, often use embedded hyperlinks for easy navigation to required information, as well as allow for real time searches by text string. Online or electronic versions save paper and ink resources and reduce the need for hard copy storage and manual updating of outdated material.

- Collaborative Stage Data Collection System Manual
- SEER Multiple Primary and Histology Coding Rules
- SEER Summary Staging Manual
  Directly coded SEER Summary Stage is required regardless of facility type or diagnosis year.
- ICD-O-3 SEER Primary Site/Histology Validation List
- Facility Oncology Registry Data Standards (FORDS)
- Hematopoietic and Lymphoid Neoplasm Database and the Hematopoietic and Lymphoid Neoplasm Coding Manual
- SEER*Rx - Interactive Antineoplastic Drugs Database
- International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) – This book can be purchased through any book store or ordered from online sources. Electronic CSV database files or print copies of the classifications are available from the World Health Organization.
- ICD-O-3 errata and clarifications
- AJCC Cancer Staging Manual – Beginning with cases diagnosed Jan. 1, 2016 and forward, directly coded TNM Stage values are required by the Michigan Cancer Surveillance Program for Hospitals with a Registry and for Hospitals without a Registry.
RESPONSIBILITIES OF THE MICHIGAN CANCER SURVEILLANCE PROGRAM (MCSP)

1. Provide all reporting facilities the current cancer report form and/or software for reporting.
2. Provide educational workshops and instructions to locate online reference materials.
3. Perform all computer data entry of manually submitted reports and process patient data updates.
5. Edit the file following NAACCR and NPCR standards.
6. Clarify and resolve issues relative to data quality that are encountered during the editing process.
7. Provide specific reports to verify data submission as requested by the reporting facility.
8. Release a statistical report, Cancer Incidence and Mortality, annually and have available on the web at MDHHS - Cancer Statistics.
PREPARATION OF THE CANCER REPORT FORM (ABSTRACT)

Whenever a cancer case is diagnosed or first treated within a hospital or laboratory, an abstract of the case must be prepared and forwarded to the MCSP. The abstract MUST be sent within 180 days or six months from the initial date of diagnosis or initial treatment.

The instructions contained in this MCSP Program Manual are intended to outline what information is needed and to provide specific guidance for completing the form, and meeting state reporting requirements. Should the instructions need clarification, or if special problems exist that make reporting as outlined difficult, do not hesitate to contact MCSP to discuss the matter.

Specific instructions for identifying cases, determining primary site, assigning histology and stage are discussed in detail in sections to follow.

GENERAL REPORTING INSTRUCTIONS

Upon reaching a diagnosis of an in situ or invasive cancer or providing treatment for a patient diagnosed elsewhere, a hospital or laboratory is to report the case via a paper or electronic abstract. In addition, any tumor diagnosed October 1, 2004 or later with a behavior code of “0” or “1” for the following site codes must be reported: meninges (C70.0 – C70.9); brain (C71.0 – C71.9); spinal cord, cranial nerves, and other parts of the central nervous system (C72.0 – C72.9); pituitary gland (C75.1); craniopharyngeal duct (C75.2); and pineal gland (C75.3).

The abstract MUST be in a format provided or approved by MCSP and submitted within 180 days or six months from the initial date of diagnosis.

- Each primary cancer diagnosed or treated within a hospital or laboratory must be reported to the MCSP on a separate cancer abstract.
- The diagnosis and/or treatment of a patient for a primary tumor that was previously reported by the facility need not be reported a second time.
- However, revisions and corrections to previously submitted information are important and should be reported to MCSP. (See “Submitting Updates (Corrections)” later in this section for instructions on how to report revisions or corrections to previously submitted abstracts.)
- New primary tumors diagnosed in previously reported patients are reportable.

As abstracts are received by the department, they will be reviewed, queried, electronically recorded and edited. In the course of assembling the data into a registry, duplicate reports of primary tumor diagnoses will be identified and tagged. The resulting file can therefore be used to develop accurate incidence information. There will be no active follow-up on the status or treatment of reported cases. MCSP maintains an incidence-based central registry – follow-up is limited to quality control issues or specific research projects.

The use of acceptable casefinding and record abstracting procedures are essential to complete reporting. The basic elements of reporting include sound casefinding techniques, correct identification of reportable cases, as well as the proper preparation and prompt submission of completed cancer reports.

Because the state maintains an incidence registry only, the information required for the state cancer report is limited compared to what is collected by a typical hospital cancer registry. Reporting of annual follow-up information on the status of a case is not necessary. However, a change in basic items of information that identify and describe the patient or that relate to the reportable conditions with which the patient has been diagnosed must be submitted as a case report update. In addition, information regarding the types of therapy provided as the first
course of therapy is also required. The instructions which follow are organized alphabetically by NAACCR data item name.

Because the majority of quality-related problems are associated with a set of essential data items, these items are routinely queried for clarification during internal quality control reviews.

<table>
<thead>
<tr>
<th>Data Field</th>
<th>Typical Quality-Related Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient’s First Name</td>
<td>Blank, Inconsistent, Unknown, Illegible</td>
</tr>
<tr>
<td>Patient’s Last Name</td>
<td>Blank, Unknown, Illegible</td>
</tr>
<tr>
<td>Complete Address</td>
<td>Blank, Illegible, Inconsistent</td>
</tr>
<tr>
<td>Sex</td>
<td>Blank, Inconsistent with name or site</td>
</tr>
<tr>
<td>Date of Birth</td>
<td>Blank, Inconsistent with site, report date, or date of diagnosis</td>
</tr>
<tr>
<td>Social Security Number</td>
<td>Blank</td>
</tr>
<tr>
<td>Primary Site</td>
<td>Blank, Inconsistent with histology</td>
</tr>
<tr>
<td>Laterality</td>
<td>A paired organ is reported for the primary site, but laterality is blank</td>
</tr>
<tr>
<td>Histology</td>
<td>Blank, Inconsistent with the primary site, Indicates the condition may not be reportable</td>
</tr>
<tr>
<td>Stage</td>
<td>Blank, Inconsistent with histology</td>
</tr>
<tr>
<td>Method of Diagnosis</td>
<td>Blank, Inconsistent, e.g., in situ diagnosis not based upon a microscopic method of diagnosis</td>
</tr>
<tr>
<td>First Course of Treatment</td>
<td>Blank, but the report is from a hospital with a treatment center</td>
</tr>
</tbody>
</table>
An abstract report for each separate primary tumor is required. A second report is NOT required if a patient is diagnosed with a recurrence that is confirmed to NOT be a second primary.

If mailed via United States Postal Service, send completed cancer report forms to:
MDHHS
Cancer Surveillance Section, 2nd Floor
Attention: Elaine Snyder
P.O. Box 30691
Lansing, MI 48909

If shipped via commercial courier such as FedEx or UPS, send completed cancer report forms to:
MDHHS
Cancer Surveillance Section, 2nd Floor
Attention: Elaine Snyder
333 S. Grand Ave., 2nd Floor
Lansing, MI 48933

ELECTRONIC SUBMISSION

Facilities submitting cases electronically must submit their data in the NAACCR format version specified by MCSP. In order to avoid data submission backlogs, facilities are requested to submit completed abstracts on a monthly basis.

Labeling Your Electronic Submission File
Once the export file has been created, enter a file name that begins with MI (Michigan) followed by your 5-digit Michigan Facility Number, then add the date stamp (YYYYMMDD) which is the date the file was created. For example, facility 98765 creates an export file on April 28, 2017. The file will be named MI9876520170428, plus the extension assigned by their software. The extension for Metriq is either .xva (new case) or .xvm (updated case) and will be assigned automatically.

If you are sending more than one file at a time, please make sure that each file is numbered appropriately by adding -1ofX, -2ofX, -3ofX, etc. to the end of the file name. For example, facility 98765 could have two files – MI9876520170428-1of2.xva and MI9876520170428-2of2.xva

It is important that you accurately label your file for security reasons – if a file is not accurately labeled, it cannot be loaded into the MCSP registry. **MCSP no longer accepts submissions that are incorrectly labelled.**

Submission of Data Using Web Plus
Electronic submission of date to the MCSP on or after January 1, 2016 must be submitted through Web Plus.

Web Plus is a web-based application that collects cancer data securely over the public internet. Web Plus supports three main functions: online abstracting, file upload and download, and follow-back efforts. Web Plus’ online abstracting capability is ideal for reporting from physicians’ offices and other low-volume reporting sources, while the file upload feature can be used for electronic submission of data to MCSP by reporting sources.

All records are saved in a database at the central cancer registry, and cases entered by one facility or office are not visible to other facilities. Data are validated by the CDC EDITS engine running on a Web server. Users, display types, and edit configurations are managed by the hosting central registry. Web Plus is hosted on a secure Web server that has a digital certificate installed; the communication between the client and the server is encrypted with Secure Sockets Layer (SSL) technology.
1. Go to https://mcsp.state.mi.us/WebPlus_Surv/logonen.aspx
2. Enter your User ID and Password that was provided by MCSP.
3. Enter PIN based on your assigned Web Plus PIN Matrix
4. Select Upload File link
5. Select New Upload tab
6. Load file
   A. Select the NAACCR version of the flat file. If the version is not listed, you will need to use the NORTHCON application to convert the file to one of the listed versions. The Non-NAACCR option is only for uploading reports. Abstract files uploaded via the Non-NAACCR method will NOT be counted.
   B. Click the Browse button and select the file to be uploaded.
   C. Click the Upload button
7. Once all records have been uploaded to the system, an edit report will open up as a pop-up window. (Make sure your browser is set to allow pop-up windows.)
8. If there are errors, you should print the edit report to aid in making corrections.
9. Make the corrections to your patient record.
10. Regenerate the submission file.
11. Delete the previous erroneous submission file from Web Plus.
12. Re-submit the new, clean, submission file.

➤ Note: Any file containing edit errors will NOT be processed by MCSP.

For detailed instructions on how to access Web Plus and upload data files, refer to the Web Plus Login and File Upload Instructions document on the MCSP web page.

Web Plus User Account Request Form
To establish a Web Plus user account, complete and submit a copy of the MCSP Web Plus User Account Request Form from the MCSP web page. Instructions are provided on the form. User instructions will be provided to the Local Administrator once the Web Plus account has been established.

For detailed instructions on how to access Web Plus and upload data files, refer to the Web Plus Login and File Upload Instructions document on the MCSP web page.

If you have any questions regarding Web Plus and/or completion of the MCSP Web Plus User Account Request Form, please contact David Westover at 517-335-9624 or WestoverD1@michigan.gov.

Electronic Software
The software programs used by facilities in Michigan that are approved by the American College of Surgeons (ACoS) include Metriq and OncoLog.

Facilities with 100 or more yearly cases must submit electronic abstract data generated by abstracting software such as Metriq or OncoLog. Non-registry hospitals, clinics, and laboratories may use the cancer case abstraction function of Web Plus for electronic submission of case reports.

Web Plus is a web-based application that collects cancer data securely over the public internet. Web Plus supports three main functions: online abstracting, file upload and download, and follow-back efforts. Web Plus online abstracting capability is ideal for reporting from physicians’ offices and other low-volume reporting sources, while the file upload feature can be used for electronic submission of data to MCSP by reporting sources.

All records are saved in a database at the central cancer registry, and cases entered by one facility or office are not visible to other facilities. Data are validated by the CDC EDITS engine running on a Web server. Users, display
types, and edit configurations are managed by the hosting central registry. Web Plus is hosted on a secure Web server that has a digital certificate installed; the communication between the client and the server is encrypted with Secure Sockets Layer (SSL) technology.

To establish a Web Plus user account, complete and submit a copy of the MCSP Web Plus User Account Request Form from the MCSP web page. Instructions are provided on the form. User instructions will be provided to the Local Administrator once the Web Plus account has been set up by MCSP.

If you have any questions regarding Web Plus and/or completion of the MCSP Web Plus User Account Request Form, please contact David Westover at 517-335-9624 or WestoverD1@michigan.gov. For individual training in the abstracting function of Web Plus, please contact Jetty Alverson at 517-335-8855 or AlversonG@michigan.gov.

**SUBMITTING UPDATES (CORRECTIONS)**

Beginning January 1, 2016 MCSP requires submission of a case report update when changes are made to certain data items for a reported primary.

A correction to the previously submitted report MUST be forwarded when one of the following conditions occurs:

- A cancer case has been reported but is later determined to be not reportable
- Information to resolve an unknown variable has been obtained
- Information for a particular variable of a previously submitted case was later determined to be submitted incorrectly
- A change has been made to one of the reportable fields on the following table since the last data submission:

<table>
<thead>
<tr>
<th>New or altered values for these data fields require an update submission</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Behavior Code ICD-O-3</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 1</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 2</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 3</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 4</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 5</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 6</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 7</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 8</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 9</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 10</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 11</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 12</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 13</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 14</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 15</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 16</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 17</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 18</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 19</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 20</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 21</strong></td>
</tr>
<tr>
<td><strong>CS Site Specific Factor 22</strong></td>
</tr>
</tbody>
</table>
Manual Updates (Corrections) Submission
1. Make a photocopy of the cancer abstract report form that was originally submitted.
2. Draw a line through the INCORRECT information.
3. Pencil in and HIGHLIGHT the corrected information.
4. Check UPDATE in the upper right hand corner.
5. Mail corrected cancer report forms via United States Postal Service to:
   MDHHS
   Cancer Surveillance Section, 2nd Floor
   Attention: Elaine Snyder
   P.O. Box 30691
   Lansing, MI 48909

Electronic Updates (Corrections) Submission
Proprietary abstracting software designates updated abstracts as “M” files because the file suffix for these documents is “.xvm” rather than “.xva” (new case). “M” files are uploaded to MCSP via Web Plus. For detailed instructions on how to access Web Plus and upload data files, refer to the Web Plus Login and File Upload Instructions document on the MCSP web page.
Note: Text documentation is required regardless of facility type. An abstract submitted with codes that lack supporting text data will be rejected in its entirety.

Text documentation is an essential component of a complete abstract and is heavily utilized for quality control and special studies. Text is required to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry.

The purpose of text information is to provide the opportunity to review and check coded values. To accomplish this, important information that documents the disease process should be entered manually from the medical record. Another registrar should be able to completely and accurately re-abstract the case relying solely on the furnished text data. This text must not be electronically generated from the coded values, as doing so would invalidate this re-abstracting quality check.

Do not leave text fields blank. If there is no information to record in the text field, type “NR” (Not Reported) or “No Info”, By doing so, you confirm that information was sought, but none could be found; otherwise it will be assumed that the information is actually missing if the field is left blank.

**Examples**

**Physical Examination (PE)**
- 2016/02/15: 49 year old white, non-Hispanic male presenting w/enlarged prostate. Retired farmer.

**Lab Tests**
- 02/15/2016: PSA elevated 4.6 ng/ml
- 2016/04/20: ER/PR positive or (+), HER2 negative or (-)

**Pathology**
- 11/12/2016 colon polyp, 1.2 x 1.0 x 0.8cm. Adenocarcinoma contained within polyp showing invasion of submucosa. Stalk: no evidence of adenocarcinoma or dysplasia.
- 2016/07/04 mastectomy of breast for R upper outer quadrant mass; 1.0 x 1.3 x 0.9cm. Ductal carcinoma, infiltrating, Grade III. Margins clear; 01/12/12: lymph nodes negative for cancer; no metastasis noted; Positive histology; ERA negative.

For guidance on the collection of supporting text, refer to General Coding Instructions for Text Field Items along with TEXT -- and RX TEXT-- item-specific instructions for capturing pertinent text data. Registrars may also refer to NAACCR Chapter X: Data Dictionary for instructions on how to record data in text fields.

*Note: Data field names used in the MCSP Cancer Program Manual match those in the NAACCR Data Dictionary.*
REQUIRED LEVEL OF FOLLOW-BACK EFFORT BY ITEM AND FACILITY TYPE

FACILITY TYPES

When two facilities with different reporting requirement levels coordinate reporting responsibilities, the requirements for reporting are determined by the facility with the highest reporting level. For example, should a laboratory and a hospital with a registry agree to share reporting responsibilities, the reporting requirement to meet would be of a ‘hospital with a registry.’

Once you have determined your facility type, use the table on the following pages to determine the level of follow-back effort required to report appropriate value for each data item. The definitions for the three facility types are as follows:

- **Hospital with a Registry** - an entity that has an approved cancer program by the American College of Surgeons (ACoS) or is working towards ACoS approval or is a regional registry that houses data for surrounding facilities.

- **Hospital without a Registry** - geared towards smaller entities that do not have an approved cancer program or have limited resources to diagnosis and treat cancer patients.

- **Independent Laboratories** - a separate laboratory from a hospital that reads specimens for either a hospital or physician’s office.

Note: Regardless of facility type, all data item fields must contain appropriate, allowable values. If a value is required, but it does not exist or cannot be found, then the appropriate default value must be entered. **Fields cannot be left blank except for the following nine data items:**

- Addr at DX--Supplemental ...............NAACCR item 2335
- Addr Current--Supplemental ..........NAACCR item 2355
- Date of Inpt Adm ..........................NAACCR item 590
- Date of Inpt Adm Flag .....................NAACCR item 591
- Date of Inpt Disch ..........................NAACCR item 600
- Date of Inpt Disch Flag .................NAACCR item 601
- Name--Alias ...............................NAACCR item 2280
- Name--Maiden .............................NAACCR item 2390
- Name--Middle .............................NAACCR item 2250

All other fields must contain the appropriate, allowable value. The default NOS value may be used depending upon the facility’s required level of follow-back effort.

REQUIRED LEVEL OF FOLLOW-BACK EFFORT

Not all facilities are required to meet the same level of follow-back effort to ascertain and record data. Data reporting requirements are determined by data item and facility type.

Specific reporting requirements for hospitals with a registry, hospitals without a registry, and independent laboratories are summarized in the table below. The need to report an item has been assigned to the levels of required, reportable, and not required. These requirements are patterned after the American College of Surgeons (ACoS) levels for inclusion of information within a hospital registry. **The practical definitions of these levels of reportability are best termed as levels of effort associated with collecting and providing the information.**
[REQ] Required

The facility MUST collect and report the information with data collection efforts including review of the patient’s hospital charts, outpatient records or other available records, as well as making inquiries with other facilities or the physician on record as is necessary to obtain the information.

NOTE: For instructions on how to code missing information, refer to the applicable coding manual for that data item.

[REP] Reportable

The facility MUST report the information if it can be located within the patient’s chart, outpatient records or other available records, but need not make inquiries of other facilities or physician’s offices. For example, if AJCC Stage is documented in the medical record, it must be reported. A Reportable designation does not mean that the field may be left blank. An appropriate default value must be reported for all Reportable items.

[N/R] Not Required/Non-Reportable

Item considered generally not available to the facility and/or not considered as reliably available. Information may be reported if available to the facility. An N/R designation does not mean that the field may be left blank. An appropriate default value must be reported for N/R items.

If there is no information available, and inquiries have been made, do not leave the item blank (unless specifically noted in the individualized data item instructions, e.g. Name--Alias.) Instead, record the appropriate NOS or default code.

Examples:

Data item: Primary Site
All facilities are required to report appropriate primary site ICD-O-3 code for the tumor

Data item: Name--Alias
Facilities may enter appropriate information if available or leave field blank if unknown/not applicable.

Data item: Grade
Hospitals with registries are required to do necessary follow-back to report correct value for this item. Hospitals without registries and laboratories are to enter the correct grade if it is available, but these facilities are not required to do follow-back to determine the tumor grade. If the value is unknown, they may record the appropriate default or NOS value for this item. In all cases, a value must be entered regardless of facility type or level of follow-back effort – this field must not be left blank.

<p>| TABLE: FOLLOW-BACK REQUIREMENTS BY DATA ITEM AND FACILITY TYPE (Data Item List) |
|---------------------------------|-----------------|-----------------|-----------------|-----------------|
| <strong>NAACCR Item Name</strong> | <strong>NAACCR Item</strong> | <strong>Hospital with Registry</strong> | <strong>Hospital without Registry</strong> | <strong>Independent Laboratory</strong> | <strong>MCSP 2016 Report Form Item</strong> |
| Abstracted By | 570 | REQ | REQ | REQ | 100 |
| Accession Number--Hosp | 550 | REQ | N/R | N/R | 21 |
| Addr at DX--City | 70 | REQ | REQ | REQ | 5b |
| Addr at DX--Country | 102 | REQ | REQ | REQ | 5g |
| Addr at DX--No &amp; Street | 2330 | REQ | REQ | REQ | 5a |
| Addr at DX--Postal Code | 100 | REQ | REQ | REQ | 5e |
| Addr at DX--State | 80 | REQ | REQ | REQ | 5d |</p>
<table>
<thead>
<tr>
<th>Data Item</th>
<th>Value 1</th>
<th>Value 2</th>
<th>Value 3</th>
<th>Value 4</th>
<th>N/R</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Addr at DX--Supplemental</td>
<td>2335</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>5c</td>
<td></td>
</tr>
<tr>
<td>Addr Current--City</td>
<td>1810</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Addr Current--Country</td>
<td>1832</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Addr Current--No &amp; Street</td>
<td>2350</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Addr Current--Postal Code</td>
<td>1830</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Addr Current--State</td>
<td>1820</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Addr Current--Supplemental (May be left blank)</td>
<td>2355</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Alcohol Use (State-specific item 9521)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>17</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Behavior Code ICD-O-3</td>
<td>523</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>33b</td>
<td></td>
</tr>
<tr>
<td>Birthplace--Country</td>
<td>254</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>8b</td>
<td></td>
</tr>
<tr>
<td>Birthplace--State</td>
<td>252</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>8a</td>
<td></td>
</tr>
<tr>
<td>Casefinding Source</td>
<td>501</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>Cause of Death</td>
<td>1910</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>103</td>
<td></td>
</tr>
<tr>
<td>Class of Case</td>
<td>610</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>Comorbid/Complication (1-10) ICD-9-CM codes only</td>
<td>3110-3164</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>14a</td>
<td></td>
</tr>
<tr>
<td>County at DX</td>
<td>90</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>5f</td>
<td></td>
</tr>
<tr>
<td>County--Current</td>
<td>1840</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>CS Extension (DX year 2004 - 2015)</td>
<td>2810</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>CS Lymph Nodes (DX year 2004 - 2015)</td>
<td>2830</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>CS Lymph Nodes Eval (DX year 2004 - 2015)</td>
<td>2840</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>CS Mets at Diagnosis (DX year 2004 - 2015)</td>
<td>2850</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>CS Mets at DX - Bone (DX year 2004 - 2015)</td>
<td>2851</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>CS Mets at DX - Brain (DX year 2004 - 2015)</td>
<td>2852</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>CS Mets at DX - Liver (DX year 2004 - 2015)</td>
<td>2853</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>CS Mets at DX - Lung (DX year 2004 - 2015)</td>
<td>2854</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>CS Mets Eval (DX year 2004 - 2015)</td>
<td>2860</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>—</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 1 (DX year 2004 and later)</td>
<td>2880</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>48</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 2 (DX year 2004 and later)</td>
<td>2890</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>49</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 3 (DX year 2004 and later)</td>
<td>2900</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 4 (DX year 2004 and later)</td>
<td>2910</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 5 (DX year 2004 and later)</td>
<td>2920</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 6 (DX year 2004 and later)</td>
<td>2930</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 7 (DX year 2004 and later)</td>
<td>2861</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 8 (DX year 2004 and later)</td>
<td>2862</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 9 (DX year 2004 and later)</td>
<td>2863</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>56</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 10 (DX year 2004 and later)</td>
<td>2864</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 11 (DX year 2004 and later)</td>
<td>2865</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 12 (DX year 2004 and later)</td>
<td>2866</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 13 (DX year 2004 and later)</td>
<td>2867</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 14 (DX year 2004 and later)</td>
<td>2868</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 15 (DX year 2004 and later)</td>
<td>2869</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Data Item</td>
<td>Type</td>
<td>Status</td>
<td>Notes</td>
<td>Code</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------</td>
<td>--------</td>
<td>--------</td>
<td>-------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 16 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 17 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>64</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 18 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 19 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>66</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 20 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 21 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>68</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 22 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>69</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 23 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>70</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 24 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>71</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Site-Specific Factor 25 (DX year 2004 and later)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>72</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Tumor Size (DX year 2004 and later)</td>
<td>REQ</td>
<td>REQ</td>
<td></td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CS Tumor Size/Ext Eval (DX year 2004 - 2015)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>—</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date 1st Crs RX CoC</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>74a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date 1st Crs RX CoC Flag</td>
<td></td>
<td></td>
<td></td>
<td>74b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date Case Completed</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>105</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of 1st Contact</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>29</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of 1st Contact Flag</td>
<td></td>
<td></td>
<td></td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Birth</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Death</td>
<td></td>
<td></td>
<td></td>
<td>102</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Diagnosis</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Inpt Adm (May be left blank)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>27a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Inpt Adm Flag (May be left blank)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>27b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Inpt Disch (May be left blank)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>28a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Inpt Disch Flag (May be left blank)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>28b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Last Contact</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>94a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Date of Last Contact Flag</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>94b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnostic Confirmation</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>36</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Family History of Cancer (State-specific item 9520)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>16a-c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Histologic Type ICD-O-3</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>33a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Report Number (State-specific item 9507)</td>
<td>REP</td>
<td>REP</td>
<td>REQ</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laterality</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>32</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymph-vascular Invasion</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marital Status at DX</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>12</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical Record Number</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mets at DX-Bone (DX year 2016 and forward)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mets at DX-Brain (DX year 2016 and forward)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mets at DX-Distant LN (DX year 2016 and forward)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>44</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mets at DX-Liver (DX year 2016 and forward)</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>45</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mets at DX-Lung</strong> (DX year 2016 and forward)</td>
<td>1116</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td><strong>Mets at DX-Other</strong> (DX year 2016 and forward)</td>
<td>1117</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td><strong>Michigan Facility Number</strong> (State-specific item 9508)</td>
<td></td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td><strong>Name--Alias</strong> (May be left blank)</td>
<td>2280</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Name--First</strong></td>
<td>2240</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>1b</td>
<td></td>
</tr>
<tr>
<td><strong>Name--Last</strong></td>
<td>2230</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>1a</td>
<td></td>
</tr>
<tr>
<td><strong>Name--Maiden</strong> (May be left blank)</td>
<td>2390</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>Name--Middle</strong> (May be left blank)</td>
<td>2250</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>1c</td>
<td></td>
</tr>
<tr>
<td><strong>Place of Death--Country</strong></td>
<td>1944</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>104b</td>
<td></td>
</tr>
<tr>
<td><strong>Place of Death--State</strong></td>
<td>1942</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>104a</td>
<td></td>
</tr>
<tr>
<td><strong>Primary Payer at DX</strong></td>
<td>630</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td><strong>Primary Site</strong></td>
<td>400</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td><strong>Race</strong> (1-5)</td>
<td>160-164</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td><strong>Rad--Regional RX Modality</strong></td>
<td>1570</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td><strong>Reason for No Radiation</strong></td>
<td>1430</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>83</td>
<td></td>
</tr>
<tr>
<td><strong>Reason for No Surgery</strong></td>
<td>1340</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>76</td>
<td></td>
</tr>
<tr>
<td><strong>Regional Nodes Examined</strong></td>
<td>830</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td><strong>Regional Nodes Positive</strong></td>
<td>820</td>
<td>REQ</td>
<td>REQ</td>
<td>N/R</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td><strong>Reporting Facility</strong></td>
<td>540</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>24a</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date BRM</strong></td>
<td>1240</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>90a</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date BRM Flag</strong></td>
<td>1241</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>90b</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Chemo</strong></td>
<td>1220</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>85a</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Chemo Flag</strong></td>
<td>1221</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>85b</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Hormone</strong></td>
<td>1230</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>88a</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Hormone Flag</strong></td>
<td>1231</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>88b</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Mst Defn Srg</strong></td>
<td>3170</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>77c</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Mst Defn Srg Flag</strong></td>
<td>3171</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>77d</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Other</strong></td>
<td>1250</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>92a</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Other Flag</strong></td>
<td>1251</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>92b</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Radiation</strong></td>
<td>1210</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>82a</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Radiation Flag</strong></td>
<td>1211</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>82b</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Surgery</strong></td>
<td>1200</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>77a</td>
<td></td>
</tr>
<tr>
<td><strong>RX Date Surgery Flag</strong></td>
<td>1201</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>77b</td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ--BRM</strong></td>
<td>1410</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ--Chemo</strong></td>
<td>1390</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ--Hormone</strong></td>
<td>1400</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ--Other</strong></td>
<td>1420</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ--Scope Reg NL Sur</strong></td>
<td>1292</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>80</td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ--Surg Oth Reg/Dis</strong></td>
<td>1294</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td><strong>RX Summ--Surg Prim Site</strong> (Code the most definitive surgical procedure of primary site)</td>
<td>1290</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>RX Summ--Surg/Rad Seq</td>
<td>1380</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>----</td>
<td></td>
</tr>
<tr>
<td>RX Summ--Systemic/Sur Seq</td>
<td>1639</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>75</td>
<td></td>
</tr>
<tr>
<td>RX Summ--Transplant/Endocr</td>
<td>3250</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>RX Summ--Treatment Status</td>
<td>1285</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>RX Text--BRM</td>
<td>2660</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>RX Text--Chemo</td>
<td>2640</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>RX Text--Hormone</td>
<td>2650</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>RX Text--Other</td>
<td>2670</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>98</td>
<td></td>
</tr>
<tr>
<td>RX Text--Radiation (Beam)</td>
<td>2620</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>RX Text--Radiation Other</td>
<td>2630</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>RX Text--Surgery</td>
<td>2610</td>
<td>REQ</td>
<td>REP</td>
<td>N/R</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Secondary Diagnosis (1-10) ICD-10-CM codes only</td>
<td>3780-3798</td>
<td>REP</td>
<td>REP</td>
<td>N/R</td>
<td>14b</td>
<td></td>
</tr>
<tr>
<td>SEER Summary Staging 2000 (Directly coded)</td>
<td>759</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>Sequence Number--Hospital</td>
<td>560</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>220</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>Social Security Number</td>
<td>2320</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Spanish/Hispanic Origin</td>
<td>190</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Text--DX Proc--Lab Tests</td>
<td>2550</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Text--DX Proc--OP</td>
<td>2560</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>78</td>
<td></td>
</tr>
<tr>
<td>Text--DX Proc--Path</td>
<td>2570</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>33a</td>
<td></td>
</tr>
<tr>
<td>Text--DX Proc--PE</td>
<td>2520</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Text--DX Proc--Scopes</td>
<td>2540</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>Text--DX Proc--X-ray/Scan</td>
<td>2530</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>96</td>
<td></td>
</tr>
<tr>
<td>Text--Histology Title</td>
<td>2590</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>33a</td>
<td></td>
</tr>
<tr>
<td>Text--Place of Diagnosis</td>
<td>2690</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>24b</td>
<td></td>
</tr>
<tr>
<td>Text--Primary Site Title</td>
<td>2580</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>31</td>
<td></td>
</tr>
<tr>
<td>Text--Remarks</td>
<td>2680</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>99</td>
<td></td>
</tr>
<tr>
<td>Text--Staging</td>
<td>2600</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>Text--Usual Industry</td>
<td>320</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>15b</td>
<td></td>
</tr>
<tr>
<td>Text--Usual Occupation</td>
<td>310</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>15a</td>
<td></td>
</tr>
<tr>
<td>TNM Clin Descriptor (Directly assigned)</td>
<td>980</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>TNM Clin M (Directly assigned)</td>
<td>960</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>TNM Clin N (Directly assigned)</td>
<td>950</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>TNM Clin Stage Group (Directly assigned)</td>
<td>970</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>TNM Clin T (Directly assigned)</td>
<td>940</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>TNM Edition Number</td>
<td>1060</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>TNM Path Descriptor (Directly assigned)</td>
<td>920</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>TNM Path M (Directly assigned)</td>
<td>900</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>TNM Path N (Directly assigned)</td>
<td>890</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>TNM Path Stage Group (Directly assigned)</td>
<td>910</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>TNM Path T (Directly assigned)</td>
<td>880</td>
<td>REQ</td>
<td>REP</td>
<td>REP</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Data Item</td>
<td>Code</td>
<td>Report</td>
<td>Repeat</td>
<td>Priority</td>
<td>Status</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------</td>
<td>--------</td>
<td>--------</td>
<td>----------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>Tobacco Use (State-specific item)</td>
<td>9522</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Tumor Size Clinical (DX year 2016 and forward)</td>
<td>752</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Tumor Size Pathologic (DX year 2016 and forward)</td>
<td>754</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Tumor Size Summary (DX year 2016 and forward)</td>
<td>756</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Type of Reporting Source</td>
<td>500</td>
<td>REQ</td>
<td>REQ</td>
<td>REQ</td>
<td>22</td>
<td></td>
</tr>
<tr>
<td>Vital Status</td>
<td>1760</td>
<td>REP</td>
<td>REP</td>
<td>REP</td>
<td>101</td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** If your registry is located within Wayne, Oakland, or Macomb counties and you have questions regarding submission of data, please contact your SEER-State Coordinator, Jeanne Witlock at 313-578-4219 or whitlock@med.wayne.edu.
GENERAL CODING INSTRUCTIONS FOR FIRST COURSE OF TREATMENT DATA ITEMS

The first course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence. “Active surveillance” is a form of planned treatment for some patients; its use is coded in the RX SUMM--TREATMENT STATUS item. “No therapy” is a treatment option that occurs if the patient refuses treatment, the family or guardian refuses treatment, the patient dies before treatment starts, or the physician recommends no treatment be given. If the patient refuses all treatment, code “patient refused” (code 7 or 87) for all treatment modalities.

DO NOT leave treatment items blank. If a particular treatment (or any type of treatment) was not administered, enter the “Unknown” value for that item.

Treatment Plan
A treatment plan describes the type(s) of therapies intended to modify, control, remove, or destroy proliferating cancer cells. The documentation confirming a treatment plan may be found in several different sources; for example, medical or clinic records, consultation reports, and outpatient records.

- All therapies specified in the physician(s) treatment plan are a part of the first course of treatment if they are actually administered to the patient.
- A discharge plan must be part of the patient’s record in a Joint Commission-accredited hospital and may contain part or all of the treatment plan.
- An established protocol or accepted management guidelines for the disease can be considered a treatment plan in the absence of other written documentation.
- If there is no treatment plan, established protocol, or management guidelines, and consultation with a physician advisor is not possible, use the principle: “initial treatment must begin within four months of the date of initial diagnosis.”

Time Periods for First Course of Treatment
If first course treatment was provided, the Date of First Course of Treatment is the earliest of Date of First Surgical Procedure, Date Radiation Started, Date Systemic Therapy Started, or Date Other Treatment Started.

- If no treatment is given, record the date of the decision not to treat, the date of patient refusal, or the date the patient expired if the patient died before treatment could be given.
- If active surveillance (“watchful waiting”) was selected, record the date of that decision.
- Additional data items further define the parameters for specific treatments and treatment modalities, as described in the following sections.
- RX SUMM--TREATMENT STATUS summarizes whether the patient received any first course treatment, no treatment, or is being managed by active surveillance.

All Malignancies except Leukemias
The first course of treatment includes all therapy planned and administered by the physician(s) during the first diagnosis of cancer. Planned treatment may include multiple modes of therapy and may encompass intervals of a year or more. Any therapy administered after the discontinuation of first course treatment is subsequent treatment.
Leukemias
The first course of treatment includes all therapies planned and administered by the physician(s) during the first diagnosis of leukemia. Record all remission-inducing or remission-maintaining therapy as the first course of treatment. Treatment regimens may include multiple modes of therapy. The administration of these therapies can span a year or more. A patient may relapse after achieving a first remission. All therapy administered after the relapse is secondary or subsequent treatment.

SURGERY
First course surgery items describe the most definitive type of surgical treatment the patient received from any facility, when it was performed, and its efficacy. When no surgical treatment is given, the reason is recorded. Major aspects of surgical care provided by the individual facility are also recorded so that hospital cancer programs can evaluate local patient care.

Relationships among Surgical Items
Date of First Surgical Procedure is the date that the first Surgical Procedure of Primary Site, Scope of Regional Lymph Node Surgery, or Surgical Procedure/Other Site is performed as part of first course treatment.

- If surgery was the only type of first course treatment performed or was the first of multiple treatment modalities, Date of First Surgical Procedure is the same as Date of First Course of Treatment. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.

Surgical Procedure of Primary Site, Scope of Regional Lymph Node Surgery, and Surgical Procedure/Other Site record three distinct aspects of first course therapeutic surgical procedures that may be performed during one or multiple surgical events. If multiple primaries are treated by a single surgical event, code the appropriate surgical items separately for each primary.

- Surgical Procedure of Primary Site is a site-specific item that describes the most invasive extent of local tumor destruction or surgical resection of the primary site and of surrounding tissues or organs that are removed in continuity with the primary site.

- Scope of Regional Lymph Node Surgery describes the removal, biopsy, or aspiration of sentinel nodes and other regional lymph nodes that drain the primary site and may include surgical procedures that aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose and/or stage disease as well as removal of nodes for treatment of the disease.

Surgical Procedure/Other Site describes first course resection of distant lymph node(s) and/or regional or distant tissue or organs beyond the Surgical Procedure of the Primary Site code.

If surgery of the respective type was performed, the code that best describes the surgical procedure is recorded whether or not any cancer was found in the resected portion. Incidental removal of tissue or organs, when it is not performed as part of cancer treatment (for example, incidental removal of an appendix), does not alter code assignment.

The code ranges and corresponding descriptions for site-specific Surgical Procedure of Primary Site code are grouped according to the general nature of the procedure:

- Codes 10 through 18 are site-specific descriptions of tumor-destruction procedures that do not produce a pathologic specimen.

- Codes 20 through 80 are site-specific descriptions of resection procedures.
• The special code 98 applies to specific tumors that cannot be clearly defined in terms of primary non-primary site. Surgical Procedure of Primary Site should be coded 98 for any tumor characterized by the specific sites and/or morphologies identified in the site-specific code instructions for Unknown and Ill-Defined Primary Sites and Hematopoietic/Reticuloendothelial/Immune proliferating/Myeloproliferative Disease. The item Surgical Procedure/Other Site is used to indicate whether surgery was performed for these tumors.

When multiple first course primary site surgical procedures are performed for a single tumor, the most extensive or definitive is the last performed, and the code represents the cumulative effect of the separate procedures.

Response categories are defined in logical sequence. Within groups of codes, procedures are defined with increasing degrees of descriptive precision. Succeeding groups of codes define progressively more extensive forms of resection.

For codes 00 through 79, the descriptions of the surgical procedures are hierarchical. Last-listed responses take precedence over earlier-listed responses (regardless of the code or numeric value).

To the extent possible, codes and their definitions are the same as those previously assigned in ROADS to accommodate analysis in registries that maintain unconverted data. As a result of added and modified codes, however, the numeric code sequence may deviate from the order in which the descriptions of the surgical procedures are listed.

Example A rectosigmoid primary surgically treated by polypectomy with electrocautery, which is listed after polypectomy alone, is coded 22.

  20 Local tumor excision, NOS
  26 Polypectomy
  27 Excisional biopsy
  Combination of 20 or 26–27 WITH
  21 Photodynamic therapy (PDT)
  22 Electrocautery
  23 Cryosurgery
  24 Laser ablation
  25 Laser excision

Scope of Regional Lymph Node Surgery distinguishes between sentinel lymph node biopsy and removal of other regional lymph nodes and distinguishes removal of regional lymph nodes during the same surgical procedure as a sentinel node biopsy from subsequent removal.

One important use of registry data is the tracking of treatment patterns over time. In order to compare contemporary treatment to previously published treatment based on the former codes, or to data still unmodified from pre-1998 definitions, the ability to differentiate surgeries in which four or more regional lymph nodes are removed is desirable. The compromise incorporated in the Scope of Regional Lymph Node Surgery codes separates removal of one to three nodes (code 4) from removal of four or more nodes in the response categories (code 5). It is important to note that this distinction is made to permit comparison of current surgical procedures with procedures coded in the past when the removal of fewer than four nodes was not reflected in surgery codes. The distinction between fewer than four nodes and four or more nodes removed is not intended to reflect clinical significance when applied to a particular surgical procedure.

Surgical Procedure/Other Site describes surgery performed on tissue or organs other than the primary site or regional lymph nodes. It is also used to describe whether surgery was performed for tumors having unknown or ill-,
defined primary sites or hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease morphologies. If any surgical treatment was performed on these cancers, Surgical Procedure/Other Site is coded 1.

### RADIATION

Date Radiation Started is the date that the first radiation therapy was delivered to the patient as part of all of the first course of therapy. This item in combination with Date Radiation Ended allows the duration of treatment to be calculated.

If radiation was the only type of first course treatment performed or was the first of multiple treatment modalities, Date Radiation Started is the same as Date of First Course of Treatment. Both dates can be used to describe lag time between diagnosis and initialization of specific aspects of treatment.

The type of regional dose therapy and its concomitant dose are captured by the items Regional Treatment Modality and Regional Dose (cGy). These two items describe the type of radiation delivered to the patient and the most significant therapeutic dose delivered.

- Codes 20 through 32 of Regional Treatment Modality apply to the delivery of beam radiation. If the patient record does not specify the specific modality employed, then code the most general description of the modality, code 20.

- Codes 40 through 43 describe proton radiation (code 40) and specific type of stereotactic radiotherapy (codes 41–43). If stereotactic radiotherapy is delivered to a patient but the exact modality is not recorded, use code 41 (Stereotactic radiosurgery, NOS).

- Codes 50 through 55 are used to record different types of brachytherapy administration, also known as radioactive seed implants. Code 50 should be used to record the application of radioactive materials not otherwise specified.

- Codes 60 through 62 provide codes to describe the administration of specific radioisotopes. Code 60 (Radioisotopes, NOS) should be used when specific details of the radioisotope administration is not available.

- Code 98 is reserved for cases where it is known that radiation therapy was delivered but the modality is not recorded in the patient record.

- The unit of measure for radiologic dosing is the centigray (cGy), which has replaced the use of “rads” to describe radiation dose.

- If only one radiation treatment modality is delivered to a patient and it is not specified as either regional or boost treatment, assume it’s regional treatment and code the items Regional Treatment Modality accordingly. A boost treatment is provided to a smaller volume within the same volume as regional radiation in order to enhance the effect of the regional treatment.

- The boost dose may or may not employ the same treatment modality. For example, external beam radiation may be used for regional treatment and be followed by brachytherapy to provide the boost dose.

- Not all patients who receive radiation therapy receive a boost dose radiation. For these cases, boost modality and dose should be coded as 00 and 00000, respectively.

- Radiation/Surgery Sequence identifies those instances where radiation therapy and the surgical management of the patient are not discrete and overlap with respect to time. Radiation therapy can precede the surgical resection of a tumor and then be continued after the patient’s surgery, or radiation can be administered intraoperatively.
• Reason for No Radiation identifies why radiation therapy was not provided to the patient and distinguishes a physician’s not recommending this therapy due to contraindicating conditions from a patient’s refusal of a recommended treatment plan.

**SYSTEMIC THERAPY**

Systemic therapy encompasses the treatment modalities captured by the items chemotherapy, hormone therapy, and immunotherapy. The systemic therapy items on the cancer report form separate the administration of systemic agents or drugs from medical procedures which affect the hormonal or immunologic balance of the patient.

<table>
<thead>
<tr>
<th>Clarification of Systemic Therapy Terms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Term</strong></td>
</tr>
<tr>
<td>Chemotherapy</td>
</tr>
<tr>
<td>Hormone Therapy</td>
</tr>
<tr>
<td>Immunotherapy / Biologic Response Modifier (BRM)</td>
</tr>
<tr>
<td>Endocrine Therapy</td>
</tr>
<tr>
<td>Hematologic Transplants</td>
</tr>
</tbody>
</table>

Chemotherapy agents are administered in treatment cycles, either singly or in a combination regimen of two or more chemotherapy drugs. If a patient has an adverse reaction, the managing physician may change one of the agents in a combination regimen. If the replacement agent belongs to the same group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) as the original agent, there is no change in the regimen. However, if the replacement agent is of a different group than the original agent, the new regimen represents the start of subsequent therapy, only the original agent or regimen is recorded as first course therapy. Refer to the [SEER*Rx Interactive Drug Database](#) for a list of chemotherapeutic agents.

Systemic agents may be administered by intravenous infusion or given orally. Other methods of administration include the following:

<table>
<thead>
<tr>
<th>Method</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intrathecal</td>
<td>Administered directly into the cerebrospinal fluid through a lumbar puncture needle into an implanted access device (for example, Ommaya reservoir).</td>
</tr>
<tr>
<td>Pleural/Pericardial</td>
<td>Injected directly into pleural or pericardial space to control malignant effusions.</td>
</tr>
<tr>
<td>Intraperitoneal</td>
<td>Injected into the peritoneal cavity.</td>
</tr>
<tr>
<td>Hepatic Artery</td>
<td>Injected into a catheter inserted into the artery that supplies blood to the liver.</td>
</tr>
</tbody>
</table>

**Relationships among Systemic Therapy Items**

The data item Date Systemic Therapy Started describes the first date on which any first course systemic treatment was administered to the patient. Nine out of 10 patients treated with systemic therapy receive only a single class of drugs (chemotherapy, hormone therapy, or immunotherapy). Of the remaining patients who receive a combined
regimen of systemic therapies, two-thirds begin these combined regimens simultaneously. For the purposes of clinical surveillance, the collection of multiple dates to describe the sequence of systemic therapy administration is not necessary.

The data items Chemotherapy, Hormone Therapy, and Immunotherapy describe whether or not each respective class of agent(s) or drug(s) were administered to the patient as part of first course therapy, based on SEER*Rx. In the case of chemotherapy, additional distinction is allowed for instances where single or multi-agent regimens were administered. Each of these three items includes code values that describe the reason a particular class of drugs is not administered to the patient and distinguishes a physician’s not recommending systemic therapy due to contraindicating conditions from a patient’s refusal of a recommended treatment plan.

Hematologic Transplant and Endocrine Procedures captures those infrequent instances in which a medical, surgical, or radiation procedure is performed on a patient that has an effect on the hormonal or immunologic balance of the patient. Hematologic procedures, such as bone marrow transplants or stem cell harvests, are typically employed in conjunction with administration of systemic agent(s), usually chemotherapy.

- Endocrine procedures, either radiologic or surgical, may be administered in combination with systemic agent(s), typically hormonal therapeutic agents.

- As first course therapy, hematologic procedures will rarely be administered in conjunction with endocrine radiation or surgery. The use of code 40 in response to this data item should be reviewed and confirmed with the managing physician(s).

OTHER TREATMENT
Other Treatment encompasses first course treatment that cannot be described as surgery, radiation, or systemic therapy according to the defined data items found in this manual.

This item is also used for supportive care treatment for reportable hematopoietic diseases that do not meet the usual definition in which treatment “modifies, controls, removes, or destroys proliferating cancer tissue.” Treatments such as phlebotomy, transfusions, and aspirin are recorded in Other Treatment data item for certain hematopoietic diseases, and should be coded 1.

The National Cancer Institute provides a website that describes typical treatment modalities for a wide variety of cancer types. Additionally, as a component of its Clinical Practice Guidelines in Oncology project, the National Comprehensive Cancer Network (NCCN) posts NCCN Guidelines for Treatment of Cancer by Site.
INSTRUCTIONS FOR COMPLETING ALL MCSP REPORTABLE DATA ITEMS

In describing the proper reporting of cancer patient information, frequent reference is made to standard-setting organizations and source materials. Links to these references can be found at the back of this manual. Reference sources are abbreviated within the instructions as follows:

- SEER  Surveillance, Epidemiology and End Results
- CoC  Commission on Cancer within the American College of Surgeons
- ACoS  American College of Surgeons
- FORDS  Facility Oncology Registry Data Standards manual produced by the CoC
- NAACCR  North American Association of Central Cancer Registries
- AJCC  American Joint Committee on Cancer
- CS  Collaborative Stage Data Collection System Manual
- NPCR  National Program of Cancer Registries

Data field names used in the MCSP Cancer Program Manual match those used in the NAACCR Data Dictionary and are presented in alphabetic order. For those using paper reporting forms, refer to the MCSP 2016 Report Form Item column of the chart that begins on page 32 of this manual. The paper form field number that corresponds to the NAACCR item is shown in this column.

**Item:** ABSTRACTED BY  NAACCR Item 570

An alphanumeric code assigned by the reporting facility that identifies the individual abstracting the case. If the paper cancer report form is used, enter the name and phone number of the person who prepared the report form.

**Do not leave this data item blank.**

**Item:** ACCESSION NUMBER--HOSP  NAACCR Item 550

Alternate Name: Accession Number

The Accession Number is required only for hospitals with a registry, (i.e., approved by CoC with an approved cancer program) in which case, the number would be assigned as the patient is enrolled into the system.

The accession number is a unique nine-digit identifier that indicates when the patient was first seen at the reporting facility for the diagnosis and/or treatment of cancer. Registry software usually assigns this identifier automatically. The first four digits of the accession number specify the year in which the patient was first seen at the reporting institution for the diagnosis and/or treatment of cancer. The last five digits of the accession number is the numeric order in which the registrar entered the case into the registry.
The accession number is used by the facility to uniquely identify the patient; therefore the same accession number must be used for any subsequent primary tumors that patient develops in the future.

When a patient is deleted from the database, DO NOT reuse the accession number for another patient. A patient’s accession number is never reassigned.

Numeric gaps are allowed in accession numbers.

**Examples**

<table>
<thead>
<tr>
<th>Code</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>201600054</td>
<td>Patient enters the hospital in 2016, and is diagnosed with prostate cancer. The patient is the fifty-fourth patient accessioned in 2016.</td>
</tr>
<tr>
<td>201600092</td>
<td>Patient diagnosed in staff physician office in November 2015, now enters the reporting facility in February 2012, and is the ninety-second case accessioned in 2016.</td>
</tr>
<tr>
<td>201600235</td>
<td>A patient with the accession number 201600235 for a colon primary returns to the hospital with a subsequent prostate primary in 2017. The accession number will remain the same. The Sequence Number will identify this primary.</td>
</tr>
</tbody>
</table>

**Item: ADDR AT DX--CITY**  
*Alternate Name: City/Town at Diagnosis*

Enter the postal city, village or town in which the patient resides at the initial time of diagnosis.

Do not update this data item if the patient’s address changes.

If the patient has more than one primary tumor, the city at diagnosis may be different for each primary.

**Do not leave this data item blank.** If the city is unknown, enter “unknown.”

For details regarding approved formatting for all Address at Diagnosis and Current Address fields, refer to [NAACCR Chapter X: Data Dictionary](#).

**Item: ADDR AT DX--COUNTRY**  
*NAACCR Item 102*

Enter the country of the patient’s residence at the time of diagnosis.

If the country is the United States, enter USA.

If the patient has multiple tumors, the country at diagnosis may be different for each tumor.

If the country is NOT the United States and country is unknown, enter ZZU or Unknown.

ISO alpha-3 Country Codes can be found at the [back of this manual](#) or refer to Appendix B of the [SEER Program Code Manual](#).

**Item: ADDR AT DX--NO & STREET**  
*Alternate Name: Patient Address (Number and Street) at Diagnosis*

Enter the Number and Street address of the patient’s usual residence at the time the reportable tumor was diagnosed. DO NOT update this data item if the patient’s address changes – always maintain the address in which the patient resided at the time of diagnosis.
Geocoding turns address data into longitude and latitude coordinates to determine census tracks and population groups that are used in statistical analysis. Because this field is used for geocoding cancer cases, there are some exceptions to the federal Postal Addressing Standards. For example, additional address information such as apartment number, apartment complex, lot number, facility name, or nursing home should be excluded from this field and correctly entered as supplemental information in field ADDR AT DX--SUPPLEMENTL (NAACCR Item 2335).

If a rural route number or post office box is given, this can be recorded, but ONLY if the street and numbers are NOT available. If post office box is given in addition to full street address, enter the post office information in the ADDR AT DX--SUPPLEMENTL (NAACCR Item 2335).

The address should be fully spelled out with standardized use of abbreviations. Use CAPITAL LETTERS. Avoid all punctuation.

*Examples:*

- 35 South Main Street  
  *Should be entered as:*  
  35 S MAIN ST in the ADDR AT DX--NO & STREET field

- 4705 Butler Blvd. S.W., Apt. B  
  *Should be entered as:*  
  4705 BUTLER BLVD SW in the ADDR AT DX--NO & STREET field  
  APT B is entered in ADDR AT DX--SUPPLEMENTL field

If the patient has more than one primary tumor, the address at diagnosis may be different for each primary.

**Do not leave this data item blank.** If the address is unknown, enter “unknown.”

For details regarding approved formatting for all Address at Diagnosis and Current Address fields, refer to NAACCR Chapter X: Data Dictionary.

<table>
<thead>
<tr>
<th>Item: ADDR AT DX--POSTAL CODE</th>
<th>Alternate Name: Zip Code, Postal Code at Diagnosis</th>
<th>NAACCR Item 100</th>
</tr>
</thead>
</table>

Type the patient’s extended (nine digit) Postal Code at the time of diagnosis and treatment. (If the extended zip code is not available, enter the five-digit zip code. For Canadian residents, record the six-character postal code.)

When available, record the postal code for other countries.

If “Not US and Not Canada,” and if the postal code is unknown, enter “888888888.”

If “US/Canada” but the postal code is unknown; OR if the residence is unknown, enter “999999999.”

Do not update this data item if the patient’s postal code changes.

If the patient has multiple tumors, the postal code may be different for subsequent primaries.

**Do not leave this data item blank.**

For details regarding approved formatting for all Address at Diagnosis and Current Address fields, refer to *NAACCR Chapter X: Data Dictionary*. 
Item: ADDR AT DX--STATE

Alternate Name: State at Diagnosis

Enter the U.S. Postal abbreviation for the state, territory, commonwealth, U.S. possession, or Canadian province or territory in which the patient resides at the time the reportable tumor was diagnosed.

If the patient has multiple tumors, the state of residence may be different for each tumor.

Codes other than United States:

- CD  Resident of Canada, NOS (province/territory unknown)
- US  Resident of United States, NOS (state/commonwealth/territory/possession unknown)
- XX  Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is known.
- YY  Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is unknown
- ZZ  Residence unknown

NOTE: Reports are required for both Michigan residents and nonresidents. Do not leave this data item blank. If the information is unknown or unreported in the patient’s record, enter “ZZ” or “Unknown.”

A complete list of state, territory, commonwealth, U.S. possession, or Canadian province or territory codes can be found at the back of this manual, or refer to Appendix B of the SEER Program Code Manual.

Item: ADDR AT DX--SUPPLEMENTL

Alternate Name: Patient Address (Number and Street) at Diagnosis--Supplemental

This data item may be left blank if not applicable or unknown.

Type the apartment number, place or facility (e.g., a nursing home or name of an apartment complex) of the patient’s usual residence at the time the reportable tumor was diagnosed.

Examples:

35 South Main Street
PO Box 593
Should be entered as:
35 S MAIN ST in the ADDR AT DX--NO & STREET field
PO BOX 593 is entered in ADDR AT DX--SUPPLEMENTL field)

4705 Butler Blvd. S.W., Apt. B
Should be entered as:
4705 BUTLER BLVD SW in the ADDR AT DX--NO & STREET field
APT B is entered in ADDR AT DX--SUPPLEMENTL field

Do not update this data item if the patient’s address changes.
If the patient has more than one primary tumor, this supplemental address information may be different for each primary.

For details regarding approved formatting for all Address at Diagnosis and Current Address fields, refer to NAACCR Chapter X: Data Dictionary.

**Item: ADDR CURRENT--CITY**

*Alternate Name: City/Town--Current*

This data item provides a current city used for follow-up purposes. It may or may not be different than the patient’s address at the initial time of diagnosis. If the patient has multiple tumors, the current city must be the same for ALL tumors.

Enter the postal city, village or town in which the patient currently resides.

**Do not leave this data item blank.** If the city is unknown, enter “unknown.”

For details regarding approved formatting for all Address at Diagnosis and Current Address fields, refer to NAACCR Chapter X: Data Dictionary.

**Item: ADDR CURRENT--COUNTRY**

*Alternate Name: Patient Address (Number and Street)-Current*

This data item provides a current country used for follow-up purposes. It may or may not be different than the patient’s address at the initial time of diagnosis. If the patient has multiple tumors, the current country must be the same for ALL tumors.

Enter the country of the patient’s current residence.

If the country is the United States, enter USA.

If the country is NOT the United States and country is unknown, enter ZZU or Unknown.

ISO alpha-3 Country Codes can be found at the back of this manual or refer to Appendix B of the SEER Program Code Manual.

**Item: ADDR CURRENT--NO & STREET**

This data item provides a current address used for follow-up purposes. It may or may not be different than the patient’s address at the initial time of diagnosis. If the patient has multiple tumors, the current address must be the same for ALL tumors.

Additional address information such as apartment number, apartment complex, lot number, facility name, or nursing home should be excluded from this field and correctly entered as supplemental information in field ADDR AT DX--SUPPLEMENTL (NAACCR Item 2355).

If a rural route number or post office box is given, this can be recorded, but ONLY if the street and numbers are NOT available. If post office box is given in addition to full street address, enter the post office information in the ADDR CURRENT -- SUPPLEMENTL (NAACCR Item 2355).
The address should be fully spelled out with standardized use of abbreviations. Use CAPITAL LETTERS. Avoid all punctuation.

**Examples:**

- 35 South Main Street
  - Should be entered as
  - 35 S MAIN ST

- 4705 Butler Blvd. S.W., Apt. B
  - Should be entered as
  - 4705 BUTLER BLVD SW
  - (APT B is to be entered in ADDR CURRENT--SUPPLEMENTL field)

If the patient has more than one primary tumor, the address at diagnosis may be different for each primary.

**Do not leave this data item blank.** If the address is unknown, enter “unknown.”

For details regarding approved formatting for all Address at Diagnosis and Current Address fields, refer to NAACCR Chapter X: Data Dictionary.

**Item:** ADDR CURRENT--POSTAL CODE  NAACCR Item 1830
**Alternate Name:** Postal Code--Current

This data item provides a current postal code used for follow-up purposes. It may or may not be different than the patient’s postal code at the initial time of diagnosis. If the patient has multiple tumors, the current postal code must be the same for ALL tumors.

Type the patient’s current extended (nine digit) Postal Code. (If the extended zip code is not available, enter the five-digit zip code. For Canadian residents, record the six-character postal code.)

When available, record the postal code for other countries.

If “Not US and Not Canada,” and if the postal code is unknown, enter “888888888.”

If “US/Canada” but the postal code is unknown; OR if the residence is unknown, enter “999999999.”

**Do not leave this data item blank.**

For details regarding approved formatting for all Address at Diagnosis and Current Address fields, refer to NAACCR Chapter X: Data Dictionary.

**Item:** ADDR CURRENT--STATE  NAACCR Item 1820
**Alternate Name:** State--Current

This data item provides a current state or province used for follow-up purposes. It may or may not be different than the patient’s state/province at the initial time of diagnosis. If the patient has multiple tumors, the current state/province must be the same for ALL tumors.

Enter the U.S. Postal abbreviation for the state, territory, commonwealth, U.S. possession, or Canadian province or territory in which the patient currently resides.

Codes other than United States:
CD  Resident of Canada, NOS (province/territory unknown)

US  Resident of United States, NOS (state/commonwealth/territory/possession unknown)

XX  Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is known.

YY  Resident of country other than the United States (including its territories, commonwealths, or possessions) or Canada, and country is unknown

ZZ  Residence unknown

**Do not leave this data item blank.** If the information is unknown or unreported in the patient’s record, enter “ZZ” or “Unknown.”

A complete list of state, territory, commonwealth, U.S. possession, or Canadian province or territory codes can be found at the back of this manual, or refer to Appendix B of the SEER Program Code Manual.

<table>
<thead>
<tr>
<th>Item: ADDR CURRENT--SUPPLEMENTL</th>
<th>NAACCR Item 2355</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternate Name: Patient Address (Number and Street) Current--Supplemental</td>
<td></td>
</tr>
</tbody>
</table>

**⇒ This data item may be left blank if not applicable or unknown.**

This data item provides supplemental address information used for follow-up purposes. It may or may not be different than that at the initial time of diagnosis. If the patient has multiple tumors, the supplemental address information must be the same for ALL tumors.

Type the place or facility (e.g., a nursing home or name of an apartment complex) of the patient’s current residence.

For details regarding approved formatting for all Address at Diagnosis and Current Address fields, refer to NAACCR Chapter X: Data Dictionary.

<table>
<thead>
<tr>
<th>Item: ALCOHOL USE</th>
<th>State-Specific Item 254</th>
</tr>
</thead>
</table>

Records whether or not the patient has a history of alcohol use.

This is a Michigan-specific data item. Abstracts submitted with incorrect format or missing values will be rejected by MCSP.

**Paper form submission:**

**Paper Form Item 17:** Mark appropriate value: current use, prior use, never used or unknown.

**Do not leave this data item blank.** If unknown, enter “9” or “Unknown.”

Supporting text documentation for selected data value must be entered in **Paper Form Field 95: TEXT - PHYSICAL EXAM** even when value is “9” or “Unknown.”

**Electronic submission:**
This is a Michigan-specific data item. Starting with data submitted in NAACCR version 13, facilities that submit electronic abstract data to MCSP must coordinate with their software vendors to ensure that data value is recorded in NAACCR record layout, column number 2448. Abstracts submitted with incorrect format or missing values will be rejected by MCSP.

Do not leave this data item blank. If unknown, enter “9.”

Alcohol History Data Values

<table>
<thead>
<tr>
<th>Code</th>
<th>Current</th>
<th>Prior</th>
<th>Never</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td>Blank</td>
<td>Blank</td>
</tr>
<tr>
<td>2</td>
<td>Blank</td>
<td>Yes</td>
<td>Blank</td>
</tr>
<tr>
<td>3</td>
<td>Blank</td>
<td>Blank</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>Blank (Unknown)</td>
<td>Blank (Unknown)</td>
<td>Blank (Unknown)</td>
</tr>
</tbody>
</table>

Item: BEHAVIOR CODE ICD-O-3
Alternate Name: Behavior Code

You MUST obtain and use these required reference and coding resources:

- [Multiple Primary and Histology Coding Rules Manual](#)
- [International Classification of Diseases for Oncology, Third Edition (ICD-O-3)](#) coding book. This book can be purchased through any book store or ordered from online sources. Electronic CSV database files or print copies of the classifications are available from the World Health Organization.
- [Hematopoietic and Lymphoid Neoplasm Database and the Hematopoietic and Lymphoid Neoplasm Coding Manual](#) to assist with coding these primaries. These references apply only to cases diagnosed January 1, 2010 and forward.

The Hematopoietic and Lymphoid Neoplasm Database and the Hematopoietic and Lymphoid Neoplasm Coding Manual apply to only those non-solid tumor cases diagnosed January 1, 2010 and forward. The ICD-O-3 coding book is obsolete for coding non-solid tumors after this date. You must use the [Hematopoietic and Lymphoid Neoplasm Database and Coding Manual](#) to assign the histology code.

Record the behavior of the tumor being reported. The fifth digit of the morphology code is the behavior code. The behavior code is used by pathologists to describe whether tissue samples are benign (0), borderline (1), in situ (2), or invasive (3).

Code 3 if any invasion is present, no matter how limited. If the specimen is from a metastatic site, code the histology of the metastatic site and code 3 for behavior code for the behavior of the tumor being reported.

EXCEPTION 1: Juvenile astrocytoma, listed as 9421/1 in ICD-O-3, is REQUIRED and should be recorded as 9421/3 in the registry.

Nonmalignant primary intracranial and central nervous system tumors diagnosed on or after January 1, 2004, with an ICD-O-3 behavior code of 0 or 1 are required for the following sites: meninges (C70._), brain (C71._), spinal cord, cranial nerves, and other parts of central nervous system (C72._), pituitary gland (C75.1), craniopharyngeal duct (C75.2) and pineal gland (C75.3).
<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Benign</td>
<td>• Benign</td>
</tr>
<tr>
<td>1</td>
<td>Borderline</td>
<td>• Uncertain whether benign or malignant</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Borderline malignancy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Low malignant potential</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Uncertain malignant potential</td>
</tr>
<tr>
<td>2</td>
<td>In situ and/or carcinoma in situ</td>
<td>• Adenocarcinoma in an adenomatous polyp with no invasion of stalk</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clark level 1 for melanoma (limited to epithelium)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Comedocarcinoma, non-infiltrating (C50._)</td>
</tr>
<tr>
<td></td>
<td>Synonymous with in situ</td>
<td>• Confined to epithelium</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Hutchinson melanotic freckle, NOS (C44._)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Intracystic, non-infiltrating</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Intraductal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Intraepidermal, NOS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Intraepithelial, NOS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Involvement up to, but not including the basement membrane</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lentigo maligna (C44._)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lobular neoplasia (C50._)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Lobular, non-infiltrating (C50._)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Non-infiltrating</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• No stromal involvement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Papillary, non-infiltrating or intraductal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Precancerous melanosis (C44._)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Queyrat erythroplasia (C60._)</td>
</tr>
<tr>
<td>3</td>
<td>Invasive</td>
<td>• Invasive or micro-invasive</td>
</tr>
</tbody>
</table>

Do not leave this item blank.

**Item: BIRTHPLACE--COUNTRY**

NAACCR Item 254

Enter the name or code for the country of the patient’s birth. If the country is the United States, enter USA.

If the patient has multiple primaries, the country of birth is the same for each tumor.

**Do not leave this data item blank.** If unknown or unreported in the patient’s record, enter “ZZU” or “Unknown.”

ISO alpha-3 Country Codes can be found at the [back of this manual](#) or refer to Appendix B of the SEER Program Code Manual.

**Item: BIRTHPLACE--STATE**

NAACCR Item 252

Enter the USPS abbreviation for the state, commonwealth, U.S. possession; or CanadaPost abbreviation for the Canadian province/territory in which the patient was born. For example, if the state in which the patient was born is Michigan, use “MI.”

If the patient has multiple primaries, the state of birth is the same for each tumor.

**Do not leave this data item blank.** If the information is unknown or unreported in the patient’s record, enter “ZZ” or “Unknown.”
A complete list of state, territory, commonwealth, U.S. possession, or Canadian province or territory codes can be found at the back of this manual, or refer to Appendix B of the SEER Program Code Manual.

Item: CASEFINDING SOURCE NAACCR Items 501

This item records where the case was first identified and what mechanism was used to identify the case for review. It applies to cases diagnosed in 2006 or later only.

Each case may have a different casefinding source.

If a death certificate, independent pathology laboratory report, consultation-only report from a hospital, or other report was used to identify a case that was then abstracted from a different source, enter the code for the source that first identified that case, not the source from which it was subsequently abstracted.

Codes are as follows:

10 Reporting Hospital, NOS
20 Pathology Department Review (surgical pathology reports, autopsies, or cytology reports)
21 Daily Discharge Review (screen charts of discharged patients in medical records)
22 Disease Index Review (review of disease index in the medical records department)
23 Radiation Therapy Department/Center
24 Laboratory Reports (other than pathology report code 20)
25 Outpatient Chemotherapy
26 Diagnostic Imaging/Radiology (other than radiation therapy code 23; includes nuclear medicine)
27 Tumor Board
28 Hospital Rehabilitation Service or Clinic
29 Other Hospital Source (including clinic, NOS or outpatient department, NOS)

Case first identified by source other than a reporting facility covered in the codes above:

30 Physician-Initiated Case
40 Consultation-only or Pathology-only Report (not abstracted by reporting hospital)
50 Independent (non-hospital) Pathology-Laboratory Report
60 Nursing Home-Initiated Case
70 Coroner’s Office Records Review
75 Managed Care Organization (MCO) or Insurance Records
80 Death Certificate (case identified through death clearance)
85 Out-of-State Case Sharing
90 Other Non-Reporting Hospital Source
95 Quality Control Review (case initially identified through quality control activities such as casefinding audit of a regional/central registry)
99 Unknown

Do not leave this item blank if case was diagnosed in 2006 or later. Leave field blank if the case was diagnosed prior to 2006.

Item: CAUSE OF DEATH NAACCR Items 1910

Alternate Name: Underlying Cause of Death

Official cause of death as coded from the death certificate in valid ICD-7, ICD-8, ICD-9, and ICD-10 codes.

Special codes in addition to ICD-7, ICD-8, ICD-9, and ICD-10 (refer to SEER Program Code Manual for additional instructions.)
0000 - Patient alive at last contact
7777 - State death certificate not available
7797 - State death certificate available but underlying cause of death is not coded

Do not leave this item blank; if unknown, enter 0000 “alive.”

<table>
<thead>
<tr>
<th>Item: CLASS OF CASE</th>
<th>NAACCR Items 610</th>
</tr>
</thead>
</table>

**NOTE: Class of Case is a REQUIRED data item regardless of facility type.**

Class of Case divides cases into two groups. Analytic cases (codes 00-22) are those that are required by CoC to be abstracted because of the program’s primary responsibility in managing the cancer. Analytic cases are grouped according to the location of diagnosis and treatment. Treatment and outcome reports may be limited to analytic cases. Nonanalytic cases (codes 30-49 and 99) may be abstracted by the facility to meet State central registry requirements or because of a request by the facility’s cancer program. Nonanalytic cases are grouped according to the reason a patient who received care at the facility is nonanalytic, or the reason a patient who never received care at the facility may have been abstracted. Refer to Facility Oncology Registry Data Standards (FORDS) for additional instructions.

Michigan considers the reporting of non-analytical cases to be an example of active casefinding. Non-analytic cases (codes 30-49) should be reported to MCSP by labs and physician offices, or in “path only” hospital cases.

**Initial diagnosis at reporting facility**

- 00 Initial diagnosis at the reporting facility AND all treatment or a decision not to treat was done elsewhere
- 10 Initial diagnosis at the reporting facility or in a staff physician’s office AND part or all of first course treatment or a decision not to treat was at the reporting facility, NOS
- 11 Initial diagnosis in staff physician’s office AND part of first course treatment was done at the reporting facility
- 12 Initial diagnosis in staff physician’s office AND all first course treatment or a decision not to treat was done at the reporting facility
- 13 Initial diagnosis at the reporting facility AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere.
- 14 Initial diagnosis at the reporting facility AND all first course treatment or a decision not to treat was done at the reporting facility

**Initial diagnosis elsewhere**

- 20 Initial diagnosis elsewhere AND all or part of first course treatment was done at the reporting facility, NOS
- 21 Initial diagnosis elsewhere AND part of first course treatment was done at the reporting facility; part of first course treatment was done elsewhere.
- 22 Initial diagnosis elsewhere AND all first course treatment or a decision not to treat was done at the reporting facility

**Patient appears in person at reporting facility**
30 Initial diagnosis and all first course treatment elsewhere AND reporting facility participated in diagnostic workup (for example, consult only, treatment plan only, staging workup after initial diagnosis elsewhere)

31 Initial diagnosis and all first course treatment elsewhere AND reporting facility provided in-transit care; or hospital provided care that facilitated treatment elsewhere (for example, stent placement)

32 Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease recurrence or persistence (active disease)

33 Diagnosis AND all first course treatment provided elsewhere AND patient presents at reporting facility with disease history only (disease not active)

34 Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis AND part or all of first course treatment by reporting facility

35 Case diagnosed before program’s Reference Date AND initial diagnosis AND all or part of first course treatment by reporting facility

36 Type of case not required by CoC to be accessioned (for example, a benign colon tumor) AND initial diagnosis elsewhere AND all or part of first course treatment by reporting facility

37 Case diagnosed before program’s Reference Date AND initial diagnosis elsewhere AND all or part of first course treatment by facility

38 Initial diagnosis established by autopsy at the reporting facility, cancer not suspected prior to death

**Patient does not appear in person at reporting facility**

40 Diagnosis AND all first course treatment given at the same staff physician’s office

41 Diagnosis and all first course treatment given in two or more different staff physician offices

42 Non-staff physician or non-CoC accredited clinic or other facility, not part of reporting facility, accessioned by reporting facility for diagnosis and/or treatment by that entity (for example, hospital abstracts cases from an independent radiation facility)

43 Pathology or other lab specimens only

49 Death certificate only

99 Nonanalytic case of unknown relationship to facility (not for use by CoC accredited cancer programs for analytic cases).

Do not leave this item blank.

**Item:** COMORBID/COMPLICATION (1-10)  NAACCR Items 3110-3164

**Alternate Name:** Comorbidities and Complications (#1-#10)

 ➔ For cases using ICD-9-CM codes only. ICD-9-CM coding allowed prior to 10/1/2015 only.

Records the patient’s preexisting medical conditions, factors influencing health status, and/or complications during the patient’s hospital stay for the treatment of this cancer using ICD-9-CM values. All are considered
secondary diagnoses. Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcomes statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Co-morbidities are pre-existing medical conditions, factors influencing health status, and/or complications during the patient’s hospital stay for the treatment of this cancer using ICD-9-CM or ICD-10-CM codes. All are considered secondary diagnoses or conditions that were present at the time the patient was diagnosed with this cancer (e.g. chronic conditions such as COPD, diabetes, and hypertension). Depending on whether the hospital has implemented use of ICD-10-CM, this information may be identified either in ICD-9-CM or ICD-10-CM form.

Use this item to record ICD-9-CM codes. Use SECONDARY DIAGNOSIS (1-10) (NAACCR Items 3780-3798) to record ICD-10-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.

**NOTE: DO NOT record ICD-10-CM codes in the COMORBID/COMPLICATION (1-10) fields.**

Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available. Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.

Five digits must be entered in order for the code to pass edits. Example: 401.9 must be entered as 40190. Omit the decimal point when coding. If no secondary diagnoses are documented, or if this information is unknown or unavailable, leave this data item blank.

Report the secondary diagnoses for this cancer using the following priority rules.

Surgically treated patients:
   a) Following the most definitive surgery of the primary site
   b) Following other non-primary site surgeries

Non-surgically treated patients:
   Following the first treatment encounter/episode

In cases of non-treatment:
   Following the last diagnostic/evaluative encounter

The following codes are reportable ICD-9-CM comorbidities/complications:

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition and instructions</th>
</tr>
</thead>
<tbody>
<tr>
<td>00000</td>
<td>No comorbid conditions or complications documented</td>
</tr>
<tr>
<td>00100-13980, 24000-99990</td>
<td>Comorbid conditions: Omit the decimal point between the third and fourth characters.</td>
</tr>
<tr>
<td>E8700-E8799, E9300-E9499</td>
<td>Complications: Omit the decimal point between the fourth and fifth characters.</td>
</tr>
<tr>
<td>V0720-V0739, V1000-V1590, V2220-V2310, V2540, V4400-V4589, V5041-V5049</td>
<td>Factors affecting health status: Omit the decimal point between the fourth and fifth characters.</td>
</tr>
</tbody>
</table>

Do NOT review the medical record and assign codes to these conditions – only record the above conditions if they have been identified by the medical records coder and appear on the face sheet.
For more information, refer to Facility Oncology Registry Data Standards (FORDS).

**Do not leave this data item blank.** If no comorbid conditions or complications documented, enter “00000.”

**Item:** COUNTY AT DX  
Alternate Name: County, County at Diagnosis

Enter the county FIPS code of the county of the patient’s residence at the time of diagnosis.

If the county is unknown or unobtainable, or if Out-of-State county or non-US resident, enter 999 (or “unknown” if submitting paper reporting form.)

**Do not leave this data item blank.**

For a complete listing of Michigan county names and FIPS codes, see the FIPS County Codes for Michigan Counties table at the back of this manual.

**Item:** COUNTY--CURRENT

This data item provides a current county used for follow-up purposes. It may or may not be different than the patient’s county at the initial time of diagnosis. If the patient has multiple tumors, the current county must be the same for ALL tumors.

Enter the FIPS code of the county of the patient’s current residence.

If the county is unknown or unobtainable, or if Out-of-State county or non-US resident, enter 999 (or “unknown” if submitting paper reporting form.)

**Do not leave this data item blank.**

For a complete listing of Michigan county names and FIPS codes, see the FIPS County Codes for Michigan Counties table at the back of this manual.

**Item:** CS EXTENSION

➤ *This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.*

For information on this data item, refer to CS Collaborative Stage Data Collection System

**Item:** CS LYMPH NODES

➤ *This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.*

For information on this data item, refer to CS Collaborative Stage Data Collection System

**Item:** CS LYMPH NODES EVAL

➤ *This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.*

For information on this data item, refer to CS Collaborative Stage Data Collection System
Item: CS METS AT DIAGNOSIS  

→ This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.

For information on this data item, refer to CS Collaborative Stage Data Collection System

Item: CS METS AT DX - BONE  

→ This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.

For information on this data item, refer to CS Collaborative Stage Data Collection System

Item: CS METS AT DX - BRAIN  

→ This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.

For information on this data item, refer to CS Collaborative Stage Data Collection System

Item: CS METS AT DX - LIVER  

→ This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.

For information on this data item, refer to CS Collaborative Stage Data Collection System

Item: CS METS AT DX - LUNG  

→ This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.

For information on this data item, refer to CS Collaborative Stage Data Collection System

Item: CS METS EVAL  

→ This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.

For information on this data item, refer to CS Collaborative Stage Data Collection System

Item: CS SITE-SPECIFIC FACTORS (1-25)  

→ This data item applies to cases diagnosed 1/1/2004 and later.

These schema-specific factors identify additional information needed to generate stage (for cases diagnosed 2004 - 2015), or prognostic factors that have an effect on stage or survival.

All facilities must report values for site-specific factor fields as documented in the medical record for cases diagnosed in 2004 and later. If applicable value is not found within the medical record, then facilities are to report the appropriate default value for the field. Not all site-specific factors are required for all schemas. Refer to site/histology-specific instructions in the applicable Collaborative Stage Data Collection System Manual for schema-specific information.

For additional staging information, see Cancer Staging section in this manual.
Do not leave these data items blank for cases diagnosed in 2004 or later. If unknown or NA, enter default values.

Item: CS TUMOR SIZE
NAACCR Item 2800

⇒ This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.

For information on this data item, refer to CS Collaborative Stage Data Collection System

Item: CS TUMOR SIZE/EXT EVAL
NAACCR Item 2820

⇒ This data item applies to cases diagnosed 1/1/2004 through 12/31/2015 only.

For information on this data item, refer to CS Collaborative Stage Data Collection System

Item: DATE 1ST CRS RX COC
NAACCR Item 1270
Alternate Name: Date of First Course Treatment

Enter the year, month and day (YYYY/MM/DD) for the date of first course of treatment. Consider ALL therapies that have been administered. This includes any surgery, radiation therapy, chemotherapy, hormone therapy or immunotherapy (biological response modifier therapy) that has been described as a recommended part of the treatment plan. The date of first treatment includes the date a decision was made not to treat the patient.

Record the FIRST date that the patient received treatment.

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

Item: DATE 1ST CRS RX COC FLAG
NAACCR Item 1271
Alternate Name: Date of 1st Crs Rx Flag

This flag explains why there is no appropriate value in the corresponding date field, DATE 1ST CRS RX COC.

Codes are as follows:
10 No information whatsoever can be inferred from this exceptional value; unknown if treatment was given
11 No proper value is applicable in this content (for example, autopsy only)
12 A proper value is applicable but not known. This event occurred, but the date is unknown (for example, treatment was given, but date is unknown.)
BLANK - Valid date provided for item DATE 1ST CRS RX COC

An allowable value must be in this Flag field or its corresponding Date field. Both fields cannot be blank.

Item: DATE CASE COMPLETED
NAACCR Item 2090

Enter the year, month, and day (YYYY/MM/DD) the abstract or cancer report form was completed.

Item: DATE OF 1ST CONTACT
NAACCR Item 580
Alternate Name: Date of Adm/First Contact

Enter the year, month and day (YYYY/MM/DD) for the first date of contact.
Date of first contact with the reporting facility for diagnosis and/or treatment of this cancer. Record the date the patient first had contact with the facility as either an inpatient or outpatient for diagnosis and/or first course treatment of a reportable tumor. The date may be the date of an outpatient visit for a biopsy, x-ray, or laboratory test, or the date a pathology specimen was collected at the hospital.

If this is an autopsy-only or death certificate-only case, then use the date of death.

When a patient is diagnosed in a staff physician’s office, the date of first contact is the date the patient is physically first seen at the reporting facility.

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

**Item: DATE OF 1ST CONTACT FLAG**  
**NAACCR Item 581**  
**Alternate Name: Date of First Contact Flag**

This flag explains why there is no appropriate value in the corresponding date field.

12 A proper value is applicable but not known (e.g., date of 1st contact is unknown)

Blank - A valid date value is provided in item DATE OF 1ST CONTACT

An allowable value must be in this Flag field or its corresponding Date field. Both fields cannot be blank.

**Item: DATE OF BIRTH**  
**NAACCR Item 240**  
**Alternate Name: Birth Date**

Enter the date of birth of the patient using YYYY/MM/DD (for example 1958/09/12) as the format.

If age at diagnosis and year of diagnosis are known, but year of birth is unknown, then year of birth should be calculated and so coded.

For in utero diagnosis and treatment, record the actual date of birth. It will follow one or both dates for these events.

Estimate date of birth when information is not available. It is better to estimate than to leave birthdate unknown.

**Do not leave this data item blank.**

**Item: DATE OF DEATH**  
**NAACCR Item 1750**

Required on paper reporting form only. See instructions for DATE OF LAST CONTACT

**Item: DATE OF DIAGNOSIS**  
**NAACCR Item 390**  
**Alternate Name: Date of Initial Diagnosis**

Enter the year, month and day (YYYY/MM/DD) for the date of diagnosis.

Date of initial diagnosis by a recognized medical practitioner for the tumor being reported whether clinically or microscopically confirmed.
If the diagnosis was determined by pathological examination, *use the date the specimen was collected* (date of biopsy or surgery), *not the date the specimen was read* by the pathologist or the date the report was dictated, transcribed or printed.

If the physician states that in retrospect the patient had cancer at an earlier date, then use the earlier date as the date of diagnosis.

Though the original diagnosis may be a clinical diagnosis that is later confirmed through pathological examination or other procedures, the clinical diagnosis date should be reported.

*Example*  

Ambiguous terminology must be taken into consideration when determining the initial date of diagnosis.  

**Refer to the Ambiguous Terminology section for a list of specific terms and further instructions.**

If the year is unknown, estimate the diagnosis year based upon documentation in the medical record and how long the patient has had the diagnosis.

If an approximation is not possible, use the date first confirmed, first treated, or in the case of death, the date of death, whichever is earliest.

If a patient is diagnosed elsewhere before entering the reporting facility and the date of diagnosis is unknown, record the date the patient was first seen at the reporting hospital.

Use the date therapy was started as the date of diagnosis if the patient receives cancer directed treatment before a definitive diagnosis.

The date of death is the date of diagnosis for cases diagnosed at autopsy.

If information is limited to a description, use the following guidelines.

- Spring of 2016 code date of diagnosis as April 15, 2016
- Middle of 2016 code date of diagnosis as July 15, 2016
- Fall of 2016 code date of diagnosis as October 15, 2016
- Winter of 2016 code date of diagnosis as December 15, 2016 or January 15, 2017 (further investigation may need to be done to determine the year of diagnosis.)

**Do not leave this data item blank.** As of 2010, month and day may be left blank if unknown.

<table>
<thead>
<tr>
<th>Item: DATE OF INPT ADM</th>
<th>NAACCR Item 590</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alternate Name:</strong> Date of Inpatient Admission</td>
<td></td>
</tr>
</tbody>
</table>

⇒ This data item may be left blank if not applicable or unknown.

This item is not required for any facility type, but may be reported if available to the facility. If unknown, the appropriate value must be entered for item DATE OF INPT ADM FLAG (NAACCR Item 591).
Enter the year, month and day (YYYY/MM/DD) of the inpatient admission.

Date of the inpatient admission to the reporting facility for the most definitive surgery. In the absence of surgery, use date of inpatient admission for any other therapy. In the absence of therapy, use date of inpatient admission for diagnostic evaluation.

**Item:** DATE OF INPT ADM FLAG

**NAACCR Item 591**

This flag explains why there is no appropriate value in the corresponding date field.

*⇒ This data item may be left blank if not applicable or unknown.*

**Codes are as follows:**

10  No information whatsoever can be inferred from this exceptional value (e.g., unknown if patient was an inpatient.)

11  No proper value is applicable in this context (e.g., patient was never an inpatient at the reporting facility.)

12  A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., the patient was an inpatient but the date is unknown.)

BLANK - Valid date provided for item DATE OF INPT ADM

**Item:** DATE OF INPT DISCH

**NAACCR Item 600**

Alternate Name: Date of Inpatient Discharge

*⇒ This data item may be left blank if not applicable or unknown.*

This item is not required for any facility type, but may be reported if available to the facility. If unknown, the appropriate value must be entered for item DATE OF INPT DISCH FLAG (NAACCR Item 601).

Enter the year, month and day (YYYY/MM/DD) of the inpatient discharge.

Date of the inpatient discharge from the reporting facility after the most definitive surgery. In the absence of surgery, use date of inpatient discharge for other therapy. In the absence of therapy, use date of inpatient discharge for diagnostic evaluation. This discharge date corresponds to the admission date described by Date of Inpatient Admission.

**Item:** DATE OF INPT DISCH FLAG

**NAACCR Item 601**

This flag explains why there is no appropriate value in the corresponding date field.

*⇒ This data item may be left blank if not applicable or unknown.*

**Codes are as follows:**

10  No information whatsoever can be inferred from this exceptional value (e.g., unknown if patient was an inpatient.)

11  No proper value is applicable in this context (e.g., patient was never an inpatient at the reporting facility.)
12 A proper value is applicable but not known. This event occurred, but the date is unknown (e.g., the patient was an inpatient but the date is unknown.)

BLANK - Valid date provided for item DATE OF INPT DISCH

**Item:** DATE OF LAST CONTACT  
**Alternate Name:** Date of Last Contact or Death

Enter the year, month and day (YYYY/MM/DD) for the last date of contact.

Records the date of last contact with the patient or the date of death.

Record the last date on which the patient was known to be alive or the date of death.

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

**Item:** DATE OF LAST CONTACT FLAG

This flag explains why there is no appropriate value in the corresponding date field.

Codes are as follows:

12 A proper value is applicable but not known. This event occurred, but the date is unknown (that is, the date of last contact is unknown.)

BLANK - Valid date provided for item DATE OF INPT DISCH item field.

An allowable value must be in this Flag field or its corresponding Date field. Both fields cannot be blank.

**Item:** DIAGNOSTIC CONFIRMATION

*Note: There are separate coding schemes for solid tumors and for non-solid tumors/hematopoietic and lymphoid neoplasms M9590-9992.*

**Instructions for Coding Solid Tumors (all tumors except M9590-9992)**

- The codes are in priority order; code 1 has the highest priority. Always code the procedure with the lower numeric value when presence of cancer is confirmed with multiple diagnostic methods. This data item must be changed to the lower (higher priority) code if a more definitive method confirms the diagnosis at any time during the course of the disease.

- Assign code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, autopsy or D&C or from aspiration of biopsy of bone marrow specimens.

- Assign code 2 when the microscopic diagnosis is based on cytologic examination of cells such as sputum smears, bronchial brushings, bronchial washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. CoC does not require programs to abstract cases that contain ambiguous terminology regarding a cytologic diagnosis.

- Assign code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer.
• Assign code 6 when the diagnosis is based only on the surgeon’s operative report from a surgical exploration or endoscopy or from gross autopsy findings in the absence of tissue or cytological findings.

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Positive histology</td>
<td>Assign code 1 when the microscopic diagnosis is based on histologic confirmation, i.e., tissue that has been microscopically examined. Assign code 1 when the microscopic diagnosis is based on bone marrow specimens from aspiration or biopsy.</td>
</tr>
<tr>
<td>2</td>
<td>Positive cytology</td>
<td>Cytologic confirmation (no tissue microscopically examined; fluid cells microscopically examined.) Fine needle aspiration (FNA) is frequently used to obtain a cytologic specimen. Cells may be recovered from exudate, secretions, or washings from tissue.</td>
</tr>
<tr>
<td>4</td>
<td>Positive microscopic confirmation, method not specified</td>
<td>Microscopic confirmation is all that is known. It is unknown if the cells were examined by histology or cytology.</td>
</tr>
<tr>
<td>5</td>
<td>Positive laboratory test/marker study</td>
<td>A clinical diagnosis of cancer is based on certain laboratory tests or marker studies that are CLINICALLY DIAGNOSTIC for cancer. Examples include alpha-fetoprotein for liver cancer and an abnormal electrophoretic spike for multiple myeloma. An elevated PSA is NOT diagnostic of cancer. If the physician uses the PSA as a basis for diagnosing prostate cancer with no other work-up, record as a code 5.</td>
</tr>
<tr>
<td>6</td>
<td>Direct visualization without microscopic confirmation</td>
<td>The tumor was visualized during a surgical or endoscopic procedure only; NO tissue was resected for microscopic examination.</td>
</tr>
<tr>
<td>7</td>
<td>Radiography and other imaging techniques without microscopic confirmation</td>
<td>The malignancy was reported by the physician from an imaging technique report only. Example: ultrasound, computerized (axial) tomography (CT or CAT scans) and magnetic resonance imaging (MRI).</td>
</tr>
<tr>
<td>8</td>
<td>Clinical diagnosis only, other than 5, 6, or 7</td>
<td>Cases diagnosed by clinical methods not mentioned previously. e.g., mass in breast suspect a malignancy; no biopsies were taken. Refer to the list of “Ambiguous Terminology” for language that represents a diagnosis of cancer.</td>
</tr>
<tr>
<td>9</td>
<td>Unknown whether or not microscopically confirmed</td>
<td>A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed.</td>
</tr>
</tbody>
</table>

**Instructions for Coding Non-Solid Tumors/Hematopoietic and Lymphoid Neoplasms (M9590-9992)**

• There is no priority hierarchy for coding Diagnostic Confirmation for hematopoietic and lymphoid tumors. Most commonly, the specific histologic type is diagnosed by immunophenotyping or genetic testing. See the Hematopoietic Database (DB) for information on the definitive diagnostic confirmation for specific types of tumors.

• Assign code 1 when the microscopic diagnosis is based on tissue specimens from biopsy, frozen section, surgery, or autopsy or bone marrow specimens from aspiration or biopsy.
For leukemia only, code 1 when the diagnosis is based only on the complete blood count (CBC), white blood count (WBC) or peripheral blood smear. DO NOT use code 1 if the diagnosis was based on immunophenotyping or genetic testing using tissue, bone marrow, or blood.

Assign code 2 when the microscopic diagnosis is based on cytologic examination of cells (rather than tissue) including but not limited to spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid. These methods are rarely used for hematopoietic or lymphoid tumors.

Assign code 3 when there is a histology positive for cancer AND positive immunophenotyping and/or positive genetic testing results. DO NOT use code 3 for neoplasms diagnosed prior to January 1, 2010.

Assign code 5 when the diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for that specific cancer, but no positive histologic confirmation.

Assign code 6 when the diagnosis is based only on the surgeon’s report from a surgical exploration or endoscopy or from gross autopsy findings without tissue or cytological findings.

Assign code 8 when the case was diagnosed by any clinical method that cannot be coded as a 6 or 7. A number of hematopoietic and lymphoid neoplasms are diagnosed by tests of exclusion where the tests for the disease are equivocal and the physician makes a clinical diagnosis based on the information from the equivocal tests and the patient’s clinical presentation.

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Positive histology</td>
<td>Histologic confirmation; tissue microscopically examined.</td>
</tr>
<tr>
<td>2</td>
<td>Positive cytology</td>
<td>Cytologic confirmation (no tissue microscopically examined; fluid cells microscopically examined.)</td>
</tr>
<tr>
<td>3</td>
<td>Positive histology PLUS * Positive immunophenotyping AND/OR * positive genetic studies</td>
<td>Histology is positive for cancer, and there are also positive immunophenotyping and/or genetic test results. For example, bone marrow examination is positive for acute myeloid leukemia (9861/3). Genetic testing shows AML with inv (16)(p13.1q22) (9871/3.) NOTE: Do not use this code for neoplasms diagnosed prior to January 1, 2010.</td>
</tr>
<tr>
<td>4</td>
<td>Positive microscopic confirmation, method not specified</td>
<td>Microscopic confirmation is all that is known. It is unknown if the cells were examined by histology or cytology.</td>
</tr>
<tr>
<td>5</td>
<td>Positive laboratory test/marker study</td>
<td>A clinical diagnosis of cancer is based on laboratory tests or marker studies which are clinically diagnostic for cancer.</td>
</tr>
<tr>
<td>6</td>
<td>Direct visualization without microscopic confirmation</td>
<td>The tumor was visualized during a surgical or endoscopic procedure only; NO tissue was resected for microscopic examination.</td>
</tr>
<tr>
<td>7</td>
<td>Radiography and other imaging techniques without microscopic confirmation</td>
<td>The malignancy was reported by the physician from an imaging technique report only.</td>
</tr>
<tr>
<td>8</td>
<td>Clinical diagnosis only, other than 5, 6 or 7</td>
<td>The malignancy was reported by the physician in the medical record.</td>
</tr>
</tbody>
</table>
### Method of Diagnosis - Codes for Hematopoietic and Lymphoid Neoplasms

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Unknown whether or not microscopically confirmed</td>
<td>A statement of malignancy was reported in the medical record, but there is no statement of how the cancer was diagnosed.</td>
</tr>
</tbody>
</table>

Do not leave this data item blank.

**Item: FAMILY HISTORY OF CANCER**  
State-specific Item 9520

This item records whether or not the patient has a family history of cancer.

This is a Michigan-specific data item. Abstracts submitted with incorrect format or missing values will be rejected by MCSP.

Explanation of terminology:

“Immediate Family Member”: Mother, Father, Brother, Sister, Son, Daughter.

“Non-Immediate Family Member”: Aunt, Uncle, Niece, Nephew, Cousin, Half-brother, and Half-sister.

An immediate relative, or first degree family member, is any blood-relative who is one meiosis away from a particular individual in a family (i.e., parent, sibling, and offspring). A half-brother, half-sister, would be considered as a non-immediate family member, or second-degree family member.

There will be cases in which a cancer patient has both a first degree blood-relative and a second degree relative with a history of cancer. If the patient and a relative share a common primary site, record these fields in regard to the relative with same primary site, regardless of degree of relationship. If the patient and all relatives have tumors involving non-similar primary sites, record these fields in regard to the cancer history of the first degree blood-relative.

**Example 1**  
Patient is diagnosed with breast cancer. Father has history of colon cancer; maternal aunt has history of breast cancer.  
*Provided she is a blood-relative, refer to the aunt's cancer history since she shares the same primary site.*

**Example 2**  
Patient is diagnosed with breast cancer. Father has history of colon cancer; a maternal uncle has history of prostate cancer.  
*Refer to the father’s cancer history since he is the immediate (first degree) family member.*

Supporting text documentation for patient and family history of cancer must be recorded in TEXT--DX PROC--PE field even when value is “9” or “Unknown.”

**Example 1**  
Family Medical History negative [or FMH (-)] Personal Medical History negative [or PMH (-)]

**Example 2**  
FMH (-) PMH (+) STAGE 1 DUCTAL CA, RT BREAST 1999, TX’D WITH LUMPECTOMY

**Example 3**  
FMH UNK, PMH (-)
Paper form submission:

**Item 16a. Family History of Cancer**

Enter whether or not the patient has a family history of cancer.

**Item 16b. If yes, Immediate Family Member**

Enter whether or not the patient is an immediate family member.

**Item 16c. If yes, Same Anatomical Site**

Enter whether or not the individual has the same type of cancer as the patient. “Same Cancer” means the same organ site or, in the case of a sarcoma, leukemia and lymphomas, the same cancer type.

**Do not leave items 16a, 16b, or 16c blank.** If unknown, enter “9” or “Unknown.”

Supporting text documentation for selected data value must be entered in **Paper Form Field 95: TEXT - PHYSICAL EXAM** even when value is “9” or “Unknown.”

Electronic submission:

**This is a Michigan-specific data item.** Starting with data submitted in NAACCR version 13, facilities that submit electronic abstract data to MCSP must coordinate with their software vendors to ensure that data value is recorded in NAACCR record layout, column number 2449. After that date, abstracts submitted with incorrect format or missing values will be rejected by MCSP.

**Family History of Cancer Data Values**

<table>
<thead>
<tr>
<th>Code</th>
<th>Family History</th>
<th>Immediate Family Member</th>
<th>Same Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>1</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>Yes</td>
<td>Yes</td>
<td>Blank</td>
</tr>
<tr>
<td>6</td>
<td>Yes</td>
<td>Blank</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>Yes</td>
<td>Blank</td>
<td>No</td>
</tr>
<tr>
<td>8</td>
<td>Yes</td>
<td>Blank</td>
<td>Blank</td>
</tr>
<tr>
<td>A</td>
<td>Yes</td>
<td>No</td>
<td>Blank</td>
</tr>
<tr>
<td>9</td>
<td>Blank (Unknown)</td>
<td>Blank (Unknown)</td>
<td>Blank (Unknown)</td>
</tr>
</tbody>
</table>

**Do not leave this data item blank.** If unknown, enter “9.”

**Item: GRADE**

Alternate Name: Grade, Differentiation, or Cell Lineage Indicator

Refer to [SEER Instructions for Coding Grade for 2014+] (https://seer.cancer.gov/tools/grade/) for complete instructions to determine grade, differentiation or cell indicator.

The tumor grade applies to the primary site ONLY.
Do not leave this data item blank. If unknown, enter appropriate unknown, not stated, or not applicable code.

Code the grade or differentiation as stated in the final pathologic diagnosis. If grade is not stated in the final pathologic diagnosis, use the information from the microscopic description or comments.

Example Microscopic Description: Poorly differentiated, squamous cell carcinoma, invading the adventitia. Final Description: Squamous cell carcinoma, invading the adventitia. Code the tumor grade as: 3 - poorly differentiated

The grade of a tumor represents the pathological description of the degree to which the tumor tissue resembles normal tissue for that primary site. This is expressed in degrees of differentiation.

Grade/Differentiation for solid tumors (codes 1, 2, 3, 4, 9) and Cell Indicator for Lymphoid Neoplasms (Codes 5, 6, 7, 8, 9).

Hematopoietic and Lymphoid Neoplasms Cell Indicator (Codes 5, 6, 7, 8, 9)

Cell Indicator (Codes 5, 6, 7, 8) describes the lineage or phenotype of the cell. Codes 5, 6, 7, and 8 are used only for hematopoietic and lymphoid neoplasms. Code 9 indicates cell type not determined, not stated, or not applicable.

Coding Grade for Hematopoietic and Lymphoid Neoplasms

1. Determine the histology based on the current Hematopoietic and Lymphoid Neoplasm Database and Coding Manual.
2. Determine the Cell Indicator by applying the “Grade of Tumor Rules” within the current Hematopoietic and Lymphoid Neoplasm Database and Coding Manual to code the grade.

Grade codes for hematopoietic and lymphoid neoplasms

<table>
<thead>
<tr>
<th>Terminology</th>
<th>Grade Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>T-cell; T-precursor</td>
<td>5</td>
</tr>
<tr>
<td>B-cell; Pre-B; B-precursor</td>
<td>6</td>
</tr>
<tr>
<td>Null cell; Non T-non B</td>
<td>7</td>
</tr>
<tr>
<td>NK cell (natural killer cell)</td>
<td>8</td>
</tr>
<tr>
<td>Grade unknown, not stated, or not applicable</td>
<td>9</td>
</tr>
</tbody>
</table>

DO NOT use “high grade,” “low grade,” or “intermediate grade” descriptions for lymphomas as a basis for differentiation. These terms are categories in the Working Formulation of Lymphoma Diagnoses and do not relate to grade/differentiation.

Codes 5–8 define T-cell or B-cell origin for leukemias and lymphomas. T-cell, B-cell, or null cell classifications have precedence over grading or differentiation.

Solid Tumors

Grade/Differentiation (Codes 1, 2, 3, 4, 9)

Pathologic examination determines the grade, or degree of differentiation, of the tumor. For these cancers, the grade is a measurement of how closely the tumor cells resemble the parent tissue (organ of origin). Well-differentiated tumor cells closely resemble the tissue from the organ of origin. Poorly differentiated and undifferentiated tumor cells are disorganized and abnormal looking; they bear little (poorly differentiated) or no
(undifferentiated) resemblance to the tissue from the organ of origin. These similarities/differences may be based on pattern (architecture), cytology, nuclear (or nucleolar) features, or a combination of these elements, depending upon the grading system that is used. Some grading systems use pattern, for example Gleason grading in prostate. Others use only a nuclear grade (usually size, amount of chromatin, degree of irregularity, and mitotic activity.) Fuhrman’s grade for kidney is based only on nuclear features. Most systems use a combination of pattern and cytologic and nuclear features; for example Nottingham’s for breast combines numbers for pattern, nuclear size and shape, and mitotic activity. The information from this data item is useful for determining prognosis and treatment.

Pathologists describe the tumor grade using three systems or formats:
1. Two levels of similarity; also called a two-grade system
2. Three levels of similarity; also called a three-grade system (code according to “Coding for solid tumors.”)
   a. Grade I, well
   b. Grade II, moderately
   c. Grade III, poorly (undifferentiated carcinoma is usually separated from this system, since “poorly” bears some, albeit little, similarity to the host tissue, while “undifferentiated” has none, e.g., Undifferentiated carcinoma).
3. Four levels of similarity; also called a four-grade system. The four-grade system describes the tumor as:
   a. Grade I; also called well-differentiated
   b. Grade II; also called moderately differentiated
   c. Grade III; also called poorly differentiated
   d. Grade IV; also called undifferentiated or anaplastic

Breast and prostate grades may convert differently than other sites. These exceptions are noted in “Coding for Solid Tumors”, #7-8 below.

Coding for Solid Tumors

1. Systemic treatment and radiation can alter a tumor’s grade. Therefore, it is important to code grade based on information prior to neoadjuvant therapy even if grade is unknown. If there is no pathology report prior to neoadjuvant treatment, assign code 9.

2. Code the grade from the primary tumor only.
   a. Do NOT code grade based on metastatic tumor or recurrence. In the rare instance that tumor tissue extends contiguously to an adjacent site and tissue from the primary site is not available, code grade from the contiguous site.
   b. If primary site is unknown, code grade to 9.

3. Code the grade shown below (6th digit) for specific histologic terms that imply a grade.
   - Carcinoma, undifferentiated (8020/34)
   - Carcinoma, anaplastic (8021/34)
   - Follicular adenocarcinoma, well differentiated (8331/31)
   - Thymic carcinoma, well differentiated (8585/31)
   - Sertoli-Leydig cell tumor, poorly differentiated (8631/33)
   - Sertoli-Leydig cell tumor, poorly differentiated with heterologous elements (8634/33)
   - Undifferentiated sarcoma (8805/34)
   - Liposarcoma, well differentiated (8851/31)
   - Seminoma, anaplastic (9062/34)
   - Malignant teratoma, undifferentiated (9082/34)
Malignant teratoma, intermediate type (9083/3)
Intraosseous osteosarcoma, well differentiated (9187/3)
Astrocytoma, anaplastic (9401/3)
Oligodendroglioma, anaplastic (9451/3)
Retinoblastoma, differentiated (9511/3)
Retinoblastoma, undifferentiated (9512/3)

4. In situ and/or combined in situ/invasive components:
   a. If a grade is given for an in situ tumor, code it. Do NOT code grade for dysplasia such as high
grade dysplasia.
   b. If there are both in situ and invasive components, code the grade for the invasive portion even if
      its grade is unknown. If the invasive component grade is unknown, then code 9.

There are several diagnoses that usually do not have a statement as to the tumor grade, therefore the
tumor grade is coded as “9 - Unknown.” However, if a tumor grade is specified by a pathologist for
any of these diagnoses, it MUST be coded accordingly. These diagnoses are as follows:
   In-situ lesions (any site)
   Lobular carcinoma of the breast
   Malignant melanoma of the skin
   Multiple myeloma (bone marrow)
   Unknown primary site

5. If there is more than one grade, code the highest grade within the applicable system. Code the highest
   grade even if it is only a focus (ICD-O-3 Rule G, ICD-O-3 code book, p. 21).

   Examples
   Moderate to poorly differentiated carcinoma.
   *Code the tumor grade as: 3 - poorly differentiated*

   Predominately grade II, focally grade III.
   *Code the tumor grade as: 3 - poorly differentiated*

   If a needle biopsy or incisional biopsy of a primary site has a differentiation given and the excision or
   resection does NOT, code the grade from the biopsy or incisional biopsy.

   Example
   Biopsy of sigmoid colon: poorly differentiated adenocarcinoma. Sigmoidectomy: adenocarcinoma
   invading the pericolonic tissue.
   *Code the tumor grade as: 3 - poorly differentiated*

   When there is no tissue diagnosis, it may be possible to establish grade through magnetic resonance
   imaging (MRI) or positron emission tomography (PET). When available, code grade based on the
   recorded findings from these imaging reports.

   Example
   MRI of the brain indicated as mass in the temporal lobe. Suspect anaplastic
   astrocytoma, recommend biopsy.
   *Code the tumor grade as: 4 - anaplastic*

A tumor grade will often be described using a slash (/) or a dash (-). The slash describes a specific
grading system and the dash describes a range. Code the tumor grade using the slash according to the
grading system. Code the tumor grade using the dash to the numerically higher grade code described.
Examples
Mucinous adenocarcinoma of the rectum, Grade 1/2.
*Code the tumor grade as: 2 - low grade*

Transitional cell carcinoma of the bladder, Grade 1-2/3.
*Code the tumor grade as: 3 - poorly differentiated*

Large cell carcinoma of the lung, Grade 2-3/4
*Code the tumor grade as: 3 - poorly differentiated*

Code grade in the following priority order using the first applicable system:

a. special grade systems for the sites listed in Coding for Solid Tumors #6
b. differentiation: use Coding for Solid Tumors #7: 2-, 3-, or 4-grade system
c. nuclear grade: use Coding for Solid Tumors #7: 2-, 3-, or 4-grade system
d. If it isn’t clear whether it is a differentiation or nuclear grade and a 2-, 3-, or 4-grade system was used, code it.
e. Terminology (use Coding for Solid Tumors #8)

**FIGO Stage/Grade**
**DO NOT code FIGO stage/grade as a tumor grade.** FIGO stage is based on the percentage of non-squamous portions of the tumor and corresponds roughly to a three grade differentiation system. For a diagnosis that includes a term and a FIGO stage, such as “moderately differentiated, FIGO grade II,” disregard the FIGO grade and code according to the term “moderately differentiated.”

6. Use the information from the special grade systems first. If no special grade can be coded, continue with Coding for Solid Tumors #7-9.

**Special grade systems for solid tumors**

Grade information based on CS Site-specific factors for breast, prostate, heart, mediastinum, peritoneum, retroperitoneum, soft tissue, and kidney parenchyma is used to code grade. See **Special Grade System Rules** section below for details on how to use this information to code grade.

<table>
<thead>
<tr>
<th>CS Schema</th>
<th>Special Grade System</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>Nottingham or Bloom-Richardson (BR) Score/Grade (SSF 7)</td>
</tr>
<tr>
<td>Prostate</td>
<td>Gleason’s Score on Needle Core Biopsy/Transurethral Resection of Prostate (TURP) (SSF 8)</td>
</tr>
<tr>
<td>Prostate</td>
<td>Gleason’s Score on Prostatectomy/Autopsy (SSF 10)</td>
</tr>
<tr>
<td>Heart, Mediastinum</td>
<td>Grade for Sarcomas (SSF 1)</td>
</tr>
<tr>
<td>Peritoneum</td>
<td>Grade for Sarcomas (SSF 1)</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>Grade for Sarcomas (SSF 1)</td>
</tr>
<tr>
<td>Soft Tissue</td>
<td>Grade for Sarcomas (SSF 1)</td>
</tr>
<tr>
<td>Kidney Parenchyma</td>
<td>Fuhrman Nuclear Grade (SSF 6)</td>
</tr>
</tbody>
</table>

Do not use these tables to code grade for any other groups including WHO (CNS tumors), WHO/ISUP (bladder, renal pelvis), or FIGO (female gynecologic sites) grades.

7. Use the Two-, Three- or Four-grade system information

a. Two-grade system

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
<th>Grade Code</th>
<th>Exception for Breast and Prostate Grade Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/2, I/II</td>
<td>Low grade</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>2/2, II/II</td>
<td>High grade</td>
<td>4</td>
<td>3</td>
</tr>
</tbody>
</table>
In transitional cell carcinoma for bladder, the terminology high grade TCC and low grade TCC are coded in the two-grade system.

b. Three-grade system

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
<th>Grade Code</th>
<th>Exception for Breast and Prostate Grade Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/3</td>
<td>Low grade</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>2/3</td>
<td>Intermediate grade</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>3/3</td>
<td>High grade</td>
<td>4</td>
<td>3</td>
</tr>
</tbody>
</table>

*Example*  
Adenocarcinoma of the sigmoid colon. Grade 2 of 3.  
*Code the tumor grade as: 3*

c. Four-grade system: Any four-grade system including Edmondson and Steiner grade for liver.

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
<th>Grade Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/4</td>
<td>Grade I; Well differentiated</td>
<td>1</td>
</tr>
<tr>
<td>2/4</td>
<td>Grade II; Moderately differentiated</td>
<td>2</td>
</tr>
<tr>
<td>3/4</td>
<td>Grade III; Poorly differentiated</td>
<td>3</td>
</tr>
<tr>
<td>4/4</td>
<td>Grade IV; Undifferentiated</td>
<td>4</td>
</tr>
</tbody>
</table>

*Example*  
Squamous cell carcinoma, Grade 3/4 of the distal esophagus.  
*Code the tumor grade as: 3 - poorly differentiated*

8. Terminology: use the “Description” column or the “Grade” column to code grade. Breast and Prostate use the same grade code with a few noted exceptions.
### Description | Grade | Assign Grade Code | Exception for Breast and Prostate Grade Code
--- | --- | --- | ---
Differentiated, NOS | I | 1 | 
Well differentiated | I | 1 | 
Only stated as “Grade I” | I | 1 | 
Fairly well differentiated | II | 2 | 
Intermediate differentiation | II | 2 | 
Low grade | I-II | 2 | 1
Mid differentiated | II | 2 | 
Moderately differentiated | II | 2 | 
Moderately well differentiated | II | 2 | 
Partially differentiated | II | 2 | 
Partially well differentiated | I-II | 2 | 1
Relatively/generally well differentiated | II | 2 | 
Only stated as “Grade II” | II | 2 | 
Medium grade, intermediate grade | II-III | 3 | 2
Moderately poorly differentiated | III | 3 | 
Moderately undifferentiated | III | 3 | 
Poorly differentiated | III | 3 | 
Relatively poorly differentiated | III | 3 | 
Relatively undifferentiated | III | 3 | 
Slightly differentiated | III | 3 | 
Dedifferentiated | III | 3 | 
Only stated as “Grade III” | III | 3 | 
High grade | III-IV | 4 | 3
Undifferentiated, anaplastic, not differentiated | IV | 4 | 
Only stated as “Grade IV” | IV | 4 | 
Non-high grade | | 9 | 

9. If no description fits or grade is unknown prior to neoadjuvant therapy, code as a 9 (unknown).

Assign code 9 for death certificate only (DCO) cases when grade is unknown.

### SPECIAL GRADE SYSTEMS RULES

#### Breast (site: breast excluding lymphomas; CS schema: breast)

Use Bloom Richardson (BR) or Nottingham score/grade to code grade based on CSv2 site-specific factor 7 (SSF) as stated below. If your registry does not collect this SSF, use the description in the table below to determine grade. If you collect this SSF, codes 030-130 could be automatically converted into the grade field.

BR could also be referred to as: Bloom-Richardson, modified Bloom-Richardson, BR, BR grading, Scarff-Bloom-Richardson, SBR grading, Elston-Ellis modification of Bloom-Richardson score, Nottingham modification of Bloom-Richardson score, Nottingham modification of Scarff-Bloom-Richardson, Nottingham-Tenovus grade, or Nottingham grade.

Code the tumor grade using the following priority order
a. BR scores 3-9
b. BR grade (low, intermediate, high)
BR score may be expressed as a range, 3-9. The score is based on three morphologic features: degree of tubule formation/histologic grade, mitotic activity, nuclear pleomorphism/nuclear grade of tumor cells. If a report uses words such as low, intermediate, or high rather than numbers, use the table below to code grade.

If only a grade of 1 through 4 is given with no information on the score and it is unclear if it is a Nottingham or BR Grade, do not use the table below. Continue with the next priority according to “Coding for Solid Tumors” #7 above.

Code the highest score if multiple scores are reported (exclude scores from tests after neoadjuvant therapy began). Examples: different scores may be reported on multiple pathology reports for the same primary cancer; different scores may be reported for multiple tumors assigned to the same primary cancer.

### CS Site-Specific Factor 7: Nottingham or Bloom-Richardson (BR) Score/Grade

<table>
<thead>
<tr>
<th>Description</th>
<th>CS Code</th>
<th>Grade Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Score of 3</td>
<td>030</td>
<td>1</td>
</tr>
<tr>
<td>Score of 4</td>
<td>040</td>
<td>1</td>
</tr>
<tr>
<td>Score of 5</td>
<td>050</td>
<td>1</td>
</tr>
<tr>
<td>Score of 6</td>
<td>060</td>
<td>2</td>
</tr>
<tr>
<td>Score of 7</td>
<td>070</td>
<td>2</td>
</tr>
<tr>
<td>Score of 8</td>
<td>080</td>
<td>3</td>
</tr>
<tr>
<td>Score of 9</td>
<td>090</td>
<td>3</td>
</tr>
<tr>
<td>Low Grade, Bloom-Richardson (BR) grade 1, score not given</td>
<td>110</td>
<td>1</td>
</tr>
<tr>
<td>Medium (Intermediate) Grade, BR grade 2, score not given</td>
<td>120</td>
<td>2</td>
</tr>
<tr>
<td>High Grade, BR grade 3, score not given</td>
<td>130</td>
<td>3</td>
</tr>
</tbody>
</table>

**Examples**
- Ductal carcinoma of the breast, Bloom-Richardson 3 + 2 + 4 = 9.
  Code the tumor grade as: 3 - poorly differentiated
- Ductal adenocarcinoma of the breast, Bloom-Richardson, low grade.
  Code the tumor grade as: 1 - well differentiated

### Kidney Parenchyma (site: kidney parenchyma excluding lymphomas; CS schema: KidneyParenchyma):

#### Fuhrman Nuclear Grade

The Fuhrman Nuclear Grade should be used to code grade for kidney parenchyma only based on CSv2 SSF 6 as stated below. Do not use for kidney renal pelvis. If your registry does not collect this SSF, use the description in the table to determine grade. If you collect this SSF, the information could be automatically converted into the grade field if it is coded 010-040. Fuhrman nuclear grade is a four-grade system based on nuclear diameter and shape, the prominence of nucleoli, and the presence of chromatin clumping in the highest grade.

<table>
<thead>
<tr>
<th>Description</th>
<th>CS Code</th>
<th>Grade Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>010</td>
<td>1</td>
</tr>
<tr>
<td>Grade 2</td>
<td>020</td>
<td>2</td>
</tr>
<tr>
<td>Grade 3</td>
<td>030</td>
<td>3</td>
</tr>
<tr>
<td>Grade 4</td>
<td>040</td>
<td>4</td>
</tr>
</tbody>
</table>

**SoftTissue (sites excluding lymphomas: soft tissue, heart, mediastinum, peritoneum, and retroperitoneum; for CS users: SoftTissue, Heart(Mediastinum, Peritoneum, Retroperitoneum schemas): Grade for Sarcomas**
The Grade for Sarcomas should be used to code grade based on CSv2 SSF 1 as stated below. If your registry does not collect this SSF, use the description in the table to determine grade. If you collect this SSF, the information could be automatically converted into the grade field if it is coded 010-200. The grading system of the French Federation of Cancer Centers Sarcoma Group (FNCLCC) is the preferred system.

Record the grade from any three-grade sarcoma grading system the pathologist uses. For terms such as “well differentiated” or “poorly differentiated,” go to Coding for Solid Tumors #8.

In some cases, especially for needle biopsies, grade may be specified only as “low grade” or “high grade.” The numeric grade takes precedence over “low grade” or “high grade.”

<table>
<thead>
<tr>
<th>Description</th>
<th>CS Code</th>
<th>Grade Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specified as Grade 1 [of 3]</td>
<td>010</td>
<td>2</td>
</tr>
<tr>
<td>Specified as Grade 2 [of 3]</td>
<td>020</td>
<td>3</td>
</tr>
<tr>
<td>Specified as Grade 3 [of 3]</td>
<td>030</td>
<td>4</td>
</tr>
<tr>
<td>Grade stated as low grade, NOS</td>
<td>100</td>
<td>2</td>
</tr>
<tr>
<td>Grade stated as high grade, NOS</td>
<td>200</td>
<td>4</td>
</tr>
</tbody>
</table>

**Prostate (site: prostate excluding lymphomas; CS schema: prostate)**

Use the highest Gleason score from the biopsy/TURP or prostatectomy/autopsy. Use a known value over an unknown value. Exclude results from tests performed after neoadjuvant therapy began. This information is collected in CSv2 SSF 8 (Gleason score from biopsy/TURP) and SSF 10 (Gleason score from prostatectomy/autopsy) as stated below. Use the table below to determine grade even if your registry does not collect these SSFs. If you collect these SSFs, the information could be converted into the grade field automatically.

Usually prostate cancers are graded using Gleason score or pattern. Gleason grading for prostate primaries is based on a 5-component system (5 histologic patterns). Prostatic cancer generally shows two main histologic patterns. The primary pattern, the pattern occupying greater than 50% of the cancer, is usually indicated by the first number of the Gleason grade, and the secondary pattern is usually indicated by the second number. These two numbers are added together to create a pattern score, ranging from 2 to 10. If there are two numbers, assume that they refer to two patterns (the first number being the primary pattern and the second number the secondary pattern), and sum them to obtain the score. If only one number is given on a particular test and it is less than or equal to 5 and not specified as a score, do not use the information because it could refer to either a score or a grade. If only one number is given and it is greater than 5, assume that it is a score and use it. If the pathology report specifies a specific number out of a total of 10, the first number given is the score. Example: The pathology report says Gleason 3/10. The Gleason score would be 3.

<table>
<thead>
<tr>
<th>Description</th>
<th>CS Code</th>
<th>Grade Code</th>
<th>AJCC 7th</th>
<th>SEER 2003-2013</th>
<th>AJCC 6th</th>
<th>SEER prior 2003</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>002</td>
<td>1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
</tr>
<tr>
<td>3</td>
<td>003</td>
<td>1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
</tr>
<tr>
<td>4</td>
<td>004</td>
<td>1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
<td>G1</td>
</tr>
<tr>
<td>5</td>
<td>005</td>
<td>1</td>
<td>G1</td>
<td>G2</td>
<td>G2</td>
<td>G2</td>
</tr>
<tr>
<td>6</td>
<td>006</td>
<td>1</td>
<td>G1</td>
<td>G2</td>
<td>G2</td>
<td>G2</td>
</tr>
<tr>
<td>7</td>
<td>007</td>
<td>2</td>
<td>G2</td>
<td>G3</td>
<td>G3</td>
<td>G2</td>
</tr>
<tr>
<td>8</td>
<td>008</td>
<td>3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
</tr>
<tr>
<td>9</td>
<td>009</td>
<td>3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
</tr>
<tr>
<td>10</td>
<td>010</td>
<td>3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
<td>G3</td>
</tr>
</tbody>
</table>
Examples  Adenocarcinoma of the prostate, Gleason 4 + 5 = 9.  
*Code the tumor grade as: 3 - poorly differentiated*

**Malignant Brain and Spinal Cord**

Oftentimes, brain and spinal cord diagnoses are assigned a WHO (World Health Organization) grade. This type of grading is NOT the same as the ICD-O differentiation or tumor grade code. The WHO grading system is used to estimate prognosis and is for the purpose of staging.

If the ICD-O grade or differentiation code is used for central nervous system tumors, coders should give preference to terms from the diagnosis - such as low grade (Code 2) or anaplastic (Code 4) - rather than using the reported WHO grade. In many cases, there will be no verbal description of the grade and these cases must be coded as: “9 - Unknown” for the ICD-O grade/differentiation.

In the absence of other information on grade, code cases as follows:

<table>
<thead>
<tr>
<th>Description</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astrocytoma grade 1</td>
<td>1</td>
</tr>
<tr>
<td>Astrocytoma grade 2</td>
<td>2</td>
</tr>
<tr>
<td>Astrocytoma (low grade)</td>
<td></td>
</tr>
<tr>
<td>Astrocytoma grade 3</td>
<td>3</td>
</tr>
<tr>
<td>Astrocytoma grade 4</td>
<td></td>
</tr>
<tr>
<td>Anaplastic astrocytoma</td>
<td>4</td>
</tr>
<tr>
<td>Glioblastoma multiforme (grade unspecified)</td>
<td></td>
</tr>
<tr>
<td>Pilocytic astrocytoma (grade unspecified)</td>
<td>9</td>
</tr>
<tr>
<td>Astrocytoma, NOS (grade unspecified)</td>
<td></td>
</tr>
</tbody>
</table>

*Examples*  Glioblastoma multiforme of the frontal lobe, WHO grade 3.  
*Code the tumor grade as: 9 – unknown*

Anaplastic astrocytoma of the cerebellum.  
*Code the tumor grade as: 4 – anaplastic*

**Benign/Borderline Brain and CNS**

The tumor grade for benign/borderline intracranial and CNS tumors is ALWAYS coded as a “9 – not determined, not stated or not applicable.” DO NOT record the World Health Organization (WHO) grade in the sixth digit of the histology code.

The World Health Organization (WHO) grade should be recorded in site specific factor 1 of the Collaborative Stage Data Collection System Manual. Attention must be paid to the preservation of histologic grade, which will continue to be collected as the histology sixth digit “Grade.”

For additional information review the “Grade, Differentiation or Cell Indicator” section of the SEER Program Coding and Staging Manual.

**Item:** HISTOLOGIC TYPE ICD-O-3  
**Alternate Name:** ICD-O-3 Histology

Codes for the histologic type of the tumor being reported using ICD-O-3. This data item is required by all standard-setting organizations for tumors diagnosed on or after January 1, 2001, and recommended (by
conversion from ICD-O-2 codes when conversion algorithms and tables are available) for tumors diagnosed before 2001.

See full histology coding instructions in current FORDS manual.

**Do not leave this data item blank.**

The Hematopoietic and Lymphoid Neoplasm Database and the Hematopoietic and Lymphoid Neoplasm Coding Manual apply to only those non-solid tumor cases diagnosed January 1, 2010 and forward. The ICD-O-3 coding book is obsolete for coding non-solid tumors after this date. Use the Hematopoietic and Lymphoid Neoplasm Database and Coding Manual to assign the histology code.

**Item: LABORATORY REPORT NUMBER**

State-specific Item 9507

If a case has been assigned a laboratory record number or pathology report specimen number, enter that number. This number can be alphanumeric. If more than one laboratory record number has been assigned to the case, enter the number which most closely corresponds with the initial diagnosis of the primary tumor being reported.

If no laboratory number exists, enter “none.”

**Item: LATERALITY**

Alternate Name: Laterality at Diagnosis

Laterality (paired organs) refers to a specific side of the body or lobe of an organ. In the case of paired or bilateral organs, it is important to indicate whether the primary site of the tumor is the right organ, the left organ, or bilateral involvement. Laterality refers to the primary site only; DO NOT code the laterality of the metastatic site(s).

**NOTE:** Laterality reporting rules vary depending upon standard-setter. MCSP and other central cancer registries have not adopted the revision to laterality rules found in FORDS. MCSP reporting requirements for laterality follow current SEER guidelines.

**Do not leave this data item blank.** If the primary site is reported as “unknown primary site,” code the laterality to “0 - not a paired site.”

If the primary site being reported is NOT defined as a paired site, laterality must be coded as “0 – not a paired site” regardless of facility type.

Codes are as follows:

- 0 Not a paired site
- 1 Right: origin of primary
- 2 Left: origin of primary
- 3 Only one side involved, right or left origin unspecified
- 4 Bilateral involvement at time of diagnosis, lateral origin unknown for a single primary; or both ovaries involved simultaneously, single histology; bilateral retinoblastomas; bilateral Wilms tumors
- 5 Paired site: midline tumor *
- 9 Paired site, but no information concerning laterality

* "Midline" in this context refers to the point where the "right" and "left" sides of paired organs come into direct contact and a tumor forms at that point. Most paired sites cannot develop midline tumors.
Code 5 - Midline is an allowable value for the following sites only: C700, C710-C714, C722-C725, C443, and C445.

Laterality MUST be recorded for the following paired organs as 1-5 or 9.

Use code “3 - One side only, NOS” if the laterality is not known but the tumor is confined to a single side of a paired organ.

**Examples**

The pathology report states that the “patient has a 2 cm carcinoma in the upper pole of the kidney.”

*Code laterality as “3 - One side only, NOS” because laterality is not specified but the tumor is not present on both sides of a paired site.*

Admitting history states that the patient has a positive, sputum cytology but is being treated with radiation for painful bony metastases.

*Code laterality as “9 - Unknown,” because there is no information concerning laterality in the implied diagnosis of lung cancer and the case is metastatic.*

Patient has a melanoma of skin just above the umbilicus.

*Code laterality as “5 - Midline.”*

The skin of the lip, scalp and neck is NOT considered a paired organ, laterality for these subcategories is coded as “0 - Not a paired site.”

If reporting the primary site of the skin as “skin, NOS (C44.9)” the laterality is coded as “0 - Not a paired site.”

**NOTE:** The prostate and thyroid are made up of lobes, which are represented by left and right - **DO NOT code as a paired organ.**

**NOTE:** The description of right colon and left colon does NOT apply to laterality, but to the exact location (sub-site) of the tumor origin in the colon. Code right colon to ascending colon (C18.2) and the left colon to descending colon (C18.6). **DO NOT code as a paired organ.**

This chart lists sites for which laterality codes must be recorded:

<table>
<thead>
<tr>
<th>Primary Site Description</th>
<th>Topography Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Acoustic nerve (excluding diagnoses prior to 2004)</td>
<td>C72.4</td>
</tr>
<tr>
<td>Adrenal gland</td>
<td>C74.0 – C74.9</td>
</tr>
<tr>
<td>Breast</td>
<td>C50.0 - C50.9</td>
</tr>
<tr>
<td>Carotid body</td>
<td>C75.4</td>
</tr>
<tr>
<td>*Cerebral meninges, NOS (excluding diagnoses prior to 2004)</td>
<td>C70.0</td>
</tr>
<tr>
<td>*Cerebrum (excluding diagnoses prior to 2004)</td>
<td>C71.0</td>
</tr>
<tr>
<td>Connective, subcutaneous and other soft tissue of upper limb and shoulder</td>
<td>C49.1</td>
</tr>
<tr>
<td>Connective, subcutaneous, and other soft tissue of lower limb and hip</td>
<td>C49.2</td>
</tr>
<tr>
<td>*Cranial Nerve, NOS (excluding diagnoses prior to 2004)</td>
<td>C72.5</td>
</tr>
<tr>
<td>Epididymis</td>
<td>C63.0</td>
</tr>
<tr>
<td>Eye and lacrimal gland</td>
<td>C69.0 – C69.9</td>
</tr>
<tr>
<td>Fallopian tube</td>
<td>C57.0</td>
</tr>
<tr>
<td>Frontal lobe (excluding diagnoses prior to 2004)</td>
<td>C71.1</td>
</tr>
<tr>
<td>Frontal sinus</td>
<td>C31.2</td>
</tr>
<tr>
<td>Primary Site Description</td>
<td>Topography Code</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Kidney, NOS</td>
<td>C64.9</td>
</tr>
<tr>
<td>Long bones of lower limb and associated joints</td>
<td>C40.2</td>
</tr>
<tr>
<td>Long bones of upper limb, scapula and associated joints</td>
<td>C40.0</td>
</tr>
<tr>
<td>Lung</td>
<td>C34.1 – C34.9</td>
</tr>
<tr>
<td>Main bronchus (excluding carina - code 0)</td>
<td>C34.0</td>
</tr>
<tr>
<td>Maxillary sinus</td>
<td>C31.0</td>
</tr>
<tr>
<td>Middle ear</td>
<td>C30.1</td>
</tr>
<tr>
<td>Nasal cavity (excluding nasal cartilage and nasal septum - code 0)</td>
<td>C30.0</td>
</tr>
<tr>
<td>*Occipital lobe (excluding diagnoses prior to 2004)</td>
<td>C71.4</td>
</tr>
<tr>
<td>*Olfactory nerve (excluding diagnoses prior to 2004)</td>
<td>C72.2</td>
</tr>
<tr>
<td>*Optic nerve (excluding diagnoses prior to 2004)</td>
<td>C72.3</td>
</tr>
<tr>
<td>Ovary</td>
<td>C56.9</td>
</tr>
<tr>
<td>Parietal lobe (excluding diagnoses prior to 2004)</td>
<td>C71.3</td>
</tr>
<tr>
<td>Parotid gland</td>
<td>C07.9</td>
</tr>
<tr>
<td>Pelvic bones (excluding sacrum, coccyx and symphysis pubis - code “0’)</td>
<td>C41.4</td>
</tr>
<tr>
<td>Peripheral nerves and autonomic nervous system of lower limb and hip</td>
<td>C47.2</td>
</tr>
<tr>
<td>Peripheral nerves and autonomic nervous system of upper limb and shoulder</td>
<td>C47.1</td>
</tr>
<tr>
<td>Pleura</td>
<td>C38.4</td>
</tr>
<tr>
<td>Renal pelvis</td>
<td>C65.9</td>
</tr>
<tr>
<td>Rib and clavicle (excluding sternum - code 0)</td>
<td>C41.3</td>
</tr>
<tr>
<td>Short bones of lower limb and associated joints</td>
<td>C40.3</td>
</tr>
<tr>
<td>Short bones of upper limb and associated joints</td>
<td>C40.1</td>
</tr>
<tr>
<td>Skin of external ear</td>
<td>C44.2</td>
</tr>
<tr>
<td>Skin of eyelid</td>
<td>C44.1</td>
</tr>
<tr>
<td>Skin of lower limb and hip</td>
<td>C44.7</td>
</tr>
<tr>
<td>*Skin of other unspecified parts of face</td>
<td>C44.3</td>
</tr>
<tr>
<td>*Skin of trunk</td>
<td>C44.5</td>
</tr>
<tr>
<td>Skin of upper limb and shoulder</td>
<td>C44.6</td>
</tr>
<tr>
<td>Spermatic cord</td>
<td>C63.1</td>
</tr>
<tr>
<td>Sublingual gland</td>
<td>C08.1</td>
</tr>
<tr>
<td>Submandibular gland</td>
<td>C08.0</td>
</tr>
<tr>
<td>Temporal lobe (excluding diagnoses prior to 2004)</td>
<td>C71.2</td>
</tr>
<tr>
<td>Testis</td>
<td>C62.0 – C62.9</td>
</tr>
<tr>
<td>Tonsil, NOS (faucial tonsil, palatine tonsil)</td>
<td>C09.9</td>
</tr>
<tr>
<td>Tonsil, overlapping lesion</td>
<td>C09.8</td>
</tr>
<tr>
<td>Tonsillar fossa</td>
<td>C09.0</td>
</tr>
<tr>
<td>Tonsillar pillar</td>
<td>C09.1</td>
</tr>
<tr>
<td>Ureter</td>
<td>C66.9</td>
</tr>
</tbody>
</table>

*Site includes code 5 - midline tumor

For a standalone list of allowable laterality codes by primary site code and description, download “MCSP Laterality Codes by Primary Site” from the [MCSP website](#).

**Item:** LYMPH-VASCULAR INVASION

NAACCR Item 1182
This field records the absence or presence of tumor cells in lymphatic channels (not lymph nodes) or blood vessels within the primary tumor as noted microscopically by the pathologist. The presence of lymph-vascular invasion may affect the patient’s prognosis.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Lymph-vascular invasion not present (absent)/Not identified</td>
</tr>
<tr>
<td>1</td>
<td>Lymph-vascular invasion present/Identified</td>
</tr>
<tr>
<td>8</td>
<td>Not applicable</td>
</tr>
<tr>
<td>9</td>
<td>Unknown if lymph-vascular invasion present; Indeterminate</td>
</tr>
</tbody>
</table>

Lymph-vascular invasion is defined as the presence of tumor cells found inside small blood vessels or lymphatic channels within the tumor and surrounding tissues in the primary site. The tumor cells have broken free of the primary tumor and now have the capability to float throughout the body. Other names for lymph-vascular invasion are LVI, lymphovascular invasion, vascular invasion, blood vessel invasion, and lymphatic invasion. Vascular invasion is not the same as direct tumor extension from the primary tumor into adjacent blood vessels; LVI cells are not attached to or growing into the wall of the blood vessel. Lymphatic invasion is not the same as involvement of regional lymph nodes. Lymph-vascular invasion does not include perineural invasion.

1. Code from pathology report(s). Code the absence or presence of lymph-vascular invasion as described in the medical record.
   a. The primary sources of information about lymph-vascular invasion are the pathology check lists (synoptic reports) developed by the College of American Pathologists. If the case does not have a checklist or synoptic report, code from the pathology report or a physician’s statement, in that order.
   b. Do not code perineural invasion in this field.
   c. Information to code this field can be taken from any specimen from the primary tumor.
   d. If lymph-vascular invasion is identified anywhere in the resected specimen, it should be coded as present/identified.

2. Use of codes.
   a. Use code 0 when the pathology report indicates that there is no lymph-vascular invasion. This includes cases of purely in situ carcinoma, which biologically have no access to lymphatic or vascular channels below the basement membrane.
   b. Use code 1 when the pathology report or a physician’s statement indicates that lymph-vascular invasion (or one of its synonyms) is present in the specimen.
   c. Use code 8 for the following primary sites.
      Hodgkin and Non-Hodgkin lymphoma
      Leukemias
      Hematopoietic and reticuloendothelial disorders
      Myelodysplastic syndromes including refractory anemias and refractory cytopenias
      Myeloproliferative disorders
   d. Use code 9 when
      i. There is no microscopic examination of a primary tissue specimen
      ii. The primary site specimen is cytology only or a fine needle aspiration
      iii. The biopsy is only a very small tissue sample
      iv. It is not possible to determine whether lymph-vascular invasion is present
v. The pathologist indicates the specimen is insufficient to determine lymph-vascular invasion
vi. Lymph-vascular invasion is not mentioned in the pathology report

Do not leave this data item blank.

Item: MARITAL STATUS AT DX  NAACCR Item 150
Alternate Name: Marital Status at Diagnosis

Enter the marital status of the patient at time of diagnosis. The codes are as follows:

1 Single (never married)
2 Married (including common law)
3 Separated
4 Divorced
5 Widowed
6 Unmarried or Domestic Partner
9 Unknown

NOTE: If the patient has multiple tumors, the Marital Status may be different for each tumor.

Do not leave this data item blank.

Item: MEDICAL RECORD NUMBER  NAACCR Item 2300

If the patient has been assigned a medical record number, enter that number.

If your hospital registry abstracts cases for another hospital, it should have a system that identifies the facility associated to the patient. This can be done by assigning a unique suffix or a prefix number to correspond with each facility and by communicating the system to the state registry staff.

If no medical record number exists for the patient, enter “none” or “NA” (not applicable.)

Item: METS AT DX-BONE  NAACCR Item 1112

⇒ This data item applies to cases diagnosed 1/1/2016 and forward only.

This field identifies whether bone is an involved metastatic site. The six Mets at Dx-Metastatic Sites fields provide information on specific metastatic sites for data analysis.

Codes
0 - None; no bone metastases
1 - Yes; distant bone metastases
8 - Not applicable
9 - Unknown whether bone is an involved metastatic site. Not documented in patient record.

Do not leave this data item blank.

Item: METS AT DX-BRAIN  NAACCR Item 1113

⇒ This data item applies to cases diagnosed 1/1/2016 and forward only.
This field identifies whether brain is an involved metastatic site. The six Mets at Dx-Metastatic Sites fields provide information on specific metastatic sites for data analysis.

**Codes**
- 0 - None; no brain metastases
- 1 - Yes; distant brain metastases
- 2 - Not applicable
- 9 - Unknown whether brain is involved metastatic site. Not documented in patient record.

**Do not leave this data item blank.**

**Item:** METS AT DX-DISTANT LN  
**NAACCR Item 1114**

⇒ This data item applies to cases diagnosed 1/1/2016 and forward only.

This field identifies whether distant lymph node(s) are an involved metastatic site. The six Mets at Dx-Metastatic Sites fields provide information on specific metastatic sites for data analysis.

**Codes**
- 0 - None; no distant lymph node metastases
- 1 - Yes; distant lymph node metastases
- 8 - Not applicable
- 9 - Unknown whether distant lymph node(s) are involved metastatic site. Not documented in patient record.

**Do not leave this data item blank.**

**Item:** METS AT DX-LIVER  
**NAACCR Item 1115**

⇒ This data item applies to cases diagnosed 1/1/2016 and forward only.

This field identifies whether liver is an involved metastatic site. The six Mets at Dx-Metastatic Sites fields provide information on specific metastatic sites for data analysis.

**Codes**
- 0 - None; no liver metastases
- 1 - Yes; distant liver metastases
- 8 - Not applicable
- 9 - Unknown whether liver is involved metastatic site. Not documented in patient record.

**Do not leave this data item blank.**

**Item:** METS AT DX-LUNG  
**NAACCR Item 1116**

⇒ This data item applies to cases diagnosed 1/1/2016 and forward only.

This field identifies whether lung is an involved metastatic site. The six Mets at Dx-Metastatic Sites fields provide information on specific metastatic sites for data analysis.

**Codes**
- 0 - None; no lung metastases
- 1 - Yes; distant lung metastases
8 - Not applicable
9 - Unknown whether lung is involved metastatic site. Not documented in patient record.

Do not leave this data item blank.

Item: METS AT DX-OTHER NAACCR Item 1117

⇒ This data item applies to cases diagnosed 1/1/2016 and forward only.

This field identifies whether other metastatic involvement, other than bone, brain, liver, lung or distant lymph nodes exists. Some examples include but are not limited to the adrenal gland, bone marrow, pleura, peritoneum and skin. The six Mets at Dx-Metastatic Sites fields provide information on specific metastatic sites for data analysis.

Codes
0 - None; no other metastases
1 - Yes; distant metastases in known site(s) other than bone, brain, liver, lung or distant lymph nodes
8 - Not applicable
9 - Unknown whether any other metastatic site. Not documented in patient record.

Do not leave this data item blank.

Item: MICHIGAN FACILITY NUMBER State-specific Item 9508

Enter the 5-digit Michigan Facility Number that has been assigned to your institution by the Michigan Cancer Surveillance Program. Note: This number may have a leading zero, e.g., 01234.

If you do not know your Michigan Facility Number, contact your field representative.

Do not leave this data item blank.

Item: NAME--ALIAS NAACCR Item 2280
Alternate Name: Alias

⇒ This data item may be left blank if not applicable or unknown.

Enter the alternate name or “AKA” (also known as) used by the patient. Note that maiden name is entered in Maiden Name field.

Item: NAME--FIRST NAACCR Item 2240
Alternate Name: First Name

Type the legal First Name of the patient. Truncate if more than 40 letters long, but do not abbreviate, e.g., do not use “Robt” for “Robert.” Blank spaces or hyphens between multiple-word names are allowed. Do not use other punctuation such as apostrophes. Do not use nicknames in this field; nicknames should be used in Alias Name field only.

If the patient’s first name is not available, type Unknown.

This field may be updated, if the last name changes. For information on how to submit corrections, refer to Submitting Updates (Corrections) in the MCSP Cancer Reporting Manual.
Do not leave this data item blank.

Item: NAME--LAST  

Alternate Name: Last Name

Type the legal Last Name of the patient. Truncate name if more than 40 letters long. Blank spaces or hyphens between multiple-word names are allowed. Do not use other punctuation such as apostrophes. Include JR (junior) or SR (senior) with the last name when applicable.

If the last name is not available, type Unknown.

This field may be updated, if the last name changes. For information on how to submit corrections, refer to Submitting Updates (Corrections) in the MCSP Cancer Reporting Manual.

Do not leave this data item blank.

Item: NAME--MAIDEN  

Alternate Name: Maiden Name

⇒ This data item may be left blank if not applicable or unknown.

Enter the Maiden Name of female patients who are or have been married. Do not abbreviate. Blank spaces or hyphens between multiple-word names are allowed. Do not use other punctuation such as apostrophes. Leave this item blank if it is not appropriate for the patient being reported, or is not available in the records, or when not reporting this item.

Do not leave this data item blank.

Item: NAME--MIDDLE  

Alternate Name: Middle Name

⇒ This data item may be left blank if not applicable or unknown.

Type the legal Middle Name or Middle Initial of the patient. If only an initial is available for the middle name, enter the initial. Blank spaces or hyphens between multiple-word names are allowed. Do not use other punctuation such as apostrophes. If no middle name or initial, leave field blank.

This field may be updated, if the last name changes. For information on how to submit corrections, refer to Submitting Updates (Corrections) in the MCSP Cancer Reporting Manual.

Item: PLACE OF DEATH--COUNTRY  

Alternate Name: Country

Enter the name or code for the country where the patient expired. If the country is the United States, enter “USA.”

If the patient has multiple primaries, the Place of Death - Country is the same for each tumor.

If the information is unknown or unreported in the patient’s record, enter “ZZU.”

If the patient is still alive, leave this field BLANK.

ISO alpha-3 Country Codes can be found at the back of this manual or refer to Appendix B of the SEER Program Code Manual.
**Item: PLACE OF DEATH--STATE**

Enter the USPS abbreviation for the state, commonwealth, U.S. possession; or CanadaPost abbreviation for the Canadian province/territory in which the patient expired. For example, if the state in which the patient expired is Michigan, use “MI.”

If the patient has multiple primaries, the Place of Death - State is the same for each tumor.

If the information is unknown or unreported in the patient’s record, enter “ZZ” or “Unknown.”

If the patient is still alive, leave this field BLANK.

A complete list of state, territory, commonwealth, U.S. possession, or Canadian province or territory codes can be found at the back of this manual, or refer to Appendix B of the SEER Program Code Manual.

**Item: PRIMARY PAYER AT DX**

*Alternate Name: Primary Payer at Diagnosis*

Enter primary payer/insurance carrier at the time of initial diagnosis at the reporting facility. If the patient is diagnosed elsewhere or the payer at the time of diagnosis is not known, record the payer when the patient is initially admitted for treatment.

Record the type of insurance reported on the patient’s admission page.

Codes 21 and 65–68 are to be used for patients diagnosed on or after January 1, 2006.

If more than one payer or insurance carrier is listed on the patient’s admission page, record the first.

**Do not change the initially recorded code if the patient’s payer or insurance carrier changes, or if an initially uninsured patient subsequently acquires health insurance.**

*Example* At time of diagnosis, patient is not covered by insurance. A week later, the patient becomes eligible for Medicaid. *Code data item “01 – Not insured.”*

Do NOT update the Primary Payer at DX code for a particular primary tumor; however, multiple primaries may have different codes depending upon the insurance in effect at time of diagnosis.

**Do not leave this data item blank.** If the Insurance status is unknown or not reporting, enter “99.”

Codes are as follows:

- 01 Not insured
- 02 Not insured, self-pay
- 10 Insurance, NOS
- 20 Private Insurance: Managed care, HMO, or PPO
- 21 Private Insurance: Fee-for-Service
- 31 Medicaid
- 35 Medicaid Administered through a Managed Care plan
- 60 Medicare/Medicare, NOS
- 61 Medicare with supplement, NOS
62 Medicare Administered through a Managed Care plan
63 Medicare with private supplement
64 Medicare with Medicaid eligibility
65 TRICARE
66 Military
67 Veterans Affairs
68 Indian/Public Health Service
99 Insurance status unknown

<table>
<thead>
<tr>
<th>Item: PRIMARY SITE</th>
<th>NAACCR Item 400</th>
</tr>
</thead>
</table>

**Do not leave this data item blank.** Do not report the metastatic site as the primary site. After investigation, if the primary site cannot be determined, code the primary site as unknown primary site C809.

Enter the primary anatomical site where the cancer began or originated. Include description of tumor origin or primary site. For example: C341 = upper lobe lung

For solid tumors: Use the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) coding book to assign the topography code or primary site.

For non-solid tumors: Use the Hematopoietic and Lymphoid Neoplasm Database and the Hematopoietic and Lymphoid Neoplasm Coding Manual to assist with coding these primaries. These references apply only to cases diagnosed January 1, 2010 and forward.

The primary site can be located on the pathology report, history and physical examination, discharge summary, operative report, x-rays and scans.

Be as specific as possible, as many organs can be sub-divided into specific segments.

*Example* The pathology report indicates the tumor originated in the ascending colon.

*The primary site should be recorded as C182, ascending colon and NOT C189, colon, NOS.*

For leukemia and multiple myeloma, enter the primary site as bone marrow C421.

Record the primary anatomical site where the cancer began or originated. If multiple primary tumors are diagnosed, complete a separate cancer report form for each primary site.

*Examples* Bilateral mammogram impression: Development of a 1cm irregularly marginated and slightly spiculated mass in the upper outer quadrant of the right breast, surgical consultation recommended. Right breast mastectomy: “Infiltrating moderately differentiated ductal cell carcinoma.”

*Record the primary site as reported in the mammogram as “breast, UOQ C504.”*

Operative report, right colectomy: Gross description revealed a tan-pink mass 2.5cm in size located at approximately 52cm, in the sigmoid colon. Right colectomy: “Infiltrating poorly differentiated mucinous producing adenocarcinoma.”

*Record the primary site as reported in the operative report as “sigmoid colon C187 or “colon, 52cm.”*

*Examples* Fine needle aspiration (FNA) of the liver: “Metastatic adenocarcinoma, possible primary sites to consider include the colon, breast and lung.” Discharge summary: Liver consistent with
metastatic adenocarcinoma, primary site not determined. 
*Record the primary site as “unknown primary site C809.”*

Left upper lobe bronchoscopy: “Metastatic adenocarcinoma, consistent with breast primary.”
Subsequently a bilateral mammogram was performed and revealed a poorly defined lesion in the lower outer quadrant of the left breast, suspicious for malignancy. Discharge summary:
Metastatic adenocarcinoma of the lung, consistent with breast primary.
*Record the primary site as “breast, LOQ C505.”*

It is important to be as specific as possible when recording the primary site. Many organs can be sub-divided into specific segments.

*Example* 
The pathology report indicates adenocarcinoma of the left upper lobe, lung.
*Record the primary site as “lung, upper lobe C341.”*

When recording the primary site, following are examples of sites to be sub-divided. (This is not an all-inclusive list).

**Breast**

- Nipple (areola) C500
- Central portion (subareolar, retroareolar) C501
- Axillary tail C506
- Inner/outer/lower/upper breast, midline (overlapping lesion) C508

<table>
<thead>
<tr>
<th>Right Side</th>
<th>Left Side</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper-inner quadrant (UIQ) C502 (12:00 o’clock to 3:00 o’clock)</td>
<td>Upper-inner quadrant (UIQ) C502 (9:00 o’clock to 12:00 o’clock)</td>
</tr>
<tr>
<td>Lower-inner quadrant (LIQ) C503 (3:00 o’clock to 6:00 o’clock)</td>
<td>Lower-inner quadrant (LIQ) C503 (6:00 o’clock to 9:00 o’clock)</td>
</tr>
<tr>
<td>Upper-outer quadrant (UOQ) C504 (9:00 o’clock to 12:00 o’clock)</td>
<td>Upper-outer quadrant (UOQ) C504 (12:00 o’clock to 3:00 o’clock)</td>
</tr>
<tr>
<td>Lower-outer quadrant (LOQ) C505 (6:00 o’clock to 9:00 o’clock)</td>
<td>Lower-outer quadrant (LOQ) C505 (3:00 o’clock to 6:00 o’clock)</td>
</tr>
</tbody>
</table>

*NOTE 1:* If the pathology report indicates that the mass is located at the 12:00, 3:00, 6:00 or 9:00 position, consider the lesion to be overlapping and code to “breast, overlapping lesion C50.8.”

*NOTE 2:* If the exact location of the mass is not reported in the operative or pathology report, review the mammogram and/or history and physical examination report for the specific location.

**Esophagus C15.0 - C15.9**
The esophagus is a muscular tube about ten inches (25 cm) long extending from the hypopharynx to the stomach. The location of esophageal lesions is frequently measured from the incisors (front teeth) and may be approximated as follows.

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>Topography Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical - begins at the lower border of the cricoid cartilage and ends at the thoracic inlet (suprasternal notch) approximately 18 cm measuring from the upper incisors</td>
<td>C15.0</td>
</tr>
</tbody>
</table>
### Primary Site | Topography Code
---|---
Upper thoracic - extends from the thoracic inlet to the level of the tracheal bifurcation, approximately 24 cm from the upper incisors | C15.1
Mid thoracic - proximal half of the esophagus between the tracheal bifurcation and the esophago-gastric junction. The lower level is approximately 32 cm from the upper incisor teeth | C15.2
Upper third (proximal) - extends from the sixth cervical vertebra to the sixth thoracic vertebra | C15.3
Middle third - extends from the sixth thoracic vertebra to the ninth thoracic vertebra | C15.4
Lower third (distal) - extends from the ninth thoracic vertebra to the cardioesophageal junction | C15.5

### Stomach C16.0 - C16.9
The stomach lies just below the diaphragm in the upper part of the abdominal cavity primarily to the left of the midline under a portion of the liver.

#### Primary Site | Topography Code
---|---
Cardia - portion of the stomach surrounding the cardioesophageal junction, or cardiac orifice (the opening of the esophagus into the stomach) | C16.0
Fundus (or Fornix) – enlarged portion to the left and above the cardiac orifice | C16.1
Body (or Corpus) - central part of the stomach | C16.2
Pyloric antrum – between the body of the stomach and the pyloric canal | C16.3
Pylorus – distal section of stomach connecting to the duodenum (the beginning of the small intestine) | C16.4

### Small Intestine C17.0 - C17.9
The small intestine is a tube measuring about 2.5 cm in diameter and over 20 feet (600 cm) in length coiled in loops which fills most of the abdominal cavity.

#### Primary Site | Topography Code
---|---
Duodenum - located just below the pyloric portion of the stomach and is about 25 cm long. The duodenum extends from the pyloric sphincter and becomes the jejunum where the tube turns forward and downward | C17.0
Jejunum - continues for over 200 cm and then becomes the ileum, although there is no demarcation between the two divisions | C17.1
Ileum - over 300 cm long and joins the large intestine at the ileocecal valve | C17.2

### Large Intestine C18.0 - C20.9
The large intestine (colon, rectum and anus) is approximately five feet (150 cm) long with a diameter of about 6cm, decreasing towards the lower end. The measurements listed next to each sub-site are from the anal verge.

#### Primary Site | Measurement | Topography Code
---|---|---
Rectum - extends down to the anal canal | 4 - 12 cm | C20.9
Primary Site                                    | Measurement   | Topography Code |
------------------------------------------------|---------------|-----------------|
Rectosigmoid - upper part of the rectum, generally that above the peritoneal reflection | 10 - 17 cm    | C19.9           |
Sigmoid - joins the rectum at the rectosigmoid junction | 17 - 57 cm    | C18.7           |
Descending (left colon) - starts at the splenic flexure and passes downward until it turns towards the midline at the rim of the pelvis and continues downward to become the sigmoid colon | 57 - 82 cm    | C18.6           |
Transverse (middle colon) - begins at the hepatic flexure passing horizontally across the abdomen, below the liver and stomach and above the small intestine. On the left side of the abdomen near the spleen, the colon turns downward at the junction of the transverse and descending colon forming the splenic flexure | 82 - 132 cm   | C18.4           |
Ascending (right colon) - extends upward from the cecum on the right side of the abdomen to the under surface of the right lobe of the liver where it turns to the left forming the hepatic flexure | 132 - 147 cm  | C18.2           |
Cecum - large cul-de-sac at the lower end of the ascending colon (proximal to the entrance of the ileum into the colon; it comprises the first 5-7 cm of the large intestine) | at 150 cm      | C18.0           |
Hepatic Flexure - connects ascending to transverse (lies under the right lobe of the liver near the duodenum) |                | C18.3           |
Splenic Flexure - connects transverse to descending (located near the spleen and tail of the pancreas) |                | C18.5           |
Anal Canal - constitutes the final 2.5cm of the digestive tract. It begins at the anorectal junction and ends at the anal verge where the anal tube turns outward to blend with the perianal skin |                | C21.1           |

NOTE: Each individual’s anatomic make-up is different, as such the measurements listed above should be used as guidelines only.

**Lung C34.0 - C34.9**

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>Topography Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main bronchus (Carina, Hilar)</td>
<td>C34.0</td>
</tr>
<tr>
<td>Upper lobe (Apex, Lingual)</td>
<td>C34.1</td>
</tr>
<tr>
<td>Middle lobe (only the right lung has a middle lobe)</td>
<td>C34.2</td>
</tr>
<tr>
<td>Lower lobe</td>
<td>C34.3</td>
</tr>
</tbody>
</table>

**Lymphoma**

Refer to the [Hematopoietic and Lymphoid Neoplasm Database](#) and the [Hematopoietic and Lymphoid Neoplasm Coding Manual](#) to assist with coding these primaries. These references apply only to cases diagnosed January 1, 2010 and forward.

Lymphomas are considered a systemic (generalized) disease in contrast to solid tumors, such as breast or stomach cancer. The majority of lymphomas arise in lymph nodes C77.0 - C77.9 or lymphatic tissue, such
as tonsils C09.2, spleen C42.2, Waldeyer’s Ring C14.2, or thymus C37.9. These are all called “nodal” lymphomas.

Lymphomas that arise from lymphatic cells in organs, such as stomach or intestine, are called extranodal or extralymphatic. The terms extranodal and extralymphatic are sometimes used interchangeably. Extranodal means that the lymphoma does not arise in a lymph node but may arise in one of the lymphatic tissues mentioned above. While extralymphatic means the lymphoma arises in a non-lymphatic organ or tissue. When referring to nodal versus extra nodal lymphomas, it is important to identify the primary site of the tumor, which may not be the site of the biopsy, the site of spread, or metastasis. For example, diffuse large B-cell lymphoma can be either a nodal or extranodal tumor depending on the primary site. The biopsy may be of a lymph node, but the bulk of the primary disease may be in a primary extranodal organ.

If the site of origin of the lymphoma is in the lymph nodes, record/code the primary site to that specific lymph node chain C770 - C775.

Example A 60 year old female was seen with an enlarged left cervical lymph node that had been present for three months. History and physical examination revealed left cervical lymphadenopathy, and the remainder of examination is within normal limits. Excision of left cervical lymph node revealed: “diffuse large cell non-Hodgkin lymphoma.” Staging work-up included a CT scan of the abdomen/pelvis and a bone marrow biopsy, both of which were negative for malignancy.

*Record the primary site as “cervical lymph node C770.”*

If a lymphoma mass is identified as “retroperitoneal,” “inguinal,” “mediastinal,” or “mesentery,” record/code the primary site that specific lymph node region/chain. For example, a retroperitoneal mass would be coded to retroperitoneal lymph nodes C772.

If a lymphoma involves multiple lymph node regions, record/code the primary site as “lymph nodes of multiple regions C778.” DO NOT code a specific lymph node chain.

Example A 53 year old male relatively healthy and physically active recently noted fatigue and groin soreness. Physical examination revealed several small 1cm nodes in the supraclavicular and axillary areas and two larger 2cm firm inguinal lymph nodes. The rest of the exam was within normal limits. Supraclavicular lymph node biopsy was positive for “B-cell chronic lymphocytic lymphoma.”

*Record the primary site as “multiple lymph nodes C778.”*

NOTE: Supraclavicular lymph node is C77.0; axillary lymph node is C77.3; inguinal lymph node is C77.4. Each of the lymph nodes is in a different region, therefore the primary site code is C77.8 for multiple regions and is recorded as C778.

If a lymphoma arises in an extranodal site, record/code the site of origin, which may or may not be the site of the biopsy.


*Record the primary site as “body of stomach C162.”*

Code the primary site to lymph nodes, NOS C779 when lymph node(s) are involved but no primary site/particular lymph node region is identified.
Code the primary site to bone marrow C421 when lymphoma is present only in the bone marrow.

**Example**  
Bone marrow biopsy positive for “diffuse large cell non-Hodgkin lymphoma. CT scan impression: Retroperitoneal mass suspicious for malignancy. 
*Record the primary site as ‘retroperitoneal lymph nodes, C772.’*

Record/code mycosis fungoides and cutaneous lymphomas to the appropriate site of the skin C44.0 - C44.9.

**Example**  
Patient presented with a large, raised mole on the back of the left arm. A biopsy revealed: mycosis fungoides. *Record the primary site as ‘skin, arm C446.’*

NOTE: The World Health Organization (WHO) diagnosis of “B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma” is coded as 9823/3, and cross-referred to 9670/3, “malignant lymphoma, small B lymphocytic.” Code to the following scenarios.

If this WHO term is diagnosed in blood or bone marrow, record/code the histology as “B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma 9823/3” and record the primary site as “bone marrow C421.”

If this WHO term is diagnosed in tissue, lymph nodes or any organ in combination with blood or bone marrow, record/code the histology as “B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma,” which is cross referenced to “small B-Cell lymphocytic lymphoma (9670/3)” and record the primary site to the “specific lymph node chain C770 -C779 or to the extranodal site of origin.”

**Melanoma of the Skin C44.0 - C44.9**

Each occurrence of melanoma of the skin is a NEW AND SEPARATE primary unless a physician states otherwise. If a patient is diagnosed with metastatic melanoma and the primary site is not identified, record as “skin, NOS C449.”

**Examples**  
A 46 year old female presented in January 2012, with a skin biopsy positive for “malignant melanoma.” Past medical history was positive for malignant melanoma of the right arm in July 2011. Pathology report impression: “skin, right arm positive for malignant melanoma.” *Record as a new/separate primary ‘skin, arm C446.’*

Wide excision skin of mid back: “metastatic malignant melanoma.” Past medical history negative for malignant melanoma. Physical exam revealed scar of mid back from recent excision. Remainder of exam within normal limits, no other skin lesions identified. *Record the primary site as ‘skin, NOS C449.’*

Code to skin, NOS C44.9 if a patient is diagnosed with metastatic melanoma at the time of diagnosis and the primary site is not identified.

**Kaposi Sarcoma**

Code to the site in which it arises. If Kaposi sarcoma arises in the skin and another site simultaneously, code to skin C449.

**Leukemia (C42.1)**

Code the primary site for leukemia as “bone marrow C421.”

**Multiple Myeloma (C42.1)**
Code the primary site for multiple myeloma as “bone marrow C421.”

| Item: | RACE (1-5) | NAACCR Item 160-164 |

Enter the patient’s race according to the documentation in the medical record.

NOTE: ALL tumors for the same patient should have the same race code(s).

If multi-racial, enter each race according to the documentation in the patient’s chart, for a total of five races.

In general, race should be reported as American Indian, white, black, etc.

White includes Mexican, Puerto Rican, Cuban, and all other Caucasians.

If Asian, enter the national origin as Chinese, Vietnamese, Japanese, Hmong, etc.

Race is a required data item for all facilities regardless of the facility type. If the patient’s race is not available in the medical record, it may be necessary to contact the physician’s office.

- If the patient is multiracial, code all races using Race 1 through Race 5. Code any subsequent unused Race fields as 88 (no further race documented.)

- If the person is multiracial and one of the races is white, code the other race(s) first with white in the next race field.

- If the person is multiracial and one of the races is Hawaiian, code Hawaiian as Race 1, followed by the other race(s).

- If Race 1 is coded 99, then Race 2 through Race 5 must all be coded 99.

The codes are as follows:

01 White
02 Black
03 American Indian/Aleutian/Eskimo (includes all indigenous populations of the Western hemisphere)
04 Chinese
05 Japanese
06 Filipino
07 Hawaiian
08 Korean
09 Code retired; do not use.
10 Vietnamese
11 Laotian
12 Hmong
13 Kampuchean (Cambodian)
14 Thai
15 Asian Indian or Pakistani, NOS (coded 09 prior to NAACCR Version 12)
16 Asian Indian
17 Pakistani
20 Micronesian, NOS
21 Chamorran
22 Guamanian, NOS
25 Polynesian, NOS
26 Tahitian
27 Samoan
28 Tongan
30 Melanesian, NOS
31 Fiji Islander
32 New Guinean
88 No further race documented
96 Other Asian, including Asian, NOS and Oriental, NOS
97 Pacific Islander, NOS
98 Other
99 Unknown

Do not leave this data item blank. If race is not documented, then follow-back is required.
Record race description in TEXT--DX PROC--PE field. If unknown, and if follow-back has been conducted, record as such in this field so it is clear that follow-back has been attempted.

Item: RAD--REGIONAL RX MODALITY

Alternate Name: Regional Treatment Modality

Record the dominant modality of radiation therapy used to deliver the most clinically significant dose to the primary volume of interest during the first course of treatment.

Include a description and sites radiated along with start dates.

Radiation treatment modality will typically be found in the radiation oncologist’s summary letter for the first course of treatment.

Codes are as follows:

00 No radiation treatment - Radiation therapy was not administered to the patient; diagnosed at autopsy.
20 External beam, NOS - The treatment is known to be by external beam, but there is insufficient information to determine the specific modality.
21 Orthovoltage - External beam therapy administered using equipment with a maximum energy of less than one (1) million volts (MV). Orthovoltage energies are typically expressed in units of kilovolts (kV).
22 Cobalt-60, Cesium-137 - External beam therapy using a machine containing either a Cobalt-60 or Cesium-137 source. Intracavitary use of these sources is coded either 50 or 51.
23 Photons (2–5 MV) - External beam therapy using a photon producing machine with a beam energy in the range of 2–5 MV.
24 Photons (6–10 MV) - External beam therapy using a photon producing machine with a beam energy in the range of 6–10 MV.
25 Photons (11–19 MV) - External beam therapy using a photon producing machine with a beam energy in the range of 11–19 MV.
26 Photons (>19 MV) - External beam therapy using a photon producing machine with a beam energy of more than 19 MV.
27 Photons (mixed energies) - External beam therapy using more than one energy over the course of treatment.

28 Electrons - Treatment delivered by electron beam.

29 Photons and electrons mixed - Treatment delivered using a combination of photon and electron beams.

30 Neutrons, with or without photons/electrons - Treatment delivered using neutron beam.

31 IMRT - Intensity modulated radiation therapy, an external beam technique that should be clearly stated in patient record.

32 Conformal or 3-D therapy - An external beam technique using multiple, fixed portals shaped to conform to a defined target volume. Should be clearly described as conformal or 3-D therapy in patient record.

40 Protons - Treatment delivered using proton therapy.

41 Stereotactic radiosurgery, NOS - Treatment delivered using stereotactic radiosurgery, type not specified in patient record.

42 Linac radiosurgery - Treatment categorized as using stereotactic technique delivered with a linear accelerator.

43 Gamma Knife Treatment - categorized as using stereotactic technique delivered using a Gamma Knife machine.

50 Brachytherapy, NOS- Brachytherapy, interstitial implants, molds, seeds, needles, radioembolization, or intracavitary applicators of radioactive materials not otherwise specified.

51 Brachytherapy, Intracavitary, LDR- Intracavitary (no direct insertion into tissues) radio-isotope treatment using low dose rate applicators and isotopes (Cesium-137, Fletcher applicator).

52 Brachytherapy, Intracavitary, HDR- Intracavitary (no direct insertion into tissues) radioisotope treatment using high dose rate after-loading applicators and isotopes.

53 Brachytherapy, Interstitial, LDR- Interstitial (direct insertion into tissues) radioisotope treatment using low dose rate sources.

54 Brachytherapy, Interstitial, HDR- Interstitial (direct insertion into tissues) radioisotope treatment using high dose rate sources.

55 Radium- Infrequently used for low dose rate (LDR) interstitial and intracavitary therapy.

60 Radioisotopes, NOS Iodine-131, Phosphorus-32, etc.

61 Strontium-89 - Treatment primarily by intravenous routes for bone metastases.

62 Strontium-90
98  Other, NOS - Other radiation, NOS; Radiation therapy administered, but the treatment modality is not specified or is unknown.

99  Unknown - It is unknown whether radiation therapy was administered.

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item: REASON FOR NO RADIATION**  
**Alternate Name: Reason for No Regional Radiation Therapy**

Records the reason that no regional radiation therapy was administered to the patient.

0  Radiation therapy was administered.

1  Radiation therapy was not administered because it was not part of the planned first course treatment.

2  Radiation therapy was not recommended/administered because it was contraindicated due to other patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned radiation etc.).

5  Radiation therapy was not administered because the patient died prior to planned or recommended therapy.

6  Radiation therapy was not administered; it was recommended by the patient’s physician, but was not administered as part of first course treatment. No reason was noted in patient record.

7  Radiation therapy was not administered; it was recommended by the patient’s physician, but this treatment was refused by the patient, the patient’s family member, or the patient’s guardian. The refusal was noted in record.

8  Radiation therapy was recommended, but it is unknown whether it was administered.

9  It is unknown if radiation therapy was recommended or administered. Death certificate and autopsy cases only

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item: REASON FOR NO SURGERY**  
**Alternate Name: Reason for No Cancer-Directed Surgery, Reason for No CA Dir Surgery**

Enter the reason no cancer directed surgery was performed for the primary site. Use the number that best describes why the primary site surgery was not performed.

If Surgical Procedure of Primary Site is coded 00, then record the reason based on documentation in the patient record.

- Code 1 if the treatment plan offered multiple options and the patient selected treatment that did not include surgery of the primary site, or if the option of “no treatment” was accepted by the patient.

- Code 1 if Surgical Procedure of Primary Site is coded 98.
• Code 7 if the patient refused recommended surgical treatment, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.

• Code 8 if it is known that a physician recommended primary site surgery, but no further documentation is available yet to determine whether surgery was performed.

• Cases coded 8 should be followed and updated to a more definitive code as appropriate.

• Code 9 if the treatment plan offered multiple choices, but it is unknown which treatment, if any was provided.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Surgery of primary site was performed.</td>
</tr>
<tr>
<td>1</td>
<td>Surgery of the primary site was not performed because it was not part of the planned first course treatment.</td>
</tr>
<tr>
<td>2</td>
<td>Surgery of the primary site was not recommended/performed because it was contraindicated due to patient risk factors (comorbid conditions, advanced age, progression of tumor prior to planned surgery etc.)</td>
</tr>
<tr>
<td>5</td>
<td>Surgery of the primary site was not performed because the patient died prior to planned or recommended surgery.</td>
</tr>
<tr>
<td>6</td>
<td>Surgery of the primary site was not performed; it was recommended by the patient’s physician, but was not performed as part of the first course of therapy. No reason was noted in patient record.</td>
</tr>
<tr>
<td>7</td>
<td>Surgery of the primary site was not performed; it was recommended by the patient’s physician, but this treatment was refused by the patient, the patient’s family member, or the patient’s guardian. The refusal was noted in patient record.</td>
</tr>
<tr>
<td>8</td>
<td>Surgery of the primary site was recommended, but it is unknown if it was performed. Further follow-up is recommended.</td>
</tr>
<tr>
<td>9</td>
<td>It is unknown whether surgery of the primary site was recommended or performed. Diagnosed at autopsy or death certificate only.</td>
</tr>
</tbody>
</table>

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item:** REGIONAL NODES EXAMINED  
**Alternate Name:** Number of Regional Lymph Nodes Examined, Regional Lymph Nodes Examined  
**NAACCR Item 830**

This field records the total number of regional lymph nodes that were removed and examined by the pathologist.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>No nodes examined</td>
</tr>
<tr>
<td>01 – 89</td>
<td>1 to 89 lymph nodes are examined (code exact number of nodes examined.)</td>
</tr>
<tr>
<td>90</td>
<td>90 or more nodes are examined</td>
</tr>
<tr>
<td>95</td>
<td>No regional nodes removed, but aspiration or core biopsy of regional nodes performed. See rule 5.</td>
</tr>
<tr>
<td>96</td>
<td>Regional lymph node removal documented as a sampling, and the number of nodes unknown/not stated. See rule 7.</td>
</tr>
<tr>
<td>97</td>
<td>Regional lymph node removal documented as dissection, and the number of nodes unknown/not stated. See rule 8.</td>
</tr>
<tr>
<td>Code</td>
<td>Description</td>
</tr>
<tr>
<td>------</td>
<td>-------------</td>
</tr>
<tr>
<td>98</td>
<td>Regional lymph nodes surgically removed, but number of lymph nodes unknown/not stated and not documented as sampling or dissection; nodes examined, but the number unknown. See rule 4e.</td>
</tr>
<tr>
<td>99</td>
<td>Unknown whether nodes are examined; not applicable or negative; not documented in patient record.</td>
</tr>
</tbody>
</table>

**Instructions for Coding**

1. **Regional lymph nodes only.** Record information about only regional lymph nodes in this field. Distant lymph node information should be coded in the METS AT DX-DISTANT LN field.

2. This field is **based on pathologic information only.** This field is to be recorded regardless of whether the patient received preoperative treatment.

3. **Use of code 00.** Code 00 may be used in several situations.
   a. When the assessment of lymph nodes is clinical.
   b. When no lymph nodes are removed and examined.
   c. When a “dissection” of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination.
   d. If Regional Nodes Examined is coded 00, Regional Nodes Positive is coded as 98.

4. **Cumulative nodes removed and examined.** Record the total number of regional lymph nodes removed and examined by the pathologist.
   a. The number of regional lymph nodes examined is cumulative from all procedures that removed lymph nodes through the completion of surgeries in the first course of treatment with the exception of aspiration or core biopsies coded to 95.
   b. Do not count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Examined.
      
      **Example** Lung cancer patient has a mediastinoscopy and positive core biopsy of a hilar lymph node. Patient then undergoes right upper lobectomy that yields 3 hilar and 2 mediastinal nodes positive out of 11 nodes dissected. **Code Regional Nodes Positive as 05 and Regional Nodes Examined as 11 because the core biopsy was of a lymph node in the same chain as the nodes dissected.**
   c. If the positive aspiration or core biopsy is from a node in a different node region, include the node in the count of Regional Nodes Examined.
      
      **Example** Breast cancer patient has a positive core biopsy of a supraclavicular node and an axillary dissection showing 3 of 8 nodes positive. **Code Regional Nodes Positive as 04 and Regional Nodes Examined as 09 because the supraclavicular lymph node is in a different, but still regional, lymph node chain.**
   d. If the location of the lymph node that is aspirated or core-biopsied is not known, assume it is part of the lymph node chain surgically removed, and DO NOT include it in the count of Regional Nodes Examined.
      
      **Example** Patient record states that core biopsy was performed at another facility and 7/14 regional lymph nodes were positive at the time of resection. **Code Regional Nodes Positive as 07 and Regional Nodes Examined as 14.**
e. When neither the type of lymph node removal procedure nor the number of lymph nodes examined is known, use code 98.

5. **Priority of lymph node counts.** If there is a discrepancy regarding the number of lymph nodes examined, use information in the following priority: final diagnosis, synoptic report (also known as CAP protocol or pathology report checklist), microscopic, gross.

6. **Use of code 95.** Use code 95 when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue).

   *Example* Patient with esophageal cancer. Enlarged mid-esophageal node found on CT scan, which is aspirated and found to be positive. Patient undergoes radiation therapy and no surgery. *Code Regional Nodes Positive as 95 and Regional Nodes Examined as 95.*

7. **Lymph node biopsy.** If a lymph node biopsy was performed, code the number of nodes removed, if known. If the number of nodes removed by biopsy is not known, use code 96.

8. **Definition of “sampling” (code 96).** A lymph node “sampling” is removal of a limited number of lymph nodes. Other terms for removal of a limited number of nodes include lymph node biopsy, berry picking, sentinel lymph node procedure, sentinel node biopsy, selective dissection. Use code 96 when a limited number of nodes are removed but the number is unknown.

9. **Definition of “dissection” (code 97).** A lymph node “dissection” is removal of most or all of the nodes in the lymph node chain(s) that drain the area around the primary tumor. Other terms include lymphadenectomy, radical node dissection, lymph node stripping. Use code 97 when more than a limited number of lymph nodes are removed and the number is unknown.

10. **Multiple lymph node procedures.** If both a lymph node sampling and a lymph node dissection are performed and the total number of lymph nodes examined is unknown, use code 97.

11. **Use of code 99.** If it is unknown whether nodes were removed or examined, code as 99.

12. **Primary sites always coded 99.** For the following schemas, the Regional Nodes Examined field is ALWAYS coded as 99.
   - Placenta
   - Brain and Cerebral Meninges
   - Other Parts of Central Nervous System
   - Intracranial Gland
   - Hematopoietic, Reticuloendothelial, Immunoproliferative and Myeloproliferative Neoplasms
   - Hodgkin and non-Hodgkin Lymphoma
   - Myeloma and Plasma Cell Disorders
   - Other and Ill-Defined Primary Sites
   - Unknown Primary Site

**Do not leave this data item blank.**

<table>
<thead>
<tr>
<th>Item: REGIONAL NODES POSITIVE</th>
<th>NAACCR Item 820</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alternate Name: Pathologic Review of Regional Lymph Nodes, Regional Lymph Nodes Positive</td>
<td></td>
</tr>
</tbody>
</table>

This field records the exact number of regional lymph nodes examined by the pathologist and found to contain metastases.
<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>All nodes examined are negative</td>
</tr>
<tr>
<td>01–89</td>
<td>1 to 89 lymph nodes are positive (code exact number of nodes positive.)</td>
</tr>
<tr>
<td>90</td>
<td>90 or more nodes are positive</td>
</tr>
<tr>
<td>95</td>
<td>Positive aspiration or core biopsy of lymph node(s) was performed. See rule 6.</td>
</tr>
<tr>
<td>97</td>
<td>Positive nodes are documented, but the number is unspecified. See rule 7.</td>
</tr>
<tr>
<td>98</td>
<td>No nodes were examined. See rule 8.</td>
</tr>
<tr>
<td>99</td>
<td>It is unknown whether nodes are positive; not applicable; not stated in patient record.</td>
</tr>
</tbody>
</table>

**Instructions for Coding**

1. **Regional lymph nodes only.** Record information about only regional lymph nodes in this field. Involved distant lymph nodes should be coded in the METS AT DX-DISTANT LN field.

2. This field is **based on pathologic information only.** This field is to be recorded regardless of whether the patient received preoperative treatment.

3. True in situ cases cannot have positive lymph nodes, so the only allowable codes are 00 (negative) or 98 (not examined). Codes 01-97 and 99 are not allowed.

4. **Cumulative nodes positive.** Record the total number of regional lymph nodes removed and found to be positive by pathologic examination.
   
   a. The number of regional lymph nodes positive is cumulative from all procedures that remove lymph nodes through the completion of surgeries in the first course of treatment.
   
   b. Do not count a positive aspiration or core biopsy of a lymph node in the same lymph node chain removed at surgery as an additional node in Regional Nodes Positive when there are positive nodes in the resection. In other words, if there are positive regional lymph nodes in a lymph node dissection, DO NOT count the core needle biopsy or the fine needle aspiration if it is in the same chain. See also Definition of Code 95 below.

   **Example**
   
   Lung cancer patient has a mediastinoscopy and positive core biopsy of a hilar lymph node. Patient then undergoes right upper lobectomy that yields 3 hilar and 2 mediastinal nodes positive out of 11 nodes dissected.
   
   *Code Regional Nodes Positive as 05 and Regional Nodes Examined as 11 because the core biopsy was of a lymph node in the same chain as the nodes dissected.*

   **Example**
   
   Positive right cervical lymph node aspiration followed by right cervical lymph node dissection showing 1 of 6 nodes positive.
   
   *Code Regional Nodes Positive as 01 and Regional Nodes Examined as 06.*

   c. If the positive aspiration or core biopsy is from a node in a different node region, include the node in the count of Regional Nodes Positive.

   **Example**
   
   Breast cancer patient has a positive core biopsy of a supraclavicular node and an axillary dissection showing 3 of 8 nodes positive.
   
   *Code Regional Nodes Positive as 04 and Regional Nodes_examined as 09 because the supraclavicular lymph node is in a different, but still regional, lymph node chain.*
d. If the location of the lymph node that is core-biopsied or aspirated is not known, assume it is part of the lymph node chain surgically removed, and DO NOT include it in the count of Regional Nodes Positive.

**Example**
Patient record states that core biopsy was performed at another facility and 7/14 regional lymph nodes were positive at the time of resection.
*Code Regional Nodes Positive as 07 and Regional Nodes Examined as 14.*

5. **Priority of lymph node counts.** If there is a discrepancy regarding the number of positive lymph nodes, use information in the following priority: final diagnosis, synoptic report (also known as CAP protocol or pathology report checklist), microscopic, gross.

6. **Use of code 95.** Use code 95 when the only procedure for regional lymph nodes is a needle aspiration (cytology) or core biopsy (tissue).

a. Use code 95 when a positive lymph node is aspirated and there are no surgically resected lymph nodes.

**Example**
Patient with esophageal cancer. Enlarged mid-esophageal node found on CT scan, which is aspirated and found to be positive. Patient undergoes radiation therapy and no surgery.
*Code Regional Nodes Positive as 95 and Regional Nodes Examined as 95.*

b. Use code 95 when a positive lymph node is aspirated and surgically resected lymph nodes are negative.

**Example**
Lung cancer patient has aspiration of suspicious hilar mass, which shows metastatic squamous carcinoma in lymph node tissue. Patient undergoes preoperative radiation therapy followed by lobectomy showing 6 negative hilar lymph nodes.
*Code Regional Nodes Positive as 95 and Regional Nodes Examined as the 06 nodes surgically resected.*

7. **Definition of code 97.** Use code 97 for any combination of positive aspirated, biopsied, sampled or dissected lymph nodes if the number of involved nodes cannot be determined on the basis of cytology or histology. Code 97 includes positive lymph nodes diagnosed by either cytology or histology.

**Example**
Patient with carcinoma of the pyriform sinus has a mass in the mid neck. Fine needle aspiration (FNA) of one node is positive. The patient has neoadjuvant chemotherapy, then resection of the primary tumor and a radical neck dissection. In the radical neck dissection “several” of 10 nodes are positive; the remainder of the nodes show chemotherapy effect.
*Code Regional Nodes Positive as 97 because the total number of positive nodes biopsied and removed is unknown, and code Regional Nodes Examined as 10.*

**NOTE:** For primary sites where the number of involved nodes must be known in order to map to N1, N2, etc., code 97 maps to N1 and therefore should be avoided.

**NOTE:** If the aspirated node is the only one that is microscopically positive, use code 95.

**NOTE:** Avoid using Regional Nodes Positive code 97 if possible, even if this means slightly undercounting the number of nodes positive.

8. **Use of code 98.** Code 98 may be used in several situations.

a. When the assessment of lymph nodes is clinical only.
b. When no lymph nodes are removed and examined.

c. When a “dissection” of a lymph node drainage area is found to contain no lymph nodes at the time of pathologic examination.

d. If Regional Nodes Positive is coded as 98, Regional Nodes Examined is usually coded 00.

9. **Isolated tumor cells (ITCs) in lymph nodes.** For all primary sites except cutaneous melanoma and Merkel cell carcinoma of skin, count only lymph nodes that contain micrometastases or larger (metastases greater than 0.2 millimeters in size). DO NOT include in the count of lymph nodes positive any nodes that are identified as containing isolated tumor cells (ITCs). If the path report indicates that nodes are positive but the size of metastasis is not stated, assume the metastases are larger than 0.2 mm and count the lymph node(s) as positive.

   a. For cutaneous melanoma and Merkel cell carcinoma, count nodes with ITCs as positive lymph nodes.

10. **Use of code 99.** Use code 99 if it is unknown whether regional lymph nodes are positive.

11. **Primary sites always coded 99.** For the following primary sites and histologies, the Regional Nodes Positive field is ALWAYS coded as 99:

    Placenta
    Brain and Cerebral Meninges
    Other Parts of Central Nervous System
    Intracranial Gland
    Hodgkin and non-Hodgkin Lymphoma
    Hematopoietic, Reticuloendothelial, Immunoproliferative and Myeloproliferative Neoplasms
    Myeloma and Plasma Cell Disorders
    Other and Ill-Defined Primary Sites
    Unknown Primary Site

Do not leave this data item blank.

**Item:** REPORTING FACILITY NAACCR Item 540

The Reporting Facility ten-digit identification number or FIN is used to identify a reporting facility in the central registry database and is useful for monitoring data submission, ensuring the accuracy of data and identifying areas for special studies.

[American College of Surgeons Facility Identification Number (FIN) List](#)

Do not leave this data item blank.

**Item:** RX DATE BRM NAACCR Item 1240

*Alternate Name: Date Immunotherapy Started, RX Date--BRM*

Date of initiation for immunotherapy, a.k.a. biological response modifier (BRM), which is part of the first course of treatment.

Enter the year, month and day (**YYYY/MM/DD**) for the date immunotherapy/BRM was started.
Record the date on which immunotherapy/BRM was administered at any facility that is part of the first course of treatment.

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

**Item: RX DATE BRM FLAG**

*Alternate Name: RX Date--BRM Flag*

This flag explains why there is no appropriate value in the corresponding date field.

Codes are as follows:
10 No information whatsoever can be inferred from this exceptional value (that is, unknown if any immunotherapy/BRM was given.)

11 No proper value is applicable in this context (for example, no immunotherapy/BRM given.)

12 A proper value is applicable but not known. This event occurred, but the date is unknown (that is, immunotherapy/BRM was given but the date is unknown.)

15 Information is not available at this time, but it is expected that it will be available later (that is, immunotherapy/BRM is planned as part of first course treatment, but had not yet started at the time of the last follow-up.)

**BLANK - Valid date provided for item RX DATE BRM**

An allowable value must be in this Flag field or its corresponding Date field. Both fields cannot be blank.

**Item: RX DATE CHEMO**

*Alternate Name: Date Chemotherapy Started, RX Date--Chemo*

Enter the year, month and day (YYYY/MM/DD) for the date chemotherapy was started.

Record the date on which chemotherapy was administered at any facility that is part of the first course of treatment.

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

**Item: RX DATE CHEMO FLAG**

*Alternate Name: RX Date--Chemo Flag*

This flag explains why there is no appropriate value in the corresponding date field.

Codes are as follows:
10 No information whatsoever can be inferred from this exceptional value (that is, unknown if any chemotherapy was given).

11 No proper value is applicable in this context (for example, no chemotherapy given).

12 A proper value is applicable but not known. This event occurred, but the date is unknown (that is, chemotherapy was given but the date is unknown).
15 Information is not available at this time, but it is expected that it will be available later (that is, chemotherapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up).

BLANK - Valid date provided for item RX DATE CHEMO

An allowable value must be in this Flag field or its corresponding Date field. Both fields cannot be blank.

**Item:** RX DATE HORMONE  
*Alternate Name: Date Hormone Therapy Started, RX Date--Hormone*

Enter the year, month and day (YYYY/MM/DD) for the date hormone was started.

Record the date on which hormone was administered at any facility that is part of the first course of treatment.

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

**Item:** RX DATE HORMONE FLAG  
*Alternate Name: RX Date--Hormone Flag*

This flag explains why there is no appropriate value in the corresponding date field.

Codes are as follows:

10 No information whatsoever can be inferred from this exceptional value (that is, unknown if any hormone therapy was given.)

11 No proper value is applicable in this context (for example, no hormone therapy given.)

12 A proper value is applicable but not known. This event occurred, but the date is unknown (that is, hormone therapy was given but the date is unknown.)

15 Information is not available at this time, but it is expected that it will be available later (that is, hormone therapy is planned as part of first course treatment, but had not yet started at the time of the last follow-up.)

BLANK - Valid date provided for item RX DATE HORMONE

An allowable value must be in this Flag field or its corresponding Date field. Both fields cannot be blank.

**Item:** RX DATE MST DEFN SRG  
*Alternate Name: Date of Most Definitive Surgical Resection of the Primary Site, RX Date--Most Defin Surg*

Record the date (YYYY/MM/DD) of the most definitive surgical procedure of the primary site performed as part of the first course of treatment.

Record the date on which the surgery described by Surgical Procedure of Primary Site was performed at this or any facility.

If surgery is the first or only treatment administered to the patient, then the date of surgery should be the same as the date entered into the item Date of First Course of Treatment.
An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

Item: RX DATE MST DEFN SRG FLAG  
NAACCR Item 3171

This flag explains why there is no appropriate value in the corresponding date field.

Codes are as follows:
10 No information whatsoever can be inferred from this exceptional value; unknown if surgery performed

11 No proper value is applicable in this context (no surgery performed.)

12 A proper value is applicable but not known. This event occurred, but the date is unknown (surgery was performed, but date is unknown.)

BLANK - Valid date provided for item RX DATE MST DEFN SRG

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

Item: RX DATE OTHER  
NAACCR Item 1250
Alternate Name: Date Other Treatment Started, RX Date--Other

Enter the year, month and day (YYYY/MM/DD) for the date other treatment was started.

Record the date on which other treatment was administered at any facility that is part of the first course of treatment.

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

Item: RX DATE OTHER FLAG  
NAACCR Item 1251
Alternate Name: RX Date--Other Flag

This flag explains why there is no appropriate value in the corresponding date field.

Codes are as follows:
10 No information whatsoever can be inferred from this exceptional value (that is, unknown if any Other Treatment was given.)

11 No proper value is applicable in this context (for example, no Other Treatment given).

12 A proper value is applicable but not known. This event occurred, but the date is unknown (that is, Other Treatment was given but the date is unknown).

15 Other therapy is planned as part of the first course of treatment, but had not been started at the time of the most recent follow-up.

BLANK - Valid date provided for item RX DATE OTHER

An allowable value must be in this Flag field or its corresponding Date field. Both fields cannot be blank.

Item: RX DATE RADIATION  
NAACCR Item 1210
Alternate Name: Date Radiation Started, RX Date--Radiation
Enter the year, month and day (YYYY/MM/DD) for the date radiation was started.

Record the date on which radiation therapy began at any facility that is part of the first course of treatment.

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

**Item:** RX DATE RADIATION FLAG  
**Alternate Name:** RX Date--Radiation Flag

This flag explains why there is no appropriate value in the corresponding date field.

Codes are as follows:

10  No information whatsoever can be inferred from this exceptional value (that is, unknown if any radiation was given).

11  No proper value is applicable in this context (for example, no radiation given).

12  A proper value is applicable but not known. This event occurred, but the date is unknown (that is, radiation was given but the date is unknown).

15  Information is not available at this time, but it is expected that it will be available later (for example, radiation therapy is planned as part of the first course of therapy, but had not been started at the time of the most recent follow-up).

BLANK - Valid date provided for item RX DATE RADIATION

An allowable value must be in this Flag field or its corresponding Date field. Both fields cannot be blank.

**Item:** RX DATE SURGERY  
**Alternate Name:** Date of Cancer-Directed Surgery, Date of Surgery, Date of First Surgical Procedure, RX Date--Surgery

Record the date (YYYY/MM/DD) of the first surgical procedure of the primary site performed as part of the first course of treatment.

Record the date on which the surgery described by Surgical Procedure of Primary Site was performed at this or any facility.

If surgery is the first or only treatment administered to the patient, then the date of surgery should be the same as the date entered into the item Date of First Course of Treatment.

An allowable value must be in this Date field or its corresponding Flag field. Both fields cannot be blank.

**Item:** RX DATE SURGERY FLAG  
**Alternate Name:** RX Date--Surgery Flag

This flag explains why there is no appropriate value in the corresponding date field.

Codes are as follows:

10  No information whatsoever can be inferred from this exceptional value; unknown if surgery performed
11 No proper value is applicable in this content (no surgery performed.)

12 A proper value is applicable but not known. This event occurred, but the date is unknown (surgery was performed, but date is unknown.)

BLANK - Valid date provided for item RX DATE SURGERY

An allowable value must be in this Flag field or its corresponding Date field. Both fields cannot be blank.

**Item:** RX SUMM–BRM

*Alternate Name: Biological Response Modifiers*

Records the type of immunotherapy – biologic response modifiers (BRM) – administered as first course treatment at this facility. If immunotherapy was not administered, then this item records the reason it was not administered to the patient. Immunotherapy consists of biological or chemical agents that alter the immune system or change the host’s response to tumor cells.

Refer to the [SEER*Rx Interactive Drug Database](https://seer.cancer.gov/rx_drugdatabase/) for a list of immunotherapeutic/BRM agents.

- Code 00 if immunotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.

- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include immunotherapy.

- If it is known that immunotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.

- Code 87 if the patient refused recommended immunotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.

- Code 88 if it is known that a physician recommended immunotherapy but no further documentation is available yet to confirm its administration.

- Code 88 to indicate a referral was made to a medical oncologist about immunotherapy and the registry should follow the case to determine whether it was given or why not. If follow-up to the specialist or facility determines the patient was never there, code 00.

- Cases coded 88 should be followed and the code updated as appropriate.

- Code 99 if it is not known whether immunotherapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.

**Codes are as follows:**

- 00 None, immunotherapy was not part of the planned first course of therapy. Diagnosed at autopsy.

- 01 Immunotherapy administered as first course therapy.

- 82 Immunotherapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age).
85 Immunotherapy was not administered because the patient died prior to planned or recommended therapy.

86 Immunotherapy was not administered. It was recommended by the patient’s physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.

87 Immunotherapy was not administered. It was recommended by the patient’s physician, but this treatment was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in patient record.

88 Immunotherapy was recommended, but it is unknown if it was administered.

89 It is unknown whether an immunotherapeutic agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item:** RX SUMM--CHEMO  
**Alternate Name:** Chemotherapy  
**NAACCR Item 1390**

Records the type of chemotherapy administered as first course treatment at this facility. If chemotherapy was not administered, then this item records the reason it was not administered to the patient. Chemotherapy consists of a group of anticancer drugs that inhibit the reproduction of cancer cells by interfering with DNA synthesis and mitosis.

Refer to the [SEER*Rx Interactive Drug Database](#) for a list of chemotherapeutic agents.

- Code 00 if chemotherapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.

- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include chemotherapy.

- If it is known that chemotherapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.

- Code 87 if the patient refused recommended chemotherapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.

- Code 88 if it is known that a physician recommended the patient receive chemotherapy but no further documentation is available yet to confirm its administration.

- Code 88 to indicate referral was made medical oncologist and the registry must follow to determine whether it was given. If follow-up with the specified specialist or facility indicates the patient was never there, code 00.

- Cases coded 88 must be followed to determine what kind of chemotherapy was administered or why it was not.

- Code 99 if it is not known whether chemotherapy is usually administered for this type and stage of cancer and there is no mention in the patient record whether it was recommended or administered.
• Code chemoembolization as 01, 02, or 03 depending on the number of chemotherapeutic agents involved.

• If the managing physician changes one of the agents in a combination regimen, and the replacement agent belongs to a different group (chemotherapeutic agents are grouped as alkylating agents, antimetabolites, natural products, or other miscellaneous) than the original agent, the new regimen represents the start of subsequent therapy, and **only the original agent or regimen is recorded as first course therapy**.

Codes are as follows:

00  None; no chemotherapy administered

01  Chemotherapy administered as first course therapy; type/agents not documented

02  Single-agent chemotherapy administered as first course therapy

03  Multi-agent chemotherapy administered as first course therapy

82  Chemo was not recommended/administered because it was contraindicated due to patient risk factors

85  Chemotherapy was not administered because patient expired prior to planned therapy

86  Chemotherapy recommended but not administered; reason unknown

87  Chemotherapy recommended but refused by patient or family

88  Chemotherapy recommended but unknown if administered

99  Unknown whether chemotherapy was recommended or administered

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item:** RX SUMM–HORMONE  
**Alternate Name:** Hormone Therapy  
**NAACCR Item 1400**

Records the type of hormone therapy administered as first course treatment at this and all other facilities. If hormone therapy was not administered, then this item records the reason it was not administered to the patient. Hormone therapy consists of a group of drugs that may affect the long-term control of a cancer’s growth. It is not usually used as a curative measure.

Refer to the [SEER*Rx Interactive Drug Database](https://seer.cancer.gov/rx/treatment.html) for a list of hormonal agents.

• Record prednisone as hormonal therapy when administered in combination with chemotherapy, such as MOPP (mechlorethamine, vincristine, procarbazine, prednisone) or COPP (cyclophosphamide, vincristine, procarbazine, prednisone).

• **DO NOT** code prednisone as hormone therapy when it is administered for reasons other than chemotherapeutic treatment.

• Tumor involvement or treatment may destroy hormone-producing tissue. Hormone replacement therapy will be given if the hormone is necessary to maintain normal metabolism and body function. **DO NOT** code hormone replacement therapy as part of first course therapy.
• Code 00 if hormone therapy was not administered to the patient, and it is known that it is not usually administered for this type and stage of cancer.

• Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include hormone therapy.

• Code 01 for thyroid replacement therapy which inhibits TSH (thyroid-stimulating hormone). TSH is a product of the pituitary gland that can stimulate tumor growth.

• If it is known that hormone therapy is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.

• Code 87 if the patient refused recommended hormone therapy, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.

• Code 88 if it is known that a physician recommended hormone therapy, but no further documentation is available yet to confirm its administration.

• Code 88 to indicate the patient was referred to a medical oncologist and the registry should follow the case for hormone therapy. If follow-up with the specified specialist or facility indicates the patient was never there, code 00.

• Cases coded 88 should be followed to determine whether they received hormone therapy or why not.

• Code 99 if it is not known whether hormone therapy is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.

Codes are as follows:

00  None, hormone therapy was not part of the planned first course of therapy. Diagnosed at autopsy.

01  Hormone therapy administered as first course therapy.

82  Hormone therapy was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of tumor prior to administration, etc.)

85  Hormone therapy was not administered because the patient died prior to planned or recommended therapy.

86  Hormone therapy was not administered. It was recommended by the patient’s physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.

87  Hormone therapy was not administered. It was recommended by the patient’s physician, but this treatment was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in patient record.

88  Hormone therapy was recommended, but it is unknown if it was administered.

99  It is unknown whether a hormonal agent(s) was recommended or administered because it is not stated in patient record. Death certificate only.
**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

<table>
<thead>
<tr>
<th>Item: RX SUMM–OTHER</th>
<th>NAACCR Item 1420</th>
</tr>
</thead>
</table>

**Alternate Name: Other Treatment, Other Cancer-Directed Therapy**

Identifies other treatment that cannot be defined as surgery, radiation, or systemic therapy according to the defined data items in this manual.

- The principal treatment for certain reportable hematopoietic diseases could be supportive care that does not meet the usual definition of treatment that “modifies, controls, removes, or destroys” proliferating cancer tissue. Supportive care may include phlebotomy, transfusion, or aspirin. In order to report the hematopoietic cases in which the patient received supportive care, SEER and the Commission on Cancer have agreed to record treatments such as phlebotomy, transfusion, or aspirin as “Other Treatment” (Code 1) for the hematopoietic diseases ONLY. (See instructions for coding in Section One).
- Code 1 for embolization using alcohol as an embolizing agent.
- Code 1 for embolization to a site other than the liver where the embolizing agent is unknown.
- Code 1 for PUVA (psoralen and long-wave ultraviolet radiation.)
- **DO NOT** code pre-surgical embolization that given for a purpose to shrink the tumor.
- Code 8 if it is known that a physician recommended treatment coded as Other Treatment, and no further documentation is available yet to confirm its administration.
- Code 8 to indicate referral to a specialist for Other Treatment and the registry should follow. If follow-up with the specialist or facility determines the patient was never there, code 0.

Codes are as follows:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None – All cancer treatment was coded in other treatment fields (surgery, radiation, systemic therapy). Patient received no cancer treatment. Diagnosed at autopsy.</td>
</tr>
<tr>
<td>1</td>
<td>Other – Cancer treatment that cannot be appropriately assigned to specified treatment data items (surgery, radiation, systemic therapy).</td>
</tr>
<tr>
<td>2</td>
<td>Other - Experimental – This code is not defined. It may be used to record participation in institution based clinical trials.</td>
</tr>
<tr>
<td>3</td>
<td>Other - Double Blind – A patient is involved in a double-blind clinical trial. Code the treatment actually administered when the double-blind trial code is broken.</td>
</tr>
<tr>
<td>6</td>
<td>Other - Unproven – Cancer treatments administered by nonmedical personnel.</td>
</tr>
<tr>
<td>7</td>
<td>Refusal - Other treatment was not administered. It was recommended by the patient’s physician, but this treatment (which would have been coded 1, 2, or 3) was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in the patient record.</td>
</tr>
<tr>
<td>8</td>
<td>Recommended; unknown if administered; Other treatment was recommended, but it is unknown whether it was administered.</td>
</tr>
</tbody>
</table>
9 Unknown - It is unknown whether other treatment was recommended or administered, and there is no information in the medical record to confirm the recommendation or administration of other treatment. Death certificate only.

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item:** RX SUMM--SCOPE REG NL SUR

**Alternate Name:** Scope of Regional Lymph Node Surgery

Identifies the removal, biopsy, or aspiration of regional lymph node(s) at the time of surgery of the primary site or during a separate surgical event.

- The scope of regional lymph node surgery is collected for each surgical event even if surgery of the primary site was not performed.

- Record surgical procedures which aspirate, biopsy, or remove regional lymph nodes in an effort to diagnose or stage disease in this data item. Record the date of this surgical procedure in data item Date of First Course of Treatment and/or Date of First Surgical Procedure if applicable.

- Codes 0–7 are hierarchical. If only one procedure can be recorded, code the procedure that is numerically higher.

- For intracranial and central nervous system primaries (C70.0-C70.9, C71.0-C71.9, C72.0-C72.9, C75.1-C75.3), code 9.

- For lymphomas (M-9590-9726, 9728-9732, 9734-9740, 9750-9762, 9811-9831, 9940, 9948 and 9971) with a lymph node primary site (C77.0-C77.9), code 9.

- For an unknown or ill-defined primary site (C76.0-C76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992), code 9.

- DO NOT code distant lymph nodes removed during surgery to the primary site for this data item. Distant nodes are coded in the data field Surgical Procedure/Other Site.

Codes are as follows:

<table>
<thead>
<tr>
<th>Code</th>
<th>Label</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>None</td>
<td>No regional lymph node surgery. No lymph nodes found in the pathologic specimen. Diagnosed at autopsy.</td>
</tr>
<tr>
<td>1</td>
<td>Biopsy or aspiration of regional lymph node, NOS</td>
<td>Biopsy or aspiration of regional lymph node(s) regardless of the extent of involvement of disease.</td>
</tr>
<tr>
<td>2</td>
<td>Sentinel lymph node biopsy</td>
<td>Biopsy of the first lymph node or nodes that drain a defined area of tissue within the body. Sentinel node(s) are identified by the injection of a dye or radio label at the site of the primary tumor.</td>
</tr>
<tr>
<td>Code</td>
<td>Label</td>
<td>Definition</td>
</tr>
<tr>
<td>------</td>
<td>-------</td>
<td>------------</td>
</tr>
<tr>
<td>3</td>
<td>Number of regional lymph node removed unknown or not stated; regional lymph node, NOS</td>
<td>Sampling or dissection of regional lymph node(s) and the number of nodes removed is unknown or not stated. The procedure is not specified as sentinel node biopsy.</td>
</tr>
<tr>
<td>4</td>
<td>1 to 3 regional lymph nodes removed</td>
<td>Sampling or dissection of regional lymph node(s) with fewer than four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.</td>
</tr>
<tr>
<td>5</td>
<td>4 or more regional lymph nodes removed</td>
<td>Sampling or dissection of regional lymph nodes with at least four lymph nodes found in the specimen. The procedure is not specified as sentinel node biopsy.</td>
</tr>
<tr>
<td>6</td>
<td>Sentinel node biopsy and code 3, 4 or 5 at same time, or timing not stated</td>
<td>Code 2 was performed in a single surgical event with code 3, 4, or 5. Or, code 2 and 3, 4, or 5 were performed, but timing was not stated in patient record.</td>
</tr>
<tr>
<td>7</td>
<td>Sentinel node biopsy and code 3, 4, or 5 at different times</td>
<td>Code 2 was followed in a subsequent surgical event by procedures coded as 3, 4, or 5.</td>
</tr>
<tr>
<td>9</td>
<td>Unknown or not applicable</td>
<td>It is unknown whether regional lymph node surgery was performed; death certificate-only; for lymphomas with a lymph node primary site; an unknown or ill-defined primary; or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease.</td>
</tr>
</tbody>
</table>

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item:** RX SUMM--SURG OTH REG/DIS  
**Alternate Name:** Surgery of Other Regional Site(s), Distant Site(s) or Distant Lymph Nodes  
**NAACCR Item 1294**

Record the surgical removal of distant lymph nodes or other tissue(s)/organ(s) beyond the primary site.

If other tissue or organs are removed during primary site surgery that are not specifically defined by the site specific Surgical Procedure of the Primary Site code, assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.

- Assign the highest numbered code that describes the surgical resection of other tissue or organs beyond the primary site surgical code.

- Assign the highest numbered code that describes the surgical resection of distant lymph node(s).

- Incidental removal of tissue or organs is not a “Surgical Procedure/Other Site.”

- Surgical Procedure/Other Site is collected for each surgical event even if surgery of the primary site was not performed.

- Code 1 if any surgery is performed to treat tumors of unknown or ill-defined primary sites (C76.0–76.8, C80.9) or for hematopoietic, reticuloendothelial, immunoproliferative, or myeloproliferative disease (C42.0, C42.1, C42.3, C42.4 or M-9727, 9733, 9741-9742, 9764-9809, 9832, 9840-9931, 9945-9946, 9950-9967, and 9975-9992).
Codes are as follows:

- 0  None
- 1  Non-primary surgical procedure performed
- 2  Non-primary surgical procedure to other regional sites
- 3  Non-primary surgical procedure to distant lymph node(s)
- 4  Non-primary surgical procedure to distant site
- 5  Combination of codes 2, 3, or 4
- 9  Unknown

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item:** RX SUMM--SURG PRIM SITE  
**Alternate Name:** Surgery of Primary Site

Site-specific codes for this data item can be found in Appendix B of the current Facility Oncology Registry Data Standards (FORDS) Manual.

**Record the most definitive surgical procedure(s) performed to the primary site.** If registry software allows only one procedure to be collected, document the most definitive surgical procedure for the primary site.

- For codes 00 through 79, the response positions are hierarchical. Last-listed responses take precedence over responses written above. Code 98 takes precedence over code 00. Use codes 80 and 90 only if more precise information about the surgery is not available.
- Excisional biopsies (those that remove the entire tumor and/or leave only microscopic margins) are to be coded in this item.
- Surgery to remove regional tissue or organs is coded in this item only if the tissue/organs are removed in continuity with the primary site, except where noted.
- If a previous surgical procedure to remove a portion of the primary site is followed by surgery to remove the remainder of the primary site, then code the total or final results.

In addition to the procedure code, record the description as documented on the operative report.

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item:** RX SUMM--SURG/RAD SEQ  
**Alternate Name:** Radiation Sequence with Surgery

Records the sequencing of radiation and surgical procedures given as part of the first course of treatment.

Codes are as follows:

- 0  No radiation therapy and/or surgical procedure(s)
- 2  Radiation therapy before surgery
- 3  Radiation therapy after surgery
- 4  Radiation therapy both before AND after surgery
- 5  Intraoperative radiation therapy
6  Intraoperative radiation therapy w/other therapy administered before OR after surgery
9  Sequence unknown

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

**Item:**  RX SUMM--SYSTEMIC/SUR SEQ  
**Alternate Name:** Systemic/Surgery Sequence

Record the sequencing of systemic therapy and surgical procedures given as part of the first course of treatment.

Codes are as follows:
- 0  No systemic therapy and/or surgical procedure(s)
- 2  Systemic therapy before surgery
- 3  Systemic therapy after surgery
- 4  Systemic therapy both before AND after surgery
- 5  Intra-operative systemic therapy
- 6  Intra-operative systemic therapy w/other systemic therapy administered before OR after surgery
- 9  Sequence unknown

**Do not leave this data item blank.**

**Item:**  RX SUMM--TRANSPLNT/ENDOCR  
**Alternate Name:** Hematologic Transplant and Endocrine Procedures

Identifies systemic therapeutic procedures administered as part of the first course of treatment at this and all other facilities. If none of these procedures were administered, then this item records the reason they were not performed. These include bone marrow transplants, stem cell harvests, surgical and/or radiation endocrine therapy.

- Bone marrow transplants should be coded as either autologous (bone marrow originally taken from the patient) or allogeneic (bone marrow donated by a person other than the patient). For cases in which the bone marrow transplant was syngeneic (transplanted marrow from an identical twin), the item is coded as allogeneic.

- Stem cell harvests involve the collection of immature blood cells from the patient and the reintroduction by transfusion of the harvested cells following chemotherapy or radiation therapy.

- Endocrine irradiation and/or endocrine surgery are procedures which suppress the naturally occurring hormonal activity of the patient and thus alter or affect the long-term control of the cancer’s growth. These procedures must be bilateral to qualify as endocrine surgery or endocrine radiation. If only one gland is intact at the start of treatment, surgery and/or radiation to that remaining gland qualifies as endocrine surgery or endocrine radiation.

- Code 00 if a transplant or endocrine procedure was not administered to the patient, and it is known that these procedures are not usually administered for this type and stage of cancer.

- Code 00 if the treatment plan offered multiple options, and the patient selected treatment that did not include a transplant or endocrine procedure.

- If it is known that a transplant or endocrine procedure is usually administered for this type and stage of cancer, but was not administered to the patient, use code 82, 85, 86, or 87 to record the reason why it was not administered.
• Code 87 if the patient refused a recommended transplant or endocrine procedure, made a blanket refusal of all recommended treatment, or refused all treatment before any was recommended.

• Code 88 if it is known that a physician recommended a hematologic transplant or endocrine procedure, but no further documentation is available yet to confirm its administration.

• Code 88 to indicate referral to a specialist for hematologic transplant or endocrine procedures and the registry should follow the case. If follow-up to the specified specialist or facility determines the patient was never there, code 00.

• Cases coded 88 should be followed to determine whether they were given a hematologic transplant or endocrine procedure or why not.

• Code 99 if it is not known whether a transplant or endocrine procedure is usually administered for this type and stage of cancer, and there is no mention in the patient record whether it was recommended or administered.

Codes are as follows:

00   No transplant procedure or endocrine therapy was administered as part of first course therapy. Diagnosed at autopsy.

10   A bone marrow transplant procedure was administered, but the type was not specified.

11   Bone marrow transplant–autologous.

12   Bone marrow transplant–allogeneic.

20   Stem cell harvest and infusion. Umbilical cord stem cell transplant.

30   Endocrine surgery and/or endocrine radiation therapy.

40   Combination of endocrine surgery and/or radiation with a transplant procedure. (Combination of codes 30 and 10, 11, 12, or 20.)

82   Hematologic transplant and/or endocrine surgery/radiation was not recommended/administered because it was contraindicated due to patient risk factors (ie, comorbid conditions, advanced age, progression of disease prior to administration, etc.).

85   Hematologic transplant and/or endocrine surgery/radiation was not administered because the patient died prior to planned or recommended therapy.

86   Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient’s physician, but was not administered as part of the first course of therapy. No reason was stated in patient record.

87   Hematologic transplant and/or endocrine surgery/radiation was not administered. It was recommended by the patient’s physician, but this treatment was refused by the patient, a patient’s family member, or the patient’s guardian. The refusal was noted in patient record.

88   Hematologic transplant and/or endocrine surgery/radiation was recommended, but it is unknown if it was administered.
99 It is unknown whether hematologic transplant and/or endocrine surgery/radiation was recommended or administered because it is not stated in patient record. Death certificate only.

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.

<table>
<thead>
<tr>
<th>Item: RX SUMM–TREATMENT STATUS</th>
<th>NAACCR Item 1285</th>
</tr>
</thead>
</table>

Summary of the status for ALL treatment modalities (i.e., surgery, chemotherapy, radiation therapy, BRM, immunotherapy, etc.)

Codes are as follows:
- 0 No treatment given
- 1 Treatment given
- 2 Active Surveillance (watchful waiting)
- 9 Unknown if treatment given

**Do not leave this data item blank.** If no treatment (surgery, chemo, radiation, hormone, immunotherapy or other) was administered, enter value “9 - Unknown” into the field.
Note: Text documentation is required regardless of facility type. An abstract submitted with codes that lack supporting text data will be rejected in its entirety.

**General Instructions for Text Field Entries** (RX TEXT-- and TEXT-- data items)
Text documentation is an essential component of a complete electronic abstract and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry. The text field MUST contain a description that has been entered by the abstractor independently from the code(s). If cancer abstraction software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values. When the supporting text information is printed for review, one should be able to re-abstract the case without obtaining additional medical records and have the same codes as the original abstract.

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

Only use standard abbreviations in text fields. For a list of recommended abbreviations, refer to NAACCR Data Dictionary Appendix G: Recommended Abbreviations for Abstractors.

<table>
<thead>
<tr>
<th>Item: RX TEXT--BRM</th>
<th>NAACCR Items 2660</th>
</tr>
</thead>
<tbody>
<tr>
<td>Text area for manual documentation of information regarding the treatment of the tumor being reported with biological response modifiers or immunotherapy.</td>
<td></td>
</tr>
<tr>
<td><strong>Required for Text:</strong></td>
<td></td>
</tr>
<tr>
<td>• When Treatment was given, e.g., at this facility; at another facility</td>
<td></td>
</tr>
<tr>
<td>• Type of BRM agent, e.g., Interferon, BCG</td>
<td></td>
</tr>
<tr>
<td>• BRM procedures, e.g., bone marrow transplant, stem cell transplant</td>
<td></td>
</tr>
<tr>
<td>• Other treatment information, e.g., treatment cycle incomplete; unknown if BRM was given</td>
<td></td>
</tr>
<tr>
<td><strong>Do not leave this data item blank.</strong> If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item: RX TEXT--CHEMO</th>
<th>NAACCR Items 2640</th>
</tr>
</thead>
<tbody>
<tr>
<td>Text area for information regarding chemotherapy treatment of the reported tumor.</td>
<td></td>
</tr>
<tr>
<td><strong>Required for Text:</strong></td>
<td></td>
</tr>
<tr>
<td>• Date when chemotherapy began</td>
<td></td>
</tr>
<tr>
<td>• Where treatment was given, e.g., name of agent(s) or protocol</td>
<td></td>
</tr>
<tr>
<td>• Other treatment information, e.g., treatment cycle incomplete, unknown if chemotherapy was given</td>
<td></td>
</tr>
<tr>
<td><strong>Do not leave this data item blank.</strong> If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.</td>
<td></td>
</tr>
</tbody>
</table>
## Item: RX TEXT--HORMONE  
### NAACCR Items 2650

Text area for information about hormonal treatment

**Required for Text:**
- Date treatment was started
- Where treatment was given, e.g., at this facility, at another facility
- Type of hormone or antihormone, e.g., Tamoxifen
- Type of endocrine surgery or radiation, e.g., 3-D conformal
- Other treatment information, e.g., treatment cycle incomplete; unknown if hormones were given.

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

## Item: RX TEXT--OTHER  
### NAACCR Items 2670

Text area for manual documentation of information regarding the treatment of the tumor being reported with treatment that cannot be defined as surgery, radiation, or systemic therapy. This includes experimental treatments (when the mechanism of action for a drug is unknown), and blinded clinical trials. If the mechanism of action for the experimental drug is known, code to the appropriate treatment field.

**Required for Text:**
- Date treatment was started
- Where treatment was given, e.g., at this facility, at another facility
- Type of other treatment, e.g., blinded clinical trial, hyperthermia
- Other treatment information, e.g., treatment cycle incomplete; unknown if other treatment was given.

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

## Item: RX TEXT--RADIATION (BEAM)  
### NAACCR Items 2620

Text area for manual documentation of information regarding treatment of the tumor being reported with beam radiation.

**Required for Text:**
- Date radiation treatment began
- Where treatment was given, e.g., at this facility, at another facility
- Type(s) of beam radiation, e.g., Orthovoltage, Cobalt 60, MV X-rays, Electrons, Mixed modalities
- Other treatment information, e.g., patient discontinued after 5 treatments; unknown if radiation was given

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

## Item: RX TEXT--RADIATION OTHER  
### NAACCR Items 2630
Text area for manual documentation of information regarding treatment of the tumor being reported with radiation other than beam radiation. This includes brachytherapy and systemic radiation therapy.

**Required for Text:**
- Date treatment was started
- Where treatment was given, e.g., at this facility, at another facility
- Type(s) of non-beam radiation, e.g., High Dose rate brachytherapy, seed implant, Radioisotopes (I-131)
- Other treatment information, e.g., unknown if radiation was given

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

**Item:** RX TEXT--SURGERY

Text area for information describing all surgical procedures performed as part of treatment.

**Required for Text:**
- Date of each procedure.
- Type(s) of surgical procedure(s), including excisional biopsies and surgery to other and distant sites.
- Lymph nodes removed.
- Regional tissues removed.
- Metastatic sites.
- Facility where each procedure was performed.
- Record positive and negative findings. Record positive findings first.
- Other treatment information, e.g., planned procedure aborted; unknown if surgery performed.

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

**Item:** SECONDARY DIAGNOSIS (1-10)

Alternate Name: Secondary DX ICD-10 (1-10)

➔ **For cases using ICD-10-CM codes only. ICD-10-CM coding required beginning 10/1/2015.**

The COMORBID/COMPLICATION (1-10) items (NAACCR Items 3110-3164) were based on ICD-9-CM codes and only allowed 5 characters. The introduction of ICD-10-CM requires the accommodation of 7-character codes – these codes are to be recorded in the SECONDARY DIAGNOSIS (1-10) fields (NAACCR Items 3780-3798).

Records the patient’s preexisting medical conditions, factors influencing health status, and/or complications during the patient’s hospital stay for the treatment of this cancer using ICD-10-CM values. Preexisting medical conditions, factors influencing health status, and/or complications may affect treatment decisions and influence patient outcomes. Information on comorbidities is used to adjust outcome statistics when evaluating patient survival and other outcomes. Complications may be related to the quality of care.

Use this item to record ICD-10-CM codes. Use COMORBID/COMPLICATION (1-10) (NAACCR Items 3110-3164) to record ICD-9-CM codes. During the adoption of ICD-10-CM codes, it is possible both will appear in the same patient record.
NOTE: While the ICD-9-CM COMORBID/COMPLICATION codes were to be followed by zeroes if they did not fill the 5-character field, only the actual ICD-10-CM code is to be entered for SECONDARY DIAGNOSIS fields, leaving blanks beyond those characters. Omit the decimal point when coding. If no secondary diagnoses are documented, or if this information is unknown or unavailable, leave this data item blank. **DO NOT use ICD-9-CM codes in the SECONDARY DIAGNOSIS (1-10) fields.**

Secondary diagnoses are found on the discharge abstract. Information from the billing department at your facility may be consulted when a discharge abstract is not available. Code the secondary diagnoses in the sequence in which they appear on the discharge abstract or are recorded by the billing department at your facility.

Report the secondary diagnoses for this cancer using the following priority rules.
Surgically treated patients:
   a) Following the most definitive surgery of the primary site  
   b) Following other non-primary site surgeries

Non-surgically treated patients:
   Following the first treatment encounter/episode

In cases of non-treatment:
   Following the last diagnostic/evaluative encounter

The codes start with a character and have a presumed decimal point between the third and fourth characters in the reported value. The following are reportable ICD-10-CM Secondary Diagnoses:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>00000000</td>
<td>No applicable ICD-10-CM codes are recorded in patient record.</td>
</tr>
<tr>
<td>A00.0-B99.9</td>
<td>Infectious and parasitic diseases</td>
</tr>
<tr>
<td>E00.0-E89.89</td>
<td>Endocrine and metabolic diseases</td>
</tr>
<tr>
<td>G00.0-P96.9</td>
<td>Diseases of the nervous system, eye, ear, skin, circulatory, respiratory, and digestive, musculoskeletal, genitourinary systems, pregnancy, childbirth and perinatal conditions.</td>
</tr>
<tr>
<td>R00.0-S99.929</td>
<td>Symptoms, signs and abnormal clinical and lab findings</td>
</tr>
<tr>
<td>T36.0-T50.996</td>
<td>Medical poisonings</td>
</tr>
<tr>
<td>Y62.0-Y84.9</td>
<td>Medical misadventures</td>
</tr>
<tr>
<td>Z14.0-Z22.9</td>
<td>Genetic susceptibility/infection disease carrier</td>
</tr>
<tr>
<td>Z68.1-Z68.54</td>
<td>BMI</td>
</tr>
<tr>
<td>Z80.0-Z80.9</td>
<td>Family history of malignant neoplasms</td>
</tr>
<tr>
<td>Z85.0-Z99.89</td>
<td>Personal history of malignant neoplasms; other personal health status</td>
</tr>
</tbody>
</table>

Do NOT review the medical record and assign codes to these conditions – only record the above conditions if they have been identified by the medical records coder and appear on the face sheet.

For more information, refer to [Facility Oncology Registry Data Standards (FORDS)](https://www.facilityoncologyregistrydatastandards.org).

**Do not leave this data item blank.** If unknown, enter “000000,” i.e., no applicable ICD-10-CM codes are recorded in patient record.
Directly coded SEER Summary Stage 2000 values are Required by the Michigan Cancer Surveillance Program for all cases regardless of diagnosis year. For more information refer to the SEER Summary Stage 2000 manual. For SEER Summary Stage coding training, refer to the “For Cancer Registrars” tab on the SEER website.

The summary stage should include all information available through completion of surgery(ies) in the first course of treatment or within four months from the date of initial diagnosis.

For additional staging information, see Cancer Staging section in this manual.

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>In situ, Intraepithelial, Non-invasive, Non-infiltrating</td>
</tr>
<tr>
<td>1</td>
<td>1</td>
<td>Localized ONLY (within organ)</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>Regional by direct extension ONLY</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>Regional to lymph node(s) ONLY</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>Regional by BOTH direct extension AND regional lymph node(s) involved</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>Regional, NOS (not otherwise specified)</td>
</tr>
<tr>
<td>7</td>
<td>7</td>
<td>Distant site(s)/lymph node(s) involved or Systemic</td>
</tr>
<tr>
<td>8</td>
<td>8</td>
<td>Benign</td>
</tr>
<tr>
<td>9</td>
<td>9</td>
<td>Unknown if extension or metastasis ; Unknown primary site</td>
</tr>
</tbody>
</table>

The Sequence Number uniquely identifies separate primary tumors for each patient. It indicates the sequence of malignant and nonmalignant neoplasms over the lifetime of the patient. It is used by hospitals with or without a registry.

This item is required for hospitals with and without a registry. If sequence is unknown, labs and physician providers may enter “99”.

If two or more invasive or in situ neoplasms are diagnosed at the same time, assign the lowest sequence number to the diagnosis with the worst prognosis. If no difference in prognosis is evident the decision is arbitrary.

Any tumor in the patient’s past which is reportable or reportable-by-agreement at the time the current tumor is diagnosed must be taken into account when sequencing subsequently accessioned tumors. However, DO NOT reassign sequence numbers if one of those tumors becomes non-reportable later.

Sequence numbers should be reassigned if the facility learns later of an unaccessioned tumor that affects the sequence, e.g. a new primary diagnosed at another facility.

Malignant or In Situ Primaries:

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>One malignant or in situ primary only in the patient’s lifetime</td>
</tr>
<tr>
<td>01</td>
<td>First of two or more independent malignant or in situ primaries</td>
</tr>
<tr>
<td>02</td>
<td>Second of two or more independent malignant or in situ primaries</td>
</tr>
<tr>
<td>---</td>
<td>(Actual sequence of this malignant or in situ primary)</td>
</tr>
<tr>
<td>Code</td>
<td>Definition</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
</tr>
<tr>
<td>---</td>
<td>(Actual sequence of this malignant or in situ primary)</td>
</tr>
<tr>
<td>---</td>
<td>(Actual sequence of this malignant or in situ primary)</td>
</tr>
<tr>
<td>59</td>
<td>Fifty-ninth of 59 or more independent malignant or in situ primaries</td>
</tr>
<tr>
<td>99</td>
<td>Unknown number of malignant or in situ primaries</td>
</tr>
</tbody>
</table>

### Non-Malignant Primaries:

<table>
<thead>
<tr>
<th>Code</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>60</td>
<td>One non-malignant primary only in the patient’s lifetime.</td>
</tr>
<tr>
<td>61</td>
<td>First of two or more independent non-malignant primaries</td>
</tr>
<tr>
<td>62</td>
<td>Second of two or more independent non-malignant primaries</td>
</tr>
<tr>
<td>---</td>
<td>(Actual sequence of this non-malignant or in situ primary)</td>
</tr>
<tr>
<td>---</td>
<td>(Actual sequence of this non-malignant or in situ primary)</td>
</tr>
<tr>
<td>87</td>
<td>Twenty-seventh of 27 or more independent non-malignant primaries</td>
</tr>
<tr>
<td>88</td>
<td>Unspecified number of independent non-malignant primaries</td>
</tr>
</tbody>
</table>

### Examples

<table>
<thead>
<tr>
<th>Code</th>
<th>Explanation</th>
</tr>
</thead>
<tbody>
<tr>
<td>00</td>
<td>Patient with no previous history of cancer diagnosed with in situ breast carcinoma on June 13, 2011</td>
</tr>
<tr>
<td>01</td>
<td>The sequence number is changed when the patient with an in situ breast carcinoma diagnosed June 13, 2011, is diagnosed with a subsequent melanoma on August 30, 2011</td>
</tr>
<tr>
<td>02</td>
<td>Sequence number assigned to the melanoma diagnosed on August 30, 2011, following a breast cancer in situ diagnosed on June 13, 2011</td>
</tr>
<tr>
<td>04</td>
<td>A nursing home patient is admitted to the hospital for first course surgery for a colon adenocarcinoma. The patient has a prior history of three malignant cancers of the type the registry is required to accession, though the patient was not seen for these cancers at the hospital. No sequence numbers 01, 02, or 03 are accessioned for this patient.</td>
</tr>
<tr>
<td>60</td>
<td>The sequence number assigned to a benign brain tumor diagnosed on November 1, 2013, following a breast carcinoma diagnosed on June 13, 2011, and a melanoma on August 30, 2011</td>
</tr>
<tr>
<td>63</td>
<td>Myeloproliferative disease (9975/1) is diagnosed by the facility in 2011 and accessioned as Sequence 60. A benign brain tumor was diagnosed and treated elsewhere in 2010; the patient comes to the facility with a second independent benign brain tumor in 2012. Un-accessioned earlier brain tumor is counted as Sequence 61, myeloproliferative disease is re-sequenced to 62, and second benign brain tumor is Sequence 63.</td>
</tr>
</tbody>
</table>

The above tables and information can be found in Facility Oncology Registry Data Standards (FORDS) Manual. 

Do not leave this data item blank.

**Item:** SEX  
**Note:** The word “hermaphrodite” formerly classified under code 3 is outdated. Beginning with cases diagnosed in 2016, the definition has been updated to code “3 - Other (intersex, disorders of sexual development/DSD).”

Record the sex of the patient by entering the corresponding code.

The codes are as follows:
1 Male
2 Female
3 Other (intersex, disorders of sexual development/DSD)
4 Transsexual, NOS
5 Transsexual, natal male
6 Transsexual, natal female
9 Not Stated/Unknown

NOTE: The same sex code should appear in each abstract for a patient with multiple tumors.

Do not leave this data item blank.

Item: SOCIAL SECURITY NUMBER

Enter the social security number of the patient. (NOTE: A patient’s Medicare claim number may not always be identical to the patient’s social security number.)

Code Social Security Numbers that end with “B” or “D” as 999-99-9999. (The patient receives benefits under the spouse’s number and this is the spouse’s Social Security Number.)

Do not leave this data item blank. Social Security Number is a required data item regardless of facility type.

If Social Security Number is not documented, then follow-back is required. If after review of the patient’s hospital charts, outpatient records, other available records, other facility inquiries, or follow-back with the physician on record, the social security number is unknown, type 999-99-9999.

Item: SPANISH/HISPANIC ORIGIN

Alternate Name: Spanish Surname or Origin

Indicate whether the patient is of Hispanic origin, by entering the number which corresponds to their status.

Codes are as follows:
0 Non-Spanish; Non-Hispanic
1 Mexican (includes Chicano)
2 Puerto Rican
3 Cuban
4 South or Central American (except Brazil)
5 Other specified Spanish/Hispanic origin
6 Spanish, NOS; Hispanic NOS; Latino NOS
7 Spanish surname ONLY
8 Dominican Republic
9 Unknown whether Spanish or not

Note: Record “0- Non-Spanish, Non-Hispanic” when there is no documentation of Hispanic descent in the medical record.

Do not leave this data item blank. EXCEPTION: Independent laboratories are not expected to report this item and may leave the item blank.
Note: Text documentation is required regardless of facility type. An abstract submitted with codes that lack supporting text data will be rejected in its entirety.

General Instructions for Text Field Entries (RX TEXT-- and TEXT-- data items)
Text documentation is an essential component of a complete electronic abstract and is heavily utilized for quality control and special studies. Text is needed to justify coded values and to document supplemental information not transmitted within coded values. High-quality text documentation facilitates consolidation of information from multiple reporting sources at the central registry. The text field MUST contain a description that has been entered by the abstractor independently from the code(s). If cancer abstraction software generates text automatically from codes, the text cannot be utilized to check coded values. Information documenting the disease process should be entered manually from the medical record and should not be generated electronically from coded values. When the supporting text information is printed for review, one should be able to re-abstract the case without obtaining additional medical records and have the same codes as the original abstract.

Do not leave this data item blank. If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

Only use standard abbreviations in text fields. For a list of recommended abbreviations, refer to NAACCR Data Dictionary Appendix G: Recommended Abbreviations for Abstractors

<table>
<thead>
<tr>
<th>Item: TEXT--DX PROC--LAB TESTS</th>
<th>NAACCR Item 2550</th>
</tr>
</thead>
<tbody>
<tr>
<td>Text area for information from laboratory examinations other than cytology or histopathology. Data should verify/validate the coding of the following fields: Date of Diagnosis, Primary Site, Laterality, Histology ICD-O-3, Grade, CS Site-Specific Factors, and Diagnostic Confirmation.</td>
<td></td>
</tr>
</tbody>
</table>

Required for Text:
- Type of lab test/tissue specimen(s)
- Record both positive and negative findings, record positive test results first.
- Information can include tumor markers, serum and urine electrophoresis, special studies, etc.
- Date(s) of lab test(s)
- Tumor markers included, but are not limited to:
  - Breast Cancer: Estrogen Receptor Assay (ERA), Progesterone Receptor Assay (PRA), HER 2/NEU.
  - Prostate Cancer: Prostatic Specific Antigen (PSA)
  - Testicular Cancer: Human Chorionic Gonadotropin (hCG), Alpha Fetoprotein (AFP), Lactate Dehydrogenase (LDH)

Do not leave this data item blank. If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

<table>
<thead>
<tr>
<th>Item: TEXT--DX PROC--OP</th>
<th>NAACCR Item 2560</th>
</tr>
</thead>
<tbody>
<tr>
<td>Text area for manual documentation of all surgical procedures that provide information for staging. Data should verify/validate the coding of date of first positive biopsy; date of diagnosis; diagnostic and staging procedures; primary surgery site.</td>
<td></td>
</tr>
</tbody>
</table>

Required for Text:
Dates and descriptions of biopsies and all other surgical procedures from which staging information was derived
Number of lymph nodes removed
Size of tumor removed
Documentation of residual tumor
Evidence of invasion of surrounding areas
Reason primary site surgery could not be completed

Do not leave this data item blank. If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

Item: TEXT--DX PROC--PATH

Review the pathology report and type in the text from cytology and histopathology reports.

Required for Text:
- Date(s) of procedure(s)
- Anatomic source of specimen
- Type of tissue specimen(s)
- Tumor type and grade (include all modifying adjectives, i.e., predominantly, with features of, with foci of, elements of, etc.)
- Gross tumor size
- Extent of tumor spread
- Involvement of resection margins
- Number of lymph nodes involved and examined
- Record both positive and negative findings. Record positive test results first.
- Note if path report is a slide review or a second opinion from an outside source, i.e., AFIP, Mayo, etc.
- Record any additional comments from the pathologist, including differential diagnoses considered and any ruled out or favored

Examples
- 11/12/2006 colon polyp, 1.2x1.0x.0.8 cm. Adenocarcinoma contained within polyp showing invasion of submucosa. Stalk: no evidence of adenocarcinoma or dysplasia.
- 7/4/06 mastectomy of breast for R upper outer quadrant mass; 1.0 x 1.3 x .9 cm. Ductal carcinoma, infiltrating, Grade III. Margins clear; 12/12 lymph nodes negative for cancer; no metastasis noted; Positive histology; ERA negative.

Do not leave this data item blank. If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

Item: TEXT--DX PROC--PE

Text area for the history and physical examination related to the current tumor and the clinical description of the tumor.

Required for Text:
- Date of physical exam
- Age, sex, race/ethnicity
- Family history of cancer
- History of tobacco use
- History of alcohol use
- Personal history of previous cancers
- Primary site
- Histology (if diagnosis prior to this admission)
- Tumor location
- Tumor size
- Palpable lymph nodes
- Record positive and negative clinical findings. Record positive results first
- Treatment plan

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

**Item:** TEXT--DX PROC--SCOPES  NAACCR Item 2540

Text area for endoscopic examinations that provide information for staging and treatment.

**Required for Text:**
- Date(s) of endoscopic exam(s)
- Primary site
- Histology (if given)
- Tumor location
- Tumor size
- Lymph nodes
- Record positive and negative clinical findings. Record positive results first

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

**Item:** TEXT--DX PROC--X-RAY/SCAN  NAACCR Item 2530

Text area for all X-rays, scan, and/or other imaging examinations that provide information about staging.

**Required for Text:**
- Date(s) of X-ray/Scan(s)
- Age, sex, race/ethnicity (when given)
- Primary site
- Histology (if given)
- Tumor location
- Tumor size
- Lymph nodes
- Record positive and negative clinical findings. Record positive results first
- Distant disease or metastasis

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.
Review the pathology report and type in the histologic type (adenocarcinoma, squamous cell cancer, etc.), the behavior (malignant, in situ, benign), and the tumor grade (differentiation) of the tumor being reported.

**Required for text:**
- Histologic type and behavior
- Information on differentiation from scoring system such as Gleason score, Bloom-Richardson for tumor grade; laterality (if paired site)

**Examples**
- Adenocarcinoma of transverse colon, invasive, grade III
- Adenocarcinoma of prostate, Gleason score 5, Grade 2
- Melanoma skin right arm, in situ, grade 0
- Melanoma skin left leg, in situ, grade not stated

**You MUST obtain and use these required reference and coding resources:**
- [Multiple Primary and Histology Coding Rules Manual](#)
- [International Classification of Diseases for Oncology, Third Edition (ICD-O-3) coding book](#). This book can be purchased through any book store or ordered from online sources. Electronic CSV database files or print copies of the classifications are available from the World Health Organization.
- [Hematopoietic and Lymphoid Neoplasm Database and the Hematopoietic and Lymphoid Neoplasm Coding Manual](#) to assist with coding these primaries. These references apply only to cases diagnosed January 1, 2010 and forward.

The Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual and the Hematopoietic and Lymphoid Neoplasms Database, applies to only those **non-solid tumor cases diagnosed January 1, 2010 and forward**. The ICD-O-3 coding book is obsolete for coding non-solid tumors after this date. You must use the Hematopoietic and Lymphoid Neoplasms Database to assign the histology code.

Record the clinical/histological diagnosis for the primary site being reported. For hematopoietic and lymphoid neoplasms, code the histology diagnosed by the definitive diagnostic method(s) stated in the Hematopoietic database. The definitive diagnostic method can be a clinical diagnosis, genetic test, immunophenotyping, cytology, or pathology. When a pathology report is the definitive diagnostic method, code the histology from the final diagnosis, comment on the final diagnosis, addenda to the final diagnosis, or CAP protocol.

Be as specific as possible when describing the histology of the primary site, as multiple terms may describe a single histology. Record ALL histological types and descriptive adjectives identified.

**Example**
The pathology report diagnosis is that of a “diffuse, large cell, non-cleaved lymphoma.”

*Record the histology as “diffuse, large cell, non-cleaved lymphoma (9680/3)” — not just “lymphoma.”*

Review ALL pathology reports as specimens from the surgery are usually the most explicit.
Example: The histology from a colon biopsy is reported as “adenocarcinoma, NOS 8140/3).” The histology from the right hemicolectomy is reported as ‘mucinous carcinoma (8480/3).’

Record the histology as “mucinous carcinoma (8480/3).”

EXCEPTION: There may be times when the biopsy removes all the tumor and the margins are negative. A wide excision will be performed for precautionary measures.

Example: The pathology report from a skin biopsy identifies “superficial malignant melanoma (8720/3).” At wide excision, no residual tumor is identified.

Record the histology as “superficial malignant melanoma (8720/3)” from the biopsy.

Record the histology from the most representative tumor specimen examined and from the final diagnosis. The pathology reports takes precedence over ALL other reports.

NOTE 1: Use information from addenda and comments associated with the final diagnosis to code the histology.

NOTE 2: A revised/amended diagnosis replaces the original final diagnosis. Code the histology from the revised/amended diagnosis.

NOTE 3: The new rules limit the information to the final diagnosis. The old rules allowed coding from information in the microscopic description. You will only use information from the microscopic portion of the pathology report when instructed to do so in one of the site-specific rules.

If there is NOT a pathology report and a cytology report is available, use the cytology report to determine the histology.

When you do not have either a pathology report or cytology report:
   a. use documentation in the medical record that references pathology or cytology findings
   b. assign the histology from mention of a type of cancer (histology) in the medical record

The words “carcinoma” and “adenocarcinoma” and “cancer” are NOT interchangeable.

Record the histology exactly as it is reported.

If the histology is reported as “carcinoma,” record the histology as “carcinoma (8010/3).”

If the histology is reported as “adenocarcinoma,” record the histology as “adenocarcinoma, NOS (8140/3).”

If the diagnosis is “cancer” and there is no mention of a specific histology type (carcinoma or adenocarcinoma), record the histology as “cancer, NOS (8000/3).”

If no microscopic diagnosis is available, record the clinical diagnosis that describes the primary tumor being reported.

Example: MRI of the brain demonstrates a mass in the frontal lobe. The radiologist indicates that the diagnosis is an anaplastic astrocytoma.

Record the clinical diagnosis of “anaplastic astrocytoma (9401/3)” made from MRI.

If no histological diagnosis can be reached, or if no microscopic exam is available but a reportable diagnosis is suspected by a physician, report the suspected diagnosis.
Example
Chest x-ray and CT scan reveals a mass in the right upper lobe. Right upper lobe bronchoscopy is performed and the diagnosis is negative for malignancy. Discharge diagnosis is reported as “right lung cancer.” Record the histology as “cancer,” which is the suspected diagnosis by the managing physician.

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

**Item:** TEXT--PLACE OF DIAGNOSIS

Alternate Name: Place of Diagnosis

Text area for the facility, physician office, city, state, or county where the diagnosis was made.

**Required for Text:**
- The complete name of the hospital or the physician office where diagnosis occurred. The initials of a hospital are not adequate.
- For out-of-state residents and facilities, include the city and the state where the medical facility is located.

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

**Item:** TEXT--PRIMARY SITE TITLE

NAACCR Item 2580

Type in the primary site of the tumor being reported and the laterality (side of the body) if it is a paired site (some sites are not paired such as the prostate, uterus, esophagus, pancreas, and colon.)

**Required for text:**
- Location of the primary site of the tumor
- Available information on tumor laterality (if paired site)

**Examples**
- Lung, L lower lobe
- Prostate
- Breast, R upper outer quadrant
- Sigmoid colon
- Left temporal lobe of brain

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

**Item:** TEXT--REMARKS

NAACCR Item 2680

Type in more information that you have or use if you ran out of room in other text fields. Problematic coding issues can also be discussed in this section.

**Required for Text:**
- Overflow of information from any other Text field
- Justification of over-ride flags
• Family and personal history of cancer
• Comorbidities
• Information on sequence numbers if a person was diagnosed with another cancer out-of-state or before the registry’s reference date
• Place of birth
• Smoking history

Example
• Patient severely ill; could not undergo further surgery or staging; no treatment planned

Do not leave this data item blank. If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

Item: TEXT--STAGING

Additional text area for staging information not already entered in other TEXT or RX-TEXT fields.

Required for Text:
• Date(s) of procedure(s), including clinical procedures that provided information for assigning stage
• Organs involved by direct extension
• Size of tumor
• Status of margins
• Number and sites of positive lymph nodes
• Site(s) of distant metastasis
• Physician’s specialty and comments

Do not leave this data item blank. If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

Item: TEXT--USUAL INDUSTRY

Record the primary type of activity carried on by the business/industry at the location where the patient was employed for the most number of years before diagnosis of this tumor. Enter the kind of business or industry to which the occupation identified in TEXT--OCCUPATION (NAACCR Item 310) was related, such as insurance, automobile, government, school, church, etc. Be sure to distinguish among “manufacturing,” “wholesale,” “retail,” and “service” components within industries that perform more than one of these components.

Examples
Inadequate: “automobile industry”
Adequate: “automobile manufacturing”

Inadequate: “manufacturing”
Adequate: “automobile manufacturing”

Inadequate: “fire department”
Adequate: “city fire department”

Do NOT include descriptive terms with the Usual Industry such as “longest,” “current,” “last 10 years,” etc.
Do NOT record “retired.”

If the primary activity of the industry is unknown, record the name of the company (with city or town) in which the patient worked the most number of years before diagnosis.

If the patient was never employed, enter “never employed.”

For further information, refer to A Cancer Registrar's Guide to Collecting Industry and Occupation provided by CDC.

**Do not leave this data item blank.** If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

<table>
<thead>
<tr>
<th>Item: TEXT--USUAL OCCUPATION</th>
<th>NAACCR Item 310</th>
</tr>
</thead>
</table>

Enter the usual occupation of the patient prior to retirement. “Usual Occupation” is the kind of work the patient did during most of his/her working life before retirement, e.g., claim adjuster, farm hand, coal miner, janitor, store manager, research chemist, civil engineer, college professor, teacher, etc.

Enter “student” if the patient was a student at the time of diagnosis and was never regularly employed.

This data item applies only to patients who are 14 years of age or older at the time of diagnosis.

If the Usual Occupation is not available or is unknown, record the patient’s current or most recent occupation, or any available occupation.

*Examples*

Inadequate: “teacher”
Adequate: “preschool teacher,” “high school teacher”

Inadequate: “laborer”
Adequate: “residential bricklayer”

Inadequate: “worked in a warehouse,” “worked in a shipping department”
Adequate: “warehouse forklift operator”

Do **NOT** include descriptive terms with the Usual Occupation such as “longest,” “current,” “last 10 years,” etc.

Do not use “retired.” If the patient has retired from his or her usual occupation, the “usual occupation and business/industry” of the patient must be specified.

If the patient was never employed enter “never employed.”

If the usual occupation of the patient is unknown, enter “unknown.”

If the patient was a homemaker at the time of diagnosis, but had worked outside the household during his or her working life, enter that occupation.

If the patient was a homemaker during most of his or her working life, and never worked outside the household, enter “homemaker.”
Examples

If patient worked only at home, then record:
Occupation: “homemaker”
Industry: “own home”

If patient worked at someone else’s home for pay, then record:
Occupation: “housekeeper” (or “nurse,” “babysitter,” etc.)
Industry: “private home”

“Self-employed” by itself is incomplete. The kind of work must be determined. The entry for business/industry should include both the proper business/industry and the entry “self-employed.”

For further information, refer to A Cancer Registrar's Guide to Collecting Industry and Occupation provided by CDC.

Do not leave this data item blank. If there is no information to record in the text field, type “NR” (Not Reported) or “No Info” to indicate that there is no information, otherwise it will be assumed that the information is actually missing.

AJCC TNM STAGING
Directly assigned TNM Stage values are Required by the Michigan Cancer Surveillance Program for all cases diagnosed January 1, 2016 and forward. If information is unknown, not documented, or not applicable, then record the appropriate default value. Note that in some cases, “blank” may be the appropriate default value.

For more information, refer to the AJCC Cancer Staging Manual. For AJCC TNM Stage training, refer to the Registrar education section on the AJCC website. The site offers three particularly helpful presentations:

• Registrar’s Guide to Chapter 1, AJCC Seventh Edition
• Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging
• AJCC T, N, and M Category Options for Registry Data Items in 2016

Item: TNM CLIN DESCRIPTOR
Alternate Name: Clinical Stage (Prefix/Suffix) Descriptor

Identifies the AJCC clinical stage (prefix/suffix) descriptor as recorded by the physician. AJCC stage descriptors identify special cases that need separate data analysis. The descriptors are adjuncts to and do not change the stage group.

Codes
0 - None
1 - E (Extranodal, lymphomas only)
2 - S (Spleen, lymphomas only)
3 - M (Multiple primary tumors in a single site)
5 - E & S (Extranodal and spleen, lymphomas only)
9 - Unknown, not stated in patient record

Note: See the AJCC Cancer Staging Manual, current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see Cancer Staging section in this manual.

Do not leave this data item blank.
Item: TNM CLIN M  
**Alternate Name:** Clinical M

Detailed site-specific codes for the clinical metastases (M) as defined by AJCC and recorded by the physician.

*Note:* See the [AJCC Cancer Staging Manual](https://www.cancerstaging.org), current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see [Cancer Staging](#) section in this manual.

If information is unknown, not documented, or not applicable, then record the appropriate default value. Note that in some cases, “blank” may be the appropriate default value.

Item: TNM CLIN N  
**Alternate Name:** Clinical N

Detailed site-specific codes for the clinical nodes (N) as defined by AJCC and recorded by the physician.

*Note:* See the [AJCC Cancer Staging Manual](https://www.cancerstaging.org), current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see [Cancer Staging](#) section in this manual.

If information is unknown, not documented, or not applicable, then record the appropriate default value. Note that in some cases, “blank” may be the appropriate default value.

Item: TNM CLIN STAGE GROUP  
**Alternate Name:** Clinical Stage Group

Detailed site-specific codes for the clinical stage group as defined by AJCC and recorded by the physician.

*Note:* See the [AJCC Cancer Staging Manual](https://www.cancerstaging.org), current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see [Cancer Staging](#) section in this manual.

If information is unknown, not documented, or not applicable, then record the appropriate default value.

Item: TNM CLIN T  
**Alternate Name:** Clinical T

Detailed site-specific codes for the clinical tumor (T) as defined by AJCC and recorded by the physician.

*Note:* See the [AJCC Cancer Staging Manual](https://www.cancerstaging.org), current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see [Cancer Staging](#) section in this manual.

If information is unknown, not documented, or not applicable, then record the appropriate default value. Note that in some cases, “blank” may be the appropriate default value.
## TNM EDITION NUMBER

A code that indicates the edition of the AJCC manual used to stage the case. This applies to the manually coded AJCC fields. TNM codes have changed over time and conversion is not always simple. Therefore, a case-specific indicator is needed to allow grouping of cases for comparison.

### Codes
- **00** - Not staged (cases that have AJCC staging scheme and staging was not done)
- **01** - First Edition
- **02** - Second Edition (published 1983)
- **03** - Third Edition (published 1988)
- **05** - Fifth Edition (published 1997), recommended for use for cases diagnosed 1998-2002
- **06** - Sixth Edition (published 2002), recommended for use for cases diagnosed 2003-2009
- **07** - Seventh Edition (published 2009), recommended for use with cases diagnosed 2010+
- **08** - Not applicable (cases that do not have an AJCC staging scheme)
- **99** - Edition Unknown

For additional staging information, see [Cancer Staging](#) section in this manual.

**Do not leave this data item blank.**

## TNM PATH DESCRIPTOR

Alternate Name: Pathologic Stage (Prefix/Suffix) Descriptor

Identified the AJCC pathologic stage (prefix/suffix) descriptor as recorded by the physician. AJCC stage descriptors identify special cases that need separate data analysis. The descriptors are adjuncts to and do not change the stage group.

### Codes
- **0** - None
- **1** - E (Extranodal, lymphomas only)
- **2** - S (Spleen, lymphomas only)
- **3** - M (Multiple primary tumors in a single site)
- **4** - Y (Classification during or after initial multimodality therapy)—pathologic staging only
- **5** - E & S (Extranodal and spleen, lymphomas only)
- **6** - M & Y (Multiple primary tumors and initial multimodality therapy)
- **9** - Unknown, not stated in patient record

**Note:** See the [AJCC Cancer Staging Manual](#), current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see [Cancer Staging](#) section in this manual.

**Do not leave this data item blank.**

## TNM PATH M

Alternate Name: Pathologic M

Detailed site-specific codes for the pathologic metastases (M) as defined by AJCC and recorded by the physician.

---

Go to Table of Contents  Go to Data Item List  MCSP Cancer Program Manual • 133
Note: See the AJCC Cancer Staging Manual, current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see Cancer Staging section in this manual.

If information is unknown, not documented, or not applicable, then record the appropriate default value. Note that in some cases, “blank” may be the appropriate default value.

Item: TNM PATH N
Alternate Name: Pathologic N

Detailed site-specific codes for the pathologic nodes (N) as defined by AJCC and recorded by physician.

Note: See the AJCC Cancer Staging Manual, current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see Cancer Staging section in this manual.

If information is unknown, not documented, or not applicable, then record the appropriate default value. Note that in some cases, “blank” may be the appropriate default value.

Item: TNM PATH STAGE GROUP
Alternate Name: Pathologic Stage Group

Detailed site-specific codes for the pathologic stage group as defined by AJCC and recorded by the physician.

Note: See the AJCC Cancer Staging Manual, current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see Cancer Staging section in this manual.

If information is unknown, not documented, or not applicable, then record the appropriate default value.

Item: TNM PATH T
Alternate Name: Pathologic T

Detailed site-specific codes for the pathologic tumor (T) as defined by AJCC and recorded by the physician.

Note: See the AJCC Cancer Staging Manual, current edition for site-specific categories for the TNM elements and stage groups.

For additional staging information, see Cancer Staging section in this manual.

If information is unknown, not documented, or not applicable, then record the appropriate default value. Note that in some cases, “blank” may be the appropriate default value.

Item: TOBACCO USE

Records whether or not the patient has a history of tobacco use (cigarettes, pipe, cigars, snuff, chew).

If the patient quit smoking one year or less from the initial date of diagnosis, indicate “current use.”
This is a MCSP-required data item. Abstracts submitted with incorrect format or missing values will be rejected by MCSP.

**Paper form submission:**

**Paper Form Item 18:** Mark appropriate value: current use, prior use, never used or unknown.

**Do not leave this data item blank.** If unknown, enter “9” or “Unknown.” Supporting text documentation for selected data value must be entered in **Paper Form Field 95: TEXT - PHYSICAL EXAM** even when value is “9” or “Unknown.”

**Electronic submission:**

Enter whether or not the patient has a history of tobacco use (cigarettes, pipe, cigars, snuff, or chew.)

**This is a Michigan-specific data item.** Starting with data submitted in NAACCR version 13, facilities that submit electronic abstract data to MCSP must coordinate with their software vendors to ensure that this data value is recorded in NAACCR record layout, column number 2447. After that date, abstracts submitted with incorrect format or missing values will be rejected by MCSP.

**Do not leave this data item blank. If unknown, enter “9.”** Supporting text documentation for selected data value must be entered in TEXT--DX PROC--PE field even when value is “9.”

**Tobacco History Data Values**

<table>
<thead>
<tr>
<th>Code</th>
<th>Current</th>
<th>Prior</th>
<th>Never</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Yes</td>
<td>Blank</td>
<td>Blank</td>
</tr>
<tr>
<td>2</td>
<td>Blank</td>
<td>Yes</td>
<td>Blank</td>
</tr>
<tr>
<td>3</td>
<td>Blank</td>
<td>Blank</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>Blank (Unknown)</td>
<td>Blank (Unknown)</td>
<td>Blank (Unknown)</td>
</tr>
</tbody>
</table>

**Item:** TUMOR SIZE CLINICAL  
**NAACCR Item 752**

➤ This data item applies to cases diagnosed 1/1/2016 and forward only.

This data item records the size of a solid primary tumor before any treatment. Clinical tumor size (pretreatment size) is essential for treatment decision making and prognosis determination for many types of cancer.

Codes (Refer to the most recent version of [SEER Program Coding and Staging Manual](#) for additional instructions.)

- 000 No mass/tumor found
- 001 1 mm or described as less than 1 mm
- 002-988 Exact size in millimeters (2 mm to 988 mm)
- 989 989 millimeters or larger
- 990 Microscopic focus or foci only and no size of focus is given
- 998 Alternate descriptions of tumor size for specific sites:  
  Familial/multiple polyposis:  
  Rectosigmoid and rectum (C19.9, C20.9)  
  Colon (C18.0, C18.2-C18.9)
If no size is documented:

Circumferential:
- Esophagus (C15.0 C15.5, C15.8 C15.9)
- Diffuse; widespread: 3/4s or more; linitis plastica:
  - Stomach and Esophagus GE Junction (C16.0 C16.6, C16.8 C16.9)
- Diffuse, entire lung or NOS:
  - Lung and main stem bronchus (C34.0 C34.3, C34.8 C34.9)
- Diffuse:
  - Breast (C50.0 C50.6, C50.8 C50.9)

999 Unknown; Size not stated; Not documented in patient record; Size of tumor cannot be assessed; Not applicable

Do not leave this data item blank. If unknown, enter “999”.

Item: TUMOR SIZE PATHOLOGIC

This data item applies to cases diagnosed 1/1/2016 and forward only.

This data item records the size of a solid primary tumor that has been resected. Pathologic tumor size is an important prognostic indicator and valuable for clinical practice and research on surgically treated patients.

Codes (Refer to the most recent version of SEER Program Coding and Staging Manual for additional instructions.)

- 000 No mass/tumor found
- 001 1 mm or described as less than 1 mm
- 002-988 Exact size in millimeters (2 mm to 988 mm)
- 989 989 millimeters or larger
- 990 Microscopic focus or foci only and no size of focus is given
- 998 Alternate descriptions of tumor size for specific sites:
  - Familial/multiple polyposis:
    - Rectosigmoid and rectum (C19.9, C20.9)
    - Colon (C18.0, C18.2-C18.9)

If no size is documented:

Circumferential:
- Esophagus (C15.0 C15.5, C15.8 C15.9)
- Diffuse; widespread: 3/4s or more; linitis plastica:
  - Stomach and Esophagus GE Junction (C16.0 C16.6, C16.8 C16.9)
- Diffuse, entire lung or NOS:
  - Lung and main stem bronchus (C34.0 C34.3, C34.8 C34.9)
- Diffuse:
  - Breast (C50.0 C50.6, C50.8 C50.9)

999 Unknown; size not stated; Not documented in patient record; Size of tumor cannot be assessed; Not applicable

Do not leave this data item blank. If unknown, enter “999”.

Item: TUMOR SIZE SUMMARY

136 • MCSP Cancer Program Manual  Go to Data Item List  Go to Table of Contents
This data item applies to cases diagnosed 1/1/2016 and forward only.

This data item records the most accurate measurement of a solid primary tumor, usually measured on the surgical resection specimen. Tumor size is one indication of the extent of disease. As such, it is used by both clinicians and researchers. Tumor size that is independent of stage is also useful for quality assurance efforts.

Codes: (See the most recent version of the FORDS manual for additional instructions.)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>000</td>
<td>No mass/tumor found</td>
</tr>
<tr>
<td>001</td>
<td>1 mm or described as less than 1 mm</td>
</tr>
<tr>
<td>002-988</td>
<td>Exact size in millimeters (2mm-988mm)</td>
</tr>
<tr>
<td>989</td>
<td>989 millimeters or larger</td>
</tr>
<tr>
<td>990</td>
<td>Microscopic focus or foci only and no size of focus is given</td>
</tr>
<tr>
<td>998</td>
<td>SITE-SPECIFIC CODES</td>
</tr>
<tr>
<td></td>
<td>Alternate descriptions of tumor size for specific sites:</td>
</tr>
<tr>
<td></td>
<td>Familial/multiple polyposis:</td>
</tr>
<tr>
<td></td>
<td>Rectosigmoid and rectum (C19.9, C20.9)</td>
</tr>
<tr>
<td></td>
<td>Colon (C18.0, C18.2-C18.9)</td>
</tr>
<tr>
<td>999</td>
<td>Unknown; size not stated; Not documented in patient record; Size of tumor cannot be assessed; Not applicable</td>
</tr>
</tbody>
</table>

If no size is documented:

- Circumferential:
  - Esophagus (C15.0 C15.5, C15.8 C15.9)
- Diffuse; widespread: 3/4s or more; linitis plastica:
  - Stomach and Esophagus GE Junction (C16.0 C16.6, C16.8 C16.9)
- Diffuse, entire lung or NOS:
  - Lung and main stem bronchus (C34.0 C34.3, C34.8 C34.9)
- Diffuse:
  - Breast (C50.0 C50.6, C50.8 C50.9)

Do not leave this data item blank. If unknown, enter “999”.

<table>
<thead>
<tr>
<th>Item: TYPE OF REPORTING SOURCE</th>
<th>NAACCR Item 500</th>
</tr>
</thead>
</table>

Code the source documents used to abstract the majority of information on the tumor being reported. This may not be the source of original casefinding.

Code in the following priority order: 1, 2, 8, 4, 3, 5, 6, 7, as this reflects the addition of codes 2 and 8 as well as prioritizing laboratory reports over nursing home reports. The source facilities included in the previous code 1 (hospital inpatient and outpatient) are split between codes 1, 2, and 8.

This data item is intended to indicate the completeness of information available to the abstractor. Reports from health plans (e.g., Kaiser, Veterans Administration, military facilities) in which all diagnostic and treatment information is maintained centrally and is available to the abstractor are expected to be at least as complete as reports for hospital inpatients, which is why these sources are grouped with inpatients and given the code with the highest priority.

Sources coded with “2” usually have complete information on the cancer diagnosis, staging, and treatment. Sources coded with “8” would include, but would not be limited to, outpatient surgery and nuclear medicine services. A physician’s office that calls itself a surgery center should be coded as a physician’s office. Surgery
centers are equipped and staffed to perform surgical procedures under general anesthesia. If a physician’s office calls itself a surgery center, but cannot perform surgical procedures under general anesthesia, code as a physician office.

Codes are as follows:
1. Hospital inpatient; Managed health plans with comprehensive, unified medical records
2. Radiation Treatment Centers or Medical Oncology Centers (hospital-affiliated or independent)
3. Laboratory only (hospital-affiliated or independent)
4. Physician’s office/private medical practitioner (LMD)
5. Nursing/convalescent home/hospice
6. Autopsy only
7. Death certificate only
8. Other hospital outpatient units/surgery centers (outpatient surgery & nuclear medicine services)

**Do not leave this data item blank.** One of the above values must be recorded.

<table>
<thead>
<tr>
<th>Item</th>
<th>VITAL STATUS</th>
<th>NAACCR Item 1760</th>
</tr>
</thead>
</table>

Record the vital status of the patient as of the date of last contact. If the patient has multiple tumors, vital status should be the same for all tumors.

**Codes**
- 0 - Dead
- 1 - Alive

**Do not leave this data item blank.**
FOLLOW-UP WORK ON REPORTED CASES

Contact with the reporting entity concerning an individual cancer report or a specific patient will occur under four separate circumstances. As is consistent with Administrative Rules; the cooperation of facility personnel in these four areas is essential. Should problems or concerns arise, please feel free to contact the office.

1. As cancer reports are received and processed, each will be reviewed for completeness, legibility and consistency. Contact with the reporting entity will occur to resolve identified problems in these areas as reports are initially processed and later as final processing occurs. Contacts will generally be by e-mail (with no patient identifiers) or phone. Prompt attention to such issues by the personnel responsible for completing these reports is important for smooth processing.

2. In assessing the quality of the cancer reports received from across the state, the office will contact hospitals, laboratories or registries for access to or copies of pertinent records. This is necessary in order to evaluate the quality and completeness of the information received from individual reporting entities. Problems that are identified during such reviews will be addressed as necessary to maintain or improve data quality and usefulness.

3. Contact may also occur to conduct approved epidemiological research projects. When a research study is approved by the Director of the Michigan Department of Health and Human Services, study subjects will be drawn from the state registry. Hospitals, laboratories and registries will be contacted concerning each case reported by them to ascertain the physician treating the patient. Through this process, physicians can then be contacted and patient consent obtained.

4. Unlinked Death Survey is part of the department's passive case finding system. The Michigan Cancer Surveillance Program is required to conduct death clearance at least once a year. Through the death follow back study we add cases yearly which helps to create a more complete state cancer registry.

Death clearance match of deaths from the official mortality file from the state, territorial, or provincial vital records office (mortality file) are linked to the registry database to identify records that match and those that do NOT match. (Note: For each patient match, the registry record is updated with death and other relevant data from the mortality file.)

For records in the mortality file with a cancer diagnosis that did not match a central cancer registry record, the MCSP investigates to identify potentially missed incidence cases. If follow-back information is obtained, the case may be added as a missed incidence report. If no information is obtained other than the death certificate, the case is entered into the MI central cancer registry database as a DCO (Death Clearance Only).

When follow-back is required, the MCSP contacts the certifying physician who signed the Certificate of Death. If no information is obtained from the physician on the cancer-related death, the MCSP conducts follow-back based upon county of death.

If an Unlinked Death Survey is forwarded to a facility, the cancer-related death information could not be obtained from follow-back with the certifying physician, which may include follow-back of a health care provider more closely connected with the diagnosis and/or treatment of the patient.
REPORTABLE CONDITIONS

The first step in any casefinding effort is to outline what is reportable. The administrative rules on cancer reporting provide the definition of a reportable cancer. ALL cases satisfying this definition are reportable. The residence of the patient is NOT a factor.

Cases diagnosed on or after January 1, 1985 to date MUST be reported to the Michigan Cancer Surveillance Program within 180 days or six months from the date of initial diagnosis.

"Cancer" means all diagnoses with a behavior code of "2" (carcinoma in situ) or "3" (malignant primary site) as listed in the most recently amended International Classification of Diseases for Oncology, EXCLUDING basal, epithelial, papillary and squamous cell carcinomas of the skin, but including carcinomas of the skin prepuce, clitoris, vulva, labia, penis and scrotum.

Carcinoma in situ of the cervix (CIS) and intraepithelial neoplasia grade III (8077/2) of the cervix (CIN III), vulva (VIN III), vagina (VAIN III), and anus (AIN III) are all reportable conditions.

Juvenile astrocytoma listed as 9421/1 in ICD-O-3 are required and should be recorded as 9421/3, thereby making it a reportable condition.

Once a tumor has been identified, it is assigned a six digit morphology code (e.g. 8522/34) from the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) coding book. The first four digits record the cell type or histology. The fifth digit, after the slash or solidus (/), is the behavior code and the sixth digit is the tumor grade. ALL tumors assigned a fifth digit behavior code of “2” or “3” in the ICD-O-3 are reportable.

<table>
<thead>
<tr>
<th>Behavior Code</th>
<th>Definition</th>
<th>Reportable</th>
<th>Non-Reportable</th>
</tr>
</thead>
<tbody>
<tr>
<td>/0</td>
<td>Benign</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>EXCEPTION: Brain and CNS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>/1</td>
<td>Uncertain whether benign or malignant Borderline malignancy Low malignant potential Uncertain malignant potential</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>EXCEPTION: Brain and CNS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>/2</td>
<td>Carcinoma In Situ Intraepithelial Non-infiltrating Noninvasive</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>/3</td>
<td>Malignant, primary site</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>/6*</td>
<td>Malignant, metastatic site Malignant, secondary site</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>/9*</td>
<td>Malignant, uncertain whether primary or metastatic site * Not used by cancer registries.</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

NOTE: Screening of diagnostic codes for behavior codes “6 - malignant, metastatic site,” and “9 - malignant, uncertain whether primary or metastatic site” is necessary for casefinding. If this is the first diagnosis of this cancer and even though it is the metastatic site, it is still a reportable condition. The first time a diagnosis of cancer is made with an “unknown primary” it should be reported as such. If the primary site is determined after further study and it was originally reported as an unknown primary, a correction MUST be
reported. The behavior code of “6” is only allowed to be used by central registries. When reporting an unknown primary site, a behavior code “3 - malignant” must be used.

NEWLY REPORTABLE CONDITIONS & OTHER CHANGES

Effective January 1, 2017

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>Description</th>
<th>Use Histology/Behavior Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thyroid (C73.9)</td>
<td>Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)</td>
<td>8343/2</td>
</tr>
<tr>
<td></td>
<td>Non-invasive encapsulated follicular variant of papillary thyroid carcinoma (non-invasive EFVPTC)</td>
<td>8343/2</td>
</tr>
<tr>
<td></td>
<td>Invasive encapsulated follicular variant of papillary thyroid carcinoma (invasive EFVPTC)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Encapsulated follicular variant of papillary thyroid carcinoma, NOS (EFVPTC, NOS)</td>
<td>8343/3</td>
</tr>
<tr>
<td></td>
<td>Synonym: Papillary carcinoma, encapsulated</td>
<td></td>
</tr>
</tbody>
</table>

Effective January 1, 2016

Per the NAACCR 2016 Implementation Guidelines and Recommendations, the CDC recommends adding the following conditions/tumors to ICD-O-3 Manuals and educating reporting sources about these new updates.

1. Non-invasive mucinous cystic neoplasm of the pancreas with high-grade dysplasia replaces mucinous cystadenocarcinoma, non-invasive (8470/2).
2. Solid pseudopapillary neoplasm of pancreas (8452/3) is synonymous with solid pseudopapillary carcinoma (C25._).
3. Based on pathologist consultation, metastases have been reported in some cystic pancreatic endocrine neoplasm (CPEN) cases. With all other pancreatic endocrine tumors now considered malignant, CPEN will also be considered malignant, until proven otherwise. Most CPEN cases are non-functioning and are REPORTABLE using histology code 8150/3, unless the tumor is specified as a neuroendocrine tumor, grade 1 (assign code 8240/3) or neuroendocrine tumor, grade 2 (assign code 8249/3).
4. Laryngeal intraepithelial neoplasia, grade III (LINIII) (8077/2), C320-C329
5. Squamous intraepithelial neoplasia, grade III (SINIII) (8077/2), except Cervix and Skin
6. Mature teratoma of the testes in adults is malignant and REPORTABLE as 9080/3, but continues to be non-reportable in prepubescent children (9080/0). The following provides additional guidance:
   - Adult is defined as post puberty
   - Pubescence can take place over a number of years
   - Do not rely solely on age to indicate pre or post puberty status. Review all information (physical history, etc.) for documentation of pubertal status. When testicular teratomas occur in adult males, pubescent status is likely to be stated in the medical record because it is an important factor of the diagnosis.
   - Do not report if unknown whether patient is pre or post pubescent. When testicular teratoma occurs in a male and there is no mention of pubescence, it is likely that the patient is a child, or pre-pubescent, and the tumor is benign.

Effective January 1, 2015
The NAACCR Guidelines for ICD-O-3 Update Implementation (published December 2013) included a table of new ICD-O-3 codes and terms effective for 2015; however, the use of the new codes was postponed due to issues with adding these codes to the CSv2 software. For diagnosis year 2016, all standard setters have agreed to postpone these codes once again, and to use the alternate codes as noted in the chart below.

Hospital registrars should look for use of the terms listed below by their pathologists. Since these terms have not yet been officially adopted for cancer surveillance in North America, registrars should abstract cases using the acceptable codes listed in the chart to report them to central registries and to CoC.

<table>
<thead>
<tr>
<th>ICD-O-3 change</th>
<th>New code in ICD-O-3 (do NOT use these codes)</th>
<th>Description</th>
<th>Comment</th>
<th>Use this code</th>
</tr>
</thead>
<tbody>
<tr>
<td>New term and code</td>
<td>8158/1</td>
<td>Endocrine tumor, functioning, NOS</td>
<td>Not reportable</td>
<td></td>
</tr>
<tr>
<td>New related term</td>
<td>8158/1</td>
<td>ACTH-producing tumor</td>
<td>Not reportable</td>
<td></td>
</tr>
<tr>
<td>New term and code</td>
<td>8163/3</td>
<td>Pancreatobiliary-type carcinoma (C24.1)</td>
<td>DO NOT use new code</td>
<td>8255/3</td>
</tr>
<tr>
<td>New synonym</td>
<td>8163/3</td>
<td>Adenocarcinoma, pancreatobiliary-type (C24.1)</td>
<td>DO NOT use new code</td>
<td>8255/3</td>
</tr>
<tr>
<td>New term</td>
<td>8213/3</td>
<td>Serrated adenocarcinoma</td>
<td></td>
<td>8213/3*</td>
</tr>
<tr>
<td>New code and term</td>
<td>8265/3</td>
<td>Micropapillary carcinoma, NOS (C18.-, C19.9, C20.9)</td>
<td>DO NOT use new code</td>
<td>8507/3*</td>
</tr>
<tr>
<td>New code and term</td>
<td>8480/1</td>
<td>Low grade appendiceal mucinous neoplasm (C18.1)</td>
<td>Not reportable</td>
<td></td>
</tr>
<tr>
<td>New term and code</td>
<td>8552/3</td>
<td>Mixed acinar ductal carcinoma</td>
<td>DO NOT use new code</td>
<td>8523/3</td>
</tr>
<tr>
<td>New term and code</td>
<td>8975/1</td>
<td>Calcifying nested epithelial stromal tumor (C22.0)</td>
<td>Not reportable</td>
<td></td>
</tr>
<tr>
<td>New term and code</td>
<td>9395/3</td>
<td>Papillary tumor of the pineal region</td>
<td>DO NOT use new code</td>
<td>9361/3*</td>
</tr>
<tr>
<td>New term and code</td>
<td>9425/3</td>
<td>Pilomyxoid astrocytoma</td>
<td>DO NOT use new code</td>
<td>9421/3</td>
</tr>
<tr>
<td>New term and code</td>
<td>9431/1</td>
<td>Angiocentric glioma</td>
<td>DO NOT use new code</td>
<td>9380/1*</td>
</tr>
<tr>
<td>New term and code</td>
<td>9432/1</td>
<td>Pituicytoma</td>
<td>DO NOT use new code</td>
<td>9380/1*</td>
</tr>
<tr>
<td>New term and code</td>
<td>9509/1</td>
<td>Papillary glioneuronal tumor</td>
<td>DO NOT use new code</td>
<td>9505/1</td>
</tr>
<tr>
<td>New related term</td>
<td>9509/1</td>
<td>Rosette-forming glioneuronal tumor</td>
<td>DO NOT use new code</td>
<td>9505/1</td>
</tr>
<tr>
<td>New term and code</td>
<td>9741/1</td>
<td>Indolent systemic mastocytosis</td>
<td>Not reportable</td>
<td></td>
</tr>
</tbody>
</table>

* ICD-O-3 rule F applies (code the behavior stated by the pathologist). If necessary, over-ride any advisory messages.

**Effective January 1, 2014**

Use the following new terms, synonyms, and related terms for existing ICD-O-3 codes. **Bold** indicates a preferred term.

New preferred term…………………………………… 8150/0 **Pancreatic endocrine tumor, benign (C25._)**
Move former preferred term to synonym ........... 8150/0 Islet cell adenoma (C25._)
New related term .................................................. 8150/0  Pancreatic microadenoma (C25._)
New preferred term................................................ 8150/1  Pancreatic endocrine tumor, NOS (C25._)
Move former preferred term to synonym .................. 8150/1  Islet cell tumor, NOS (C25._)
New preferred term................................................ 8150/3  Pancreatic endocrine tumor, malignant (C25._)
Move former preferred term to synonym .................. 8150/3  Islet cell carcinoma (C25._)
New related term .................................................. 8150/3  Pancreatic endocrine tumor, nonfunctioning (C25._)
New related term .................................................. 8152/1  L-cell tumor
New related term .................................................. 8152/1  Glucagon-like peptide-producing tumor (C25._)
New related term .................................................. 8152/1  Pancreatic peptide and pancreatic peptide-like peptide within terminal tyrosine amide producing tumor
New synonym for related term .............................. 8152/1  PP/PYY producing tumor
New preferred term................................................ 8154/3  Mixed pancreatic endocrine and exocrine tumor, malignant (C25._)
New related term .................................................. 8154/3  Mixed endocrine and exocrine adenocarcinoma (C25._)
New synonym for related term .............................. 8154/3  Mixed islet cell and exocrine adenocarcinoma (C25._)
New related term .................................................. 8154/3  Mixed acinar-endocrine-ductal carcinoma
New related term .................................................. 8201/3  Cribriform comedo-type carcinoma (C18._, C19.9, C20.9)
New synonym ...................................................... 8201/3  Adenocarcinoma, cribriform comedo-type (C18._, C19.9, C20.9)
New synonym to primary term ............................... 8213/0  Traditional serrated adenoma
New related term .................................................. 8213/0  Sessile serrated adenoma
New related term .................................................. 8213/0  Sessile serrated polyp
New related term .................................................. 8213/0  Traditional sessile serrated adenoma
New related term .................................................. 8240/3  Neuroendocrine tumor, grade 1
New related term .................................................. 8240/3  Neuroendocrine carcinoma, low grade
New related term .................................................. 8240/3  Neuroendocrine carcinoma, well-differentiated
New preferred term ................................................ 8244/3  Mixed adenoneuroendocrine carcinoma
Move former preferred term to synonym ................. 8244/3  Composite carcinoid
New synonym ...................................................... 8244/3  Combined/mixed carcinoid and adenocarcinoma
New synonym ...................................................... 8244/3  MANEC
New synonym ...................................................... 8249/3  Neuroendocrine tumor, grade 2
New related term .................................................. 8249/3  Neuroendocrine carcinoma, moderately differentiated
New synonym ...................................................... 8263/0  Tubulo-papillary adenoma
New related term .................................................. 8290/0  Spindle cell oncocytoma (C75.1)
New related term .................................................. 8490/3  Poorly cohesive carcinoma
New related term .................................................. 8811/0  Plexiform fibromyxoma
New related term .................................. 8970/3  Hepatoblastoma, epithelioid (C22.0)
New related term .................................. 8970/3  Hepatoblastoma, mixed epithelial-mesenchymal (C22.0)

New related term .................................. 9471/3  Medulloblastoma with extensive nodularity
New related term .................................. 9474/3  Anaplastic medulloblastoma
New related term .................................. 9506/1  Extraventricular neurocytoma

NOTE: It is important to understand that cancer registry reportability rules based on behavior code still apply. With the exception of primary intracranial and central nervous system benign and borderline tumors, the addition of a /0 or /1 coded term to ICD-O-3 does not imply that it is now reportable.

Other Changes

**Cystic pancreatic endocrine neoplasm (CPEN) is reportable.**
Assign 8150/3 unless specified as a neuroendocrine tumor Grade 1 (8240/3) or neuroendocrine tumor Grade 2 (8249/3).

**Make the following reportability change.**
Behavior code change:
- Delete code and term, 8240/1, Carcinoid tumor, NOS, of appendix (C18.1).
- Code carcinoid tumor, NOS, of appendix to 8240/3.

**Recode the following conditions as shown.**
1. Recode all cases of enteroglucagonoma, NOS, as 8152/1.
   (Enteroglucagonoma is now a related term for glucagonoma.)
2. Then delete code 8157/1 Enteroglucagonoma, NOS.
3. Recode all cases of enteroglucagonoma, malignant as 8152/3.
   (Enteroglucagonoma, malignant is now a related term for glucagonoma, malignant.)
4. Then delete code 8157/3 Enteroglucagonoma, malignant.

NOTE: It is important to understand that cancer registry reportability rules based on behavior code still apply. With the exception of primary intracranial and central nervous system benign and borderline tumors, the addition of a /0 or /1 coded term to ICD-O-3 does not imply that it is now reportable.

**BENIGN/BORDERLINE INTRACRANIAL AND CNS TUMORS**

Non-malignant primary intracranial and central nervous system tumors diagnosed on or after **October 1, 2004** with an ICD-O-3 behavior code of “0” or “1” are required for the following sites:
- meninges (C70.0 – C70.9)
- brain (C71.0 – C71.9)
- spinal cord, cranial nerves, and other parts of the central nervous system (C72.0 – C72.9)
- pituitary gland (C75.1)
- craniopharyngeal duct (C75.2)
- pineal gland (C75.3).

Those facilities approved by the American College of Surgeons (ACoS) began collecting non-malignant primary intracranial and central nervous system tumors on January 1, 2004.
For benign/borderline intracranial and central nervous system tumors, the terms “tumor” and “neoplasm” are considered clinically diagnostic for the purpose of case reporting, in addition to the terms generally applicable to malignant tumors.

Diagnoses using the terms “hypodense mass” or “cystic neoplasm” are NOT reportable.

If the final pathologic (tissue sample) diagnosis is “CNS neoplasm” or “mass,” there MUST be an ICD-O-3 code for the mass or neoplasm. If there is not an ICD-O-3 code, the case is NOT reportable.

If only a clinical diagnosis of “CNS tumor” or “neoplasm” is available, then the case is reportable with the histology is coded as M-8000/1 (Neoplasm, NOS, uncertain whether benign or malignant.)

REPORTABLE AIN III, CIN III, HSIL/HGSIL, VAIN III, VIN III CONDITIONS

For these cases, histology is based on a histologically confirmed diagnosis that includes at least one of the following terms: “cervical intraepithelial neoplasia grade III (CIN III),” “HGSIL,” “HSIL,” or “severe dysplasia.” Histology for any of these cervical neoplasia conditions is coded as 8077 with or without the term “carcinoma in situ.”

Example: Final diagnosis on the pathology report is “high grade squamous intraepithelial neoplasia (HGSIL).”

Code histology as 8077.

Do NOT code the histology in this instance as 8070.

For pre-invasive cervical lesions, cases identified by only a PAP smear ARE NOT eligible for inclusion. The diagnosis must be confirmed by some other method, which could include a clinical diagnosis (physician’s statement) or positive tissue biopsy.

For Cervical Intraepithelial Neoplasia, Grade III, code Local Tumor Excision, Excisional Biopsy, Dilation and Curettage. Cone Biopsy with gross excision of lesion, LEEP and/or combinations of surgical procedures as defined in FORDS: Appendix B: Site-Specific Surgery Codes as first course of treatment. (Note: For invasive cancers, dilation and curettage is coded as an incision biopsy code 02 under the data item Surgical Diagnostic and Staging Procedure (NAACCR Item # 1350).

For non-invasive cancers, code Dilation and Curettage for in situ ONLY as code 25.

Example: First course of treatment for a non-invasive cancer is documented as LEEP.

Code the RX Summ–Surgery Primary Site as 28.

Code an excision biopsy, even when documented as incisional, when:

- All disease is removed (margins free) OR
- All gross disease is removed and there is only microscopic residual at the margin
- Do NOT code an excision biopsy when there is macroscopic residual disease

The following conditions are considered reportable and MUST be reported to the Michigan Cancer Surveillance Program by all providers regardless of facility type.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>D01.3</td>
<td>230.5</td>
<td>AIN III (anal intraepithelial neoplasia – histologically confirmed) “Severe dysplasia” of anus alone is reportable. “High grade dysplasia” of anus alone is not reportable</td>
<td>8077/2</td>
<td>C21.1</td>
</tr>
<tr>
<td>D06.9</td>
<td>233.1</td>
<td>CIN III (cervical intraepithelial neoplasia - histologically confirmed) with or without carcinoma in situ (CIS)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSIL (high-grade squamous intraepithelial lesion) of cervix alone is reportable</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSIL (high-grade squamous intraepithelial lesion) of cervix with carcinoma in situ (CIS)</td>
<td>8077/2</td>
<td>C53.0 - C53.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSIL (high-grade squamous intraepithelial lesion) of cervix with CIN III</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSIL (high-grade squamous intraepithelial lesion) of cervix with carcinoma in situ (CIS) and CIN III</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HSIL (high-grade squamous intraepithelial lesion) of cervix with CIN II and CIN III</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>“Severe dysplasia” of cervix alone is reportable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D07.2</td>
<td>233.31</td>
<td>VAIN III (vaginal intraepithelial neoplasia) with or without carcinoma in situ (CIS)</td>
<td>8077/2</td>
<td>C52.0 - C52.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“Severe dysplasia” of vagina alone is reportable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>“High grade dysplasia” of vagina alone is not reportable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>D07.1</td>
<td>233.32</td>
<td>VIN III (vulvar intraepithelial neoplasia - histologically confirmed) with or without carcinoma in situ (CIS)</td>
<td>8077/2</td>
<td>C51.0 - C51.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>“Severe dysplasia” of vulva alone is reportable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>“High grade dysplasia” of vulva alone is not reportable.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Instructions for Coding Histology and Histology Terminology for Pre-invasive (Non-invasive) Lesions**

Do not use a physician’s statement to decide whether the patient has a recurrence of a previous cancer or a new primary unless a pathologist compares the present tumor to the “original” tumor and specifically states that the new tumor is a recurrence of cancer from the previous primary. Refer to the *Multiple Primary & Histology Coding Rules Manual* to determine single vs. multiple tumors.

**Assigning Sequence Numbers**
These pre-invasive lesions must be coded in sequence range 00-59. **Do not use the 60-88 non-malignant sequence range or sequence 98 for these lesions** as these cases are required by the MCSP (not reportable by agreement.)

**Included Histologies**

Use histology code 8077/2 for diagnoses of HGSIL, CIN III, VIN III, VAIN III, or AIN III (Multiple Primary and Histology Coding Rules – Rule H21). All 8077 lesions are to have a coded Grade/Differentiation value of 9.

Lesions with ICD-O-3 histology codes 8010, 8050, 8052, 8070, 8071, 8072, 8076, 8077, and 8140 are eligible for inclusion. Lesions with histology code 8560 and behavior code 2 may also be eligible if it is determined that behavior code 2 is appropriate – the pathology report should specifically indicate “in situ” behavior [since histology 8560 (adenosquamous carcinoma) is normally an invasive cancer.] An entry should be made in pathology text field to the effect that “eligibility is confirmed for this 8560 case.”

**Number of Reportable Conditions**

All types of squamous histologies (8010, 8050, 8052, 8070, 8071, 8072, 8076, and 8077) are considered to be the same for determining inclusion eligibility when reviewing multiple reports for the same patient. If a patient has more than one lesion with these squamous histologies **within a 12-month period**, only the lesion with earliest diagnosis date (or one lesion, if the lesions have the same diagnosis date) is eligible for inclusion.

Histology codes 8140 (adenocarcinoma in situ) and 8560 (adenosquamous carcinoma) with behavior code 2 are considered to be the same for determining inclusion eligibility when reviewing multiple reports for the same patient. If a patient has more than one lesion with either of these histologies **within a 12-month period**, only the lesion with earliest diagnosis date (or one lesion, if the lesions have the same diagnosis date) is eligible for inclusion.

A subsequent lesion is eligible for inclusion **only if its histology is different** from the first eligible lesion. If a lesion is described as having both squamous cell carcinoma in situ and adenocarcinoma in situ, then it should be entered as two separate abstracts, one with each histology code.

If a patient is diagnosed with another pre-invasive lesion with the same histology **after** the 12-month period following the first eligible lesion, the subsequent lesion is eligible for inclusion.

If a patient has **both** an in situ and invasive diagnosis **on the same date**, or if the invasive diagnosis follows a previously included in situ diagnosis **within 60 days**, the in situ diagnosis is no longer considered to be eligible and should be removed from the database.

If a patient is diagnosed with a pre-invasive (in situ) lesion **within a 12-month period after** having been diagnosed with an invasive lesion, the pre-invasive lesion is not considered to be eligible for inclusion.

If separate tumors are diagnosed on the same date with differing histologies (adenocarcinoma, CIN III), a separate abstract is to be created for each tumor per the terminology used in the pathology description.

For pre-invasive cervical lesions, cases identified by only a PAP smear **ARE NOT** eligible for inclusion. The diagnosis must be confirmed by some other method, which could include a clinical diagnosis (physician’s statement) or positive tissue biopsy.
NON-REPORTABLE AIN I/II, CIN I/II, LSIL, VAIN I/II, VIN I/II, PIN I/II/III CONDITIONS

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>K62.82</td>
<td>569.44</td>
<td>AIN I (anal intraepithelial neoplasia) with or without mild dysplasia</td>
<td>8077/0</td>
<td>C21.1</td>
</tr>
<tr>
<td>K62.82</td>
<td>569.44</td>
<td>AIN II (anal intraepithelial neoplasia) with or without moderate dysplasia</td>
<td>8077/0</td>
<td>C21.1</td>
</tr>
<tr>
<td>N87.0</td>
<td>622.11</td>
<td>CIN I (cervical intraepithelial neoplasia) with or without mild dysplasia</td>
<td>8077/0</td>
<td>C53.0 - C53.9</td>
</tr>
<tr>
<td>N87.1</td>
<td>622.12</td>
<td>CIN II (cervical intraepithelial neoplasia) with or without moderate dysplasia</td>
<td>8077/0</td>
<td>C53.0 - C53.9</td>
</tr>
<tr>
<td>N89.3</td>
<td>795.1</td>
<td>LSIL (low-grade squamous intraepithelial lesion) with or without mild dysplasia</td>
<td>8077/0</td>
<td>C53.0 - C53.9</td>
</tr>
<tr>
<td>N89.3</td>
<td>623.0</td>
<td>VAIN I (vaginal intraepithelial neoplasia) with or without mild dysplasia</td>
<td>8077/0</td>
<td>C52.9</td>
</tr>
<tr>
<td>N89.3</td>
<td>623.0</td>
<td>VAIN II (vaginal intraepithelial neoplasia) with or without moderate dysplasia</td>
<td>8077/0</td>
<td>C52.9</td>
</tr>
<tr>
<td>N90.0</td>
<td>624.01</td>
<td>VIN I (vulvar intraepithelial neoplasia) with or without mild dysplasia</td>
<td>8077/0</td>
<td>C51.0 - C51.9</td>
</tr>
<tr>
<td>N90.1</td>
<td>624.02</td>
<td>VIN II (vulvar intraepithelial neoplasia) with or without moderate dysplasia</td>
<td>8077/0</td>
<td>C51.0 - C51.9</td>
</tr>
<tr>
<td>N42.3</td>
<td>602.3</td>
<td>PIN I (Prostatic Intraepithelial Neoplasia)</td>
<td>8077/0</td>
<td>C61.9</td>
</tr>
<tr>
<td>N42.3</td>
<td>602.3</td>
<td>PIN II (Prostatic Intraepithelial Neoplasia)</td>
<td>8077/0</td>
<td>C61.9</td>
</tr>
<tr>
<td>D07.5</td>
<td>233.4</td>
<td>PIN III (Prostatic Intraepithelial Neoplasia)</td>
<td>8077/0</td>
<td>C61.9</td>
</tr>
</tbody>
</table>

REPORTABLE VS. NON-REPORTABLE CONDITIONS OF THE SKIN

The Michigan Cancer Surveillance Program has exclusions to the collection of skin malignancies based upon the primary site and histology.

If the following histologies arise in the skin (C44.0 - C44.9) they are NOT reportable regardless of the stage at the initial time of diagnosis.

- Malignant Neoplasm (Carcinoma), NOS of the skin 8000 - 8004
- Epithelial Neoplasms (Carcinoma), NOS of the skin 8010 - 8045
- Papillary and Squamous Cell Neoplasm (Carcinoma) of the skin 8050 - 8082
- Basal Cell Neoplasm (Carcinoma) of the skin 8090 - 8110

EXCEPTION: The above histologies MUST be reported if the primary site is skin of the male and female genital sites. See “Reportable vs. Non-Reportable Conditions of the Skin” table below.

ALL other histologies of the skin ARE REPORTABLE, e.g.: melanoma, Kaposi sarcoma, mycosis fungoides, cutaneous lymphomas, Merkel cell carcinoma, etc.

Reportable vs. Non-Reportable Conditions of the Skin

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>ICD-9-CM Code</th>
<th>Primary Site</th>
<th>Topography Code</th>
<th>Reportable</th>
<th>Non-Reportable</th>
</tr>
</thead>
<tbody>
<tr>
<td>C52</td>
<td>184.0</td>
<td>Skin of Vagina</td>
<td>C52.9</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C51.2</td>
<td>184.1</td>
<td>Skin of Labia Majora</td>
<td>C51.0/ C51.1</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C51.1</td>
<td>184.2</td>
<td>Skin of Labia Minora</td>
<td>C51.1</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>ICD-10-CM Code</td>
<td>ICD-9-CM Code</td>
<td>Primary Site</td>
<td>Topography Code</td>
<td>Reportable</td>
<td>Non-Reportable</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------</td>
<td>--------------</td>
<td>-----------------</td>
<td>------------</td>
<td>---------------</td>
</tr>
<tr>
<td>C51.2</td>
<td>184.3</td>
<td>Skin of Clitoris</td>
<td>C51.2</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C51.9</td>
<td>184.4</td>
<td>Skin of Vulva, NOS</td>
<td>C51.9</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C57.8</td>
<td>184.8</td>
<td>Skin Lesion of Overlapping</td>
<td>C51.9</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C60.0</td>
<td>187.1</td>
<td>Skin of Prepuce</td>
<td>C60.0</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C60.9</td>
<td>187.4</td>
<td>Skin of Penis, NOS</td>
<td>C60.9</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C63.2</td>
<td>187.7</td>
<td>Skin of Scrotum</td>
<td>C63.2</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C44.00</td>
<td>C44.0</td>
<td>Skin of Lip*</td>
<td>C44.0</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>C44.01</td>
<td>C44.1</td>
<td>Skin of Eyelid/Other Unspecified Parts of Face</td>
<td>C44.1/C44.3</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C44.02</td>
<td>C44.2</td>
<td>Skin of External Ear/Auditory Canal</td>
<td>C44.2</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>C44.09</td>
<td>C44.3</td>
<td>Skin of Other &amp; Unspecified Parts of the Face</td>
<td>C44.3</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>
**ICD-10-CM Code** | **ICD-9-CM Code** | **Primary Site** | **Topography Code** | **Reportable** | **Non-Reportable**
---|---|---|---|---|---
C44.80 | 173.8 | Skin, Overlapping Lesion | C44.8 | | X
C44.81 |  |  |  | |  
C44.82 |  |  |  | |  
C44.89 |  |  |  | |  
C44.90 | 173.9 | Skin, NOS | C44.9 | | X
C44.91 |  |  |  | |  
C44.92 |  |  |  | |  
C44.99 |  |  |  | |  

* The codes for the mucoepidermoid portions of the lip are C00.0 - C00.9. These include the inner mucosal surface of the lip, the vermilion surface of the lip, i.e., the area where lipstick is applied and the vermilion border of the lip. Report these cases.

C44.0 is the code for the SKIN of the upper lip between the vermilion border and the nose and SKIN of the lower lip between the vermilion border and the chin. DO NOT report these cases.

## CANCER CASE REPORTABILITY SCENARIOS

The following scenarios and definitions are to assist with determining whether or not the patient has a reportable condition.

### Reportable Case Scenarios

1. If a lesion is originally assigned a behavior code of “0 - benign” or “1 - uncertain” and is later assigned a behavior code of “2 - in situ” or “3 - malignant” by the pathologist, the case is reportable.

2. If a lesion is originally assigned a behavior code of “0 - benign” or “1 - uncertain” and is later assigned a behavior code of “2 - in situ” or “3 - malignant” by the managing physician, the case is reportable.

3. If a specimen is sent to your facility from a staff physician’s office and read by your pathologist (e.g., pap smear, stereotatic needle biopsy for a breast mass, or excisional biopsy for a suspicious skin lesion) the case is to be reported.

4. An incidental finding of a malignancy at the time of an autopsy, with no suspicion of cancer prior to death, MUST be reported.

5. All malignant histologically confirmed specimens identified by your facility, e.g., tissue specimens from biopsy, frozen section, surgery, autopsy, or dilation and curettage (D&C); bone marrow biopsy, bone marrow aspiration; hematologic confirmation of leukemia (peripheral blood smear); loop electrocautery excision procedure (LEEP), are reportable.

6. All malignant cytological confirmed specimens identified by your facility, e.g., breast secretion, bronchial brushing, bronchial washings, cervical smear (pap smear), fine needle aspirate (FNA), gastric fluid, peritoneal fluid, pleural fluid, prostatic secretions, spinal fluid, sputum smears, tracheal washings, urinary sediment, vaginal smears, are reportable.

7. Patient is diagnosed in a staff physician’s office and treated at your facility.

8. Patient is diagnosed at your facility and treated elsewhere, whether by referral or by choice.

9. Patient is diagnosed at your facility and receives all or part of his/her treatment at your facility.
10. Patient is diagnosed at your facility and refuses therapy.

11. Patient is diagnosed at your facility and the family/guardian refuses therapy.

12. Patient is diagnosed at your facility and is untreatable due to age, advanced disease or other medical conditions.

13. Patient is diagnosed at your facility and specific therapy was recommended but not received at your facility or unknown if administered.

14. Patient was diagnosed elsewhere, but received all or part of his/her treatment at your facility.

15. Patient is diagnosed at your facility but unknown if therapy was recommended or administered.

16. Patient was diagnosed by death certificate only.

17. Patient receives all or part of the first course of therapy for a malignancy, regardless of where they were first diagnosed.

18. Patient is a non-resident of Michigan and is receiving treatment at your facility.

19. Patient is a Michigan resident diagnosed out of state but receiving treatment at your facility.

20. Patient is a Michigan resident diagnosed and treated out of state, e.g., The patient is diagnosed and treated in Wisconsin for breast cancer, but is admitted to the cardiac care unit at your facility. You recognize that the patient has breast cancer and is receiving their first course of treatment in Wisconsin. The patient is a Michigan resident, therefore the case is reportable.

Non-Reportable Case Scenarios

1. Precancerous or benign conditions (except benign or borderline intracranial CNS tumors).

2. Patients seen only in consultation to establish or confirm a diagnosis of cancer or treatment plan when the patient was first seen in a known Michigan facility.

3. Patient is diagnosed with a recurrence or progression of a previously diagnosed malignancy.

4. The patient’s malignancy was originally diagnosed prior to January 1, 1985.

5. Patient receives a radiographic exam (MRI, X-ray, CT) which reveals an ill-defined “mass.” If the patient does NOT return to your facility for diagnostic confirmation or treatment of cancer, the case is not reportable. For example: an outpatient CT scan of the pelvis reads, probable carcinoma of the right kidney. The patient did not return to your facility for diagnostic confirmation or treatment; therefore the case is not reportable.

NOTE: In order for a “radiographic diagnosis” to be reportable, the patient’s primary care physician MUST state in the medical record that the patient has cancer and treatment has been decided upon. Keep in mind, that refusal of treatment and the decision not to treat is still classified as treatment and the case is to be reported.
6. Patient visits your facility for blood work (lab only) and is NOT admitted for treatment, e.g., blood drawn to monitor anemia for patients receiving chemotherapy elsewhere; blood drawn to monitor PSA levels for prostate cancer.

7. Patient has an active malignancy but is admitted to your facility for an unrelated medical condition and does not receive first course of treatment for their cancer.

8. Patient is admitted to your facility with an active malignancy and receives supportive or palliative care, e.g., gastrostomy tubes for enteral nutrition, if previously reported or diagnosed/treated through another Michigan hospital.

9. Patients with a history of cancer who are clinically free of disease.

10. Patients admitted for terminal supportive care, including home care services, if previously reported or diagnosed/treated through another Michigan hospital.

11. Patients admitted to a designated hospice, if previously reported or diagnosed/treated through another Michigan hospital.

12. Patient’s specimen slides are sent to your pathologist for a second opinion.

13. Patients with skin cancer that does NOT meet the histology and site requirements listed previously.

Facility Specific Case Scenario
Your facility may receive specimens from a separate facility that are read by your pathologist due to the facility not having a pathologist or a laboratory. Once the specimen is read, the final report and specimen(s) are sent back to the original facility. You may or may not be responsible for reporting the ones that are malignancies. A verbal or written contract between the two facilities must exist that designates which facility will be responsible for reporting these cases to the Michigan Cancer Surveillance Program. If an agreement does NOT exist, BOTH facilities are expected to report each case.
AMBIGUOUS TERMINOLOGY

As part of the registry case-finding activities, ALL pathology reports should be reviewed to confirm whether a case is required. If the terminology is ambiguous, use the following guidelines to determine whether a particular case should be included. Words or phrases that appear to be synonyms of these terms DO NOT constitute a diagnosis. For example, “likely” alone does not constitute a diagnosis.

Ambiguous terms may originate from any source document, such as pathology report, radiology report, or from a clinical report.

NOTE: The ambiguous terms in this section ARE NOT USED to determine AJCC TNM Staging. TNM category assignments are entirely based on the rules and conditions presented in the AJCC TNM Staging Manual.

Ambiguous terms that constitute a diagnosis
- Apparent(ly)
- Appears
- Comparable with
- Compatible with
- Consistent with
- Favors
- Malignant appearing
- Most likely
- Neoplasm* (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3)
- Presumed
- Probable
- Suspect(ed)
- Suspicious (for)
- Tumor* (beginning with 2004 diagnoses and only for C70.0–C72.9, C75.1–75.3)
- Typical of

*additional terms for nonmalignant primary intracranial and central nervous system tumors only

EXCEPTION: If a cytology is identified only with an ambiguous term, DO NOT interpret it as a diagnosis of cancer.

- Abstract the case only if a positive biopsy or a physician’s clinical impression of cancer supports the cytology findings.

Examples of Diagnostic Terms:
- The inpatient discharge summary documents a chest X ray consistent with carcinoma of the right upper lobe. The patient refused further work-up or treatment. Consistent with carcinoma is indicative of cancer.
- The mammogram report states suspicious for malignancy. Suspicious for malignancy is indicative of cancer.

Ambiguous terms that DO NOT constitute a diagnosis without additional information
- Cannot be ruled out
- Equivocal
- Possible
- Potentially malignant
- Questionable
- Rule Out
- Suggests
- Worrisome

Examples of Non-diagnostic Terms:
• The inpatient discharge summary documents a chest x-ray consistent with neoplasm of the right upper lobe. The patient refused further work-up or treatment. Consistent with neoplasm is not indicative of cancer. While “consistent with” can indicate involvement, “neoplasm” without specification of malignancy is not considered diagnostic except for non-malignant primary intracranial and central nervous system tumors.

• Final diagnosis is reported as possible carcinoma of the breast. Possible is not a diagnostic term for cancer.

Genetic findings in the absence of pathologic or clinical evidence of reportable disease are indicative of risk only and DO NOT constitute a diagnosis.

**Interpreting ambiguous terminology for collaborative stage**

Determination of the cancer stage is both a subjective and objective assessment of how far the cancer has spread. Sometimes the clinician is hesitant to commit to a definite statement that a particular organ or tissue is involved by the cancer and uses what data collectors refer to as “ambiguous terminology.” The following lists can generally be used to interpret the intent of the clinician if there is no specific statement of involvement in the medical record. However, if individual clinicians use these terms differently, the clinician’s definitions and choice of therapy should be recognized. If a term used in a diagnostic statement is not listed below, consult the clinician to determine the intent of the statement.

NOTE: Some schemas interpret certain words as involvement, such as “encasing” the carotid artery for a head and neck site. Terminology in the schema takes priority over this list.

**The following terms are considered as involvement:**

<table>
<thead>
<tr>
<th>Term</th>
<th>Most likely</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adherent</td>
<td>Neoplasm*** (beginning with 2004 diagnoses and only for C70.0-C72.9, C75.1-C75.3)</td>
</tr>
<tr>
<td>Apparent(ly)</td>
<td></td>
</tr>
<tr>
<td>Appears to</td>
<td></td>
</tr>
<tr>
<td>Comparable with</td>
<td></td>
</tr>
<tr>
<td>Compatible with</td>
<td></td>
</tr>
<tr>
<td>Consistent with</td>
<td></td>
</tr>
<tr>
<td>Contiguous</td>
<td></td>
</tr>
<tr>
<td>Continuous with</td>
<td></td>
</tr>
<tr>
<td>Encroaching upon</td>
<td></td>
</tr>
<tr>
<td>Extension to</td>
<td></td>
</tr>
<tr>
<td>Extension into</td>
<td></td>
</tr>
<tr>
<td>Extension onto</td>
<td></td>
</tr>
<tr>
<td>Extension out onto</td>
<td></td>
</tr>
<tr>
<td>Features of</td>
<td></td>
</tr>
<tr>
<td>Fixation to structure other than primary**</td>
<td></td>
</tr>
<tr>
<td>Fixed to another structure**</td>
<td></td>
</tr>
<tr>
<td>Impending perforation of</td>
<td></td>
</tr>
<tr>
<td>Impinging upon</td>
<td></td>
</tr>
<tr>
<td>Impose on</td>
<td></td>
</tr>
<tr>
<td>Imposing on</td>
<td></td>
</tr>
<tr>
<td>Incipient invasion</td>
<td></td>
</tr>
<tr>
<td>Induration</td>
<td></td>
</tr>
<tr>
<td>Infringe</td>
<td></td>
</tr>
<tr>
<td>Infringing</td>
<td></td>
</tr>
<tr>
<td>Into *</td>
<td></td>
</tr>
<tr>
<td>Intrude</td>
<td></td>
</tr>
<tr>
<td>Invasion to into</td>
<td></td>
</tr>
<tr>
<td>Invasion onto</td>
<td></td>
</tr>
<tr>
<td>Invasion out onto</td>
<td></td>
</tr>
<tr>
<td>Up to</td>
<td></td>
</tr>
</tbody>
</table>

* interpreted as involvement whether the description is clinical, operative or pathological
** interpreted as involvement of another organ or tissue
*** additional terms for non-malignant primary intracranial and central nervous system tumors only
The following terms ARE NOT to be considered as involvement.

- Abuts
- Approaching
- Approximates
- Attached
- Cannot be excluded
- Cannot be ruled out
- Efface/effacing/effacement
- Encased
- Encasing
- Encompass(ed)
- Entrapped
- Equivocal
- Extension to without invasion
- Extension to without involvement of
- Kiss/kissing
- Matted (except for lymph nodes)
- Possible
- Questionable
- Reaching
- Rule out
- Suggests
- Very close to
- Worrisome

**Ambiguous terminology for hematopoietic and lymphoid neoplasm**

Report the case when the diagnosis of a hematopoietic or lymphoid neoplasm is preceded by one of the following ambiguous terms. For additional information, refer to the Hematopoietic and Lymphoid Neoplasm Case Reportability and Coding Manual.

**NOTE:** DO NOT report cases diagnosed only by ambiguous cytology (cytology diagnosis preceded by ambiguous term).

- Apparent(ly)
- Appears
- Comparable with
- Compatible with
- Consistent with
- Favor(s)
- Malignant appearing
- Most likely
- Presumed
- Probable
- Suspect(ed)
- Suspicious (for)
- Typical (of)

**NOTE 1:** Reportable diagnoses are described in the Reportable Conditions section of this manual.

**NOTE 2:** Use these terms when screening all diagnoses other than cytology and tumor markers.

**NOTE 3:** Report only those cases that use the words on the list or an equivalent word such as “favored” rather than “favor(s).” DO NOT substitute synonyms such as “supposed” for “presumed” or “equal” for “comparable.”
NOTE 4: Accept the reportable term and report the case when one part of the medical record uses a reportable ambiguous term such as “apparently” and another section of the medical record(s) uses a term that is not on the reportable list.

NOTE 5: Diagnoses based on ambiguous terminology require follow-back to see if the diagnosis has been confirmed or proven to be incorrect (see NOTE 6).

NOTE 6: DO NOT report the case when biopsy or physician’s statement proves the ambiguous diagnosis is wrong (for example, pathology diagnosis is benign or borderline).

Example: CT scan shows enlarged lymph nodes suspicious for lymphoma. Subsequent biopsies of the lymph nodes thought to be involved with a neoplasm are negative for malignancy. The pathology is more reliable than the scan; the negative biopsy proves that the presumed malignancy does not exist. DO NOT report the case.
CASEFINDING PROCEDURES

Casefinding is a systematic process used to identify all cases eligible to be included in the central cancer registry. Cases include those patients that were diagnosed and/or treated with a reportable condition in your facility.

One source for casefinding is NOT enough to identify all cancer cases diagnosed or treated at your facility and multiple sources MUST be used to obtain a complete description of each patient’s course of cancer care.

Each facility should have written procedures and instructions for carrying out complete casefinding. This will ensure that casefinding is performed on a regular basis and allow personnel to know the status of casefinding at all times. A written log or tracking system should be in place to monitor all casefinding sources. Casefinding sources may be monitored daily, weekly, monthly or quarterly.

Having a system for recognizing reportable conditions is essential to complete reporting. A process which will identify all cancer cases that are diagnosed or treated within a facility must be devised. All pertinent medical records which may contain information on any case of diagnosed cancer must be reviewed, whether that diagnosis is clinical or histological. The hospital where a diagnosis is reached or a patient is treated must endeavor to report all cases regardless of the patient’s status. This includes outpatients and patients diagnosed elsewhere when the place of diagnosis is unknown or is outside the state. An independent laboratory must similarly ascertain needed information upon determining that a reportable condition exists. It is important to report all patients, including patients who DO NOT live in Michigan.

Patients who were diagnosed elsewhere and newly admitted to your facility for further treatment, are to be reported provided the first diagnosis occurred after the start date of the state registry on January 1, 1985. This may result in multiple reports on one patient, but it will enable the MCSP to have the most comprehensive data on each case and serves as a quality control mechanism.

Cancer registries should first examine the sources used to identify malignant CNS tumors and expand the procedures to include non-malignant CNS tumors.

Since surgery is often the treatment for CNS tumors of all behaviors, pathology reports are an excellent casefinding source. Inpatient and outpatient surgery logs should also be reviewed. Many patients with CNS tumors of all behaviors are treated with adjuvant radiation therapy and review of radiation oncology appointment logs is a way to identify these cases.

Gamma/cyber knife is becoming a common treatment for non-malignant CNS tumors. If the hospital has a gamma/cyber knife center, review logs and schedules as part of casefinding. Hormone therapy and immunotherapy are medical treatments given for both non-malignant and malignant CNS tumors.

Reports are necessary for outpatients who are diagnosed as having cancer based upon a laboratory diagnosis of submitted specimens as well as those cases where outpatient surgery is the only means of diagnosis. Outpatients initially treated for cancer who were not diagnosed within a facility should also be reported if receiving outpatient radiotherapy or chemotherapy.

A report is not required when initially treating a patient diagnosed elsewhere if it is known that the patient was first diagnosed AND treated in some other MICHIGAN hospital, and you have the name of the diagnosing hospital in the medical record. Patients that have been diagnosed out of state e.g. Mayo Clinic or in an unknown facility, who come to your facility for treatment must be reported. This requirement includes the reporting of “historic” cases that otherwise meet the definition of a reportable case.
In many facilities, these functions and/or record systems are coordinated which can greatly simplify the process of casefinding. What is important, is that all sources of information pertinent to case identification must be reviewed. The development of a coordinated screening of these various files is essential to assuring complete reporting.

A second report is not necessary upon confirmation or re-diagnosis of a specific primary tumor or the metastasis therefrom, if that specific primary is known to have been reported earlier. Send a second report only if the information first reported on the patient requires correction or can be reported more completely than previously known.

It is very important to report ALL cases regardless of state residency. Data on all cancer cases is of value in several ways. In particular, Michigan currently has resident data exchange agreements with several states concerning cancer cases diagnosed and/or treated within our respective borders. Michigan sends reports of nonresident patients to their state of residency and these states reciprocate by sending MCSP records of MI residents diagnosed or treated for cancer in their state.

When in doubt about submitting a cancer case to the Michigan Cancer Surveillance Program (MCSP), ask these three questions:

1. Does the patient have a diagnosis of cancer that is reportable?
2. Is it a new reportable condition?
3. Was the case diagnosed since the start date of the central registry January 1, 1985?

If the answer is yes to these questions and the case has not yet been submitted by your hospital, report the case.

If you have questions about a particular case, submit the case with an attached note of explanation or call the state registry.

A record of those cases submitted to the central state registry MUST be maintained. It is recommended for those facilities that submit manually, to make a copy of the completed cancer report form, submit the original form to the state central cancer registry and file the copy alphabetically by last name combining all diagnosis years. For those facilities that submit electronically, a list of cases submitted to the state central cancer registry can easily be generated via the software.

The MCSP recommends retaining copies of the cancer report forms or submission log for a period of three full years. Legislation indicates that an audit may be conducted “not more than once every two years for the purpose of assessing the quality and completeness of cancer reporting.” During the audit process, the MDI and submission logs are reviewed. As a result, maintaining these records for a period of three years, will be useful during the audit process.

If a submission log is maintained, it should contain at a minimum, the following items: patient’s full name, medical record number, social security number, date of birth, date of diagnosis, primary site, laterality and summary stage. The submission log is not necessarily the best mechanism for keeping track of those cases submitted to the MCSP, but those facilities that wish to maintain a log are free to do so.

Examples and definitions of sources for casefinding are as follows:

**PATHOLOGY REPORTS**

Review ALL pathology reports from the pathology department for reportable conditions on a weekly, monthly or quarterly basis.
If the final pathologic diagnosis is “CNS neoplasm” or “mass,” there must be an ICD-O-3 code for the mass or neoplasm. If there is not an ICD-O-3 code, the case is NOT reportable.

If the ONLY diagnosis available is “CNS tumor” or “neoplasm” the case is reportable and the histology is coded as M-8000/1 (Neoplasm, NOS, uncertain whether benign or malignant.)

This includes specimens sent to your facility from physician’s offices to be read by the hospital pathologist.

**CYTOLOGY REPORTS**

Review ALL cytology reports from the pathology department for reportable conditions on a weekly, monthly or quarterly basis.

This includes pap smears, or specimens sent to your facility from a physician’s offices to be read by the hospital pathologist.

**BONE MARROW REPORTS**

Review ALL bone marrow reports from the pathology department for reportable conditions on a weekly, monthly or quarterly basis.

**AUTOPSY REPORTS**

Review ALL autopsy reports from the pathology department at least twice a year. Review all diagnoses recorded, not just the cause of death, as occult or unexpected malignancies can be found on autopsy reports. If your facility does not perform autopsies, these reports may be located in the health information department.

**MEDICAL ONCOLOGY LOGS (CHEMOTHERAPY)**

Chemotherapy is administered either as an inpatient, outpatient, in a free-standing facility or a physician’s office. Develop a system for identifying patients who receive chemotherapy at any facility affiliated with the reporting institution. Review the list of patients on a monthly or quarterly basis. e.g., billing, summary sheet, appointment book, treatment record.

**RADIATION ONCOLOGY LOGS**

Radiation therapy is administered either as an inpatient, outpatient or in a free-standing facility. Develop a system for identifying patients who receive radiation therapy at any facility affiliated with the reporting institution. Review the list of patients on a monthly or quarterly basis. e.g., billing, summary sheet, appointment book, treatment record.

**RADIOLOGY**

Review CT scans of the head, MRI’s of the head and any additional scans of the head to identify reportable benign conditions of the brain and/or central nervous system. Review the reports from radiology on a monthly or quarterly basis.

For benign/borderline intracranial and central nervous system tumors, the terms “tumor” and “neoplasm” are considered diagnostic for the purpose of case reporting, in addition to the terms generally applicable to malignant tumors.

Diagnoses like “hypodense mass” or “cystic neoplasm” are NOT reportable even for CNS sites.
MASTER DISEASE INDEX (MDI)

Generate a MDI on a monthly or quarterly basis by discharge date which is based upon the diagnosis year.

Use the applicable ICD-CM codes from casefinding list to generate the MDI.

Select those patients seen at your facility as an inpatient and/or as an outpatient for surgery, endoscopy, chemotherapy, radiation therapy, etc. **Exclude laboratory visits. Include radiology visits ONLY for benign/borderline brain/CNS tumors.**

List the principle code, primary code and secondary codes to include up to six diagnostic codes that have been assigned.

The MDI should include the following items: last name, first name, middle initial, date of birth, social security number, medical record number, laboratory number (if applicable), admit date, discharge date, patient type, the six ICD-CM codes and ICD-CM code descriptions that have been assigned.

Once the MDI has been generated, it must be compared with the log (or copies) of previously submitted cases. Sort the MDI **alphabetically** by last name. This will make it easier when comparing the MDI to previously submitted cases.

If the name from the MDI appears on the log of previously submitted cases, determine whether this is a new primary, recurrence or progression of disease from the original primary. (Refer to the Multiple Primary and Histology Coding Rules for clarification.)

   a. A separate report MUST be submitted for each NEW primary.
   b. Additional reports for recurrence or progression of disease are NOT required.

If the name from the MDI does NOT appear on the log of previously submitted cases, determine whether this a NEW case, MISSED case or NON-REPORTABLE CONDITION.

   a. A separate report MUST be submitted for a new or missed case.
   b. If a non-reportable condition exists, document on the MDI next to the patient’s name the condition that was determined to be non-reportable. This will be helpful when reviewing future MDI’s.

**Examples:**

   John Doe - NR SCC skin (non-reportable squamous cell carcinoma)
   James Doe - NR recurrent bladder cancer

Based upon your facility’s needs, it may be beneficial to maintain a separate log of those cases determined to be non-reportable. This can easily be achieved by completing the demographic information only on the cancer report form and documenting the non-reportable condition in the primary anatomical site field.

The MCSP recommends retaining the MDI log for a period of **three full years**. Legislation indicates that an audit may be conducted “not more than once every two years for the purpose of assessing the quality and completeness of cancer reporting.” During the audit process, the MDI and submission logs are reviewed. As a result, maintaining these records for a period of three years, will be useful during the audit.

The tables that follow illustrate the applicable ICD-CM codes that should be used to generate the Master Disease Index (MDI). Please refer to the **Newly Reportable Conditions & Other Changes** section for ICD-0-3 Updates and for dates these changes are effective.
ICD-9-CM CASEFINDING LIST. Effective only until 9/30/2015.

<table>
<thead>
<tr>
<th>ICD-9-CM Code</th>
<th>Explanation of Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>140.0 – 172.9, 174.0 – 208.9</td>
<td>Malignant neoplasms: stated or presumed to be primary (of specified sites and certain specified histologies)</td>
</tr>
<tr>
<td>209.0 – 209.29</td>
<td>Neuroendocrine tumors</td>
</tr>
</tbody>
</table>
| 209.30 | Malignant poorly differentiated neuroendocrine tumors; Other malignant neuroendocrine tumors  
Reportable inclusion terms:  
High grade neuroendocrine carcinoma, any site  
Malignant poorly differentiated neuroendocrine tumor, NOS, any site |
| 209.31 – 209.36 | Merkel cell carcinoma  
NOTE: Effective date 10/1/09 |
| 209.70 – 209.74 | Secondary neuroendocrine tumors  
NOTE: Effective Date 10/1/09  
Reportable inclusion terms:  
Secondary carcinoid tumors  
NOTE: ALL neuroendocrine or carcinoid tumors specified as secondary are malignant. |
| 209.75 | Secondary Merkel cell carcinoma  
Reportable inclusion terms:  
Merkel cell carcinoma nodal presentation  
Merkel cell carcinoma visceral metastatic presentation  
Secondary Merkel cell carcinoma, any site  
NOTE: ALL neuroendocrine or carcinoid tumors specified as secondary are malignant. |
| 209.79 | Secondary neuroendocrine tumors of other sites  
NOTE: ALL neuroendocrine or carcinoid tumors specified as secondary are malignant. |
| 225.0 – 225.9 | Benign neoplasm of brain and other parts of nervous system |
| 227.3 | Benign neoplasm of pituitary gland and craniopharyngeal duct (pouch)  
Reportable inclusion terms:  
Benign neoplasm of Craniobuccal pouch, Hypophysis, Rathke’s pouch or Sella turcica |
| 227.4 | Benign neoplasm of pineal gland (pineal body) |
| 227.9 | Benign neoplasm of unspecified endocrine gland |
| 228.02 | Hemangioma; of intracranial structures  
Reportable inclusion terms:  
Angioma, NOS  
Cavernous nevus  
Gломус tumor  
NOTE: Venous angioma of the brain/CNS is not reportable. Venous angioma is a malformation (developmental venous anomaly), not a tumor. |
| 228.1 | Lymphangioma, any site  
NOTE: Includes only lymphangioma of the brain, other parts of nervous system and endocrine gland. |
| 230.0 – 234.9 | Carcinoma in situ  
Reportable inclusion terms:  
Cervical Intraepithelial neoplasia, Grade III  
Erythroplasia, Queryrat’s  
AIN III, CIN III, VAIN III, VIN III |
| 237.0 – 237.1 | Neoplasm of uncertain behavior [borderline] of Endocrine glands and Nervous system:  
Pituitary gland, Craniopharyngeal duct and Pineal gland |
<table>
<thead>
<tr>
<th>ICD-9-CM Code</th>
<th>Explanation of Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>237.5, 237.6, 237.9</td>
<td>Neoplasm of uncertain behavior [borderline] of Endocrine glands and Nervous system: Brain and Spinal cord, Meninges, Endocrine glands and Other and unspecified parts of nervous system</td>
</tr>
<tr>
<td>238.4</td>
<td>Polycythemia vera (9950/3): Excludes: Familial polycythemia (D75.0) Secondary polycythemia (D75.1)</td>
</tr>
<tr>
<td>238.6</td>
<td>Plasma cells</td>
</tr>
<tr>
<td>238.7</td>
<td>Other Lymphatic and Hematopoietic tissues NOTE: This code was expanded in 10/2006. It is now a subcategory and is no longer valid for coding purposes; however, it should be included in extract programs for quality control purposes.</td>
</tr>
<tr>
<td>238.71 – 238.77, 238.79</td>
<td>Other Lymphatic and Hematopoietic tissues: Essential thrombocythemia, Myelodysplastic syndromes, Lymphoproliferative disorders, and Other lymphatic and hematopoietic tissues</td>
</tr>
<tr>
<td>239.6, 239.7</td>
<td>Neoplasms of unspecified nature; Brain, Endocrine glands and Other parts of Nervous system NOTE: Category D49 classifies by site neoplasms of unspecified morphology and behavior. The term “mass,” unless otherwise stated, is not to be regarded as a neoplastic growth. Includes: ‘growth, NOS’ ‘neoplasm, NOS’ ‘new growth, NOS’ ‘tumor, NOS’ ‘neoplasm of uncertain behavior” (D37-D44, D48) Excludes: Neoplasm of unspecified behavior of cerebral meninges (D49.7) Neoplasm of unspecified behavior of cranial nerves (D49.7) Neoplasm of unspecified behavior of peripheral, sympathetic, and parasympathetic nerves and ganglia (D49.2)</td>
</tr>
<tr>
<td>273.2</td>
<td>Other paraproteinemias (Cryoglobulinemia) Reportable inclusion terms: Franklin’s disease (heavy chain) (9762/3) Heavy chain disease (9762/3) Mu-chain disease (9762/3)</td>
</tr>
<tr>
<td>273.3</td>
<td>Macroglobulinemia (Waldenstrom’s macroglobulinemia)</td>
</tr>
<tr>
<td>277.89</td>
<td>Other specified disorders of metabolism Reportable inclusion terms: Hand-Schuller-Christian disease Histiocytosis (acute) (chronic) Histiocytosis X (chronic) [OBS] Langerhans-cell histiocytosis, NOS (diagnosed 2010 and later)</td>
</tr>
<tr>
<td>ICD-9-CM Code</td>
<td>Explanation of Code</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>285.0</td>
<td>Sideroblastic anemia Reportable inclusion terms:</td>
</tr>
<tr>
<td></td>
<td>Acquired idiopathic sideroblastic anemia</td>
</tr>
<tr>
<td></td>
<td>Pure sideroblastic anemia</td>
</tr>
<tr>
<td></td>
<td>Refractory anemia with hemochromatosis</td>
</tr>
<tr>
<td></td>
<td>Refractory anemia with sideroblasts</td>
</tr>
<tr>
<td></td>
<td>Refractory anemia with ringed sideroblasts (RARS)</td>
</tr>
<tr>
<td></td>
<td>Sideroblastic anemia</td>
</tr>
<tr>
<td>288.3</td>
<td>Eosinophilia NOTE: This code is for eosinophilia, which is not reportable. DO NOT abstract unless diagnosis is:</td>
</tr>
<tr>
<td></td>
<td>Chronic eosinophilic leukemia (CEL)</td>
</tr>
<tr>
<td></td>
<td>Chronic eosinophilic leukemia (and the hyperosinophilic syndrome)</td>
</tr>
<tr>
<td></td>
<td>Hypereosinophilic (idiopathic) syndrome (HES)</td>
</tr>
<tr>
<td>288.4</td>
<td>Hemophagocytic syndromes (Histiocytic syndromes)</td>
</tr>
<tr>
<td>289.6</td>
<td>Familial polycythemia (synonym for polycythemia vera)</td>
</tr>
<tr>
<td>795.04</td>
<td>Papanicolaou smear of cervix with high grade squamous intraepithelial lesion (HGSIL)</td>
</tr>
<tr>
<td>795.06</td>
<td>Papanicolaou smear of cervix with cytologic evidence of malignancy</td>
</tr>
<tr>
<td>795.14</td>
<td>Papanicolaou smear of vagina with high grade squamous intraepithelial lesion (HGSIL)</td>
</tr>
<tr>
<td>795.16</td>
<td>Papanicolaou smear of vagina with cytologic evidence of malignancy</td>
</tr>
<tr>
<td>795.74</td>
<td>Papanicolaou smear of anus with high grade squamous intraepithelial lesion (HGSIL)</td>
</tr>
<tr>
<td>796.76</td>
<td>Papanicolaou smear of anus with cytologic evidence of malignancy</td>
</tr>
</tbody>
</table>

NOTE: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).

ICD-10-CM CASEFINDING LIST. Effective as of October 1, 2015.

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Explanation of Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>C00.0 – C43.9, C45.0 – C96.6, C96.9, C96.A, C96.Z</td>
<td>Malignant neoplasms: stated or presumed to be primary (of specified sites and certain specified histologies)</td>
</tr>
<tr>
<td>C4A._</td>
<td>Merkel cell carcinoma NOTE: Effective date 10/1/09</td>
</tr>
<tr>
<td>C75.0</td>
<td>Familial polycythemia (synonym for polycythemia vera)</td>
</tr>
<tr>
<td>C7A.00 – C7A.098</td>
<td>Neuroendocrine tumors</td>
</tr>
<tr>
<td>C7A.1, C7A.8</td>
<td>Malignant poorly differentiated neuroendocrine tumors; Other malignant neuroendocrine tumors Reportable inclusion terms: High grade neuroendocrine carcinoma, any site Malignant poorly differentiated neuroendocrine tumor, NOS, any site</td>
</tr>
<tr>
<td>C7B.00 – C7B.04, C7B.09</td>
<td>Secondary neuroendocrine tumors NOTE: Effective Date 10/1/09 Reportable inclusion terms: Secondary carcinoid tumors NOTE: ALL neuroendocrine or carcinoid tumors specified as secondary are malignant.</td>
</tr>
<tr>
<td>ICD-10-CM Code</td>
<td>Explanation of Code</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------------</td>
</tr>
</tbody>
</table>
| C7B.1          | Secondary Merkel cell carcinoma  
Reportable inclusion terms:  
Merkel cell carcinoma nodal presentation  
Merkel cell carcinoma visceral metastatic presentation  
Secondary Merkel cell carcinoma, any site  
NOTE: ALL neuroendocrine or carcinoid tumors specified as secondary are malignant. |
| C7B.8          | Secondary neuroendocrine tumors of other sites  
NOTE: ALL neuroendocrine or carcinoid tumors specified as secondary are malignant. |
| C88.0          | Macroglobulinemia (Waldenstrom’s macroglobulinemia) |
| C96.5, C96.6   | Other specified disorders of metabolism  
Reportable inclusion terms:  
Hand-Schuller-Christian disease  
Histiocytosis (acute) (chronic)  
Histiocytosis X (chronic) [OBS]  
Langerhans-cell histiocytosis, NOS (diagnosed 2010 and later) |
| D00.00 – D03.9, D05.00 – D09.9 | Carcinoma in situ  
Reportable inclusion terms:  
Cervical Intraepithelial neoplasia, Grade III  
Erythroplasia, Queryrat’s  
AIN III, CIN III, VAIN III, VIN III |
| D18.1          | Lymphangioma, any site  
NOTE: Includes only lymphangioma of the brain, other parts of nervous system and endocrine gland. |
| D18.02         | Hemangioma; of intracranial structures  
Reportable inclusion terms:  
Angioma, NOS  
Cavernous nevus  
Glomus tumor  
NOTE: Venous angioma of the brain/CNS is not reportable. Venous angioma is a malformation (developmental venous anomaly), not a tumor. |
| D32.0 – D33.9  | Benign neoplasm of brain and other parts of nervous system |
| D35.2 – D35.3  | Benign neoplasm of pituitary gland and craniopharyngeal duct (pouch)  
Reportable inclusion terms:  
Benign neoplasm of Craniobuccal pouch, Hypophysis, Rathke’s pouch or Sella turcica |
| D35.4          | Benign neoplasm of pineal gland (pineal body) |
| D35.9          | Benign neoplasm of unspecified endocrine gland |
| D42.0, D42.1, D42.9, D43.2, D43.3, D43.4, D43.9 | Neoplasm of uncertain behavior [borderline] of Endocrine glands and Nervous system: Brain and Spinal cord, Meninges, Endocrine glands and Other and unspecified parts of nervous system |
| D44.3 – D44.5  | Neoplasm of uncertain behavior [borderline] of Endocrine glands and Nervous system: Pituitary gland, Craniopharyngeal duct and Pineal gland |
| D45            | Polycythemia vera (9950/3):  
Excludes:  
Familial polycythemia (D75.0)  
Secondary polycythemia (D75.1) |
<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Explanation of Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>D46.0 – D46.2, D46.20 – D46.22, D46.A, D46.B, D46.C, D47.3, D46.9, D47.1, D47.Z1, D47.7, D47.9, D47.Z9</td>
<td>Other Lymphatic and Hematopoietic tissues: Essential thrombocythemia, Myelodysplastic syndromes, Lymphoproliferative disorders, and Other lymphatic and hematopoietic tissues</td>
</tr>
<tr>
<td>D47.Z9</td>
<td>Plasma cells</td>
</tr>
</tbody>
</table>
| D49.6, D49.7 | Neoplasms of unspecified nature; Brain, Endocrine glands and Other parts of Nervous system  
NOTE: Category D49 classifies by site neoplasms of unspecified morphology and behavior. The term “mass,” unless otherwise stated, is not to be regarded as a neoplastic growth.  
Includes:  
‘growth, NOS’  
‘neoplasm, NOS’  
‘new growth, NOS’  
‘tumor, NOS’  
‘neoplasm of uncertain behavior” (D37-D44, D48)  
Excludes:  
Neoplasm of unspecified behavior of cerebral meninges (D49.7)  
Neoplasm of unspecified behavior of cranial nerves (D49.7)  
Neoplasm of unspecified behavior of peripheral, sympathetic, and parasympathetic nerves and ganglia (D49.2) |
| D64.0 – D64.3 | Sideroblastic anemia  
Reportable inclusion terms:  
Acquired idiopathic sideroblastic anemia  
Pure sideroblastic anemia  
Refractory anemia with hemochromatosis  
Refractory anemia with sideroblasts  
Refractory anemia with ringed sideroblasts (RARS)  
Sideroblastic anemia |
| D72.1 | Eosinophilia  
NOTE: This code is for eosinophilia, which is not reportable. DO NOT abstract unless diagnosis is:  
Chronic eosinophilic leukemia (CEL)  
Chronic eosinophilic leukemia (and the hypereosinophilic syndrome)  
Hypereosinophilic (idiopathic) syndrome (HES) |
| D76.1 – D76.3 | Hemophagocytic syndromes (Histiocytic syndromes) |
| D89.1 | Other paraproteinemias (Cryoglobulinemia)  
Reportable inclusion terms:  
Franklin’s disease (heavy chain) (9762/3)  
Heavy chain disease (9762/3)  
Mu-chain disease (9762/3) |
| R87.613 | Papanicolaou smear of cervix with high grade squamous intraepithelial lesion (HGSIL) |
| R87.614 | Papanicolaou smear of cervix with cytologic evidence of malignancy |
| R87.623 | Papanicolaou smear of vagina with high grade squamous intraepithelial lesion (HGSIL) |
| R87.624 | Papanicolaou smear of vagina with cytologic evidence of malignancy |
### ICD-10-CM Code | Explanation of Code
---|---
R85.613 | Papanicolaou smear of anus with high grade squamous intraepithelial lesion (HGSIL)
R85.614 | Papanicolaou smear of anus with cytologic evidence of malignancy

NOTE: Pilocytic/juvenile astrocytoma M-9421 moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. However, SEER registries will CONTINUE to report these cases and code behavior as /3 (malignant).

Select those patients seen at your facility as an inpatient and/or as an outpatient for surgery, endoscopy, chemotherapy, radiation therapy, etc. **Exclude ALL laboratory visits. Include radiology visits for benign/borderline intracranial and CNS tumors ONLY:**

- Endoscopy short stay
- Inpatient admission
- Outpatient surgery, short stay
- Outpatient surgery
- Outpatient care unit
- Outpatient endoscopy
- Outpatient administration of chemotherapy
- Outpatient administration of radiation therapy

**BENIGN/BORDERLINE INTRACRANIAL AND CNS TUMORS CASEFINDING LIST**

Due to a change in the federal law affected by passage of Public Law 107-260, which requires the collection of case information for benign brain and CNS tumors, revisions to the administrative rules that govern Michigan cancer reporting have been made. Reporting of benign brain and CNS related tumors is now required. This new requirement is effective with cases diagnosed on October 1, 2004 forward.

Non-malignant primary intracranial and central nervous system tumors diagnosed on or after **October 1, 2004** with an ICD-O-3 behavior code of “0” or “1” are required for the following sites:

- meninges (C70.0 – C70.9)
- brain (C71.0 – C71.9)
- spinal cord, cranial nerves, and other parts of the central nervous system (C72.0 – C72.9)
- pituitary gland (C75.1)
- craniopharyngeal duct (C75.2)
- pineal gland (C75.3).

Juvenile astrocytomas should continue to be reported as 9421/3.
The casefinding list for Benign/Borderline Intracranial and Central Nervous System (CNS) Tumors listed below should include radiology visits.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>225.2</td>
<td>D32.0</td>
<td>C70.0</td>
<td>Cerebral Meninges</td>
</tr>
<tr>
<td>225.4</td>
<td>D32.1</td>
<td>C70.1</td>
<td>Spinal Meninges</td>
</tr>
<tr>
<td>237.6</td>
<td>D42.0, D42.1, D42.9</td>
<td>C70.9</td>
<td>Meninges, NOS</td>
</tr>
<tr>
<td>225.0</td>
<td>D33.0, D43.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>225.0, 237.5</td>
<td>D33.1, D43.1</td>
<td>C71.0</td>
<td>Cerebrum (Supratentorial, NOS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C71.1</td>
<td>Frontal Lobe</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C71.2</td>
<td>Temporal Lobe</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C71.3</td>
<td>Parietal Lobe</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C71.4</td>
<td>Occipital Lobe</td>
</tr>
<tr>
<td>225.0, 237.5</td>
<td>D33.1 – D33.9, D43.2</td>
<td>C71.5</td>
<td>Ventricle</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Includes:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ventricle, NOS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cerebral</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lateral</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Third</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Excludes:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fourth Ventricle</td>
</tr>
<tr>
<td>225.0, 237.5</td>
<td>D33.1, D43.2</td>
<td>C71.6</td>
<td>Brain, Infratentorial</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C71.7</td>
<td>Cerebellum, NOS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C71.7</td>
<td>Brain Stem</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fourth Ventricle</td>
</tr>
<tr>
<td>225.0, 237.5</td>
<td>D33.1 – D33.9, D43.2</td>
<td>C71.8</td>
<td>Overlapping lesion of Brain</td>
</tr>
<tr>
<td>225.0, 237.5</td>
<td>D33.2, D43.2</td>
<td>C71.9</td>
<td>Brain, NOS</td>
</tr>
<tr>
<td>225.3, 237.5</td>
<td>D33.4, D43.4</td>
<td>C72.0</td>
<td>Spinal Cord</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C72.1</td>
<td>Cauda Equina</td>
</tr>
<tr>
<td>225.1</td>
<td>D33.3, D43.3</td>
<td></td>
<td>Nerves: Olfactory, Optic, Acoustic, NOS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C72.2</td>
<td>Olfactory Nerve</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C72.3</td>
<td>Optic Nerve</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C72.4</td>
<td>Acoustic Nerve</td>
</tr>
<tr>
<td></td>
<td></td>
<td>C72.5</td>
<td>Cranial Nerve, NOS</td>
</tr>
<tr>
<td>225.8, 225.9, 237.9</td>
<td>D33.7, D33.9, D43.8, D43.9</td>
<td>C72.8</td>
<td>Overlapping lesion of Brain and CNS</td>
</tr>
<tr>
<td>227.3, 237.0</td>
<td>D35.2, D44.3</td>
<td>C75.1</td>
<td>Pituitary Gland</td>
</tr>
<tr>
<td>227.3, 237.0</td>
<td>D35.3, D44.4</td>
<td>C75.2</td>
<td>Craniopharyngeal Duct</td>
</tr>
<tr>
<td>227.4, 237.1</td>
<td>D35.4, D44.5</td>
<td>C75.3</td>
<td>Pineal Gland</td>
</tr>
</tbody>
</table>
Select those patients seen at your facility as an inpatient and/or as an outpatient for surgery, endoscopy, chemotherapy, radiation therapy, etc. **Exclude ALL laboratory visits. Include radiology visits for benign/borderline intracranial and CNS tumors ONLY:**

- Endoscopy short stay
- Inpatient admission
- Outpatient surgery, short stay
- Outpatient surgery
- Outpatient care unit
- Outpatient endoscopy
- Outpatient administration of chemotherapy
- Outpatient administration of radiation therapy
COMPONENTS OF GOOD REPORTING

Quality control field projects carried out within Michigan have been designed to measure the completeness and accuracy of the cancer data as well as timeliness of reporting. The results indicated the following quality control problems that need to be addressed if a facility is to satisfy the obligation to report all cancer cases. These issues are identified separately with recommendations that would help avoid reporting problems. The topics are discussed below and are divided into those that affect casefinding and those that affect the accuracy of reports.

CASEFINDING PROBLEMS

1. Completeness

Reporting responsibility placed solely in the pathology department results in cases being missed that are diagnosed through other means. This especially pertains to cases involving the primary sites of the trachea, bronchus, pancreas, brain or lung, chronic leukemia and lymphoma.

In hospitals with no tumor registry there needs to be an established procedure that ensures ALL cases are reported. These procedures must include every department in the hospital which deals with cancer patients. A procedure for reporting should be in place within all departments involved in either diagnosing or treating cancer patients. One approach is to develop a communication system between each department, and the group coordinating reporting, by placing one person in charge of reporting across all departments. Training staff within each area to follow coordinated procedures will eliminate missing cases. This should be covered within the written procedures on reporting in place within each facility.

2. Registries in Transition

Hospital cancer registries changing from manual reporting to a software system, or updating to a new software system, tend to have more missing cases. The registry staff while learning the new software system abstracts into the hospital registry while continuing to report manually this can be confusing and can result in cases that need to be sent to the state registry being overlooked.

During a transition stage a procedure needs to be developed which will ensure all cases are properly reported. One approach is to maintain a log of reported cases, or some type of recording system, to allow comparison between the cases in the hospital registry and those cases sent to the central registry. The log needs to be updated and checked on a monthly basis through this transition period.

3. Class of Case

All approved hospital registries classify cases as analytical or non-analytical. Sometimes registries mistakenly send only the analytical cases. Completeness of reporting is improved by registries being sure they are sending ALL cancer patient data regardless of class of case. Though this may result in duplication, it is the best way to ensure that all cases are reported to the state and none are skipped due to confusion on a patient's status.

The MCSP accepts ALL cases regardless of their class of case status.

4. Reporting Outpatient Cases

Outpatient cases can be overlooked by reporting facilities due to a lack of communication and lack of a reliable reporting system within the facility. It is important to establish a referral procedure that will identify and prompt the reporting of ALL outpatient cancer cases which are diagnosed or treated in your facility, clinics operated by your facility or through an affiliated laboratory.
Reporting personnel should set up a reporting system with personnel having access to outpatient records relative to outpatient treatment and outpatient diagnosis. It is important to include diagnostic work for specimens submitted to the laboratory in this process. Outpatient cancer case information can be reported independently, or preferably, routed to the personnel responsible for all cancer case reporting. This should be done on a regular basis, i.e., weekly or daily depending upon the size of the hospital, to insure timeliness of reporting and to avoid backlogs.

5. Reporting Michigan Residents Diagnosed Out of State

Michigan residents diagnosed out of state but receiving treatment in a Michigan hospital can mistakenly not be reported. If a patient has been diagnosed out of state it is important to report the case in all instances. (Michigan does have an exchange agreement with some states to exchange data concerning cancer cases of Michigan residents, BUT NOT with all states.) These cases MUST be reported regardless of the state of diagnosis. Report all cases treated in your facility that were diagnosed outside Michigan or in an UNKNOWN FACILITY.

6. Reporting Non-residents

Out of state residents are reportable. Non-resident cases cannot be skipped due to a presumption that only resident cases are necessary. ALL cancer cases are required to be reported regardless of residency.

Report ALL cases regardless of the patient's address or state of residency.

7. Referrals to Another Facility

Cases can be missed if there is a lack of communication between facilities. Especially in instances where a patient was diagnosed at one facility and then referred to a second facility for treatment and each facility assumed that the other had reported the case. The end result was often that neither had reported this case.

In a situation where hospitals are referring patients, it is recommended that the diagnosing facility and the hospital initially treating the patient both report the case. This recommendation applies to clinically diagnosed cases, in particular.
DETERMINING MULTIPLE PRIMARY TUMORS

For both solid tumors and hematopoietic/lymphoid neoplasms, there are specific rules to determine a new or subsequent primary. You must review the rules for each case to determine if a new primary exists.

SOLID TUMOR RULES

The most recent SEER Multiple Primary and Histology Coding Rules contain site-specific rules for lung, breast, colon, melanoma of the skin, head and neck, kidney, renal pelvis/ureter/bladder, and malignant and nonmalignant brain primaries. A separate set of rules addresses the specific and general rules for all other sites. The multiple primary rules guide and standardize the process of determining the number of primaries. The histology rules contain detailed histology coding instructions.

You MUST download the complete SEER Multiple Primary and Histology Coding Rules Manual.

NON-SOLID TUMOR RULES (HEMATOPOIETIC AND LYMPHOID NEOPLASMS 9590/3-9992/3)

The SEER Multiple Primary and Histology Coding Rules DO NOT apply to hematopoietic and lymphoid tumors. Use the Hematopoietic and Lymphoid Neoplasm Database and the Hematopoietic and Lymphoid Neoplasm Coding Manual to assist with coding these primaries. These references apply only to cases diagnosed January 1, 2010 and forward.
ICD-O-3 SEER SITE/HISTOLOGY VALIDATION LIST

Specific histologies arise in specific tissue types. Refer to the SEER site/histology validation list to determine valid primary site and histology combinations for cases diagnosed on or after January 1, 2001.

The Site/Histology Validation List can be downloaded by visiting the SEER website.

Most comparisons can be made to the three-digit histology code but a four-digit histology comparison is required whenever an “!” appears to the left of the three-digit histology name.

To use the SEER site/histology validation list:

- a. Locate the three-digit topography code in ICD-O-3, for the primary site in question.
- b. Locate the five-digit morphology code in ICD-O-3, for the primary site in question.
- c. Locate the three-digit topography code in the SEER site/histology validation list in the left hand column, in numeric order by topography code.
- d. Locate the five-digit morphology code in the SEER site/histology validation list in the right hand column, in numeric order by morphology code.
- e. If the five-digit morphology code is listed in the right hand column, the site/histologic type is valid.
- f. If the five-digit morphology code is NOT listed in the right hand column, the site/histologic type is NOT valid.

** Confirm with your pathologist and/or managing physician if the site/histology is valid and code appropriately.

NOTE: If the primary site/histology is valid according to the pathologist and/or managing physician, document this in the text to justify the selected codes. As the purpose of text information is to provide the opportunity for documenting and checking coded values, information documenting the disease process should be entered from the medical record and should NOT be generated electronically from coded values.
DIAGNOSTIC CONFIRMATION

Descriptions of procedures performed to determine the method of diagnosis are listed below. A low number takes precedence over all higher numbers regardless of the type of procedure performed.

POSITIVE HISTOLOGY

Use code 1 for the following methods of diagnoses.

1. Bone Marrow Biopsy - examination of a piece of bone marrow by puncture or trephine (removing a circular disc of bone) for possible diagnosis of leukemia or multiple myeloma

2. Curettage - removal of growths or other material by scraping with a curette (D&C)

3. Excisional Biopsy - the removal of a growth in its entirety and having a therapeutic as well as diagnostic purpose

4. Frozen Section - a thin slice of tissue cut from a frozen specimen, often used for rapid microscopic diagnosis

5. Hematologic examination - microscopic examination of the cells of the blood or blood-forming tissues (especially bone marrow) for possible diagnosis of leukemia or multiple myeloma

6. Incisional Biopsy - incomplete removal of a growth for the purpose of diagnostic study

7. Punch Biopsy - biopsy of material obtained from the body tissue by a punch technique

8. Surface Biopsy - scraping of cells from surface epithelium, especially from the cervix, for microscopic examination

9. Surgical Biopsy - removal of tissue from the body by surgical excision for examination

ENDOSCOPIC PROCEDURES

Use code 1 (histology) if a “piece of tissue” is taken and examined under a microscope.

Use code 2 (cytology) if “fluid” is taken and examined under a microscope.

Use code 6 (visualization) if no tissue or fluid is taken and a diagnosis of cancer is made.

Examples:

A patient undergoes a bronchoscopy with a bronchial washing.

Code the method of diagnosis as: 2 - cytology

A patient undergoes a colonoscopy with a biopsy of a mass.

Code the method of diagnosis as: 1 - histology

1. Bronchoscopy - examination of the bronchi

2. Colonoscopy - examination of the colon and rectum by means of an elongated flexible fiberscope

3. Colposcopy - examination of tissue of the cervix and vagina by use of a magnifying lens inserted into the vagina
4. Culdoscopy - visual examination of the female pelvic viscera by means of an endoscope introduced through the posterior vaginal wall into that part of the pelvic cavity known as the rectovaginal pouch or cul de sac

5. Cystoscopy - examination of the interior of the urinary bladder by means of a cystoscope

6. Esophagoscopy - observation of the interior of the esophagus

7. Gastroscopy - visual examination of the interior of the stomach

9. Laryngoscopy - examination of the larynx

10. Laparoscopy - examination of intra-abdominal structures by means of an illuminated tubular instrument inserted through a small incision in the abdominal wall

11. Mediastinoscopy - examination of the mediastinum by means of a tubular instrument permitting direct inspection of the area between the lungs

12. Nasopharyngoscopy - examination of the nasopharynx, pharynx, and the pharyngeal end of the auditory tube by lighted telescopic endoscope

13. Ophthalmoscopy - an examination in which an instrument containing a perforated mirror and lenses is used to examine the interior of the eye

14. Otoscopy - inspection of the internal ear

15. Panendoscopy - a cystoscopy that permits wide angle viewing of the urinary bladder

16. Peritoneoscopy - examination of the peritoneal cavity by an instrument inserted through the abdominal wall

17. Proctoscopy - inspection of the rectum

18. Sigmoidoscopy - inspection of the colon up to sigmoid flexure

19. Thoracoscopy - direct examination of the pleural cavity by means of an endoscope which is inserted into the cavity through an intercostal space

---

**POSITIVE CYTOLOGY**

**Use code 2 for the following methods of diagnoses.**

1. Aspiration Biopsy - biopsy of material obtained by suction through a needle attached to a syringe

2. Brushings - the procedure of brushing the lining of an organ for the purpose of obtaining cells

3. Fine Needle Aspiration (FNA) - a hollow needle used for withdrawing fluid from a cavity

4. Paracentesis - surgical puncture of a cavity, such as the abdominal cavity, for aspiration of fluid

5. Punctures - inserting a hollow needle into a cavity or organ for the purpose of removal of some portion of the contents
6. Scraping - the procedure of scraping the lining of a structure with an instrument for the purpose of obtaining cells

7. Swab - using a swab or similar device to obtain fluid and secretions which then can be used to make a smear

8. Thoracentesis - surgical puncture for aspiration of fluid from the chest

9. Washings - the removal of fluid from a hollow organ or structure for the purpose of collecting cells

**VISUALIZATION**

**Use code 6 for the following method of diagnosis.**

1. Exploratory surgery - surgery is performed to determine whether or not a cancerous condition exists and the degree to which the cancer may have affected other organs and structures within the observed area; no biopsies are taken

**RADIOGRAPHIC EXAMINATION**

**Use code 7 for the following methods of diagnosis.**

Radiographic examination refers to a negative image on photographic film made by exposure to x-rays or gamma rays that have passed through matter or tissue.

1. Angiography - radiographic study of the vascular system
   a. cerebral angiogram - x-ray of the vessels of the brain
   b. cardiac angiogram - x-ray showing the functions of the heart and large blood vessels
   c. lymphangiogram - x-ray study of the vessels of the lymphatic system
   d. arteriography - x-ray examination of arteries
   e. venography - x-ray examination of veins

2. Bronchography - radiographic study of the bronchi of the lung
   a. bronchogram - x-ray of the bronchial system

3. Cholecystography - radiologic study of the function of the gallbladder and bile ducts after an opaque medium has been introduced either orally or intravenously
   a. cholangiogram - x-ray of extrahepatic ducts
   b. cholecystogram - x-ray of the gallbladder

4. Computerized (Axial) Tomography (CT) - examination of body tissue; directs a thin, concentrated beam of radiation through a cross-section of the body to detectors; the technique involves recording of “slices” of the body with an x-ray scanner
5. Hysterosalpingography - radiography of the uterus and fallopian tubes after the injection of radiopaque material

6. Infusion Nephrotomography - radiographic visualization of the kidney by tomography after intravenous introduction of contrast medium

7. Intraoperative Imaging - an imaging procedure such as x-ray, CT scan, ultrasound, or mammogram that is performed during an operative procedure, e.g., to direct a biopsy or to verify the position of a prosthesis

8. KUB (Kidneys, Ureter, Bladder) - a frontal film of the abdomen taken in the supine position

9. Laminography - x-ray of a selected layer of the body; usually performed on joints and eye orbits

10. Lower GI series or Barium Enema - x-ray studies, following rectal injection of barium, of the large bowel; air and barium are used as contrast materials

11. Mammogram - several x-ray views are taken of one or both breasts and the radiographs are examined for the presence of a lesion, mass or calcification

12. Magnetic Resonance Imaging (MRI) - based on magnetization of the various biological tissues; does not use any ionizing radiation (such as x-rays) and is capable of direct imaging in any plane without reformatting

13. Myelography - radiologic study of the spinal cord

14. Positron Emission tomography (PET) - is a unique noninvasive technique that produces three-dimensional images within the human body. Compounds like glucose, oxygen, and carbon, which are found naturally in body chemistry, are labeled with signal-emitting tracers and injected into the body. All cells use this tracer, and cells with increased metabolism use more glucose. Because cancer cells are highly metabolic and use more glucose than normal cells, they are easily seen on a PET scan.

15. Radioisotopes - substance administered to patients in order to diagnose disease in which the radioisotopes gather in the infected area emitting gamma rays from within the body which enable the physician to visualize internal abnormalities

16. Salpingography - radiologic study of the uterus and fallopian tubes

17. Sialography - radiologic study of the salivary ducts

18. Thermography - technique for detecting cancer by differentiating regions of hot and cold in the body; the surface temperature is photographically recorded

19. Tomography - a special x-ray technique to show in detail images of structures lying in a predetermined plane of tissue while blurring or eliminating detail in images of structures in other planes; usually performed on the kidneys

20. Upper GI series or Barium Swallow - x-ray studies, following ingestion of barium, of the pharynx, esophagus, stomach, and duodenum

21. Urography - radiologic study of the urinary tract
a. Urogram - x-ray of the kidney and ureter with emphasis on the pelvis of the kidney by intravenous injection of a contrast medium

b. Cystogram - x-ray of the urinary bladder by filling the bladder by catheterization with a contrast medium

c. IVP (intravenous pyelography) - a succession of x-ray films of the urinary tract following the injection into a vein of an iodine-containing substance which is collected by the kidneys, passing into the ureters and subsequently the bladder, allowing the study of urinary tract function

d. Retrograde Urography - examination of the ureter and renal collecting structures by means of instillation of contrast material through a ureteral catheter passed through a cystoscope into the bladder and ureter

22. Ultrasound - high-frequency sound waves; waves can be bounced off of tissues using special devices. The echoes are then converted into a picture called a sonogram. Ultrasound imaging, referred to as ultrasonography, allows physicians and patients to get an inside view of soft tissues and body cavities, without using invasive techniques.
CANCER STAGING

SEER SUMMARY STAGE

| Directly coded SEER Summary Stage 2000 values are **Required** by the Michigan Cancer Surveillance Program for all cases regardless of diagnosis year. For more information refer to the SEER Summary Stage 2000 manual. For SEER Summary Stage coding training, refer to the “For Cancer Registrars” tab on the [SEER website](https://seer.cancer.gov). |

The summary stage should include all information available through completion of surgery or surgeries in the **first course of treatment or within four months from the date of initial diagnosis**.

Summary staging is a method of organizing extent of disease data into groups which have prognostic significance. A staging system is a reference or chart which indicates the category into which a specific piece of information about a case fits.

Summary stage refers to the primary site ONLY.

**Directly coded SEER Summary Stage is required for ALL cases submitted to the Michigan Cancer Surveillance Program.**

Summary stage consists of the following categories:

0  In situ, Intraepithelial, Noninvasive, Non-infiltrating

1  Localized ONLY (within organ)

2  Regional by direct extension ONLY (to adjacent organs or tissues)

3  Regional lymph node(s) involved ONLY

4  Regional by BOTH direct extension AND regional lymph node(s) involved

5  Regional, NOS (not otherwise specified)

7  Distant site(s)/lymph node(s) involved or Systemic Disease

8  BENIGN: benign brain tumors and central nervous system tumors

9  Unknown if extension or metastasis (unstaged, unknown or unspecified)
   Unknown primary site

Summary stage for all sites is based on pathologic, operative and clinical assessments with the pathologic examination taking precedence. It is important to read the pathology and operative reports for evidence of spread, microscopic extension and metastasis, as well as diagnostic imaging reports for mention of distant disease.

Exclude metastasis or disease progression that develops after the **four month interval**.

Apply the same rules when autopsy reports are used to stage the disease.

If it is not definitively known whether the tumor is in-situ or invasive, the suspected or probable status should be reported.
If the primary site is unknown, the SEER Summary Stage must be coded as “9 - unknown.”

**Do not leave this data item blank.**

**COLLABORATIVE STAGING**

Effective with cases diagnosed in 2016 and forward, CDC requires directly assigned SEER Summary Stage 2000 and AJCC TNM Clinical and Pathologic Stage. The Collaborative Stage Data Collection System will continue to be used for cases diagnosed 2004-2015 and for the collection of Site-Specific Factors (SSFs) for cases diagnosed 2004 and forward. In addition to the SSFs, Regional Node Positive and Examined and Lymph-vascular Invasion will continue to be required. All other CS input data items are no longer required.

For Schema-specific SSF data requirements, refer to [Collaborative Stage Data Collection System](#).

**AJCC TNM STAGING**

Directly assigned TNM Stage values are Required by the Michigan Cancer Surveillance Program for cases diagnosed January 1, 2016 and forward. If information is unknown, not documented, or not applicable, then record the appropriate default value. Note that in some cases, “blank” may be the appropriate default value. For more information, refer to the AJCC Cancer Staging Manual. For AJCC TNM Stage training, refer to the Registrar education section on the [AJCC website](#).

The site offers three particularly helpful presentations:

- *Registrar’s Guide to Chapter 1, AJCC Seventh Edition*
- *Explaining Blanks and X, Ambiguous Terminology and Support for AJCC Staging*
- *AJCC T, N, and M Category Options for Registry Data Items in 2016*

Physicians are responsible for documenting physician-assigned clinical and pathologic stage in the patient medical record. Hospital registrars are responsible for recording the physician-assigned stage in the registry database.
QUALITY CONTROL

Quality control measures are essential to establish accuracy, completeness and consistency of reporting within the registry. Internal quality control relates to the process that is established to check for errors and discrepancies as reports come into the registry from the reporting facilities. External quality control is a method that checks for errors and discrepancies at the reporting facility.

NOTE: Some of the edit checks are prompts to review unusual data such as a prostate gland cancer in a man less than 45 years of age. If it is something rare, please review it with your pathologist.

INTERNAL QUALITY CONTROL

Proper Completion

As the reports are received, they are reviewed for consistency and completeness. Whenever a case is incomplete or inconsistent relative to an essential data item or items the department will query the reporting facility to clarify the case. A copy of the report in question is sent to the reporting facility with a request to clarify or complete the essential data item or items. However, it is customary to make a telephone call rather send out a letter requesting clarification. Those essential data items and the more common problems that are routinely queried are:

- Patient’s first name
  - if blank or inconsistent, unknown or illegible
- Patient’s last name
  - if blank or unknown or illegible
- Complete address
  - if blank, illegible or inconsistent
- Sex
  - if blank or inconsistent with name or site
- Date of Birth
  - if blank or inconsistent with site, report date, or date of diagnosis
- Social Security Number
  - if blank
- Primary site
  - if blank or inconsistent with histology
- Laterality
  - if blank and a paired organ is reported for the primary site
- Histology
  - if blank, if inconsistent with the primary site or it indicates the condition may not be reportable
- Stage
  - if inconsistent with histology, blank, or, for TNM values, not consistent with the AJCC staging system
- Method of diagnosis
  - if blank or inconsistent as in an in situ diagnosis not based upon a microscopic method of diagnosis
- Non-diagnostic method
  - if method of diagnosis is reported as cytology and the case is in-situ, VIN III or CIN III, or a Pap smear, the case will be queried, to determine if a histological confirmation was obtained
- Treatment
  - if blank and if the report is from a hospital with a cancer treatment center
If the reporting facility cannot supply the needed data items requested, the next step is to query the attending physician. For such cases, the complete name and office address of the physician are requested from the reporting facility.

For independent laboratories that do not have access to necessary patient demographic information to complete the report, adding the name and office address of the doctor to the report is extremely helpful. This reference information on the physician should be added to the bottom of the cancer report form for any case with missing information. Be sure to supply the doctor’s full name and complete mailing address.

1. Manual checks of new reports

Routine checking of incoming reports identifies problems early in the processing. Letters are prepared to survey the hospital, laboratory or doctor to obtain information or clarification on identified problems.

The situations that will result in a letter of inquiry include when:

a. important information on the patient is missing
b. the diagnosis is vague or not clearly a malignancy
c. the diagnosis is an in situ lesion based upon a cytological diagnosis
d. diagnostic information is missing
e. logical inconsistencies are evident, such as date of birth that is the same as the date of the report, cancer sites that disagree with the patient’s sex or sites and histologies that are not compatible

If reporting a case that will likely generate a query, such as a CIN III pap smear or a patient with an unknown residence, record the physician's name and address in the lower margin of the report. This information will allow the MCSP staff to contact the doctor directly.

2. Computer edit checks

A series of edit checks are employed to scan incoming data. Many of these checks are basic screens of the data to insure all codes are valid. Other edits are more complex. These include the standard edit checks for sex and site, site and histology, histology and stage and other edits patterned after those employed at the National Cancer Institute and as recommended by NAACCR. Problems identified by these edits may result in additional inquiries concerning a cancer report.

EXTERNAL QUALITY CONTROL

A quality control field representative will visit each contributing facility to conduct a review of the quality of the cancer reporting at that facility. The field representative will help the facility identify and solve problems associated with casefinding, timeliness, abstracting, reporting, etc. Facility staff responsible for submitting reports are encouraged to contact their quality control field representative with questions about cancer reports.

FACILITY AUDIT PROCEDURE

The reporting of cancer cases by Michigan licensed hospitals and laboratories are required by Act No. 82 of 1984. Administrative Rule 325.9053 provides the Michigan Cancer Surveillance Program (MCSP) with the authority to conduct quality assurance reviews within each reporting entity to ensure consistency and completeness of the statewide cancer incidence registry.
DATA SERVICES PROVIDED TO FACILITIES

A variety of services are available to Michigan facilities providing cancer patient information to the Michigan Cancer Surveillance Program. These services are made available to support the research and planning efforts that facility staff determine are necessary and are particularly intended to aid in hospital cancer registry management and associated activities.

The key services available include:

- Hospital Specific Data or Listings
- Ad Hoc Statistical Data
- Death Searches - Death Certificates
- Death Indexes
- Microfiche - from 1985 - 1995 (135mm)
- Data Files - from 1996 to current
- Death Notices when Reported Patients Die (includes deaths in Michigan and for many other states.)

For more information on these special services contact:

Glenn Copeland, State Registrar
Division for Vital Records and Health Statistics
P.O. Box 30691
Lansing, MI 48909
Phone (517) 335-8677
Fax (517) 335-8711
E-Mail: CopelandG@michigan.gov
ABBREVIATIONS

For a list of recommended abbreviations for abstractors, refer to Appendix G: NAACCR Data Standards & Data Dictionary

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACoS</td>
<td>American College of Surgeons</td>
</tr>
<tr>
<td>ACS</td>
<td>American Cancer Society</td>
</tr>
<tr>
<td>CA</td>
<td>Carcinoma/cancer</td>
</tr>
<tr>
<td>CAP</td>
<td>College of American Pathologists</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>CoC</td>
<td>Commission on Cancer</td>
</tr>
<tr>
<td>CS</td>
<td>Collaborative Stage Data Collection System Manual</td>
</tr>
<tr>
<td>DX</td>
<td>Diagnosis</td>
</tr>
<tr>
<td>F/U</td>
<td>Follow-up</td>
</tr>
<tr>
<td>FORDS</td>
<td>Facility Oncology Registry Data Standards</td>
</tr>
<tr>
<td>H&amp;P</td>
<td>History &amp; physical</td>
</tr>
<tr>
<td>H/O</td>
<td>History of</td>
</tr>
<tr>
<td>HX</td>
<td>History</td>
</tr>
<tr>
<td>ICD-9-CM</td>
<td>International Classification of Diseases – 9th revision Clinical Modification</td>
</tr>
<tr>
<td>ICD-10-CM</td>
<td>International Classification of Diseases – 10th revision Clinical Modification</td>
</tr>
<tr>
<td>ICD-O-3</td>
<td>International Classification of Diseases for Oncology, 3rd Edition</td>
</tr>
<tr>
<td>INPT</td>
<td>Inpatient</td>
</tr>
<tr>
<td>MCSP</td>
<td>Michigan Cancer Surveillance Program</td>
</tr>
<tr>
<td>MDHHS</td>
<td>Michigan Department of Health and Human Services</td>
</tr>
<tr>
<td>NA</td>
<td>Not applicable</td>
</tr>
<tr>
<td>NR</td>
<td>Not recorded</td>
</tr>
<tr>
<td>NAACCR</td>
<td>North American Association of Central Cancer Registries</td>
</tr>
<tr>
<td>NED</td>
<td>No evidence of disease</td>
</tr>
<tr>
<td>NCI</td>
<td>National Cancer Institute</td>
</tr>
<tr>
<td>NOS</td>
<td>Not otherwise specified</td>
</tr>
<tr>
<td>NR</td>
<td>Not reported</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Opt</td>
<td>Outpatient</td>
</tr>
<tr>
<td>PE</td>
<td>Physical examination</td>
</tr>
<tr>
<td>QC</td>
<td>Quality control</td>
</tr>
<tr>
<td>R/O</td>
<td>Rule out</td>
</tr>
<tr>
<td>REP</td>
<td>Reportable</td>
</tr>
<tr>
<td>REQ</td>
<td>Required</td>
</tr>
<tr>
<td>ROADS</td>
<td>Registry Operations and Data Standards Documents for Historical Reference</td>
</tr>
<tr>
<td>RX</td>
<td>Treatment</td>
</tr>
<tr>
<td>SEER</td>
<td>Surveillance, Epidemiology and End Results</td>
</tr>
<tr>
<td>Surg</td>
<td>Surgery, surgical</td>
</tr>
<tr>
<td>TNM</td>
<td>Tumor, Node, Metastases (staging system of American Joint Committee for Cancer</td>
</tr>
<tr>
<td>TR</td>
<td>Tumor Registry</td>
</tr>
<tr>
<td>TX</td>
<td>Treatment</td>
</tr>
<tr>
<td>UNK</td>
<td>Unknown</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
## FIPS COUNTY CODES FOR MICHIGAN COUNTIES

Reference [Appendix A: NAACCR Data Standards & Data Dictionary](#)

<table>
<thead>
<tr>
<th>County</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcona</td>
<td>001</td>
</tr>
<tr>
<td>Alger</td>
<td>003</td>
</tr>
<tr>
<td>Allegan</td>
<td>005</td>
</tr>
<tr>
<td>Alpena</td>
<td>007</td>
</tr>
<tr>
<td>Antrim</td>
<td>009</td>
</tr>
<tr>
<td>Arenac</td>
<td>011</td>
</tr>
<tr>
<td>Baraga</td>
<td>013</td>
</tr>
<tr>
<td>Barry</td>
<td>015</td>
</tr>
<tr>
<td>Bay</td>
<td>017</td>
</tr>
<tr>
<td>Benzie</td>
<td>019</td>
</tr>
<tr>
<td>Berrien</td>
<td>021</td>
</tr>
<tr>
<td>Branch</td>
<td>023</td>
</tr>
<tr>
<td>Calhoun</td>
<td>025</td>
</tr>
<tr>
<td>Cass</td>
<td>027</td>
</tr>
<tr>
<td>Charlevoix</td>
<td>029</td>
</tr>
<tr>
<td>Cheboygan</td>
<td>031</td>
</tr>
<tr>
<td>Chippewa</td>
<td>033</td>
</tr>
<tr>
<td>Clare</td>
<td>035</td>
</tr>
<tr>
<td>Clinton</td>
<td>037</td>
</tr>
<tr>
<td>Crawford</td>
<td>039</td>
</tr>
<tr>
<td>Delta</td>
<td>041</td>
</tr>
<tr>
<td>Dickinson</td>
<td>043</td>
</tr>
<tr>
<td>Eaton</td>
<td>045</td>
</tr>
<tr>
<td>Emmet</td>
<td>047</td>
</tr>
<tr>
<td>Genesee</td>
<td>049</td>
</tr>
<tr>
<td>Gladwin</td>
<td>051</td>
</tr>
<tr>
<td>Gogebic</td>
<td>053</td>
</tr>
<tr>
<td>Grand Traverse</td>
<td>055</td>
</tr>
<tr>
<td>Gratiot</td>
<td>057</td>
</tr>
<tr>
<td>Hillsdale</td>
<td>059</td>
</tr>
<tr>
<td>Houghton</td>
<td>061</td>
</tr>
<tr>
<td>Huron</td>
<td>063</td>
</tr>
<tr>
<td>Ingham</td>
<td>065</td>
</tr>
<tr>
<td>Ionia</td>
<td>067</td>
</tr>
<tr>
<td>Iosco</td>
<td>069</td>
</tr>
<tr>
<td>Iron</td>
<td>071</td>
</tr>
<tr>
<td>Isabella</td>
<td>073</td>
</tr>
<tr>
<td>Jackson</td>
<td>075</td>
</tr>
<tr>
<td>Keweenaw</td>
<td>083</td>
</tr>
<tr>
<td>Kalamazoo</td>
<td>077</td>
</tr>
<tr>
<td>Kalkaska</td>
<td>079</td>
</tr>
<tr>
<td>Kent</td>
<td>081</td>
</tr>
<tr>
<td>Lake</td>
<td>085</td>
</tr>
<tr>
<td>Lapeer</td>
<td>087</td>
</tr>
<tr>
<td>Leelanau</td>
<td>089</td>
</tr>
<tr>
<td>Lenawee</td>
<td>091</td>
</tr>
<tr>
<td>Livingston</td>
<td>093</td>
</tr>
<tr>
<td>Luce</td>
<td>095</td>
</tr>
<tr>
<td>Mackinac</td>
<td>097</td>
</tr>
<tr>
<td>Macon</td>
<td>099</td>
</tr>
<tr>
<td>Manistee</td>
<td>101</td>
</tr>
<tr>
<td>Marquette</td>
<td>103</td>
</tr>
<tr>
<td>Mason</td>
<td>105</td>
</tr>
<tr>
<td>Mecosta</td>
<td>107</td>
</tr>
<tr>
<td>Menominee</td>
<td>109</td>
</tr>
<tr>
<td>Midland</td>
<td>111</td>
</tr>
<tr>
<td>Missaukee</td>
<td>113</td>
</tr>
<tr>
<td>Monroe</td>
<td>115</td>
</tr>
<tr>
<td>Montcalm</td>
<td>117</td>
</tr>
<tr>
<td>Montmorency</td>
<td>119</td>
</tr>
<tr>
<td>Muskegon</td>
<td>121</td>
</tr>
<tr>
<td>Newaygo</td>
<td>123</td>
</tr>
<tr>
<td>Oakland</td>
<td>125</td>
</tr>
<tr>
<td>Oceana</td>
<td>127</td>
</tr>
<tr>
<td>Ogemaw</td>
<td>129</td>
</tr>
<tr>
<td>Ontonagon</td>
<td>131</td>
</tr>
<tr>
<td>Osceola</td>
<td>133</td>
</tr>
<tr>
<td>Oscoda</td>
<td>135</td>
</tr>
<tr>
<td>Otsego</td>
<td>137</td>
</tr>
<tr>
<td>Ottawa</td>
<td>139</td>
</tr>
<tr>
<td>Presque Isle</td>
<td>141</td>
</tr>
<tr>
<td>Roscommon</td>
<td>143</td>
</tr>
<tr>
<td>Saginaw</td>
<td>145</td>
</tr>
<tr>
<td>St. Clair</td>
<td>147</td>
</tr>
<tr>
<td>St. Joseph</td>
<td>149</td>
</tr>
<tr>
<td>Sanilac</td>
<td>151</td>
</tr>
<tr>
<td>Schoolcraft</td>
<td>153</td>
</tr>
<tr>
<td>Shiawassee</td>
<td>155</td>
</tr>
<tr>
<td>Tuscola</td>
<td>157</td>
</tr>
<tr>
<td>Van Buren</td>
<td>159</td>
</tr>
<tr>
<td>Washtenaw</td>
<td>161</td>
</tr>
<tr>
<td>Wayne</td>
<td>163</td>
</tr>
<tr>
<td>Wexford</td>
<td>165</td>
</tr>
<tr>
<td>Out of State</td>
<td>998</td>
</tr>
<tr>
<td>Unknown</td>
<td>999</td>
</tr>
</tbody>
</table>
### U.S. State, Territory, Commonwealth, U.S. Possession, and Canadian Province or Territory Codes

Reference [Appendix B: SEER Program Coding and Staging Manual 2016](#)

<table>
<thead>
<tr>
<th>U.S. State/Territory</th>
<th>Code</th>
<th>Province/Territory</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alabama</td>
<td>AL</td>
<td>AL</td>
</tr>
<tr>
<td>Alaska</td>
<td>AK</td>
<td>NM</td>
</tr>
<tr>
<td>Alberta</td>
<td>AB</td>
<td>NY</td>
</tr>
<tr>
<td>Arizona</td>
<td>AZ</td>
<td>NL</td>
</tr>
<tr>
<td>Arkansas</td>
<td>AR</td>
<td>NC</td>
</tr>
<tr>
<td>British Columbia</td>
<td>BC</td>
<td>ND</td>
</tr>
<tr>
<td>California</td>
<td>CA</td>
<td>CA</td>
</tr>
<tr>
<td>Canada</td>
<td>CD</td>
<td>NS</td>
</tr>
<tr>
<td>Colorado</td>
<td>CO</td>
<td>NU</td>
</tr>
<tr>
<td>Connecticut</td>
<td>CT</td>
<td>OH</td>
</tr>
<tr>
<td>Delaware</td>
<td>DE</td>
<td>OK</td>
</tr>
<tr>
<td>District of Columbia</td>
<td>DC</td>
<td>ON</td>
</tr>
<tr>
<td>Florida</td>
<td>FL</td>
<td>OR</td>
</tr>
<tr>
<td>Georgia</td>
<td>GA</td>
<td>PA</td>
</tr>
<tr>
<td>Hawaii</td>
<td>HI</td>
<td>PE</td>
</tr>
<tr>
<td>Idaho</td>
<td>ID</td>
<td>PR</td>
</tr>
<tr>
<td>Illinois</td>
<td>IL</td>
<td>QC</td>
</tr>
<tr>
<td>Indiana</td>
<td>IN</td>
<td>RI</td>
</tr>
<tr>
<td>Iowa</td>
<td>IA</td>
<td>SK</td>
</tr>
<tr>
<td>Kansas</td>
<td>KS</td>
<td>SC</td>
</tr>
<tr>
<td>Kentucky</td>
<td>KY</td>
<td>SD</td>
</tr>
<tr>
<td>Louisiana</td>
<td>LA</td>
<td>TN</td>
</tr>
<tr>
<td>Maine</td>
<td>ME</td>
<td>TX</td>
</tr>
<tr>
<td>Manitoba</td>
<td>MB</td>
<td>VI</td>
</tr>
<tr>
<td>Maryland</td>
<td>MD</td>
<td>UT</td>
</tr>
<tr>
<td>Massachusetts</td>
<td>MA</td>
<td>VT</td>
</tr>
<tr>
<td>Michigan</td>
<td>MI</td>
<td>VA</td>
</tr>
<tr>
<td>Minnesota</td>
<td>MN</td>
<td>WA</td>
</tr>
<tr>
<td>Mississippi</td>
<td>MS</td>
<td>WV</td>
</tr>
<tr>
<td>Missouri</td>
<td>MO</td>
<td>WI</td>
</tr>
<tr>
<td>Montana</td>
<td>MT</td>
<td>WY</td>
</tr>
<tr>
<td>Nebraska</td>
<td>NE</td>
<td>YT</td>
</tr>
<tr>
<td>Nevada</td>
<td>NV</td>
<td>XX</td>
</tr>
<tr>
<td>New Brunswick</td>
<td>NB</td>
<td>ZZ</td>
</tr>
<tr>
<td>New Hampshire</td>
<td>NH</td>
<td></td>
</tr>
</tbody>
</table>

---

Go to Table of Contents  Go to Data Item List  MCSP Cancer Program Manual • 193
### ALPHABETIC LISTING OF COUNTRY CODES (ISO-3 ALPHA CODES)


<table>
<thead>
<tr>
<th>Country</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afghanistan</td>
<td>AFG</td>
</tr>
<tr>
<td>Africa NOS</td>
<td>ZZF</td>
</tr>
<tr>
<td>Aland Islands</td>
<td>ALA</td>
</tr>
<tr>
<td>Albania</td>
<td>ALB</td>
</tr>
<tr>
<td>Algeria</td>
<td>DZA</td>
</tr>
<tr>
<td>American Samoa</td>
<td>ASM</td>
</tr>
<tr>
<td>Andorra</td>
<td>AND</td>
</tr>
<tr>
<td>Angola</td>
<td>AGO</td>
</tr>
<tr>
<td>Anguilla</td>
<td>AIA</td>
</tr>
<tr>
<td>Antarctica</td>
<td>ATA</td>
</tr>
<tr>
<td>Antigua and Barbuda</td>
<td>ATG</td>
</tr>
<tr>
<td>Argentina</td>
<td>ARG</td>
</tr>
<tr>
<td>Armenia</td>
<td>ARM</td>
</tr>
<tr>
<td>Aruba</td>
<td>ABW</td>
</tr>
<tr>
<td>Asia NOS</td>
<td>ZZA</td>
</tr>
<tr>
<td>Australia</td>
<td>AUS</td>
</tr>
<tr>
<td>Austria</td>
<td>AUT</td>
</tr>
<tr>
<td>Azerbaijan</td>
<td>AZE</td>
</tr>
<tr>
<td>Bahamas</td>
<td>BHS</td>
</tr>
<tr>
<td>Bahrain</td>
<td>BHR</td>
</tr>
<tr>
<td>Bangladesh</td>
<td>BGD</td>
</tr>
<tr>
<td>Barbados</td>
<td>BRB</td>
</tr>
<tr>
<td>Belarus</td>
<td>BLR</td>
</tr>
<tr>
<td>Belgium</td>
<td>BEL</td>
</tr>
<tr>
<td>Belize</td>
<td>BLZ</td>
</tr>
<tr>
<td>Benin</td>
<td>BEN</td>
</tr>
<tr>
<td>Bermuda</td>
<td>BMU</td>
</tr>
<tr>
<td>Bhutan</td>
<td>BTN</td>
</tr>
<tr>
<td>Bolivia</td>
<td>BOL</td>
</tr>
<tr>
<td>Bonaire, Saint Eustatius and Saba</td>
<td>BES</td>
</tr>
<tr>
<td>Bosnia and Herzegovina</td>
<td>BIH</td>
</tr>
<tr>
<td>Botswana</td>
<td>BWA</td>
</tr>
<tr>
<td>Bouvet Island</td>
<td>BVT</td>
</tr>
<tr>
<td>Brazil</td>
<td>BRA</td>
</tr>
<tr>
<td>British Indian Ocean Territory</td>
<td>IOT</td>
</tr>
<tr>
<td>Brunei Darussalam</td>
<td>BND</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>BGR</td>
</tr>
<tr>
<td>Burkina Faso</td>
<td>BFA</td>
</tr>
<tr>
<td>Burma</td>
<td>MMR</td>
</tr>
<tr>
<td>Burundi</td>
<td>BDI</td>
</tr>
<tr>
<td>Cambodia</td>
<td>KHM</td>
</tr>
<tr>
<td>Cameroon</td>
<td>CMR</td>
</tr>
<tr>
<td>Canada</td>
<td>CAN</td>
</tr>
<tr>
<td>Cape Verde</td>
<td>CPV</td>
</tr>
<tr>
<td>Cayman Islands</td>
<td>CYM</td>
</tr>
<tr>
<td>Central African Republic</td>
<td>CAF</td>
</tr>
<tr>
<td>Central America NOS</td>
<td>ZZC</td>
</tr>
<tr>
<td>Chad</td>
<td>TCD</td>
</tr>
<tr>
<td>Chile</td>
<td>CHL</td>
</tr>
<tr>
<td>China</td>
<td>CHN</td>
</tr>
<tr>
<td>Christmas Island</td>
<td>CXR</td>
</tr>
<tr>
<td>Cocos (Keeling) Islands</td>
<td>CCK</td>
</tr>
<tr>
<td>Colombia</td>
<td>COL</td>
</tr>
<tr>
<td>Comoros</td>
<td>COM</td>
</tr>
<tr>
<td>Congo, Democratic Republic of</td>
<td>COG</td>
</tr>
<tr>
<td>Cook Islands</td>
<td>COK</td>
</tr>
<tr>
<td>Costa Rica</td>
<td>CRI</td>
</tr>
<tr>
<td>Cote d'Ivoire</td>
<td>CIV</td>
</tr>
<tr>
<td>Croatia</td>
<td>HRV</td>
</tr>
<tr>
<td>Cuba</td>
<td>CUB</td>
</tr>
<tr>
<td>Curacao</td>
<td>CUW</td>
</tr>
<tr>
<td>Cyprus</td>
<td>CYP</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>CZE</td>
</tr>
<tr>
<td>Denmark</td>
<td>DNK</td>
</tr>
<tr>
<td>Djibouti</td>
<td>DJI</td>
</tr>
<tr>
<td>Dominica</td>
<td>DMA</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>DOM</td>
</tr>
<tr>
<td>Ecuador</td>
<td>ECU</td>
</tr>
<tr>
<td>Egypt</td>
<td>EGY</td>
</tr>
<tr>
<td>El Salvador</td>
<td>SLV</td>
</tr>
<tr>
<td>England</td>
<td>ENG</td>
</tr>
<tr>
<td>Equatorial Guinea</td>
<td>GNQ</td>
</tr>
<tr>
<td>Eritrea</td>
<td>ERI</td>
</tr>
<tr>
<td>Estonia</td>
<td>EST</td>
</tr>
<tr>
<td>Ethiopia</td>
<td>ETH</td>
</tr>
<tr>
<td>Europe NOS</td>
<td>ZZE</td>
</tr>
<tr>
<td>Falkland Islands</td>
<td>FLK</td>
</tr>
<tr>
<td>Faroe Islands</td>
<td>FRO</td>
</tr>
<tr>
<td>Fijian Islands</td>
<td>FIJ</td>
</tr>
<tr>
<td>Finland</td>
<td>FIN</td>
</tr>
<tr>
<td>France</td>
<td>FRA</td>
</tr>
<tr>
<td>French Guiana</td>
<td>GUF</td>
</tr>
<tr>
<td>French Polynesia</td>
<td>PYF</td>
</tr>
<tr>
<td>French Southern Territories</td>
<td>ATF</td>
</tr>
<tr>
<td>Gabon</td>
<td>GAB</td>
</tr>
<tr>
<td>Gambia</td>
<td>GMB</td>
</tr>
<tr>
<td>Georgia</td>
<td>GEO</td>
</tr>
<tr>
<td>Germany</td>
<td>DEU</td>
</tr>
<tr>
<td>Ghana</td>
<td>GHA</td>
</tr>
<tr>
<td>Gibraltar</td>
<td>GIB</td>
</tr>
<tr>
<td>Greece</td>
<td>GRC</td>
</tr>
<tr>
<td>Greenland</td>
<td>GRL</td>
</tr>
<tr>
<td>Grenada</td>
<td>GRD</td>
</tr>
<tr>
<td>Guadeloupe</td>
<td>GLP</td>
</tr>
<tr>
<td>Guam</td>
<td>GUM</td>
</tr>
<tr>
<td>Guatemala</td>
<td>GTM</td>
</tr>
<tr>
<td>Guernsey</td>
<td>GGY</td>
</tr>
<tr>
<td>Guinea</td>
<td>GIN</td>
</tr>
<tr>
<td>Country</td>
<td>Code</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Guinea Bissau</td>
<td>GNB</td>
</tr>
<tr>
<td>Guyana</td>
<td>GUY</td>
</tr>
<tr>
<td>Haiti</td>
<td>HTI</td>
</tr>
<tr>
<td>Heard Island and McDonald Islands</td>
<td>HMD</td>
</tr>
<tr>
<td>Honduras</td>
<td>HND</td>
</tr>
<tr>
<td>Hong Kong</td>
<td>HKG</td>
</tr>
<tr>
<td>Hungary</td>
<td>HUN</td>
</tr>
<tr>
<td>Iceland</td>
<td>ISL</td>
</tr>
<tr>
<td>India</td>
<td>IND</td>
</tr>
<tr>
<td>Indonesia (Dutch East Indies)</td>
<td>IDN</td>
</tr>
<tr>
<td>Iran</td>
<td>IRN</td>
</tr>
<tr>
<td>Iraq</td>
<td>IRQ</td>
</tr>
<tr>
<td>Ireland</td>
<td>IRL</td>
</tr>
<tr>
<td>Isle of Man</td>
<td>IMN</td>
</tr>
<tr>
<td>Israel and former Jewish Palestine</td>
<td>ISR</td>
</tr>
<tr>
<td>Italy</td>
<td>ITA</td>
</tr>
<tr>
<td>Jamaica</td>
<td>JAM</td>
</tr>
<tr>
<td>Japan</td>
<td>JPN</td>
</tr>
<tr>
<td>Jersey</td>
<td>JYE</td>
</tr>
<tr>
<td>Jordan</td>
<td>JOR</td>
</tr>
<tr>
<td>Kazakhstan</td>
<td>KAZ</td>
</tr>
<tr>
<td>Kenya</td>
<td>KEN</td>
</tr>
<tr>
<td>Kiribati</td>
<td>KIR</td>
</tr>
<tr>
<td>Kuwait</td>
<td>KWT</td>
</tr>
<tr>
<td>Kyrgyzstan</td>
<td>KGZ</td>
</tr>
<tr>
<td>Laos</td>
<td>LAO</td>
</tr>
<tr>
<td>Latvia</td>
<td>LVA</td>
</tr>
<tr>
<td>Lebanon</td>
<td>LBN</td>
</tr>
<tr>
<td>Lesotho</td>
<td>LSO</td>
</tr>
<tr>
<td>Liberia</td>
<td>LBR</td>
</tr>
<tr>
<td>Libya</td>
<td>LBY</td>
</tr>
<tr>
<td>Liechtenstein</td>
<td>LIE</td>
</tr>
<tr>
<td>Lithuania</td>
<td>LTU</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>LUX</td>
</tr>
<tr>
<td>Macao</td>
<td>MAC</td>
</tr>
<tr>
<td>Macedonia</td>
<td>MKD</td>
</tr>
<tr>
<td>Madagascar</td>
<td>MDG</td>
</tr>
<tr>
<td>Malawi</td>
<td>MWI</td>
</tr>
<tr>
<td>Malaysia</td>
<td>MYS</td>
</tr>
<tr>
<td>Maldives</td>
<td>MDV</td>
</tr>
<tr>
<td>Mali</td>
<td>MLI</td>
</tr>
<tr>
<td>Malta</td>
<td>MLT</td>
</tr>
<tr>
<td>Marshall Islands</td>
<td>MHL</td>
</tr>
<tr>
<td>Martinique</td>
<td>MTQ</td>
</tr>
<tr>
<td>Mauritania</td>
<td>MRT</td>
</tr>
<tr>
<td>Mauritius</td>
<td>MUS</td>
</tr>
<tr>
<td>Mayotte</td>
<td>MYT</td>
</tr>
<tr>
<td>Mexico</td>
<td>MEX</td>
</tr>
<tr>
<td>Micronesia</td>
<td>FSM</td>
</tr>
<tr>
<td>Moldova, Republic of</td>
<td>MDA</td>
</tr>
<tr>
<td>Monaco</td>
<td>MCO</td>
</tr>
<tr>
<td>Mongolia</td>
<td>MNG</td>
</tr>
<tr>
<td>Montenegro</td>
<td>MNE</td>
</tr>
<tr>
<td>Montserrat</td>
<td>MSR</td>
</tr>
<tr>
<td>Morocco</td>
<td>MAR</td>
</tr>
<tr>
<td>Mozambique</td>
<td>MOZ</td>
</tr>
<tr>
<td>Myanmar</td>
<td>MMR</td>
</tr>
<tr>
<td>Namibia</td>
<td>NAM</td>
</tr>
<tr>
<td>Nauru</td>
<td>NRU</td>
</tr>
<tr>
<td>Nepal</td>
<td>NPL</td>
</tr>
<tr>
<td>Netherlands</td>
<td>NLD</td>
</tr>
<tr>
<td>New Caledonia</td>
<td>NCL</td>
</tr>
<tr>
<td>New Zealand</td>
<td>NZL</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>NIC</td>
</tr>
<tr>
<td>Niger</td>
<td>NER</td>
</tr>
<tr>
<td>Nigeria</td>
<td>NGA</td>
</tr>
<tr>
<td>Niue</td>
<td>NIU</td>
</tr>
<tr>
<td>Non-US/Canada NOS</td>
<td>ZZX</td>
</tr>
<tr>
<td>Norfolk Island</td>
<td>NFK</td>
</tr>
<tr>
<td>North America NOS</td>
<td>ZNZ</td>
</tr>
<tr>
<td>North Korea</td>
<td>PRK</td>
</tr>
<tr>
<td>Northern Ireland (Ulster)</td>
<td>NIR</td>
</tr>
<tr>
<td>Northern Mariana Islands</td>
<td>MNP</td>
</tr>
<tr>
<td>Norway</td>
<td>NOR</td>
</tr>
<tr>
<td>Oman</td>
<td>OMN</td>
</tr>
<tr>
<td>Pacific NOS</td>
<td>ZZP</td>
</tr>
<tr>
<td>Pakistan</td>
<td>PAK</td>
</tr>
<tr>
<td>Palau (Trust Territory of Pacific Islands)</td>
<td>PLW</td>
</tr>
<tr>
<td>Palestine</td>
<td>PSE</td>
</tr>
<tr>
<td>Panama</td>
<td>PAN</td>
</tr>
<tr>
<td>Papua New Guinea</td>
<td>PNG</td>
</tr>
<tr>
<td>Paraguay</td>
<td>PRY</td>
</tr>
<tr>
<td>Peru</td>
<td>PER</td>
</tr>
<tr>
<td>Philippines</td>
<td>PHL</td>
</tr>
<tr>
<td>Pitcairn Islands</td>
<td>PCN</td>
</tr>
<tr>
<td>Poland</td>
<td>POL</td>
</tr>
<tr>
<td>Portugal</td>
<td>PRT</td>
</tr>
<tr>
<td>Puerto Rico</td>
<td>PRI</td>
</tr>
<tr>
<td>Qatar</td>
<td>QAT</td>
</tr>
<tr>
<td>Republic of South Africa</td>
<td>ZAF</td>
</tr>
<tr>
<td>Réunion</td>
<td>REU</td>
</tr>
<tr>
<td>Romania</td>
<td>ROU</td>
</tr>
<tr>
<td>Russia</td>
<td>RUS</td>
</tr>
<tr>
<td>Rwanda</td>
<td>RWA</td>
</tr>
<tr>
<td>Samoa</td>
<td>WSM</td>
</tr>
<tr>
<td>San Marino</td>
<td>SMR</td>
</tr>
<tr>
<td>Sao Tome &amp; Principe</td>
<td>STP</td>
</tr>
<tr>
<td>Saudi Arabia</td>
<td>SAU</td>
</tr>
<tr>
<td>Scotland</td>
<td>SCT</td>
</tr>
<tr>
<td>Senegal</td>
<td>SEN</td>
</tr>
<tr>
<td>Serbia</td>
<td>SRB</td>
</tr>
<tr>
<td>Seychelles</td>
<td>SYC</td>
</tr>
<tr>
<td>Sierra Leone</td>
<td>SLE</td>
</tr>
<tr>
<td>Singapore</td>
<td>SGP</td>
</tr>
<tr>
<td>Saint-Maarten</td>
<td>SXM</td>
</tr>
</tbody>
</table>
Slovakia .................................................. SVK
Slovenia .............................................. SVN
Solomon Islands .................................. SLB
Somalia ............................................... SOM
South America NOS .............................. ZZS
South Georgia and the South Sandwich Islands ........................ SGS
South Korea ........................................... KOR
South Sudan .......................................... SSD
Spain ..................................................... ESP
Sri Lanka ............................................... LKA
St. Pierre and Miquelon ......................... SPM
St. Barthelemy ................................. BLM
St. Helena ............................................ SHN
St. Kitts and Nevis ............................... KNA
St. Lucia ............................................... LCA
St. Vincent and the Grenadines ............... VCT
Sudan .................................................... SDN
Suriname ............................................. SUR
Svalbard and Jan Mayen ....................... SJM
Swaziland ............................................. SWZ
Sweden ................................................. SWE
Switzerland ......................................... CHE
Syrian Arab Republic (Syria) ................. SYR
Taiwan .................................................. TWN
Tajikistan ............................................. TJK
Tanzania ............................................... TZA
Thailand ............................................... THA
Timor-Leste ......................................... TLS
Togo ...................................................... TGO
Tokelau Islands (New Zealand) .............. TKL
Tonga .................................................... TON
Trinidad and Tobago ............................ TTO
Tunisia ................................................... TUN
Turkey .................................................... TUR
Turkmenistan ....................................... TKM
Turks and Caicos Islands ...................... TCA
Tuvalu .................................................... TUV
Uganda ................................................... UGA
Ukraine .................................................. UKR
United Arab Emirates ......................... ARE
United Kingdom, NOS ......................... GBR
United States ....................................... USA
Uruguay ................................................... URY
U.S. Minor Outlying Islands ................ UMI
Uzbekistan ............................................ UZB
Vanuatu .................................................. VUT
Vatican City ........................................... VAT
Venezuela .............................................. VEN
Vietnam ............................................... VNM
Virgin Islands, British ....................... VGB
Virgin Islands, U.S. ............................. VIR
Wales .................................................... WLS
Wallis and Futuna ............................ WLF
Western Sahara ..................................... ESH
Yemen ................................................... YEM
Zambia ................................................... ZMB
Zimbabwe .............................................. ZWE
Unknown ............................................. ZZU
REFERENCES LINKS FOR TUMOR REPORTING PERSONNEL

American Cancer Society

American College of Surgeons (ACoS)

American Joint Commission on Cancer (AJCC)

Cancer Registrar's Guide to Collecting Industry and Occupation

Centers for Disease Control and Prevention (CDC)

Collaborative Stage Data Collection System (CS)

College of American Pathologists (CAP)

Commission on Cancer (CoC)

Facility Oncology Registry Data Standards (FORDS)

International Classification of Diseases (ICD-9, ICD-10)

International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3)

Michigan Cancer Registrar’s Association

Michigan Cancer Surveillance Program (MCSP)

National Cancer Institute (NCI)

National Cancer Registrars Association (NCRA)

National Program of Cancer Registries (NPCR)

North American Association of Central Cancer Registries (NAACCR)

SEER Hematopoietic Project

SEER Multiple Primary and Histology Coding Rules

SEER*Rx - Interactive Antineoplastic Drugs Database

SEER Program Coding and Staging Manual

SEER Summary Staging Manual – 2000

Surveillance, Epidemiology, and End Results Program (SEER)

World Health Organization (WHO) (ICD-O-3 Reference Manual)